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ABSTRACT OF DISSERTATION 
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE: EPIDEMIOLOGY, 
GENETICS, IN VITRO ACTIVITY, AND PHARMACODYNAMIC MODELING 
Background: Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) such 
as Escherichia coli and Klebsiella pneumoniae are among the most urgent threats of the 
infectious disease realm. The incidence of these infections has been increasing over the 
years and due to very limited treatment options, mortality is estimated at about 50%. By 
2050, mortality from antimicrobial resistant infections is expected to surpass cancer at 10 
million deaths annually. 
Methods: We evaluated 18 contemporary antimicrobials against 122 carbapenem-resistant 
Enterobacteriaceae using a variety of antimicrobial susceptibility testing methods 
according to Clinical Laboratory Standards Institute guidelines. Time-kill studies were 
performed on clinical isolates with variable resistance to meropenem, amikacin, and 
polymyxin B. Phenotypic expression assays were performed on all isolates and whole 
genome sequencing was performed on 8 isolates to characterize molecular resistance 
mechanisms. Pharmacodynamic modeling of meropenem and polymyxin B was also 
conducted. 
Results: CRE were primarily K. pneumoniae, and Enterobacter spp. 60% expressed 
Klebsiella pneumoniae carbapenemase (KPC) only, 16% expressed Verona Integron-
encoded Metallo-beta-lactamase (VIM) only, 5% expressed KPC and VIM, and 20% 
expressed other mechanisms of resistance. Antimicrobial susceptibility testing indicated 
the most active antimicrobials against CRE were ceftazidime/avibactam, 
imipenem/relebactam, amikacin, tigecycline, and the polymyxins. Etest® strips did not 
reliably measure polymyxin B resistance. The automated testing system, BD Phoenix™, 
consistently reported lower MICs than the gold standard broth microdilution. Time-kill 
studies showed regrowth at clinically achievable concentrations of meropenem alone (4, 
16, and 64 mg/L), polymyxin B alone (0.25 and 1 mg/L), or amikacin alone (8 and 16 
mg/L), but combinations of meropenem with either polymyxin B or amikacin were 
bactericidal and synergistic. Meropenem administered simultaneously or prior to 
polymyxin B exhibited superior activity to polymyxin B administered first.
Conclusions: Novel carbapenemase-inhibitor combinations (ceftazidime/avibactam and 
imipenem/relebactam) exhibit the best activity against KPC-producing CRE. The 
polymyxins, amikacin, and tigecycline exhibit the best activity against VIM-producing 
CRE. Meropenem in combination with polymyxin B is bactericidal and synergistic when 
the meropenem MIC is ≤32 mg/L, and meropenem should never be administered after 
polymyxin B. Meropenem and amikacin is bactericidal and synergistic when the amikacin 
MIC is ≤16 mg/L. Etest® strips should not be used for characterizing polymyxin B or 
colistin activity. Clinicians should be aware that automated testing systems may produce 
biased susceptibility results relative to the gold standard method, broth microdilution, 
which may influence interpretation of in vitro results. 
KEYWORDS: Carbapenem-resistant Enterobacteriaceae, antimicrobial susceptibility 
testing, time-kill, whole-genome sequencing, pharmacodynamic modeling 
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Chapter One: 
 
Antimicrobial Resistance 
Part of the research contained within this chapter has been published as 
Kulengowski, B. In vitro activity of polymyxin B and meropenem alone and in 
combination against carbapenem-resistant Enterobacteriaceae. 2016. Theses and 
Dissertations—Pharmacy. 57. 
Infectious disease treatment and management in patients is difficult when resistance 
to contemporary antimicrobial agents is involved. In fact, expression of resistance renders 
antimicrobial agents less effective and is associated with poor clinical outcomes, including 
increased mortality.1-10 Unfortunately, resistance usually follows the development of any 
novel antimicrobial, given enough time (Figure 1.1).11 Commonly known pathogens such 
as Escherichia coli and Klebsiella pneumoniae are among the most notorious for 
expression of drug resistance because they exist as part of the normal flora in the 
gastrointestinal tract of humans. Frequent antimicrobial consumption fosters development 
of drug resistance among these enteric bacteria for which novel antimicrobials are 
dwindling and currently available antimicrobials are few.12 With this in mind, efforts such 
as the present work contribute information to questions such as: what antimicrobials alone 
or in combination provide patients with the greatest chance of survival when confronted 
by these highly resistant pathogens? Do particular agents work better together than others? 
How many antimicrobial agents are sufficient to ensure a high probability of recovery?  
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Figure 1.1: Antimicrobial Resistance Timeline. Reprinted11 
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In March 2015, the U.S. Department of Health and Human Services (HHS) 
established the President's Advisory Council on Combating Antibiotic-Resistant Bacteria 
(PACCARB), which is responsible for providing advice, information, and 
recommendations to the Secretary of Health and Human Services regarding programs and 
policies from the National Action Plan. Within this plan is the Centers for Disease Control 
and Prevention (CDC) 2013 report which categorized a variety of antimicrobial resistance 
problems based on seven factors associated with resistant infections—clinical impact, 
economic impact, incidence, 10-year projection of incidence, transmissibility, availability 
of effective antibiotics, and barriers to prevention.  
Three threat levels were identified using these seven factors (Figure 1.2). Serious 
threats include organisms such as extended-spectrum β-lactamase (ESBL)-producing 
Enterobacteriaceae, vancomycin-resistant Enterococcus (VRE), methicillin-resistant 
Staphylococcus aureus (MRSA), multidrug resistant Pseudomonas aeruginosa, and drug-
resistant Tuberculosis, among others. Antimicrobial resistance in gram-negative 
organisms, specifically carbapenem-resistant Enterobacteriaceae (CRE), were among the 
highest of threat levels, designated as urgent (Figure 1.2).11 The present work focuses on 
this group of urgent threat level pathogens. 
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Figure 1.2: Antimicrobial Resistance Threat Levels. Reprinted11 
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Mechanisms of Resistance 
 Understanding mechanisms of resistance is important because these mechanisms 
shape the direction of research and the choice of therapy. For example, in the interest of 
obtaining clinically relevant information, it may be more advantageous to focus on 
characterizing the more common mechanisms of resistance rather than the least common 
where knowledge about a certain mechanism of resistance may afford therapeutic 
advantages (e.g. the sustained activity of aztreonam against exclusively metallo-β-
lactamase producing organisms). For this reason, a general discussion of mechanisms of 
resistance is presented here, and more detail can be found in Chapter 2: Carbapenem-
resistant Enterobacteriaceae (CRE). 
Resistance mechanisms fall generally into four categories. 1) efflux pumps actively 
removing antimicrobials from the target site of action; 2) enzymatic degradation of the 
antimicrobial agent (e.g. β-lactamases);13 3) changes in cell wall permeability which may 
slow or prevent the antimicrobial from reaching the target site (e.g. mutations in porin 
channels); and 4) target site alterations that prevent the antimicrobial from binding (Figure 
1.3). However, bacteria are not limited to only one mechanism. In fact, they often exhibit 
multiple mechanisms, which may confer resistance to multiple classes of antimicrobials. 
Concerning the focus of this dissertation, carbapenem-resistant Enterobacteriaceae, 
enzymatic degradation is the most common mechanism driving this phenotype.14 
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Figure 1.3: Mechanisms of Antibiotic Resistance. Reprinted15 
  
1 
2 
3 
4 
7 
 
History of β-lactam Resistance Development 
 Penicillin, the original β-lactam, was first administered to Anne Miller in 1942 as 
treatment for a streptococcal bloodstream infection. However, bacteria have been evolving 
to survive long before the introduction of antibiotics to humans. In fact, Edward Abraham 
and Ernst Chain identified a mechanism of penicillin resistance in 1940, two years before 
penicillin was administered to Anne Miller.16 They discovered that a particular strain of 
Escherichia coli produced AmpC, an enzyme capable of inactivating penicillin (see 
Classification of β-lactamases). It was subsequently found that previously penicillin-
sensitive Staphylococcus aureus could be made penicillin resistant after continuous 
subculture in the presence of penicillin in vitro.17 By 1943, one year following human 
introduction to penicillin, four penicillin-resistant staphylococci strains were isolated from 
patients during the course of treatment.18 The predominant mechanism of resistance among 
Staphylococcus aureus at this time was discovered to be production of β-lactamases, 
referred to now as "penicillinases."19,20 
In response, the dose of penicillin was increased to compensate for reduced 
susceptibility;21 but by 1947, a majority of hospital Staphylococcus aureus isolates were 
entirely resistant to penicillin.22 To counter the growing resistance rates, chemists 
developed anti-staphylococcal penicillins (e.g. methicillin) for gram-positive organisms 
such as Staphylococcus aureus and Staphylococcus epidermidis and aminopenicillins (e.g. 
ampicillin) for gram-negative organisms such as Escherichia coli, Klebsiella pneumoniae, 
and Serratia marcescens.23 These novel antimicrobials were not hydrolyzed by early 
penicillinase-producing organisms. 
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 Eventually, β-lactamases developed in gram-negative organisms that conferred 
resistance to aminopenicillins (classified as TEM-1 and TEM-2 in organisms like E. coli 
and SHV-1 in K. pneumoniae; Figure 1.4). These enzymes were countered by the 
development of β-lactam/β-lactamase inhibitor combinations (e.g. ampicillin/sulbactam) 
and cephalosporins. These new compounds functioned in the presence of early β-
lactamases such as TEM-1, TEM-2, and SHV-1, but once again, resistance developed with 
AmpC and ESBL-production. At first, ESBLs in the U.S. were point mutations of the TEM 
and SHV families, of which there are now hundreds of different subtypes. However, other 
ESBL families also developed and spread from other parts of the world, such as the current 
second-largest group—CTX-M—originally from the chromosome of Kluyvera spp.24 
OXA-type β-lactamases are another example of an ESBL, originally discovered in 
Pseudomonas aeruginosa isolated in Turkey.25 There are myriad other β-lactamase 
families (PER,26,27 VEB,28 GES,29,30 BES,31 TLA,32 SFO,33 and IBC34,35), discovered from 
diverse geographic locations, and even some chromosomally located ESBLs.36 
 According to the latest report by the CDC, it is estimated that 19% of healthcare-
associated Enterobacteriaceae infections in the U.S. are now caused by ESBL-producing 
organisms. Of the most common species of Enterobacteriaceae, 23% of Klebsiella 
pneumoniae and 14% of Escherichia coli infections now produce ESBL.11 For reference, 
ten years prior, the National Healthcare Safety Network (NHSN) estimated 1% of 
Klebsiella pneumoniae infections and 0.5% of E. coli infections produced ESBLs. In other 
parts of the world, ESBL-producing bacteria are as high as 52% in Thailand,37 and 70% in 
Egypt.38 Eastern Europe has also reported rates as high as 25-50%.39 Generally speaking, 
the rate of ESBLs in Europe is higher than that of the U.S., but lower than Latin American 
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or Asia.40 The antimicrobial agents of choice to use against ESBL-producing organisms 
are the carbapenems, of which there are four – ertapenem, imipenem, meropenem, and 
doripenem. However, we have reached the latest era of antimicrobial resistance—
carbapenemases. These will be discussed in more detail in Chapter 2: Carbapenem-
resistant Enterobacteriaceae (CRE), but briefly, the two most common carbapenemases 
are Klebsiella pneumoniae carbapenemases (KPCs; more common in the U.S.) and 
metallo-β-lactamases (MBLs; more common in Europe and Southeast Asia).13 
 
 
Figure 1.4: The Evolution of β-lactamases. Reprinted13  
ESBL = extended-spectrum β-lactamase 
KPC = Klebsiella pneumoniae carbapenemase 
MBL = metallo-β-lactamase 
TEM-1, TEM-2, SHV-1, TEM, SHV, CTX-M = types of β-lactamases 
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Classification of β-lactamases 
 To date, many attempts have been made to categorize β-lactamase enzymes, but 
these classification schemes can be summarized in two major approaches – classification 
based on biochemical and functional characteristics or classification based on molecular 
structure of the enzymes.41 For the former, criteria such as the spectrum of antimicrobial 
substrates, hydrolysis rate (Vmax), binding affinity (Km), isoelectric focusing (pI), molecular 
weight, and amino acid composition have been used to develop classes/subclasses but will 
not be discussed here.42,43 The simpler, molecular classification scheme uses four classes 
(Ambler classes A-D) which are described below. 
 Ambler class A is the broadest class and can most simply be thought of as a catch-
all class to enzymes not fitting one of the other classes, consisting of β-lactamase enzymes 
that are located on plasmids, transposons, or chromosomes (e.g. TEM, SHV, PER, PSE, 
hundreds of others).41,44,45 Class A enzymes range from hydrolyzing a narrow spectrum of 
β-lactams (e.g. penicillinases) to a broad spectrum (e.g. ESBL or carbapenemases). A very 
high degree of sequence variability and kinetic properties exist for this class.  
Ambler class B enzymes, also called metallo-β-lactamases (MBLs), require zinc to 
carry out their function. Common MBLs in CRE organisms are imipenem-type 
carbapenemases (IMP), Verona integron-encoded metallo-β-lactamases (VIM), and New 
Delhi metallo-β-lactamase (NDM). Class B enzymes hydrolyze all β-lactam antimicrobials 
except monobactams (e.g. aztreonam) and are not inhibited by any current β-lactamase 
inhibitors such as clavulanic acid, sulbactam, tazobactam, avibactam, vaborbactam, and 
relebactam. 
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Ambler class C enzymes, commonly known as the cephalosporinases or AmpC 
enzymes, are typically chromosomally encoded with highly conserved sequences.46-48 
AmpC enzymes hydrolyze most extended spectrum β-lactams and β-lactam/β-lactamase 
inhibitor combinations such as ceftriaxone or piperacillin/tazobactam, but usually not 
carbapenems. However, CMY-10 was among the first AmpC enzymes that hydrolyze 
carbapenems.49 Additionally, non-carbapenem hydrolyzing AmpC production in 
combination with porin channel mutations or efflux pumps can also confer resistance to 
carbapenems.41 
Ambler class D enzymes are also known as oxacillinases (OXA) due to their ability 
to hydrolyze isoxazolyl β-lactamases such as oxacillin and methicillin.50 There is a lot of 
structural similarity between class D and class A enzymes which can make differentiation, 
or even detection, difficult.41 Class D enzymes are usually not inhibited by β-lactamase 
inhibitors such as clavulanic acid, sulbactam, and tazobactam, but they are inhibited in 
vitro by sodium chloride concentrations of 100mM.51-55 Additionally, these enzymes are 
relatively inactive against cephalosporins.14 Although the OXA enzyme family consists of 
more than a hundred unique subtypes, 9 are considered ESBL and 37 are considered to be 
carbapenemases.56  
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Development of Resistance 
 Resistance to antimicrobials can be inherent. For example, this “natural” resistance 
can include inadequate uptake of an antimicrobial due to lack of transporters (e.g. 
Pseudomonas aeruginosa and tetracycline antimicrobials), lack of drug-activating 
mechanisms (e.g. metronidazole and aerobic organisms), or lack of target sites (e.g. 
penicillin binding proteins of enterococci and all cephalosporin class antimicrobials). 
Alternatively, resistance to antimicrobials can be acquired through normal mutation, 
vertically through reproduction, or horizontally through transformation, transduction, and 
conjugation (Figure 1.5). Sometimes, observable resistance requires a combination of these 
acquired resistance mechanisms. 
 
 
 
 
 
 
 
 
 
Figure 1.5: Horizontal Acquisition of Resistance. Reprinted57 
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Acquired resistance is an area of great concern because, unlike intrinsic resistance, 
these resistance profiles can be dynamic and unique for each species of bacteria and can 
change even during the course of therapy, making clinical decisions difficult and outcomes 
worse. Spontaneous mutation frequency that confers antimicrobial resistance is 
approximately on the order of 10-8 to 10-9 which means that one in every hundred billion 
to one trillion bacteria in an infection will develop resistance to an antimicrobial through 
random mutation.58 Once exposed to an environment containing an antimicrobial, resistant 
organisms are preferentially selected for survival and this resistance can then be passed 
along through reproduction or through horizontal gene transfer. 
 In the setting of horizontal gene transfer, genetic material can be exchanged 
between individual bacteria of the same or different species.58 One of the most common 
methods is conjugation where bacteria come into direct cell-to-cell contact and exchange 
small pieces of DNA called plasmids which may contribute to the explanation of why 
Ambler class A β-lactamases are so diverse in protein structure whereas class C β-
lactamases (i.e. AmpC β-lactamases, which are typically located chromosomally) retain 
such highly conserved protein sequences. Another method of gene transfer is 
transformation where parts of DNA are taken up by bacteria from the environment which 
usually originated from the death or lysis of another bacterium.58 The final method is 
transduction where bacteria-specific viruses called bacteriophages inject DNA into the 
bacteria cell (Figure 1.5). 
  
14 
 
Chapter Two: 
 
Carbapenem-resistant Enterobacteriaceae (CRE)  
Part of the research contained within this chapter has been published as 
Kulengowski, B. In vitro activity of polymyxin B and meropenem alone and in 
combination against carbapenem-resistant Enterobacteriaceae. 2016. Theses and 
Dissertations—Pharmacy. 57. 
This chapter will discuss epidemiology, therapeutic agents, and current literature 
on carbapenem-resistant Enterobacteriaceae – the group of drug resistant pathogens 
labeled an urgent threat by the CDC.11 Enterobacteriaceae include organisms such as 
Escherichia coli, Klebsiella spp., Enterobacter spp., Salmonella spp., Shigella spp., 
Proteus spp., Serratia spp., Citrobacter spp., and  Yersinia pestis. CRE-specific resistance 
mechanisms are often more complex, not always entirely understood, and can be 
multifaceted. One commonality between CRE and other gram-negative organisms is that 
enzyme production (e.g. β-lactamase) is still the most common resistance mechanism, but 
can also be present in combination with changes in cell wall permeability (e.g. porin 
channel mutations), upregulation of efflux pumps, or target site alterations which can 
further contribute to carbapenem resistance.14 Additionally, β-lactamases without intrinsic 
carbapenemase activity but with cephalosporinase activity (e.g. DHA, ACT, CMY, SHV, 
CTX-M, etc.) can contribute to carbapenemase resistance when combined with other non-
enzyme mediated mechanisms of resistance.59-62  
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Epidemiology of Carbapenem Resistance 
Understanding the present epidemiology of CRE will attest to the relevance of the 
present work and help predict the ultimate direction of future studies. Interestingly, 
substantial geographic diversity exists for CRE. For example, in the United States, 
Klebsiella pneumoniae with KPC-2 or KPC-3 (two Ambler class A serine-based enzymes) 
compose about 80% of CRE cases.14,63-65 In contrast, MBL (Ambler class B) or OXA-like 
(Ambler class D) enzymes are more clinically significant world-wide such as in India and 
Pakistan (NDM),66 Greece and Italy (VIM),67 or Turkey, Spain and North Africa (OXA-
48).14,68-72  Some countries (e.g. China) have low CRE prevalence, but significant diversity 
of carbapenemase enzymes.73,74 Coexistence of various sequence types of MBLs and KPCs 
within the same Klebsiella pneumoniae strains has also been observed.67,75-77 Ultimately, 
no two countries are the same when it comes to CRE characteristics and the prevalence can 
be drastically different, even between acute-care centers within the same country.14 
Regarding the U.S. specifically, there are no national requirements to report CRE, 
and requirements for reporting CRE vary by state.78 To facilitate data collection nationally, 
the CDC maintains two voluntary surveillance systems for CRE monitoring – Healthcare 
Associated Infections Community Interface (HAIC) which uses 10 sites across the nation 
for determining communities having or at risk for having CRE infections, and the National 
Healthcare Safety Network (NHSN) which tracks 17,000 facilities nationwide for 
healthcare-associated infections.79 Figures 2.1-2.5 show the data reported to the CDC, 
separated by β-lactamase type (KPC, NDM, VIM, OXA-48) and by state. 
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Figure 2.1: States with KPC-producing CRE Reported to the CDC. Reprinted79 
 
 
 
Figure 2.2: States with NDM-producing CRE (n=379) Reported to the CDC. Reprinted79 
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Figure 2.3: States with OXA-48-producing CRE (n=146) Reported to the CDC. 
Reprinted79 
 
 
 
Figure 2.4: States with VIM-producing CRE (n=57) Reported to the CDC. Reprinted79 
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Figure 2.5: States with IMP-producing CRE (n=36) Reported to the CDC. Reprinted79 
 
Klebsiella pneumoniae Carbapenemase (KPC; Class A) 
A KPC-producing CRE was first identified in the United States from Klebsiella 
pneumoniae cultured from a patient in North Carolina in 1996, but reported in 2001.80 
Thereafter named KPC-1, it was not the first carbapenemase to be reported in 
Enterobacteriaceae because MBLs had been identified in Enterobacteriaceae in Japan as 
early as 1991.81-83 It was, however, the first Ambler class A, serine-based carbapenemase 
to be found in Enterobacteriaceae. Subtype variants KPC-2 (later identified as identical to 
KPC-1) and KPC-3, initially concentrated in eastern states such as New York and New 
Jersey, but have since spread to all states (Figure 2.1).3,80,84-90 Among CRE sent to the CDC, 
KPC has primarily been identified in Klebsiella pneumoniae, Escherichia coli, and 
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Enterobacter spp., and the KPC-2 and KPC-3 subtype variants are the most common in the 
United States.91  As of October, 2018, Beta-Lactamase DataBase (BLDB) reports 36 KPC 
subtypes.92 
Outside the U.S., the first KPC-producing Enterobacteriaceae was identified in 
2005 from a hospital in Paris, France where a patient had been recently hospitalized in New 
York.93 The legend for European carbapenemase enzyme type can be found in Figure 2.6. 
Currently, 34 of 38 surveyed European countries have reported KPC-producing CRE 
(Figure 2.7),94,95 as well as Israel96 and China.97  
 
Figure 2.6: Epidemiological Stages by Color for European Carbapenem-resistant 
Enterobacteriaceae. 
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Figure 2.7: KPC-producing Enterobacteriaceae in 38 European Countries Based on Self-
Assessment by National Experts. Reprinted94 
 
Imipenem-like Carbapenemase (IMP; Class B) 
In 1991, the very first MBL identified in Enterobacteriaceae was IMP-1, found in 
a Serratia marcescens clinical isolate in Japan.81,82 IMP also emerged in Italy and Portugal 
in 1997 and 1998, respectively.98 The differences in European IMP subtypes and Japanese 
IMP subtypes have led to the belief that European IMP-production emerged locally rather 
than global dissemination from Japan.98 IMP has also been identified in Canada, China, 
Korea, Singapore, Taiwan and Australia to name a few more regions outside the U.S. IMP-
producing CRE in Europe is depicted in Figure 2.8.98 
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Figure 2.8: IMP-producing Enterobacteriaceae in 38 European Countries Based on Self-
Assessment by National Experts. Reprinted95 
 
From 2009 - 2010, the first IMP-producing CREs were isolated in the U.S. from 
three pediatric patients with no history of travel or receipt of medical care outside the 
United States.99 Before this, the first IMP-producing isolate was Pseudomonas aeruginosa, 
reported in 2006.100 As of October 2018, BLDB reports 78 subtypes of IMP-type β-
lactamases.92 
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Verona Integron-encoded Metallo-β-lactamase (VIM; Class B) 
A VIM-producing CRE was first identified in Greece from Escherichia coli in 
2001,101,102 and then later from other E. coli and K. pneumoniae isolates.98,103 VIM-
production has also been reported in Japan, South Korea, Portugal, Spain, Poland, Croatia, 
Chile, Venezuela, Argentina, Belgium and most recently in the United States.104-110 Figure 
2.9 depicts VIM-production in Europe whereas Figure 2.4 describes VIM-production in 
the United States, where Kentucky has reported more than all other states combined.79  
The first VIM-producing CRE identified in the U.S. was in an adult patient with 
Klebsiella pneumoniae in 2006.111 Additionally, a recent publication describes the first and 
only cluster of VIM-producing CRE in the U.S. Perirectal cultures of eight isolates (4 E. 
cloacae, 1 Raoultella sp., 1, E. coli, 2 Klebsiella pneumoniae) from six patients were 
obtained – six from a neonatal intensive care unit, and two from an adult trauma and 
surgical intensive care unit.112 To date, this is the only VIM-producing CRE colonization 
reported to include a neonatal population. Previous VIM-producing CRE have only 
involved a single species, and only one VIM-producing CRE-colonized patient had been 
reported (2013) in the same hospital. As of October 2018, BLDB reports 60 subtypes of 
VIM-type β-lactamases.113 
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Figure 2.9: VIM-producing Enterobacteriaceae in 38 European Countries Based on Self-
Assessment by National Experts. Reprinted95 
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Oxacillinase Group β-lactamase (OXA; Class D) 
In 2001, OXA-48 was the first Ambler class D carbapenemase isolated in 
Enterobacteriaceae. It was first found in a Klebsiella pneumoniae isolate from Turkey.54 
Interestingly, this particular OXA enzyme has the highest hydrolysis rate of imipenem 
compared to all other published OXA enzymes.56 OXA-48 has also been identified in 
Russia,114 South Korea,115 Argentina, India,116 Taiwan,117 North Africa,65 and the U.S.79 
(Figure 2.3). Figure 2.10 depicts OXA-48 dissemination in Europe. As of October 2018, 
BLDB reports 856 subtypes of OXA-type β-lactamases.113 
 
Figure 2.10: OXA-48-producing Enterobacteriaceae in 38 European Countries Based on 
Self-Assessment by National Experts. Reprinted95 
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New Delhi Metallo-β-lactamase (NDM; Class B) 
In 2009, an NDM-producing CRE was first identified in Sweden from Klebsiella 
pneumoniae, cultured from a patient of Indian descent who had recently traveled to New 
Delhi, India and acquired a urinary tract infection (UTI).118 This novel MBL was 
designated NDM-1. Currently, at least sporadic NDM-producing CRE has been reported 
in most European countries (Figure 2.11), but a more thorough description of NDM spread 
across Europe is described by Cantón et al.119 As of October 2018, BLDB reports 24 NDM-
type β-lactamases.92  
 
Figure 2.11: NDM-producing Enterobacteriaceae in 38 European Countries Based on 
Self-Assessment by National Experts. Reprinted95 
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In the U.S., the first NDM-producing Enterobacteriaceae was among nine isolated 
from 2009 - 2011 (5 K. pneumoniae, 2 E. coli, 1 E. cloacae, and 1 Salmonella enterica) 
from eight patients across five states (5 California, 1 Illinois, 1 Maryland, 1 Massachusetts, 
and 1 Virginia). All patients had recently been to India or Pakistan. Eight of these isolates 
were confirmed by the CDC to encode NDM-1, but the ninth isolate (E. coli) coded for 
what is now called NDM-6.66 NDM-producing isolates were also being described in other 
parts of the world by this time, consistently in patients with recent travel to India or 
Pakistan.91 Since 2012, the epidemiology in the U.S. appears to be changing as more NDM-
producing CRE are being isolated from patients without recent travel outside country, 
suggesting local acquisition.91 
 
CRE Incidence and Prevalence 
 Regarding the top 3 CRE reported in the U.S., 69% were Klebsiella 
pneumoniae/oxytoca, 18% were E. coli, and  13% were Enterobacter spp.120 Nationwide, 
carbapenem resistance among Klebsiella pneumoniae/oxytoca was <1% in 2000,121 but by 
2010, the CDC reported carbapenem resistance up to 12.8% and 12.5% for central-line 
associated bloodstream infections (CLABSIs) and catheter-associated urinary tract 
infections (CAUTIs),120 respectively. An academic medical center in New York reported 
carbapenem-resistant Klebsiella pneumoniae rates of 38% in 2008.122 A collective report 
of 14 hospitals in New York also noted overall 38% Klebsiella pneumoniae carbapenem 
resistance in 2006, but has recently reported a decrease to 29% in 2009.123  
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Conventional Antimicrobial Agents 
 CRE are complex and diverse – what may work for some organisms may not be 
universally applicable to others. In general, CRE are resistant to all β-lactams and β-
lactam/β-lactamase inhibitor combinations with the exception of ceftazidime/avibactam 
and meropenem/vaborbactam, newly approved β-lactam/β-lactamase-inhibitor 
combinations for KPC-producing gram-negative bacteria.124 Additionally, exclusively 
MBL-producing CRE may be susceptible to aztreonam. However, due to the complexity 
and commonly multi-factored resistance that accompanies most CRE, this is seldomly 
applicable.125 
 Regarding other classes of antimicrobials, CRE are typically only susceptible 
(>85%) to colistin, polymyxin B, tigecycline, fosfomycin, and variably susceptible (35-
75%) to aminoglycosides. There are limitations with each of the antimicrobials for which 
CRE are typically susceptible, including spectrum, pharmacologic characteristics, rapid 
resistance development, and toxicity/adverse events.14 Newly approved antimicrobials like 
the novel beta-lactam/beta-lactamase inhibitor combinations will be discussed briefly in 
Conventional Antimicrobial Agents against Carbapenem-resistant Enterobacteriaceae. 
The most recently approved aminoglycoside (plazomicin; July 2018)  and tetracycline 
(eravacycline; August 2018) will not be discussed beyond mention in this dissertation. 
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Polymyxins 
 The polymyxin class of antibiotics was introduced in the mid-1950s, consisting 
now of two agents – polymyxin B and polymyxin E (colistin). Both agents are cationic 
polypeptides that share a ring of amino acids and a fatty acid tail (Figure 2.12). The 
structural difference of colistin involves a substitution of the phenylalanine in polymyxin 
B with D-leucine. Additionally, both polymyxins have two major components based on the 
fatty acid chain length – polymyxin B1 and B2 and colistin A and B.14 
 
Figure 2.12: Structure of Polymyxin B. Reprinted126 
 
 The mechanism of action of the polymyxin class involves binding to negatively-
charged moieties in the lipopolysaccharide (LPS) present in the outermost membrane of 
gram-negative bacteria (Figure 2.13). This interaction results in the loss of intracellular 
products, killing the bacteria.  
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Figure 2.13: Polymyxin B/Colistin Mechanism of Action. Reprinted127 
 Polymyxins have a broad gram-negative spectrum of activity – including 
Enterobacteriaceae (except Proteus spp. and Serratia spp.), Pseudomonas aeruginosa, and 
Acinetobacter baumannii. However, their utility had been limited by the development of 
safer antimicrobials like the aminoglycosides and cephalosporins. In fact, this 
antimicrobial class was primarily reserved for cystic fibrosis patients, gastrointestinal (GI) 
tract decontamination, and topical antimicrobial therapy.14 In the '90s, this class was 
"reintroduced" to address problems with carbapenem-resistant organisms. One of the first 
published successes of polymyxin treatment for CRE involved a critically ill patient with 
a carbapenem-resistant Klebsiella pneumoniae bloodstream infection.128 
 Polymyxin B and colistin differ significantly in their pharmacokinetics. However, 
routes of administration are similar between the polymyxins with the exception that 
polymyxin B cannot be administered orally. Otherwise, both polymyxins can be 
administered intravenously, intramuscularly, intrathecally, topically, or by inhalation. 
Clinically, colistin is administered as a prodrug (colistimethate sodium; CMS) which must 
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be first hydrolyzed into various derivatives (e.g. colistin) before having any antimicrobial 
effect, whereas polymyxin B is administered as an active agent. The rates of hydrolysis are 
variable according to the physical environment within the patient (e.g. pH and 
temperature). Differences in rates and extents of hydrolysis have been observed brand-to-
brand or even batch-to-batch.129 Since there is no appreciable antimicrobial activity from 
the parent compound, rational dosing of CMS is very challenging.130,131 
 Additional challenges in CMS dosing exist in its elimination, which is primarily 
renal, and its conversion to colistin, which is non-renal. In fact, patients with normal renal 
function are often so efficient at eliminating CMS that a dose 4 to 5 times that which is 
needed to attain required plasma concentrations of colistin must be administered.131 
Colistin can also be found concentrated in the urine, but this is primarily due to post-renal 
conversion of the parent compound because colistin is primarily eliminated through a non-
renal mechanism. As a result, large interpatient and intrapatient variability exists for CMS 
dosing.132 In stark contrast, polymyxin B, which is administered as an active agent, is 
eliminated mainly by non-renal mechanisms and very little polymyxin B can be found in 
the urine.133,134 Figure 2.14 summarizes the different elimination pathways for colistin vs. 
polymyxin B.131 
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Figure 2.14: Elimination Pathways for Colistin and Polymyxin B. Reprinted131 
Thickness of the arrows indicates relative magnitude of clearance mechanism 
 The clinical implication of these pharmacokinetic differences are that, even with a 
loading dose of CMS, it takes several hours to achieve effective plasma levels of colistin 
and delay in appropriate antimicrobial therapy has been associated with increased mortality 
in critically ill patients.135,136 Furthermore, low colistin plasma levels have been associated 
with growth of colistin-resistant subpopulations.137-140 As renal function improves (or 
declines), the rate and extent of conversion of parent drug to colistin changes, and dosing 
strategies accounting for this change have not yet been perfected, rending it impossible to 
reliably achieve effective steady-state plasma concentrations in patients with creatinine 
clearance above 80 mL/min.132,141 For example, at the maximal approved dose of CMS 
(300 mg colistin base activity / day), patients with creatinine clearance > 80 mL/min 
achieved plasma concentrations < 2 mg/L.132 As a result, more recent studies have used 
larger doses of colistin at approximately 5 mg/kg loading dose and 2.5 mg/kg every 12 
hours.124 Nephrotoxicity, another independent predictor of mortality, is the dose limiting 
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adverse effect of colistin.142 Polymyxin B, however, can rapidly achieve desired plasma 
levels that can be effectively maintained134 and nephrotoxicity with polymyxin B has been 
reported to be lower than with CMS,143,144 being closer to about 14%,145 compared to 
colistin which has been reported closer to 45% using RIFLE criteria.142 However, at our 
institution, nephrotoxicity of polymyxin B and colistin have ranged 40-50%.146 
Polymyxin-resistant CRE infections are another concern altogether. Rapid 
resistance development has been observed when colistin or polymyxin B are used alone.137-
139 Colistin-resistant (MIC >2 µg/mL) CRE have occurred in various parts of the globe 
including Italy,147 Greece,148 Spain,72 and the United States.149,150 In fact, a tertiary center 
in Spain reports an increase from 13.5% to 31.7% in colistin resistance among Klebsiella 
pneumoniae isolates.72 A retrospective multi-center observational study in Italy showed a 
threefold increase in colistin-resistant KPC-producing Klebsiella pneumoniae from 2010 
to 2013 (20% resistance overall), and colistin-resistance was determined to be an 
independent risk factor for 14-day mortality (47% vs. 31%; P = 0.001).151 
 Mechanisms that lead to resistance to polymyxins in Enterobacteriaceae are not 
fully understood. One proposal is that modifications in components that make up the LPS 
layer of gram-negative organisms, like lipid A, may play a role in polymyxin-resistance. 
Specifically, phoP/phoQ and pmrA/pmrB can be activated by environmental stimuli (e.g. 
low magnesium concentrations or polymyxin exposure) or can harbor mutations which 
typically lead to constitutive expression. One result is that phosphate head-groups in lipid 
A are substituted with 4-amino-4-deoxy-L-arabinose (L-Ara4N) which inhibits polymyxin 
binding. Figure 2.15 shows possible mutations (red star symbols) and how the phoP/phoQ 
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and pmrA/pmrB system modifies the LPS layer, which ultimately leads to lower binding 
affinity (resistance) to polymyxin class antibiotics. 
 
 
Figure 2.15: Proposed Polymyxin Resistance Pathway in Gram-negative Organisms. 
Reprinted152 
 
The mobilized colistin resistance (mcr-1) gene was first identified in E. coli in 
Chinese pigs.153 This was the first polymyxin resistance gene identified which was capable 
of horizontal gene transfer. Additional mechanisms of resistance include modification of 
outer membrane proteins (e.g. OprH) which can block polymyxin merger with the cell 
membrane as well as efflux pumps.152 Regarding K. pneumoniae specifically, alterations 
in the mgrB gene (removal a negative feedback loop on the phoP/phoQ system) has been 
associated with an epidemic dissemination of colistin-resistant CRE in Italian 
hospitals154,155 but has also been identified in other parts of Europe, Asia, Africa and the 
United States.154 As a final addition, lipid A modifications in K. pneumoniae have been 
associated with cross-resistance to host defense systems as well,156 which may contribute 
to the observed increase in mortality associated with colistin-resistant CRE. 
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Tigecycline 
 Tigecycline is a glycylcycline (Figure 2.16), a class related to the tetracyclines, that 
also inhibits protein synthesis by binding to the 30S ribosomal subunit (Figure 2.17).157-159 
The charged aminoacyl-tRNA can no longer bind to the ribosome in the presence of 
tigecycline due to the distorted ribosomal acceptor site, which halts the reproduction 
process of the bacteria. As a result, tigecycline is bacteriostatic and has a broad spectrum 
of activity including both gram-positive organisms and gram-negative organisms, even 
anaerobic and atypical organisms, but it does not clinically impact Pseudomonas spp. or 
Proteus spp.160,161 
 
 
Figure 2.16: Structure of Tigecycline. Reprinted162 
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Figure 2.17: Tigecycline Mechanism of Action. Reprinted163 
 
Clinical experience with tigecycline has set its role in complicated skin and skin 
structure infections (cSSSIs) and complicated intra-abdominal infections (cIAIs).164 
Tigecycline has been associated with increased mortality when compared to other 
antimicrobial agents and so is typically reserved after failure of other antimicrobials or in 
situations where antimicrobial choices are limited such as in CRE or other multidrug 
resistant (MDR) organisms.165,166 An AUC/MIC ratio > 12.5 correlates with clinical 
outcome in cSSSI, which suggests clinical breakpoints of 0.25-0.5, but CLSI currently has 
not established a breakpoint for Enterobacteriaceae.167 The susceptibility breakpoint 
established by the FDA is ≤2 µg/mL.168 Of note, peak serum concentrations of 0.60 µg/mL 
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after a 100 mg infusion render tigecycline unable to effectively treat bloodstream 
infections.14 
 Resistance to tigecycline (MIC >2 µg/mL) is not common, but when it has been 
characterized, it is usually associated with mutations in the ramA gene which leads to 
upregulation of AcrAB-TolC, a multidrug efflux pump in Enterobacteriaceae.169 
Additionally, overproduction of marA, rarA, acrAB, and oqxAB genes can lead to 
tigecycline resistant phenotypes.170 Tigecycline resistance has been recently reported in 
China,171 Europe,172-174 and the United States.173,175 
 
Fosfomycin 
 Fosfomycin is bacterial cell-wall inhibitor, discovered in Spain in 1969, and it is 
relatively unique in structure by containing an epoxide (Figure 2.18).176,177 Peptidoglycan 
synthesis is inhibited by fosfomycin which blocks the formation of N-acetylmuramic acid 
by competitively inhibiting phosphoenol pyruvate synthetase (Figure 2.19).14 
 
 
Figure 2.18: Structure of Fosfomycin. Reprinted178 
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Figure 2.19: Fosfomycin Mechanism of Action. Reprinted179 
 
Like other cell-wall inhibitors (e.g. β-lactam antibiotics), fosfomycin is bactericidal 
and has a broad spectrum of activity that includes both gram-positive and gram-negative 
bacteria. In Europe, fosfomycin is primarily used in combination with other antimicrobials 
for CRE treatment, particularly strains with reduced susceptibility to colistin and 
tigecycline.180,181 In the U.S., fosfomycin is only approved orally for uncomplicated urinary 
tract infections due to its excellent genitourinary penetration. The optimal dosing strategy 
for treatment is still unclear. The FDA label indicates a single 3 gm daily dose whereas 
other clinical trials have evaluated 3 gm every 2 or 3 days for urinary tract infections.182 
For non-urinary infections, doses of 6-8g over 2-4h every 8h have been used in Europe.124 
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In CRE infections, a multicenter (11 ICUs), prospective case-series study from 
Greece showed favorable outcomes when fosfomycin was used in combination with 
another antimicrobial (usually colistin or tigecycline) in a majority of patients with 
fosfomycin-susceptible carbapenem-resistant infections, a majority of which (41 out of 68) 
were Klebsiella pneumoniae. Bacterial eradication was observed in 56.3% of cases overall 
and in 60% of cases caused by colistin-resistant CRE. Fosfomycin resistance developed 
during the course of treatment in three cases.183 
Fosfomycin resistance has been characterized, and usually results from either 
mutations in the transport systems (GlpT and UhpT) that are located on the chromosome 
of bacteria or through inactivating enzymes (fosA family) located on bacterial plasmids. 
The chromosomal mutations prevent the uptake of fosfomycin into the cell and, although 
these mutations are relatively quickly acquired, a high fitness cost is observed in E. coli 
which limits fosfomycin resistance when not under direct antimicrobial pressure.184 The 
same fitness cost has not been observed in Klebsiella spp. and Enterobacter spp., and 
therefore fosfomycin monotherapy may select for resistant isolates among these 
Enterobacteriaceae.185 Regarding plasmid-mediated resistance, a plasmid carrying both 
blaKPC-2 and fosA3 is circulating among carbapenem-resistant Klebsiella pneumoniae in 
China and accounts for 60% of the observed fosfomycin resistance in that country.186 
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Aminoglycosides 
 The aminoglycoside class was introduced in the 1940s with streptomycin.14 Today, 
three aminoglycosides are primarily used (four in Europe)–tobramycin, gentamicin, 
amikacin and kanamycin (in Europe). However, plazomicin was recently approved and 
exhibits improved activity against CRE relative to the other aminoglycosides. Although 
aminoglycosides are generally similar in structure (Figure 2.20) and function, those 
structural differences that do exist among this class often confer differences in stability 
against a variety of aminoglycoside modifying enzymes that would inactive these 
antimicrobials. 
 
 
Figure 2.20: Structure of Amikacin. Reprinted187 
 
 Like tigecycline, aminoglycosides function by binding to the 30S ribosomal 
subunit, but these antimicrobials can additionally facilitate the insertion of incorrect amino 
acid sequences into proteins rather than only preventing their translation (Figure 2.21). As 
a result, aminoglycosides exhibit bactericidal activity against gram-positive and gram-
negative organisms, including Pseudomonas spp., but have little affect against anaerobes.  
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Figure 2.21: Aminoglycoside Mechanism of Action. Reprinted188 
 
 Aminoglycosides are sometimes a viable option against aminoglycoside-
susceptible CRE. In fact, a superior rate of microbiologic clearance was observed in a 
retrospective cohort study of CRE bacteriuria when an aminoglycoside was used (88%) 
compared to either polymyxin B (64%) or tigecycline (43%).189 Additionally, 
aminoglycosides are associated with less nephrotoxicity (~10-20%)190 than colistin 
(~45%),142,145,146,191,192 while maintaining bactericidality and the ability to treat 
bloodstream infections over tigecycline.14 
 Resistance to aminoglycosides is primarily mediated by aminoglycoside-modifying 
enzymes (analogous to β-lactamase production) but is highly variable, showing regional 
dependence as well as differences among hospitals within the same geographic region. 
Resistance rates can even vary by strain, but in general, rates of non-susceptibility have 
been reported as ranging from 35% to 63% for gentamicin, 61% to 98% for tobramycin, 
and 16% to 82% for amikacin.193-195 Other resistance mechanisms have been identified as 
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well, including modification of the ribosome target,196 reduced permeability of the bacterial 
cell wall, and also efflux pumps.197,198 
 
Conventional Antimicrobial Agents against Carbapenem-resistant 
Enterobacteriaceae 
 A majority of cases, cases series, and the published experience of medical centers 
indicate that combination therapy might provide a mortality benefit when compared to 
monotherapy.10,68,124,185,199-203 However, the data utilized in these studies often predates the 
newest approved agents – ceftazidime/avibactam, meropenem/vaborbactam, plazomicin, 
and eravacycline. Additionally, polymyxin B, colistin, tigecycline, and fosfomycin have 
all demonstrated rapid selection for resistance when used as monotherapy against 
CRE.185,204 There are very few randomized-controlled clinical trials comparing single 
agents or their combinations, so reliance on retrospective analyses is frequent which results 
in significant limitations. Some experts conclude that a systematic review and meta-
analysis is not possible regarding CRE treatment due to the heterogeneity of available 
evidence.205 
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In Vitro Studies 
Polymyxin Combinations 
 The interaction between antimicrobial agents has primarily been characterized by 
time-kill methodology, where polymyxins are most frequently investigated in combination 
with either a carbapenem, tigecycline, fosfomycin, rifampin, an aminoglycoside, or 
sometimes with three or four agents from multiple drug classes.204 The goal of in vitro 
testing in this setting is to quickly evaluate combinations of antimicrobials that might show 
synergistic interactions when used to treat CRE. Most in vitro testing has been performed 
on KPC-producing CRE whereas MBL- and OXA-48- producing CRE have more limited 
data.14 
 In KPC-producing Enterobacteriaceae, time-kill studies have shown polymyxin B 
exhibiting synergistic activity (≥102 CFU/mL more killing than the more active agent alone 
at 24 hours) when in combination with rifampin and when in combination with 
imipenem.206 Polymyxin B in combination with both doripenem and rifampin were 
determined to interact synergistically and exhibit bactericidal activity (≥103 CFU/mL 
killing at 24 hours).207 Colistin and tigecycline have also been evaluated in combination 
together and determined to be synergistic.208 In a broth microdilution checkerboard assay 
of 12 KPC-producing Klebsiella pneumoniae isolates, polymyxin B was synergistic in 
combination with either tigecycline, doxycycline or rifampin, but no synergy was detected 
for combinations with imipenem or gentamicin.209 
In 42 VIM-producing K. pneumoniae isolates from Greece, colistin was found to 
be synergistic with imipenem in about 50% of colistin-susceptible isolates, regardless of 
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imipenem MIC, and indifferent (CFU/mL killing is the same as the more active agent alone 
at 24 hours) in the rest. For the colistin-non-susceptible isolates, the combination was 
antagonistic (CFU/mL killing was less than the more active agent alone at 24 hours) for 
56% of the isolates and synergistic for only 11%.210 
In nine colistin-resistant KPC-producing Klebsiella pneumoniae and three colistin-
susceptible KPC-producing Klebsiella pneumoniae, colistin in combination with two 
carbapenems (doripenem and ertapenem) showed synergy in 8 of 12 isolates. Colistin in 
combination with one carbapenem (doripenem) showed synergy in 6 of 12 isolates and 
colistin in combination with the other carbapenem (ertapenem) showed synergy in 5 of 12 
isolates. Interestingly, the authors noticed an association between synergy of the triple 
combination of colistin-doripenem-ertapenem and porin expression levels. Specifically, 
the eight isolates showing synergy had the highest porin expression, and receiver operator 
characteristic (ROC) analysis designated this group of eight as significantly different from 
the remaining four in terms of porin expression (P = 0.002). The authors speculated that 
permeability for both carbapenems was limited by porin channel expression and that higher 
expression provided easier access to the sites of action of both carbapenems.211 
A systematic review and meta-analysis of in vitro interactions between polymyxins 
and any carbapenem against polymyxin-susceptible CRE found an overall synergy rate of 
55%. This analysis also indicated that Etest® and checkerboard synergy testing typically 
reported lower than did time-kill methodology, and that the use of combination therapy led 
to less resistance development in vitro when post-exposure resistance testing was 
performed.212  
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Colistin (CST), meropenem (MEM), and tigecycline (TIG) interactions were 
evaluated using a 3-D checkerboard assay in 20 carbapenem-resistant K. pneumoniae 
clinical isolates. Among these, 13 were resistant to colistin and 6 were resistant to 
tigecycline. Synergy rates were 10% for MEM and TIG; 30% for CST and MEM; 30% for 
CST and TIG; and 30% CST, MEM, and TIG. It was noted by the authors that synergy was 
correlated with higher TIG MICs (>2 µg/mL) and higher CST MICs (>8 µg/mL), there 
was no antagonism, and addition of a third antimicrobial agent did not contribute to 
synergy.213 CST, MEM, and TIG were also evaluated in a time-kill study of eight CRE 
clinical isolates (4 K. pneumoniae, 2 E. coli, 1 E. cloacae, 1 S. marcescens). MEM and TIG 
were not synergistic in any of the eight strains. TIG and CST showed synergy at 
concentrations above the MICs for most strains.208 
 
Other Combinations 
 Time-kill assays involving double and triple antimicrobial combinations of 
aztreonam, ciprofloxacin, colistin, daptomycin, fosfomycin, meropenem, rifampin, 
telavancin, tigecycline, and vancomycin against MBL-producing (2 VIM and 2 NDM) 
polymyxin-susceptible K. pneumoniae isolates were used to evaluate potential combination 
therapy against MBL-producing CRE. Sample times were 0, 1, and 24 hours. Synergy was 
found in double combinations of colistin with either aztreonam, fosfomycin, meropenem, 
or rifampin and in triple combinations with colistin and meropenem with either aztreonam, 
fosfomycin, or rifampin. The most effective combination was meropenem, colistin, and 
rifampin demonstrating bactericidal and synergistic activity throughout 24 hours for all 
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four strains. Ciprofloxacin, tigecycline, daptomycin, telavancin, and vancomycin alone and 
in combination with colistin was without synergy or bactericidal activity at 24 hours.214 
In KPC-producing Klebsiella pneumoniae, fosfomycin in combination with either 
meropenem or colistin was synergistic in 64.7% and 11.8% of isolates, respectively. 
Fosfomycin in combination with gentamicin was indifferent.215 Synergy was evaluated in 
another study with fosfomycin in combination with imipenem (74%), meropenem (70%), 
doripenem (74%), colistin (36%), netilmicin (42%), and tigecycline (30%) for 50 KPC-
producing Klebsiella pneumoniae.216 
 Amikacin (AMK) 16 µg/mL was evaluated alone and in combination with 
ertapenem (ERT) 2 µg/mL, imipenem (IPM) 4 µg/mL, and meropenem (MEM) 4 µg/mL 
against four K. pneumoniae clinical isolates resistant to all four antimicrobials (MICs >8 
µg/mL for ERT, IPM, and MEM; MIC 32 µg/mL for AMK). Alone, none of the 
antimicrobials achieved bactericidal activity. Synergy was found in combinations of AMK 
with either MEM or IPM throughout 24 hours in all isolates. Bactericidal activity was 
found in 2 of 4 isolates for MEM and AMK and 1 of 4 isolates for IPM and AMK. ERT 
with AMK was not synergistic or bactericidal in any isolate.217 
  
In Vitro Pharmacodynamic Models 
 Human pharmacokinetics of meropenem were simulated to optimize meropenem 
dosing against carbapenemase-producing Klebsiella pneumoniae using a one-
compartment, chemostat model. An advantage to the 0.5 hour infusion of 1 gm every 8 
hours was found in a high dose/prolonged infusion regimen (3 hour infusion of 2 gm every 
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8 hours). Using this regimen, bactericidal activity (≥103 CFU/mL killing) was obtained by 
6 hours against all KPC-producing Klebsiella pneumoniae isolates. However, regrowth 
was observed for 9 of 11 isolates with meropenem MICs ≥ 8 µg/mL, but not for two isolates 
whose meropenem MICs were 2 and 8 µg/mL. Measured meropenem levels were lower 
than expected using the model, but this was attributed to the production of carbapenemase 
enzymes by the K. pneumoniae isolate.218 
Human pharmacokinetics of tigecycline (as 50 mg every 12 hours) in combination 
with either meropenem (as 2 gm infused over 3 hours every 8 hours)218 or rifampin (as 600 
mg every 12 hours) in lung-epithelial fluid were modeled using a one-compartment, 
chemostat model. Tigecycline alone and in combination with rifampin against 
carbapenemase-producing Klebsiella pneumoniae isolates showed little activity when used 
against isolates with meropenem MICs ≤ 2 µg/mL. However, when tigecycline was used 
in combination with meropenem, a synergistic, bactericidal effect was observed for isolates 
with tigecycline MICs up to and including 2 µg/mL and meropenem MICs up to and 
including 16 µg/mL. However, none of the regimens maintained bactericidal activity for 
the full 48-hour study period.219 
 Using time-kill methodology and a 3-dimensional response model, six 2-agent 
combinations of amikacin (AMK), doripenem (DOR), levofloxacin (LEV) and rifampin 
(RIF) were evaluated against a KPC-2-producing K. pneumoniae (MICs AMK: 64 µg/mL, 
DOR: 16 µg/mL, RIF: >64 µg/mL, LEV: 128 µg/mL) and a KPC-3-producing K. 
pneumoniae (MICs AMK: 32 µg/mL, DOR: 32 µg/mL, RIF: >256 µg/mL, LEV: 8 µg/mL). 
Clinically obtainable concentrations (AMK: 4-80 µg/mL; DOR 4-32 µg/mL; LEV 0.5-10 
µg/mL; RIF 0.25-6 µg/mL) were used in combinations to determine synergy based on the 
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3-D response model and 24-hour colony count. DOR and AMK was the only combination 
determined to be synergistic; DOR and RIF, DOR and LEV, and LEV and RIF were 
additive; AMK and RIF, and AMI and LEV were antagonistic. Murine pneumonia models 
were used to confirm results obtained through the time-kill experiments and the model for 
DOR and AMK, and AMK and LEV. As predicted by the model, DOR and AMK showed 
improved survival for both isolates whereas AMK and LEV displayed inferior survival 
rates. Although limited in design, this study is one of few models that analyzed polymyxin-
sparing regimens.220 
 
Dual-carbapenem Therapy 
Doripenem and ertapenem alone and in combination were evaluated against a 
carbapenemase-producing K. pneumoniae clinical isolate (doripenem MIC 4 µg/mL; 
ertapenem MIC 64 µg/mL) using a one-compartment chemostat model. The free 
doripenem concentrations simulated a 3-hour infusion of 2 gm every 8 hours in humans, 
and the free ertapenem concentrations simulated a dose of 1 gm every 24 hours in humans. 
Adding doripenem to ertapenem extended the bactericidal activity from 6h with 
monotherapy of either agent to 16h in the combination. Doripenem levels were above the 
MIC of the organism for a majority of the dosing interval. The primary mechanism of 
interaction of these two carbapenems was that ertapenem acted as a suicide inhibitor of the 
carbapenemases, since it is most easily hydrolyzed, leaving doripenem to exact its 
bactericidal activity against CRE.221   
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Animal Studies 
KPC-producing Enterobacteriaceae 
 In both an immunocompetent and a neutropenic murine thigh model, doripenem 
was administered to simulate human administration of a 4-hour infusion of 1 gm and 2 gm 
doripenem every 8 hours. These regimens were evaluated against KPC-producing 
Klebsiella pneumoniae with doripenem MICs ranging from 4 to 32 µg/mL. 1- and 2- gm 
doses of doripenem achieved bacteristasis in both models against K. pneumoniae isolates 
with doripenem MICs up to and including 8 and 16 µg/mL, respectively. Expectedly, there 
was significantly more killing (0.5-1 CFU/mL) in the immunocompetent murine model 
compared to the neutropenic murine model at 24 hours.222 
Doripenem and ertapenem alone and in combination were evaluated against three 
KPC-producing K. pneumoniae clinical isolates (doripenem MICs 8, 16, and 32 µg/mL; 
ertapenem MICs >64 µg/mL) using a murine thigh model of both immunocompetent and 
neutropenic mice. The free doripenem concentrations simulated a 4-hour infusion of 2 gm 
every 8 hours in humans, and the free ertapenem concentrations simulated a dose of 1 gm 
every 24 hours in humans. Although a higher degree of bacterial killing was observed in 
the combination regimens when compared to monotherapy, only the combination against 
the lowest doripenem MIC isolate (MIC 8 µg/mL) in the immunocompetent mice was 
statistically significant, and only at 72 hours (not 24 or 48).223 
Meropenem, tigecycline, and polymyxin B were evaluated in a rat model alone and 
in double and triple regimen combinations (n=10 for each regimen) against KPC-2-
producing Klebsiella pneumoniae. Additionally, time-kill assays were performed on each 
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agent alone and in combination. No pharmacokinetic studies were performed to verify 
equivalent human dosing, but all combinations involving polymyxin B showed 
significantly superior results in terms of mortality (Figure 2.22) and culture clearance. 
Interestingly, meropenem and tigecycline combinations were antagonistic by time-kill 
analysis, but this interaction was seemingly overcome by the addition of polymyxin B. This 
was observed in the rat model as well, but there was not an observable advantage in triple-
combination therapy compared to polymyxin B in combination with either meropenem or 
tigecycline.224 
 
Figure 2.22: Survival Curves of Rats Infected with KPC-2-producing Klebsiella 
pneumoniae. Reprinted224  
* P-value of <0.05 compared with other groups 
** P-value of <0.05 compared with control 
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MBL-producing Enterobacteriaceae 
 Two animal models (one murine, one rabbit) have evaluated carbapenem 
monotherapy in VIM-1-producing K. pneumoniae or E. coli. In both studies, isolate MICs 
to carbapenems were relatively low (imipenem MICs ≤4 µg/mL for all but one isolate). 
Dosing regimens were selected to simulate dosing in humans and optimize T>MIC, the 
pharmacodynamic index correlating with clinical outcome.225 In both studies, carbapenems 
were effective in significantly reduced colony counts (CFU/mL) compared to placebo, but 
were either not as effective as observed in the non-VIM producing isolate,226 or were 
surpassed by aztreonam activity, which is relatively stable in the presence of MBL 
enzymes.227 These data suggest that while carbapenems are still active as monotherapy 
against MBL-producing CRE, there may be other factors than time above the MIC that 
play a role in optimizing treatment. 
 Doripenem and ertapenem as monotherapy were evaluated in a murine thigh model 
against a wild-type K. pneumoniae, and an isogenically derived NDM-1- and a KPC-2- 
producing K. pneumoniae. Four clinical isolates of NDM-1-producing K. pneumoniae were 
also included for comparison. Dosing regimens of doripenem and ertapenem simulated a 
4-hour infusion of 2 gm every 8 hours and 1 gm every 24 hours, respectively. Interestingly, 
at least 101 CFU/mL killing was observed at 24 hours for the wild-type K. pneumoniae, the 
isogenic NDM-1- and the NDM-1-producing clinical isolates with doripenem MICs ≤ 8 
µg/mL. However, the isogenic KPC-producing K. pneumoniae showed growth (Figure 
2.23), despite a 4-fold lower MIC to ertapenem and doripenem.228 The results of the KPC-
producing isolate were consistent however with previous work performed in this lab.223 
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Figure 2.23: Change in log10 CFU/mL after 24 Hours. Reprinted228 
Wild-type K. pneumoniae strain and its derived isogenic strains harboring either an NDM-
1 or a KPC-2 plasmid after treatment with either doripenem at 2 gm every 8 hours (black) 
or ertapenem at 1 gm every 24 hours (white) in an immunocompetent mouse thigh infection 
model. Each value is the mean ± standard deviation for infected thighs for each isolate. 
 
OXA-48-producing Enterobacteriaceae 
Doripenem, ertapenem, ceftazidime, and levofloxacin were evaluated in a murine 
thigh model against an isogenic pair of wild-type K. pneumoniae and OXA-48-producing 
K. pneumoniae as well as six OXA-48-producing Enterobacteriaceae clinical isolates, with 
and without other ESBLs (doripenem MICs 0.38 - 8 µg/mL). Levofloxacin, ertapenem and 
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ceftazidime exhibited efficacy correlating with pharmacodynamic targets and in vitro MIC. 
However, similar to experiments involving isolates producing NDM-1,228 the observed 
efficacy of doripenem treatment was surprising. However, whereas doripenem seemed 
efficacious against low-MIC NDM-1-producing isolates,228 there was variable efficacy 
observed by doripenem across all OXA-48-producing isolates, despite achieving the 
pharmacodynamic target of at least 40% T>MIC.225 It was concluded by the authors that 
genotypic expression may be more important than phenotypic MIC and pharmacodynamic 
targets in selecting appropriate therapy.229 
 
Other Studies 
In a rather unique study, gene transcription levels of carbapenemase enzymes were 
analyzed in clinical isolates harboring either CTX-M-15 (ESBL; 1 K. pneumoniae and 1 
E. coli), OXA-48 (E. coli), NDM-1 (K. pneumoniae) or KPC-2 (Salmonella spp.) after 
infecting mice or inoculating test tubes. The aim of the study was to determine 
carbapenemase enzyme induction, inhibition, or lack of effect by single antimicrobials or 
combinations. For the mice studies, rifampin alone, colistin alone and colistin in 
combination with ertapenem, meropenem, imipenem, fosfomycin, kanamycin, tigecycline, 
ceftazidime, or rifampin were evaluated. For in vitro studies, colistin, meropenem, rifampin 
and tigecycline alone were evaluated as well as colistin in combination with meropenem, 
fosfomycin, rifampin, or tigecycline.230 
The authors listed likely beneficial combinations based on carbapenemase 
transcription levels observed in vitro and in vivo and mortality observed in vivo according 
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to enzyme type. For OXA-48, colistin in combination with a carbapenem, rifampin, 
fosfomycin, or tigecycline seemed most beneficial, but monotherapy with any agent was 
not recommended. For NDM-1, colistin in combination with rifampin, fosfomycin, or 
tigecycline were most effective, but again, monotherapy was not recommended with any 
agent. Finally, for KPC, colistin in combination with a carbapenem, fosfomycin or 
kanamycin were most beneficial.230 
 
Human Studies 
 Reiterating, comparisons between monotherapy and combination therapy for CRE 
treatment in humans is limited by frequent retrospective design; small sample sizes; 
varying geographical locations; lack of appropriate control for confounding variables; and 
heterogeneous definitions of primary endpoints, sources of infection, infecting 
genus/species, and patient demographics. However, most recent studies (2016-present) 
conclude that combination therapy is preferred (Table 2.1). Perez et al. selectively 
compared retrospective reports of CRE bloodstream infections in hundreds of patients 
receiving either combination or monotherapy. Their analysis concluded a mortality risk 
reduction of approximately 50% when combination antimicrobials were used compared to 
monotherapy. These studies were primarily in KPC-producing K. pneumoniae and 
combinations were usually carbapenem-containing in addition to a polymyxin or 
tigecycline.14  
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Table 2.1: Summary of Monotherapy vs. Combination Therapy in Patients against CRE 
Reference Study Design 
Mechanisms of 
Resistance 
Definition 
and Rate of 
Mortality 
Significantly 
Associated 
with Survival 
Zarkotou, 201110 Retrospective KPC-2 
Infection-
related, in-
hospital; 
M: 7/15 
C: 0/20 
C 
Qureshi, 2012199 Retrospective KPC-2; KPC-3 
28-day 
M: 11/19 
C: 2/15 
C 
Tumbarello, 
2012200 Retrospective KPC-2; KPC-3 
30-day 
M: 25/46 
C: 27/71 
C 
Capone, 2013231 Prospective 
KPC-3; VIM-1; 
CTX-M-15 w/ 
porin 
In-hospital 
M: 8/37 
C: 17/54 
Neither 
Navarro-San 
Francisco, 2013232 Retrospective OXA-48 
30-day 
M: 2/7 
C: 13/27 
M* 
Balkan, 201468 Retrospective OXA-48 
28-day 
M: 2/5 
C: 16/31 
Neither 
Daikos, 2014203 Retrospective 
KPC-2; VIM-1; 
KPC-2 and 
VIM-1 
28-day 
M: 32/73 
C: 28/103 
C 
de Oliveira, 
2014233 Retrospective KPC 
30-day 
M: 21/57 
C: 32/61 
Neither 
Kontopidou, 
2014234 Retrospective 
KPC; VIM; 
KPC and VIM 
14-day 
M: 16/64 
C: 8/43 
Neither 
Chang, 2015235 Retrospective 
AmpC or ESBL 
w/ porin; KPC-
2; IMP-8; 
NDM-1; VIM-1 
30-day 
M: 7/23 
C: 5/10 
Neither 
Freire, 2015236 Retrospective KPC-2 
30-day 
M: 8/22 
C: 21/38 
Neither 
Katsiari, 2015237 Prospective KPC-2; VIM 
Infection-
related, in-
hospital 
M: 2/7 
C: 12/25 
Neither 
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Table 2.1 (continued): Summary of Monotherapy vs. Combination Therapy in Patients 
against CRE 
Reference Study Design 
Mechanisms of 
Resistance 
Definition 
and Rate of 
Mortality 
Significantly 
Associated 
with Survival 
Lowman, 2015238 Retrospective OXA-48 
In-hospital 
M: 2/6 
C: 5/13 
Neither 
Tumbarello, 
2015151 Retrospective KPC-2; KPC-3 
14-day 
M: 118/307 
C: 107/354 
C 
de Maio Carrilho, 
2016239 Prospective KPC; few other 
Infection-
related, in-
hospital 
M: 6/29 
C: 38/98 
Neither 
Gomez 
Simmonds, 
2016240 
Retrospective KPC; few other 
30-day 
M: 34/44 
C: 28/73 
Neither 
Falcone, 2016241 Retrospective KPC 
30-day 
M: 34/44 
C: 7/64 
C 
Tofas, 2016242 Retrospective KPC; n=2 VIM 
14-day 
M: 5/10 
C: 11/30 
C 
Trecarichi, 
2016243 Prospective Unspecified 
21-day 
M: 69/77 
C: 40/72 
C 
Villegas, 2016244 Retrospective KPC; VIM; NDM 
Infection-
related, in-
hospital 
M: 5/8 
C: 17/29 
Neither 
Gutiérrez-
Gutiérrez, 2017245 Retrospective 
KPC; OXA-48; 
VIM; few other 
30-day 
M: 85/208 
C: 47/135 
C 
Machuca, 2017246 Prospective KPC 
30-day 
M: 14/32 
C: 18/72 
C 
Papadimitriou-
Olivgeris, 2017247 Retrospective 
KPC; n=3 VIM; 
n=1 NDM; KPC 
and VIM 
30-day 
M: 18/57 
C: 7/38 
C 
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Table 2.1 (continued): Summary of Monotherapy vs. Combination Therapy in Patients 
against CRE 
Reference Study Design 
Mechanisms of 
Resistance 
Definition 
and Rate of 
Mortality 
Significantly 
Associated 
with Survival 
Satlin, 2017248 Retrospective 
KPC-2; KPC-3; 
n=2 NDM-1; 
n=2 OXA-48 
30-day 
M: 21/55 
C: 22/43 
Neither 
Tuon, 2017249 Retrospective Unspecified (likely KPC) 
30-day 
M: 40/66 
C: 6/17 
C 
Adapted from Tumbarello et al.124 
*High prevalence of patients presenting with less severe infections in monotherapy arm 
M-Monotherapy 
C-Combination therapy 
Despite known resistance to carbapenems, when CRE are treated with 
combinations containing a carbapenem, there appears to be added benefit on top of the 
benefit for combination therapy, particularly in strains with lower carbapenem MIC's (MIC 
≤ 8 µg/mL). Zouvelekis et al. systematically evaluated studies using monotherapy with 
carbapenems (meropenem or imipenem) and determined that the failure rate of 50 CRE 
patients across 15 studies was found to be proportional to the MIC for the respective 
carbapenem used. Note: clinical failure definitions varied from physician to physician and 
study to study. Some definitions were patient death, superinfection or reinfection with same 
organism, prolonged hospital stay, and resistance development while on antimicrobial 
therapy, but overall clinical failure was estimated to be 75% for CRE infections with 
carbapenem MICs above 8 µg/mL. This failure rate decreased to 33.3%, 28.6%, and 25% 
when carbapenem MICs were 8, 4, and 2 µg/mL or less, respectively.204 
This observation fits in the context of the PK/PD studies in humans and the 
pharmacodynamic index for carbapenems – 40% to 50% time above the MIC (T>MIC) in 
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that higher carbapenem MICs render target attainment of 50% T>MIC more difficult. It is 
estimated that for a meropenem MIC of 4 µg/mL, the probability of attaining 50% T>MIC 
is 69% for a dosing regimen of a 30 minute infusion of 1 gm every 8 hours. When a high 
dose/prolonged infusion is used (e.g. 3-hour infusion of 2 gm every 8 hours), the 
probability of target attainment increases to 100%. When the MIC is 8, the probability of 
attaining 50% T>MIC of a high dose/prolonged infusion of meropenem is 85%.250 
Adding to the evidence of carbapenem-based combination regimens are two articles 
evaluating CRE treatment in Greece. For the first study, 103 K. pneumoniae isolates 
producing either VIM or KPC were treated with combination therapy (30% carbapenem-
based) and 72 isolates were treated with monotherapy and mortality was significantly lower 
in the combination therapy group (27.2% vs. 44.4%, p=0.018). Lower mortality was 
observed for carbapenem-containing regimens when compared to regimens without 
carbapenems (19.3% vs. 30.6%).203 For the second study, 132 VIM-producing K. 
pneumoniae and 102 KPC-producing K. pneumoniae isolates were included across nine 
studies where it was determined combination therapy was superior to monotherapy (p = 
0.01; odds ratio 2.41; 95% confidence interval 1.2-4.7) and those regimens that included 
carbapenems were associated with a 6.7% failure rate compared to a 26.9% failure rate of 
those regimens without a carbapenem (P-value 0.04).185 
In Italy, 14 day mortality was assessed in 661 patients with KPC-producing K. 
pneumoniae. Independent predictors of 14 day mortality were determined to be 
bloodstream infection, presentation with septic shock, inadequate empirical antimicrobial 
therapy, chronic renal failure, high APACHE III score, and colistin resistance. 
Combination therapy with at least two drugs showing in vitro activity against the isolate 
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was associated with lower mortality (odds ratio 0.52; (95% confidence interval 0.35-0.77). 
Combinations that included meropenem were associated with significantly higher survival 
rates when the meropenem MIC was ≤ 8 µg/mL.151 
A review article of published case reports and case series from 2001-2011 included 
105 total cases of KPC-producing infections (101 of which were Enterobacteriaceae). 
Cases receiving monotherapy were 49 (47%) whereas cases receiving combination therapy 
were 56 (53%), 19 (34%) of which included a carbapenem. Treatment failure was 
associated more with monotherapy than combination therapy (49% vs. 25%; p = 0.01). 
Other significant differences were between monotherapy vs. combination therapy 
involving pulmonary infections, polymyxins, or carbapenems, (Table 2.2).201 
Table 2.2 Treatment Failure: Monotherapy vs. Combination Therapy. 
 Monotherapy (%) Combination (%) P 
Overall Treatment Failure 24/49 (49) 14/56 (25) 0.01 
Source:    
Blood 12/24 (50) 9/32 (28) 0.09 
Pulmonary 10/15 (67) 5/17 (29) 0.03 
Urine 1/8 (13) 0/3 (0) 0.4 
Polymyxin Treatment Failure 8/11 (73) 10/34 (29) 0.02 
Carbapenem Treatment Failure 12/20 (60) 5/19 (26) 0.03 
Tigecycline Treatment Failure 2/7 (29) 7/19 (37) 0.4 
Aminoglycoside Treatment Failure 0/6 (0) 4/24 (17) 0.6 
Reprinted201 
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Another review article systematically obtained CRE case reports, case series, and 
observational studies from the across the globe (e.g. U.S., Spain, Ireland, Columbia, China, 
Israel, Brazil, Taiwan, Switzerland, and Greece). A total of 301 patients infected with 
Klebsiella pneumoniae were identified, about half KPC-producing and half MBL-
producing. Patients were stratified into seven groups based on treatment regimens (Figure 
2.21). Once more, combination therapy with a carbapenem was significantly superior to 
alternative combinations analyzed.204 
  
Figure 2.24: Outcomes of Infections Caused by Carbapenemase-producing Klebsiella 
pneumoniae, According to Treatment Regimen. Reprinted204  
Regimen A, combination therapy with ≥2 active drugs, one of which was a carbapenem; 
regimen B, combination therapy with ≥2 active drugs, not including a carbapenem; 
regimen C, monotherapy with an aminoglycoside; regimen D, monotherapy with a 
carbapenem; regimen E, monotherapy with tigecycline; regimen F, monotherapy with 
colistin; regimen G, inappropriate therapy. Regimen A was superior to regimens B, E, F, 
and G (for A versus B, E, F, and G, the P value was 0.02, 0.03, <0.0001, and <0.0001, 
respectively). Regimens B, C, and D were superior to regimen G (for B versus G, P = 
0.014; for C versus G, P = 0.04; and for D versus G, P = 0.03).  
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Finally, another recent meta-analysis by Zusman et al. indicated that antimicrobial 
combinations containing a polymyxin antimicrobial are associated with lower mortality 
than polymyxin monotherapy for carbapenem-resistant infections.251 This study combined 
the results of 22 other studies, including 3 randomized controlled clinical trials, without 
heterogeneity, for a total of 537 patients. Some limitations do exist regarding the 
applicability of these data to CRE, however. Specifically, all three randomized controlled 
trials included in the meta analysis were primarily treating Acinetobacter spp. Next, very 
low quality (but certainly not low quantity) evidence support polymyxin combination 
therapy over polymyxin monotherapy against carbapenem-resistant Enterobacteriaceae. 
Few human studies have evaluated fosfomycin against CRE. One is a multicenter 
case-series of 41 carbapenemase-producing K. pneumoniae and 17 carbapenemase-
producing P. aeruginosa. Fosfomycin (median dose 24g/day) was usually combined with 
either colistin or tigecycline with a clinical success rate at day 14 of 54%. 28 day mortality 
was 37.5%. Interestingly, resistance to fosfomycin developed in only three cases.183 The 
second study followed 11 ICU patients infected with fosfomycin susceptible, carbapenem-
resistant K. pneumoniae where fosfomycin was administered in combination with colistin 
(6 patients), gentamicin (3 patients), or piperacillin/tazobactam (1 patient). The 
combination used for the 11th patient was not mentioned by the authors. All-cause in-
hospital mortality was 18.2% (2/11 ICU patients).252  
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Recently Approved Antimicrobials against Carbapenem-resistant Enterobacteriaceae 
 
Ceftazidime/avibactam 
 Ceftazidime/avibactam was the first beta-lactam/beta-lactamase inhibitor 
combination with activity against CRE, and the FDA approved its use in February 2015. 
Its spectrum of activity is similar to ceftazidime (i.e. wild-type Enterobacteriaceae and 
Pseudomonas spp.) but avibactam (a diazabicyclooctanase)253 adds Ambler class A254 and 
D255 carbapenemase-producing Enterobacteriaceae in addition to ESBL-producing 
Enterobacteriaceae with porin channel mutations to the spectrum.254 However, limited 
activity against MBLs has been observed. Ceftazidime/avibactam has also been tested in 
vitro against KPC-producing isolates with OmpK36 porin channel mutations. All 72 KPC-
producing isolates studied were resistant to ceftazidime (MICs >64 µg/mL) but tested 
susceptible (ceftazidime MICs <4 µg/mL) with the addition of avibactam.256 
 Shields et al. published a landmark retrospective study comparing for the first time 
ceftazidime/avibactam with (n=5) or without (n=8) gentamicin to conventional treatment 
against CRE.257 Most isolates (106/109) harbored KPC-2 or KPC-3 enzymes, and 
conventional treatment was primarily a carbapenem with an aminoglycoside (CB +AG; 
n=25), a carbapenem with colistin (CB+COL; n=30), or other therapies including some 
monotherapy. Clinical success was defined as 30-day survival, resolution of signs and 
symptoms of infection, sterilization of blood cultures within 7 days of treatment initiation, 
and absence of recurrent infections (Figure 2.25). 
 
62 
 
 
Figure 2.25: 30-day Clinical Success Across Treatment Regimens. Reprinted.257 C-A – 
ceftazidime/avibactam; CB + AG – carbapenem + aminoglycosides; CB + COL – 
carbapenem + colistin; other – aminoglycoside, carbapenem, colistin, tigecycline, or 
ciprofloxacin monotherapy or colistin/tigecycline combination therapy 
 
 However, a follow-up study has reported ceftazidime/avibactam resistance in 3/10 
recurrent infections in patients previously treated with ceftazidime/avibactam258 due to 
mutations in the blaKPC-3 gene.259 Additional data are needed to determine how rapid 
ceftazidime/avibactam resistance develops, the occurrence frequency of 
ceftazidime/avibactam resistance, and whether this phenomenon is associated with 
ceftazidime/avibactam monotherapy, inappropriate dosing, or high-inoculum infections. A 
more complete overview of clinical data with ceftazidime/avibactam is presented by 
Rodriguez-Bano et al.260 
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Meropenem/vaborbactam 
 Meropenem/vaborbactam was the next antimicrobial agent approved by the FDA 
(August 2017) to combat infections caused by CRE and was the first carbapenem/beta-
lactamase inhibitor combination. In fact, the randomized, controlled clinical trial (TANGO 
2) was terminated early after an interim analysis showed superiority of 
meropenem/vaborbactam compared to best available therapy. Its spectrum of activity 
includes all organisms for which meropenem alone exhibits activity, and vaborbactam adds 
activity against organisms producing Ambler class A carbapenemases (i.e. KPC). Unlike 
ceftazidime/avibactam, very limited activity is seen against organisms producing class D 
enzymes. Vaborbactam also does not restore activity to meropenem in isolates expressing 
MBL enzymes, so alternative approaches are warranted in this case. TANGO 2 is 
continuing to recruit patients in the meropenem/vaborbactam arm to gather additional data, 
and observational studies are lending further support to its superiority over best available 
therapy (e.g. combinations of conventional antimicrobial agents). However, data is still 
very much limited at this time. Additional information on this novel antimicrobial is 
discussed by Cho et al.261 
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Summary 
1. CRE are among the top threats in infectious disease according to the CDC and the 
President's Advisory Council on Combating Antibiotic-Resistant Bacteria.11 
 
2. CRE are present throughout the world, but the characteristics of carbapenem resistance 
can vary widely depending on the country, state, or even acute care center. Within the 
U.S., KPC-producing Enterobacteriaceae compose 80% of CRE cases.14 
 
3. Significant mortality is associated with CRE infection, ranging from 24-70%.1-10 
 
4. CRE are challenging to treat, often only being susceptible to polymyxins, fosfomycin, 
tigecycline, and sometimes aminoglycosides for which there are limited data from 
randomized controlled trials directing antimicrobial therapy. 
 
5. A review of the literature favors combination therapy, usually with a carbapenem 
and/or a polymyxin, but type of carbapenemase and appropriate pharmacodynamic 
targets likely play a significant role on optimal therapy. 
 
6. There are few antimicrobials in development against CRE, and those that have been 
approved have limited data guiding their appropriate use against CRE. 
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Hypotheses 
1. Different antimicrobial susceptibility testing methods can be utilized to evaluate and 
characterize antimicrobial activity against carbapenem-resistant Enterobacteriaceae 
 
2. Novel carbapenemase inhibitor combinations, tigecycline, and the polymyxins would 
exhibit high activity against carbapenem-resistant Enterobacteriaceae 
 
3. Whole genome sequencing and phenotypic assays to identify resistance mechanisms can 
guide appropriate selection of antimicrobial therapy 
 
4. Antimicrobial agents used alone against carbapenem-resistant Enterobacteriaceae would 
be insufficient to prevent bacterial growth and prevent the emergence of resistance 
 
5. Meropenem in combination with polymyxin B or an aminoglycoside would exhibit 
synergistic, bactericidal activity against carbapenem-resistant Enterobacteriaceae having 
low and high levels of carbapenem resistance, described by the minimum inhibitory 
concentration of meropenem 
 
6. Sequencing and timing of antimicrobials in combination and the degree of carbapenem 
resistance will impact the observed interaction 
 
7. A pharmacodynamic mathematical model can describe observed behavior of carbapenem-
resistant Enterobacteriaceae under variable antimicrobial conditions  
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Specific aims 
1. To evaluate the activity of novel and conventional antimicrobial agents against 
carbapenem-resistant Enterobacteriaceae clinical isolates from the University of Kentucky 
Chandler Hospital using broth microdilution, Etest®, disk diffusion, and the BD Phoenix™ 
system 
2. To assess genotypic and phenotypic expression of antimicrobial resistance mechanisms by 
whole genome sequencing and disk diffusion methodology and their association with 
corresponding antimicrobial activity 
3. To describe the growth of different carbapenem-resistant Enterobacteriaceae when 
exposed to meropenem, amikacin, and polymyxin B alone and in combination at various 
concentrations using time-kill assays and microfiltration techniques 
4. To mathematically model the pharmacodynamic relationship of meropenem and 
polymyxin B against Enterobacteriaceae that represent different degrees of carbapenem 
resistance, indicated by the meropenem minimum inhibitor concentration 
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Chapter Three: 
 
Methods 
Part of the research contained within this chapter has been published as 
Kulengowski, B. In vitro activity of polymyxin B and meropenem alone and in 
combination against carbapenem-resistant Enterobacteriaceae. 2016. Theses and 
Dissertations—Pharmacy. 57. 
In Vitro Susceptibility Testing 
Antimicrobial Agents 
 Antimicrobial powders were obtained from the manufacturers or supply companies 
listed in Table 3.1. After adjusting for potency, these powders were used in all studies. 
Table 3.1: Sources of Antimicrobial Powders 
Antimicrobial Manufacturer/Supply Company 
Amikacin Sigma-Aldrich® St. Louis, MO 
Aztreonam Sigma-Aldrich® St. Louis, MO 
Cefepime USP Rockville, MD 
Ceftazidime Sigma-Aldrich® St. Louis, MO 
Colistin Sigma-Aldrich® St. Louis, MO 
Ertapenem Sigma-Aldrich® St. Louis, MO 
Gentamicin Sigma-Aldrich® St. Louis, MO 
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Table 3.1 (continued): Sources of Antimicrobial Powders 
Antimicrobial Manufacturer/Supply Company 
Imipenem Sigma-Aldrich® St. Louis, MO 
Levofloxacin Sigma-Aldrich® St. Louis, MO 
Meropenem USP Rockville, MD 
Minocycline Sigma-Aldrich® St. Louis, MO 
Nitrofurantoin Sigma-Aldrich® St. Louis, MO 
Piperacillin Sigma-Aldrich® St. Louis, MO 
Polymyxin B Sigma-Aldrich® St. Louis, MO 
Relebactam Merck & Co. Kenilworth, NJ 
Tazobactam LKT Laboratories, Inc. St. Paul, MN 
Tigecycline Sigma-Aldrich® St. Louis, MO 
Tobramycin Sigma-Aldrich® St. Louis, MO 
 
Antimicrobial Solution Preparation 
 Stock solutions were prepared for each antimicrobial agent using CLSI 
recommended diluents (usually sterile water).262 For water sterilization, filtered water (Q-
POD® Millipore using a 0.22 µm Millipak® 40 filter; Merck KGaA, Darmstadt, Germany) 
was autoclaved at 121˚C for 30 minutes in 1 L batches. Primary stock solutions were 
prepared using the antimicrobial powders described previously (see Antimicrobial Agents). 
10 mL of each antimicrobial agent was prepared using a volumetric flask (Kimax® 10 mL 
volumetric flask; Kimble; Cole-Parmer®, Vernon Hills, IL) and powder was weighed using 
an analytical balance (Mettler AE200, Figure 3.1; Marshall Scientific, Hampton, NH) 
according to purity (Table 3.2).   
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Figure 3.1: Analytical Balance; Marshall Scientific, Hampton, NH. 
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Table 3.2: Primary Antimicrobial Stock Solutions 
Antimicrobial Powder (mg) Potency (mg/mg) Concentration (mg/mL) 
Amikacin 263.9 0.776 20.48 
Aztreonam 212.7 0.963 20.48 
Cefepime 124.0 0.826 10.24 
Ceftazidime 232.2 0.882 20.48 
Colistin 32.7 0.783 2.56 
Ertapenem 26.6 0.962 2.56 
Gentamicin 78.0 0.655 5.12 
Imipenem 59.1 0.866 5.12 
Levofloxacin 12.9 0.99 1.28 
Meropenem 5.39 0.95 5.12 
Minocycline 28.7 0.892 2.56 
Nitrofurantoin 205 0.999 20.48 
Piperacillin 216.5 0.946 20.48 
Polymyxin B 34.4 0.745 2.56 
Relebactam 16.0 1.0 1.6 
Tazobactam 16.1 0.994 1.60 
Tigecycline 12.9 0.994 1.28 
Tobramycin 55.23 0.927 5.12 
  
Exceptions to using sterile water as the only diluent include the following 
antimicrobials: aztreonam, cefepime, ceftazidime, ertapenem, imipenem, and 
nitrofurantoin. Aztreonam stock was made by dissolving the weighed powder into a 
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saturated sodium bicarbonate solution and then filling the rest of the volumetric flask with 
sterile water. Cefepime was dissolved in a 0.1 M phosphate buffer at pH 6. Ceftazidime 
was dissolved in a solution containing sodium carbonate in an amount equal to 10% of the 
ceftazidime powder after correcting for purity (Table 3.2). Ertapenem and imipenem were 
dissolved in a 0.01 M phosphate buffer at pH 7.2. Nitrofurantoin was dissolved in DMSO. 
Phosphate buffer stock solutions were previously prepared from a 1 M dibasic 
potassium phosphate solution (Dry Powder; Sigma-Aldrich®, St. Louis, MO) and a 1M 
monobasic potassium phosphate solution (Dry Powder; Sigma-Aldrich®, St. Louis, MO) 
using proportions outlined in Table 3.3, and subsequently diluted in sterile water to 0.1 M 
or 0.01 M appropriately. Primary stock solutions were frozen at -20˚C until needed for an 
experiment, frozen and thawed no more than 5 times, and were not used beyond 1 month 
after making.263 
Table 3.3: Preparation of 1 M Phosphate Buffer Solution 
pH Volume of 1 M  K2HPO4 (mL) 
Volume of 1 M  
K1H2PO4 (mL) 
6.0 0.132 0.868 
7.2 0.717 0.283 
8.0 0.940 0.060 
 
All prepared antimicrobial stock solutions were stored in plastic conical vials (15 
mL polypropylene conical centrifuge tubes; USA Scientific, Ocala, FL). Secondary stock 
solutions were prepared using 9 parts broth to 1 part primary stock solution on the day of 
testing in similar plastic conical vials and used immediately following preparation. For 
antimicrobials that were to be on the same 96-well tray as antimicrobials requiring 
inhibitors (e.g. piperacillin or imipenem), 8.75 parts broth was used to 1.25 parts primary 
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stock to account for the extra 25 µL of volume at the end of the experiment (see Broth 
Microdilution Procedure). Inhibitors required being diluted 99 parts broth to 1 part primary 
stock solution due to the minimum weighable quantity of the analytical balance used and 
the low concentration (4 mg/L) needed in each well (see Broth Microdilution Procedure). 
Table 3.4 contains secondary stock concentrations assuming antimicrobials were diluted 
1:10 using broth. See Broth Microdilution Procedure for addition of antibiotics to the 
microtiter trays (Costar® non-treated, sterile, polystyrene 96-well; Sigma-Aldrich®, St. 
Louis, MO). 
Table 3.4: Antimicrobial Secondary Stock Concentrations and Testable MIC range 
Antimicrobial Concentration (mg/mL) Concentration Range (mg/L) 
Amikacin 2.048 0.25 – 512 
Aztreonam 2.048 0.25 – 512 
Cefepime 1.024 0.125 – 256 
Ceftazidime 2.048 0.25 – 512 
Colistin 0.256 0.03 - 64 
Ertapenem 0.256 0.03 - 64 
Gentamicin 0.512 0.06 – 128 
Imipenem 0.512 0.06 – 128 
Levofloxacin 0.128 0.015 - 32 
Meropenem 0.512 0.06 – 128 
Minocycline 0.256 0.03 - 64 
Nitrofurantoin 2.048 0.25 – 512 
Piperacillin 2.048 0.25 – 512 
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Table 3.4 (continued): Antimicrobial Secondary Stock Concentrations and Testable 
MIC range 
Polymyxin B 0.256 0.03 - 64 
Relebactam 0.016 4 
Tazobactam 0.016 4 
Tigecycline 0.128 0.015 - 32 
Tobramycin 0.512 0.06 – 128 
 
 
Bacterial Isolates 
 Clinical isolates of 612 non-duplicate, multidrug resistant (MDR), gram-negative 
organisms were collected between November 9, 2008 and October 1, 2018 from the 
Clinical Microbiology Laboratory at the University of Kentucky Chandler Medical Center 
in Lexington, Kentucky. All isolates were cultured and identified during routine testing in 
the clinical laboratory according to guidelines from the Clinical and Laboratory Standards 
Institute (CLSI).264 All isolates were frozen at -80˚C in 10% glycerol in water solution until 
needed for study.265 Multidrug resistance was defined as non-susceptibility to at least one 
agent in three or more antibiotic classes.166 Isolates were designated carbapenem-resistant 
Enterobacteriaceae (CRE) if they were Enterobacteriaceae with documented 
carbapenemase production or non-susceptibility to any of the carbapenem antimicrobials 
(ertapenem, imipenem, meropenem, or doripenem; Table 3.10).79  
 Each isolate was subcultured twice in cation-adjusted Mueller-Hinton broth 
(CAMHB) prior to conducting experiments to ensure log phase growth. Inoculation of 
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conical tubes (15 mL polypropylene conical centrifuge tubes; USA Scientific, Ocala, FL) 
containing approximately 5 mL of CAMHB was accomplished using a sterile loop 
applicator (Fisherbrand™; ThermoFisher Scientific, Waltham, MA). These cultures were 
then incubated at 35˚C in a shake incubator (Figure 3.2; MaxQ 6000; ThermoFisher 
Scientific, Waltham, MA) at 220 oscillations per minute until turbid. All isolate 
manipulations were performed in the Lee T. Todd, Jr. Building (TODD), formerly 
Biological-Pharmaceutical Complex (BPC), room 374B. ATCC® quality control (QC) 
organisms were used: E. coli ATCC® 25922, P. aeruginosa ATCC® 27853,  K. pneumoniae 
ATCC® 700603, K. pneumoniae ATCC® BAA-1705, K. pneumoniae ATCC® BAA-1706, 
K. pneumoniae ATCC® BAA-2146, and E. coli NCTC 13846. The QC E. coli and P. 
aeruginosa strains are recommended for antimicrobial susceptibility testing on 
Enterobacteriaceae. QC K. pneumoniae 700603 is a negative control for MBL testing by 
Etest® (Etest® Procedure) and MBL/KPC phenotypic testing (Modified Disk Diffusion 
Procedure for the Detection of MBL and KPC Enzymes).262 QC K. pneumoniae 1705, 
1706, and 2146 are additional control strains for MBL/KPC phenotypic testing (Modified 
Disk Diffusion Procedure for the Detection of MBL and KPC Enzymes).266 Respectively, 
these are KPC positive, wild type, and NDM positive controls. There was no available 
ATCC control strain that produces both a KPC and MBL enzyme at the time of study. QC 
E. coli NCTC 13846 is an mcr-1 positive control strain for polymyxin B resistance.267 
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Figure 3.2: MaxQ 6000; ThermoFisher Scientific, Waltham, MA. 
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Broth Microdilution Susceptibility Testing 
In vitro susceptibility testing was performed in duplicate on at least two separate 
occasions using broth microdilution according to CLSI guidelines (see Broth Microdilution 
Procedure and Minimum Inhibitory Concentration (MIC) Determination).264 Broth 
microdilution susceptibility testing was performed on 122 CRE as part of an investigator 
proposed research study funded by Merck and Co. (MISP #56367). MICs were determined 
for amikacin, gentamicin, tobramycin, colistin, polymyxin B, minocycline, tigecycline, 
ertapenem, meropenem, imipenem, levofloxacin, nitrofurantoin, cefepime, ceftazidime, 
aztreonam, piperacillin/tazobactam, and a novel β-lactam/β-lactamase inhibitor 
combination – imipenem/relebactam (Figure 3.3). Quality control organisms used in each 
experiment were E. coli ATCC® 25922 or P. aeruginosa ATCC® 27853 according to CLSI 
guidelines.268  
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          High Drug Concentration……….Low Drug Concentration  
Figure 3.3: Broth Microdilution 96-well Microtiter Tray. The green box surrounds a wells 
without visible antimicrobial growth. The red box surrounds wells with visible 
antimicrobial growth. The yellow circle indicates the well containing the lowest tested 
concentration of antimicrobial that inhibited bacterial growth to the unaided eye.   
MIC 
 NO GROWTH GROWTH 
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Automated Susceptibility Testing 
 BD Phoenix™ (Becton, Dickinson and Company; Franklin Lakes, NJ) is an 
automated system designed to identify the organism and perform antimicrobial 
susceptibility testing (Figure 3.4). The University of Kentucky Clinical Microbiology 
Laboratory evaluated each isolate with BD Phoenix™ in order to obtain MICs for 
amikacin, ampicillin, ampicillin/sulbactam, aztreonam, cefazolin, cefepime, cefoxitin, 
ceftazidime, ceftriaxone, cefuroxime, ciprofloxacin, ertapenem, gentamicin, levofloxacin, 
meropenem, nitrofurantoin, piperacillin/tazobactam, tetracycline, tobramycin, and 
sulfamethoxazole/trimethoprim. This data was originally reported for clinical use in the 
management of patients infected with these isolates. This data is available in Appendix A. 
 
Figure 3.4: BD Phoenix™; Bection, Dickinson and Company, Franklin Lakes, NJ. 
Reprinted269  
79 
 
Kirby-Bauer Disk Diffusion Susceptibility Testing 
 Kirby-Bauer disk diffusion was used to evaluate susceptibility of CRE isolates to 
ceftazidime/avibactam according to CLSI guidelines because avibactam powder was not 
commercially available for study.270 This method does not measure MICs, but instead 
indicates whether isolates are susceptible, intermediate, or resistant to the antibiotic of 
choice based on the diameter of the zone of inhibition (see Kirby-Bauer Disk Diffusion 
Procedure and Figure 3.5). P. aeruginosa ATCC® 27853 was used as a quality control 
strain. A modified disk diffusion assay was also utilized to detect whether isolates produce 
KPC, MBL, both, or neither enzyme (see Modified Disk Diffusion Procedure for the 
Detection of MBL and KPC Enzymes).266 K. pneumoniae ATCC® 700603, K. pneumoniae 
ATCC® BAA-1705, K. pneumoniae ATCC® BAA-1706, and K. pneumoniae ATCC® 
BAA-2146 were used as quality control strains. 
 
 
 
 
 
 
 
Figure 3.5: Kirby-Bauer Disk Diffusion.  
Zone of Inhibition 
Bacterial 
Growth 
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Etest® Susceptibility Testing 
Etest® strips (bioMérieux, Inc., Durham, NC) were utilized to detect metallo β-
lactamase (MBL) production in CRE isolates non-susceptible to ceftazidime/avibactam 
from Kirby-Bauer testing (see Kirby-Bauer Disk Diffusion Susceptibility Testing). Etest® 
strips were also utilized to measure MICs (Figure 3.6) like broth microdilution and were 
used for comparing polymyxin B MICs measured by Etest® to polymyxin B MICs 
measured by broth microdilution (see Polymyxin B Etest® Compared to Gold-standard 
Broth Microdilution in Carbapenem-resistant Enterobacteriaceae Exhibiting a Wide 
Range of Polymyxin B MICs).271 Klebsiella pneumoniae ATCC® 700603 was used as a 
quality negative control for MBL Etest® strips, and P. aeruginosa ATCC 27853 and E. coli 
NCTC 13846 were used as quality control organisms for polymyxin B MIC testing with 
Etest® strips. 
 
 
 
 
 
 
Source: bioMérieux, Inc., Durham, NC 
Figure 3.6: Doripenem Etest®. 
  
Zone of inhibition 
Bacterial growth 
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Glassware, Plastic Tubing, and Pipette Tip Preparation 
 All glassware and autoclavable plastic were either provided pre-sterilized by the 
manufacturer or were sterilized by autoclave at 121°C for at least 20 minutes and verified 
by autoclave indicator tape (Fisherbrand™, ThermoFisher Scientific, Waltham, MA) and 
corresponding autoclave quality control reports prior to their utilization in experiments. 
Equipment that could not be autoclaved (e.g. automated plate pourer or the laser colony 
counter) was sterilized by 70% ethanol in a spray bottle. A dispenser (Oxford®; Cole-
Parmer®, Vernon Hills, IL) was sterilized by two 70% ethanol washes followed by two 
0.22 µm filtered (Millipak® 40 filter; Merck KGaA, Darmstadt, Germany), distilled water 
washes and verified by negative growth of water dispensed onto an agar plate. A pipette 
controller (Ovation® Ali-Q™; VistaLab, Brewster, NY) that utilized disposable serological 
pipettes eventually removed the necessity of the previously mentioned Oxford dispenser. 
 
Media Preparation 
Cation-adjusted Mueller-Hinton broth (Difco™; Becton Dickinson, Sparks, MD) 
was used for antimicrobial dilution and bacterial culture. Preparation involved dissolving 
21 grams of broth powder in 1 liter of filtered, distilled water (Q-POD® Millipore using a 
0.22 µm Millipak® 40 filter; Merck KGaA, Darmstadt, Germany). The solution was then 
autoclaved at 121˚C for 30 minutes. The manufacturer reports reconstituted Mueller-
Hinton broth solutions are stable for up to one year after reconstitution (Becton, Dickinson 
and Company; personal communication, February 24, 2016). However, broth was typically 
utilized within one to two weeks of reconstitution. 
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A 10 mg/mL stock solution of calcium and a 10 mg/mL stock solution of 
magnesium were prepared by adding 3.68 g of CaCl2*2H2O to 100 mL of filtered, distilled 
water and adding 8.36 g of MgCl2*6H2O to 100 mL of filtered, distilled water. Each stock 
solution was filter sterilized again using a 0.22 micron filter (Corning® 150 mL Bottle Top 
Filter 0.22 µm; Corning Inc., Corning, NY). For every liter of Mueller-Hinton broth, 2.5 
mL of calcium chloride stock solution and 1.25 mL of the magnesium sulfate stock solution 
were added for a final concentration of 25 mg/L calcium chloride and 12.5 mg/L 
magnesium sulfate. 
Mueller-Hinton agar (Difco™; Becton Dickinson, Sparks, MD) was prepared by 
suspending 38 grams of agar powder in 1 L of filtered, distilled water. The suspension was 
then autoclaved at 121˚C for 30 minutes. Following sterilization, the suspension was 
poured by an automated machine (Figure 3.7; MP-1000 PourMatic 100mm; John Morris 
Scientific, Chatswood, Sydney, Australia) onto Petri dishes (Falcon® 100x15 mm sterile 
petri dishes; Corning Inc., Corning, NY) which were subsequently sealed in manufacturer 
supplied bags and stored in a walk-in refrigerator at 4°C until needed for use. The 
manufacturer reports Mueller-Hinton agar is stable for up to 3-5 months after reconstitution 
(Becton, Dickinson and Company; personal communication, February 24, 2016). Agar 
plates were typically utilized within one month of being reconstituted. 
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Figure 3.7: MP-1000 PourMatic® 100mm; John Morris Scientific, Chatswood, Sydney, 
Australia. 
 
 For subpopulation analysis experiments (see Subpopulation Analysis and 
Microfiltration), an extra step was added to the preparation of Mueller-Hinton agar plates. 
That is, after sterilization, but before the PourMatic® distributed the agar suspension onto 
petri dishes, antimicrobial agents were added to the agar suspension. Specifically, three 
unique types of antimicrobial plates were made – meropenem 16 µg/mL, meropenem 64 
µg/mL, and polymyxin B 4 µg/mL – by adding the appropriate volume from the primary 
stock vials (see Antimicrobial Solution Preparation). 
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 Sterilized Mueller-Hinton agar was measured in a 1000 mL graduated cylinder 
(Fisherbrand™, ThermoFisher Scientific, Waltham, MA) to the 1 L mark. A stir bar 
(Fisherbrand™, ThermoFisher Scientific, Waltham, MA) was dropped inside the cylinder 
and 3.13 mL of a 5.12 mg/mL meropenem stock solution (see Antimicrobial Solution 
Preparation) was added to the cylinder for a total concentration of 16 µg/mL meropenem. 
The agar was stirred on a hotplate (Fisherbrand™, ThermoFisher Scientific, Waltham, 
MA) for five minutes before being poured by the PourMatic® onto petri dishes which were 
subsequently sealed in manufacturer supplied bags and stored in a walk-in refrigerator at 
4°C until needed for use. This process was repeated for the other two antimicrobial 
concentrations, but 12.5 mL of 5.12 mg/mL meropenem was used for the 64 µg/mL final 
concentration and 1.56 mL of the 2.56 mg/mL stock solution of polymyxin B was used for 
the 4 µg/mL final concentration plates. 
 
Preparation of Inocula for Susceptibility Testing 
 Inocula were prepared by the McFarland Standard Method using 0.5 and 1 
McFarland standards and a Wickerham Card (Figure 3.8; ThermoFisher Scientific, 
Waltham, MA). Bacterial suspensions in log-phase growth (see Bacterial Isolates) were 
added drop-wise using an ErgoOne micropipette (Figure 3.9; USA Scientific, Ocala, FL)  
to a glass test tube (Fisherbrand™ Disposable Culture Tubes 16x125mm Borosilicate 
Glass; ThermoFisher Scientific, Waltham, MA) containing approximately 5 mL of 0.22 
micron filtered, distilled water. Using the Wickerham Card, the turbidity of the glass test 
tube was matched as closely as possible to the 0.5 McFarland standard which is 
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approximately equivalent to 1.5 x 108 CFU/mL. A spectrophotometer was not used, and 
the resulting suspension was only enumerated for Time-kill Studies, discussed later. 
 
 
Figure 3.8: Test Tube with Water, McFarland Standards and Wickerham Card; 
ThermoFisher Scientific, Waltham, MA. 
 
 
Figure 3.9: ErgoOne Micropipette; USA Scientific, Ocala, FL. 
 
86 
 
For susceptibility testing using broth microdilution, the McFarland-matched 
suspension was subsequently diluted 1:200 in two steps by first adding 100 µL to 9.9 mL 
cation-adjusted Mueller-Hinton broth, and then secondly adding 50 µL of this solution to 
50 µL of broth and antimicrobial agent during the final inoculation step of the broth 
microdilution susceptibility testing (see Broth Microdilution Procedure). For antimicrobial 
plates containing inhibitor combinations, like piperacillin/tazobactam, 50 µL of the 1:100 
diluted bacterial suspension was added to 75 µL of broth and antimicrobial agent with 
inhibitor during the final inoculation step of the broth microdilution susceptibility testing 
(see Broth Microdilution Procedure). The final bacterial concentration in each well was 
approximately 5.0 - 7.5 x 105 CFU/mL, which is acceptable according to CLSI 
guidelines.264  
For disk diffusion and Etest®, the McFarland-matched suspension was not diluted 
prior to inoculating agar plates (see Inoculation of Agar Plates). 
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Broth Microdilution Procedure 
After all necessary preparations (see Antimicrobial Solution Preparation, Media 
Preparation, and Preparation of Inocula for Susceptibility Testing), a stack of 96-well trays 
were added to the left column of the BioStack™ (Figure 3.10), sterile pipette tips were 
added to deck E, and the freshly prepared cation-adjusted Mueller-Hinton broth was added 
to each reservoir in the 4x1 reservoir. The computer that manages the Precision™ pipetting 
system is not shown in Figure 3.10, but the Precision Power™ software was launched and 
the program labeled "1 BTK Broth MIC testing (Initial 50 mcl broth only).PGM" was 
loaded and run. The arm then transferred a 96-well tray from the left column on the 
BioStack™ to deck C. The manifold picked up 12 pipette tips from deck E and aspirated 
broth from the 4x1 reservoir into each. The manifold then dispensed 50 µL into each well 
of the 96-well tray. The arm transferred the 96-well tray back to the right column of the 
BioStack™ and picked up a new plate from the left column of the BioStack™ to repeat 
this whole process for each 96-well tray. 
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Figure 3.10: BioStack™ Attached to Precision™ Pipetting System. A) The BioStack™ 
consists of the two black columns (left) which hold the unfilled and filled 96-well trays. B) 
The arm is the mechanical device that transfers 96-well trays to and from deck C. C) This 
deck holds 96-well trays for broth, antimicrobial, and organism deposition. D) This deck 
holds the 4 row by 1 column (4x1) reservoir (shown) as well as the 1x6 reservoir (not 
shown). E) This deck holds the sterile pipette tips for the manifold F. F) The manifold 
transfers fresh broth first, antibiotic second, serially dilutes the 96-well tray third, and 
lastly, adds the inoculated suspension to the 96-well tray. G) The sharps disposal container 
is placed here to catch used pipette tips. 
 
A 
B C 
 
E 
F 
G 
D 
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Once all 96-well trays contained 50µL of broth, the manifold disposed of the pipette 
tips into a waste container (placed at G) and the program terminated. The right column of 
the BioStack™ was manually exchanged with the left column, hereafter always referred to 
by relative position to each other (i.e. the old right column is now the left column) because 
each program tells the arm to pull 96-well trays from the left column. The 4x1 reservoir 
was exchanged with another 4x1 reservoir that contained a different antimicrobial agent in 
each partition of the 4x1 reservoir (see Antimicrobial Solution Preparation)  which were at 
concentrations 4x what was needed in the first well of the 96-well trays. This would, in the 
next step, provide the 8x12 tray with 2 rows of each of the 4 antibiotics in the 4x1 reservoir 
with 11 serial dilutions (Figure 3.11). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Unique 96-well Microtiter Trays. No drug present in column 12, which 
served as a positive growth control. 
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 At this point, all 96-well trays were filled with 50 µL of cation-adjusted Mueller-
Hinton broth and were in the left column of the BioStack™, ready for serial dilution of 
antimicrobials. The program "2 BTK multiDrug MIC testing (11 dilutions).PGM" was run 
which instructed the arm to take a 96-well tray from the left column BioStack™ and place 
it on deck C. The manifold picked up 12 pipette tips, aspirated 50 µL of antimicrobial 
solution into each tip from the 4x1 reservoir, and dispensed the contents into the first well. 
Following mixing (3 full dispensing and aspiration steps), 50 µL were aspirated from the 
first well and added to the second well. This dilution and mixing process repeated from 
well to well until all remaining wells (11 total) had been serially diluted and mixed. The 
12th column was skipped so it could serve as a positive growth control and the remaining 
50 µL of dilute drug solution and pipette tips were disposed of in the sharps disposal 
container (at G). The manifold next acquired 12 more sterile pipette tips while the arm 
exchanged the antimicrobial filled 96-well tray (at C) with a new one, placing the former 
into the right column BioStack™. This process repeated until all 96-well trays were filled 
with the set of antimicrobials. This program was repeated for each antimicrobial set as in 
Figure 3.11, exchanging the 4x1 reservoir for a new set of antimicrobials as needed as well 
as adding new pipette tips and changing the contents of the BioStack so that 96-well trays 
without antibiotic were on the left and the freshly serially diluted trays were set aside 
(removed from the right column). 
 For the piperacillin/tazobactam and imipenem/relebactam groups, only piperacillin 
or imipenem, respectively, was placed in the 4th row of the 4x1 reservoir to be serially 
diluted so that a constant concentration of inhibitor can be later placed into each well. Once 
this group of 96-well trays was finished, the columns of the BioStack™ were exchanged 
91 
 
and another program was loaded and run, "2.5 BTK Drug PIP TAZO MIC testing.PGM." 
However, prior to running this program, pipette tips were replaced if needed and a new 4x1 
reservoir replaced the 4x1 reservoir with rows 1-3 being filled with broth (effectively 
“placebo” inhibitor) and row 4 was filled with inhibitor at 5x the needed concentration, or 
20 mcg/mL (see Antimicrobial Solution Preparation). This program instructed the arm to 
retrieve a 96-well tray from the left column BioStack™ and place it on deck C. The 
manifold obtained 12 sterile pipette tips and aspirated broth from rows 1, 2, and 3, and 
inhibitor from row 4 of the 4x1 reservoir. 25 µL of corresponding broth or inhibitor were 
dispensed into each well, very similarly to the program that initially dispensed broth into 
each well before the serial dilutions. This program finished once all piperacillin or 
imipenem group 96-well trays had a total of 75 µL of volume in each well. 
 Once all 96-well trays had antimicrobials serially diluted across all 11 rows, each 
well now contained 50 µL of broth with antimicrobial agent (except the 
piperacillin/tazobactam or the imipenem/relebactam group trays, which contained 75 µL) 
and the 96-well trays were placed by group of common antimicrobials (Figure 3.11), one 
group at a time, in the left column of the BioStack as before. Pipette tips were replaced as 
necessary and the 4x1 reservoir was exchanged with a 1x6 reservoir which contained 6 
unique 0.5 McFarland-matched bacterial suspensions that had been diluted 1:100 (see 
Preparation of Inocula for Susceptibility Testing). 
 Before running the final program, a checklist was used to ensure that the left column 
of the BioStack contained only 1 antimicrobial group of 96-well trays and that the right 
column of the BioStack was empty to receive the completed trays. The pipette tips were 
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replaced in deck E if needed and the 1x6 reservoir contained a different bacterial 
suspension in each of the 6 compartments. 
 "3 BTK multiBug MIC testing (Lay bug 50 mcl).PGM" was loaded and run in the 
software. This program instructed the arm to add a 96-well tray to deck C and instructed 
the manifold to pick up 12 sterile pipette tips, aspirate bacterial suspension from the 1st 
column of 6 of the 1x6 reservoir and to dispense 50 µL into each of the 96 wells, finishing 
the 2nd step of the 1:200 dilution and resulting in an initial bacterial concentration of 
approximately 7.5 x 105 CFU/mL in each well. Note for plates containing the extra 25 µL 
of either broth or inhibitor, the final concentration of bacterial was approximately 6.0 x 105 
CFU/mL. The arm then placed the complete 96-well tray into the right column BioStack™ 
and retrieved another 96-well tray. The manifold disposed of the previously used pipette 
tips and obtained new ones. Following this, the 2nd column of 6 of the 1x6 reservoir was 
aspirated and 50 µL of suspension was dispensed into each well. This repeated until 6 plates 
were completed with a unique suspension in each. The program was repeated after 
replacing pipette tips if needed and changing the 1x6 reservoir for 6 new bacterial 
suspensions or a new group of antimicrobial plates if the same 6 isolates were needed to 
be plated on that set. Once all bacterial suspensions had been used for the first group of 
antimicrobial 96-well trays, these trays were placed in an incubator (Figure 3.12; 
Heratherm™ Incubator, ThermoFisher Scientific, Waltham, MA) at 35˚C and this entire 
processes was repeated again for the 2nd and 3rd group of a 96-well trays. 
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Figure 3.12: Heratherm™ Incubator; ThermoFisher Scientific, Waltham, MA. 
 
 In summary, every 96-well tray had 50 µL of cation-adjusted Mueller-Hinton broth 
aspirated into them, and a group of antimicrobial agents (Figure 3.11) were serially diluted 
across the 11 columns. Column 12 served as a growth control. 50 µL of a 1% 0.5 
McFarland-matched bacterial suspension was added to each well for a total volume of 100 
µL in each well. The only exception were the trays that had piperacillin or imipenem where 
an inhibitor was necessary. These trays which had 25 µL of 20 mg/L inhibitor or broth 
added and 50 µL of a 1% 0.5 McFarland-matched bacterial suspension for a total volume 
of 125 µL in each well. See Table 3.4 for the concentration ranges of antimicrobial agent.  
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Incubation 
 Once inoculated, all 96-well microtiter trays and Mueller-Hinton agar plates were 
sealed using the manufacturer supplied lids and incubated at 35˚C overnight for 16-24 
hours in an incubator (Heratherm™ Incubator; ThermoFisher Scientific, Waltham, MA). 
Agar plates were inverted and stacked no more than six high. 
 
Minimum Inhibitory Concentration (MIC) Determination 
 MIC is defined as the lowest concentration of antimicrobial agent required to 
completely inhibit the growth of the microorganism to the unaided eye (Figure 3.3). On the 
96-well microtiter trays, this would be a complete absence of turbidity, individual colonies, 
and stringy growth. The resulting growth by well was depicted on data sheets for each tray 
(Figure 3.13). The modal minimum inhibitory concentration (MIC) was accepted. If there 
was no modal MIC, the higher MIC was accepted unless there was categorical 
disagreement in susceptibility (e.g. isolate MICs were near the susceptibility breakpoint; 
Table 3.10). In such a case, a third or seldom fourth experiment was performed, and the 
modal MIC was then accepted. 
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Figure 3.13: Antimicrobial Susceptibility 8x12 Microtiter Data Sheet. 
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Inoculation of Agar Plates 
 After preparing the agar plates (see Media Preparation) and bacterial suspensions 
for inoculation (see Preparation of Inocula for Susceptibility Testing), a wooden, sterile, 
cotton-tipped applicator (Fisherbrand™; ThermoFisher Scientific, Waltham, MA) was 
dipped into the 0.5 McFarland-matched bacterial suspension and then rolled on the side of 
the same glass tube to remove excess suspension. The agar plate was streaked in a back-
and-forth motion as if painting the entire plate from top to bottom (Figure 3.14). The plate 
was rotated 90˚ and the same cotton swap was used to streak the plate again, but without 
dipping into the bacterial suspension a second time. This coated the agar plate with a lawn 
of bacteria. Note that CLSI recommends three streaking pattern with 60˚ turns between 
each, but a lawn was reproducible in our lab with only two passes.272 
 
  
 
 
 
 
 
 
Figure 3.14: Inoculation of Mueller-Hinton Agar Plate. 
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Kirby-Bauer Disk Diffusion Procedure 
 Following inoculation of the agar plate (see Inoculation of Agar Plates), a 
ceftazidime/avibactam (30 µg / 20 µg) impregnated disk (Actavis; Parsippany, New Jersey) 
was placed on the plate using sterile forceps (Fisherbrand™, ThermoFisher Scientific, 
Waltham, MA). The plate was then incubated (Figure 3.12; Heratherm™ Incubator; 
ThermoFisher Scientific, Waltham, MA) at 35˚C for 16-24 hours and the smallest diameter 
of the zone of inhibition (Figure 3.5) was measured in millimeters to the nearest whole 
number and recorded. Susceptibility was determined based on CLSI guidelines (≥21 mm 
susceptible; 18-20 mm intermediate; ≤17 mm resistant).262 
At the time of experiment, 152 unique MDR isolates had been collected, consisting 
of 75 CRE (Enterobacteriaceae with an ertapenem MIC >0.5 or a meropenem MIC >1). 
All 75 isolates underwent Kirby-Bauer disk diffusion testing for susceptibility to 
ceftazidime/avibactam. Isolates that had a zone of inhibition ≤ 21mm (borderline 
susceptible, intermediate, or resistant) underwent a second test to verify resistance. If a 
discrepancy between the results occurred, the test was repeated once more. 
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Modified Disk Diffusion Procedure for the Detection of MBL and KPC Enzymes 
 All 122 CRE isolates from the Merck study (MISP #56367), including the 75 
isolates that underwent ceftazidime/avibactam screening (see Kirby-Bauer Disk Diffusion 
Procedure) underwent a previously published phenotypic screening assay to determine the 
type of carbapenem resistance (i.e. KPC, MBL, both, or neither).266 Some small deviations 
from the published protocol will be discussed here. 
 A 5.12 mg/mL meropenem (MEM) stock solution was prepared as previously 
described (see Antimicrobial Solution Preparation). Phenylboronic acid (PBA; an inhibitor 
of serine carbapenemases like KPC) was dissolved in DMSO to a final concentration of 80 
mg/mL. Anhydrous EDTA (a metal chelator that inhibits MBLs like NDM, VIM, and IMP) 
was dissolved in sterile distilled water to a final concentration of 0.1 M. 
 Mueller-Hinton agar plates were prepared (see Media Preparation), bacterial 
isolates were grown and standardized 0.5 McFarland inocula were prepared (see 
Preparation of Inocula for Susceptibility Testing), plates were streaked with the 
standardized suspension (see Inoculation of Agar Plates), and four blank discs were laid 
onto the agar plates (see Kirby-Bauer Disk Diffusion Procedure), but in a diamond pattern 
rather than the center of the plate (Figure 3.15). MEM was added to each disk using 1.95 
µL of the 5.12 mg/mL MEM stock so that 10 µg of MEM was present on each disk. The 
EDTA solution was added to the left and bottom disks using 10 µL so that 292 µg would 
be present. The PBA solution was added to the right and bottom disks using 5 µL so that 
400 µg would be present. Plates were incubated for 16-24 hours (i.e. overnight) and 
interpreted according to the original study criteria.266  
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Specifically, the diameters of the zones of inhibition were measured, and the zones 
corresponding the disks containing EDTA and/or PBA were compared to the zone 
corresponding to the disk containing MEM alone. Zone differences ≥5mm were considered 
significant changes and interpreted as follows: Plates with no zones ≥5mm larger than 
MEM alone were interpreted as an isolate producing neither KPC nor MBL. Plates with 
both EDTA-containing disks ≥5mm larger than MEM alone were interpreted as an isolate 
producing MBL enzymes. Plates with both PBA-containing disks ≥5mm larger than MEM 
alone were interpreted as an isolate producing KPC enzymes. Plates with only the EDTA- 
and PBA-containing disk ≥5mm larger than MEM alone were interpreted as an isolate 
producing both MBL and KPC enzymes. See Figure 3.15. Other results were considered 
indeterminate. All isolates underwent two experiments on separate occasions, and a third 
experiment was used to choose a modal result when the first two experiments yielded 
different results or both were indeterminate. All isolates producing an MBL were 
confirmed by patient chart review or subsequent genotyping by the University of Kentucky 
Clinical Microbiology Laboratory using the Verigene® system (Luminex®, Austin, TX) 
because KPC production is the primary mechanism of resistance for CRE in the United 
States. 
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Figure 3.15: Representative Results of the Three Combined-disc Tests using discs of 
meropenem (MEM) alone and with EDTA, phenylboronic acid, or EDTA plus 
phenylboronic acid for a KPC/VIM/ESBL-possessing isolate (a), a KPC/ESBL-possessing 
isolate (b), a VIM-possessing isolate (c) and an AmpC/ESBL-possessing isolate (d). 
Reprinted.266  
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Etest® Procedure 
 Following typical preparation (see Bacterial Isolates, Media Preparation, 
Preparation of Inocula for Susceptibility Testing, and Inoculation of Agar Plates), an Etest® 
strip was placed on the plate using sterile forceps according to manufacturer protocol. The 
plate was then incubated (Heratherm™ Incubator; Figure 3.12) at 35˚C for 16-24 hours.  
MBL MP/MPI Etest® strips were interpreted as positive for MBL if 1) the MIC 
ratio of meropenem (MP) to meropenem with EDTA (MPI) was ≥8 (see Figure 3.6 for 
MIC reading of Etest®), 2) if there was a phantom zone (i.e. an extra inhibition zone 
between the MP and MPI regions; Figure 3.16), or 3) if a deformation of the MP or MPI 
ellipses was present (Figure 3.16). All CRE isolates with ceftazidime/avibactam zones of 
inhibition measuring ≤ 21mm (borderline susceptible, intermediate, or resistant; see Kirby-
Bauer Disk Diffusion Procedure) were tested for MBL production by Etest® except four 
isolates which were already known to produce MBL by PCR from information provided 
by the University of Kentucky Clinical Microbiology Laboratory.  
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Source: bioMérieux, Inc., Durham, NC 
 
Figure 3.16: MBL MP/MPI Etest® Interpretation. 
 
Selection of Bacterial Isolates for Time-kill Studies 
 Clinical isolates were selected for further testing based on the meropenem (MEM), 
amikacin (AMK), and polymyxin B (PMB) broth microdilution MICs (see Broth 
Microdilution Susceptibility Testing). For subsequent time-kill studies, four Klebsiella 
pneumoniae and four Enterobacter cloacae clinical isolates were chosen that showed PMB 
susceptibility, hereafter defined as ≤2 mg/L based on CLSI breakpoints for A. baumannii 
and P. aeruginosa and EUCAST colistin breakpoints for Enterobacteriaceae since CLSI 
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is without interpretive criteria for PMB against Enterobacteriaceae. These isolates also 
demonstrated varying degrees of MEM resistance (MEM MICs 4-128 mg/L).262 In order 
of increasing MEM resistance, the K. pneumoniae isolates selected (and MEM MICs) 
were: 34 (4 mg/L), 22 (16 mg/L), 24 (32 mg/L), and 44 (128 mg/L).273,274 These isolates 
are sometimes proceeded by “KP” to denote their genus/species. Also in order of increasing 
MEM resistance (and MEM MICs), the E. cloacae isolates were: 17 (2 mg/L), 19 (8 mg/L) 
40 (16 mg/L), and 10 (32 mg/L).275 These isolates are sometimes proceeded by “EC” to 
denote their genus/species. Isolates with MEM MICs of 16-32 mg/L and showing amikacin 
susceptibility, intermediate activity, and resistance were selected for time-kill analysis and 
were (with AMK MICs): 169 (8 mg/L), 32 (16 mg/L), 22 (32 mg/L), and 37 (64 mg/L).276 
 
Time-kill Studies 
 Time-kill experiments can be used to evaluate bacteria colony counts at various 
time points during exposure to a fixed or variable concentration of one or more 
antimicrobial agents. All time kill assays were performed at least in duplicate with a 
positive growth control and samples collected at 0, 1, 2, 4, 8, 24, and 48 hours, diluted as 
necessary, and aliquots (50µL) logarithmically plated onto Mueller-Hinton agar using a 
spiral plater (Figure 3.17; AutoPlate® spiral plater; Advanced Instruments, Inc., Norwood, 
MA), which helped control for antibiotic carryover.277 Colonies were counted using a laser 
colony counter (Figure 3.18; QCount Automated Colony Counter; Spiral Biotech, 
Advanced Instruments, Inc., Norwood, MA) with a lower limit of quantification of 102 
CFU/mL. See Time-Kill Procedure for additional details. 
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Figure 3.17: AutoPlate® Spiral Plater; Advanced Instruments, Inc., Norwood, MA. 
 
 
 
 
 
 
 
 
 
Figure 3.18: QCount Automated Colony Counter; Spiral Biotech, Advanced Instruments, 
Inc., Norwood, MA.  
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Cation-adjusted Mueller-Hinton broth was used for growth media for the selected 
bacterial isolates in log-growth phase (see Bacterial Isolates, Media Preparation, 
Preparation of Inocula for Susceptibility Testing, and Selection of Bacterial Isolates for 
Time-kill Studies). Meropenem, amikacin, and polymyxin B alone were evaluated at three 
(4, 16, and 64 mg/L), three (8, 16, and 64 mg/L), and six (0.0625, 0.125, 0.25, 1, 2, and 4 
mg/L) clinically achievable concentrations, respectively.278-280 For combination studies, 
polymyxin B concentrations of 0.25 and 1 mg/L were evaluated with all three 
concentrations of meropenem against the K. pneumoniae isolates 22, 24, 34, and 44 as well 
as the E. cloacae isolates 10, 17, 19, and 40. However, for the highly meropenem resistant 
isolate (44), polymyxin B at 4 mg/L was also evaluated in combination with the three 
concentrations of meropenem. Repeat MICs for polymyxin B were determined for 
regrowing bacteria at 24 hours (see Resistance Development Testing). Amikacin 
concentrations of 8 and 16 mg/L were evaluated with meropenem 4 and 16 mg/L against 
the E. cloacae isolates 10, 17, 19, 40 as well as isolates 22, 32, 37, and 169 (see Selection 
of Bacterial Isolates for Time-kill Studies).275,276 All time-kill data can be found in 
Appendix E.  
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Time-Kill Procedure 
 Meropenem, amikacin, polymyxin B, and combinations of meropenem/polymyxin 
B or meropenem/amikacin were added to cation-adjusted Mueller-Hinton broth (see Media 
Preparation) in conical vials (50 mL polypropylene conical centrifuge tubes; USA 
Scientific, Ocala, FL) up to a total volume of 30 mL measured by ErgoOne micropipettes 
(Figure 3.9) and a Pipet-Aid® (Figure 3.19; Drummond Scientific Co., Broomall, PA). 
Portions of the primary stock vials of antimicrobials (see Antimicrobial Solution 
Preparation) were added directly to the 50 mL conical vial according to Table 3.5 and the 
desired concentrations. 
 
 
 
 
 
 
 
Figure 3.19: Drummond Pipet-Aid®; Drummond Scientific Co., Broomall, PA. 
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Table 3.5: Time-Kill Volume Table 
Meropenem (MEM) Alone 
Antimicrobial Concentration (mg/L) 4 16 64 
Volume of 1.02 mg/mL Stock Soln. (µL) 117 469 1875 
Volume of 0.5 McFarland Soln. (µL) 150 150 150 
Volume of Broth in 50 mL vial (mL) 29.8 29.4 28.0 
Total Volume (mL) 30 30 30 
Polymyxin B (PMB) Alone 
Antimicrobial Concentration (mg/L) 0.063 0.125 0.25 1 2 4 
Volume of 1.02 mg/mL Stock Soln. (µL) 2 4 7 29 59 117 
Volume of 0.5 McFarland Soln. (µL) 150 150 150 150 150 150 
Volume of Broth in 50 mL vial (mL) 29.8 29.8 29.8 29.8 29.8 29.8 
Total Volume (mL) 30 30 30 30 30 30 
Amikacin (AMK) Alone 
Antimicrobial Concentration (mg/L) 8 16 64 
Volume of 4.1 mg/mL Stock Soln. (µL) 59 117 469 
Volume of 0.5 McFarland Soln. (µL) 150 150 150 
Volume of Broth in 50 mL Vial (mL) 29.8 29.8 29.4 
Total Volume (mL) 30 30 30 
MEM + PMB Combination* 
Meropenem Concentration (mg/L) 4 16 64 
Volume of 1.02 mg/mL MEM Soln. (µL) 117 469 1875 
Volume of 0.5 McFarland Soln. (µL) 150 150 150 
Volume of Broth in 50 mL Vial (mL) 29.7 29.4 28.0 
Total Volume (mL) 30 30 30 
MEM + AMK Combination 
Meropenem Concentration (mg/L) 4 16 64 
Volume of 1.02 mg/mL MEM Soln. (µL) 117 469 1875 
Amikacin Concentration (mg/L) 8 16 64 8 16 64 8 16 64 
Volume of 4.1 mg/mL AMK Soln. (µL) 59 117 469 59 117 469 59 117 469 
Volume of 0.5 McFarland Soln. (µL) 150 150 150 
Volume of Broth in 50 mL Vial (mL) 29.7 29.6 29.3 29.4 29.3 28.9 27.9 27.9 27.5 
Total Volume (mL) 30 30 30 
*Polymyxin B volume contribution ignored 
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After the antimicrobial agents were added to their respective conical vials, a 1:200 
dilution of the 0.5 McFarland matched suspension was made by adding 150 µL of the 
suspension to the conical vial. Immediately following this addition, the conical vial was 
mixed swiftly using the pipette tip of the ErgoOne micropipette (Figure 3.9) and a 0.5 mL 
sample was drawn and serially diluted in 1:10 dilutions in glass test tubes (Fisherbrand™ 
Disposable Culture Tubes 16x125mm Borosilicate Glass; ThermoFisher Scientific, 
Waltham, MA) containing 4.5 mL sterile water. A dispenser (Oxford®; Cole-Parmer®, 
Vernon Hills, IL) or a pipette controller (Ovation® Ali-Q™; VistaLab, Brewster, NY) was 
calibrated and used to equally measure 4.5mL volumes. Vials were then placed in a shake 
incubator (Figure 3.2) at 35˚C and 220 oscillations per minute for the remainder of the 
experiment. 
Samples were drawn by an ErgoOne micropipette (Figure 3.9) at times 0, 1, 2, 4, 
8, 24, and 48 hours. Some experiments used 3 and 6 hour time points as well. Since the 
laser colony counter (Figure 3.18) most optimally measures 103 - 105 CFU/mL, a 1:10 and 
a 1:100 dilution were made at time 0 from a 0.5 mL serially diluted sample due to an initial 
colony count of about 7.5 x 105 CFU/mL. At each time point, it was noted whether the 
conical vial contents were clear or turbid because the unaided eye can see turbidity at 
approximate 107 CFU/mL based on previous work performed in our laboratory. If clear, an 
undiluted 2.5 mL sample was drawn and a 1:100 dilution sample was made from a 0.5 mL 
serially diluted sample, both plated via spiral plater, and both placed in an incubator (Figure 
3.12). If turbid, a 1:104 and a 1:106 dilution were made from a 0.5 mL serially diluted 
sample, both plated via spiral plater, and both placed the aforementioned incubator. 
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As previously mentioned, the target measurement for the laser colony counter is 
103-105 CFU/mL and dilution choices were made based on previous time-kill studies 
performed in the laboratory. All plates incubated for 16-24 hours and were read by a laser 
colony counter. The manufacturer recommended lower limit of quantification was 102 
CFU/mL which was the colony count assumed for any time point reading less than this 
amount. 
 
Staggered Administration of Antimicrobial Agents 
When combination experiment antimicrobials were administered at times other 
than the start of the experiment (t=0), Table 3.5 was still used for the initial volumes as if 
only one drug were being administered – the antimicrobial present throughout the 
experiment (drug A). The agent administered at a later time (drug B) was added to the flask 
after sample was drawn and in sufficient volume so that the resulting concentration was as 
desired. The added drug volume (<1 mL) was less than 5% of the volume remaining in the 
flask after accounting for multiple sampling since a delay of 2 hours was used; therefore, 
no additional drug A was added to the flask.  
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Resistance Development Testing 
Following two separate time-kill studies, MIC determination by broth 
microdilution was performed on colonies growing on the 24-hour time point agar plates 
(see Time-Kill Procedure) but were tested only for changes in polymyxin B MIC (see Broth 
Microdilution Procedure). Resistance development was defined as a ≥4-fold increase in 
MIC from colonies growing at 24 hours when compared to the baseline MIC of the 
organism. An MIC > 2  was considered non-susceptible according to CLSI breakpoints for 
A. baumannii and P. aeruginosa and EUCAST breakpoints for colistin in 
Enterobacteriaceae.262,281  
 
Subpopulation Analysis and Microfiltration 
A modified time-kill procedure was used to evaluate subpopulations of the four K. 
pneumoniae isolates selected for time-kill studies (see Selection of Bacterial Isolates for 
Time-kill Studies and Time-kill Studies). The results of this study would allow us to 
explain observed regrowth in the other time-kill experiments by quantifying a particular 
subpopulation of each isolate. These subpopulations often have different MICs than the 
MIC of the majority population.140 With (only monotherapies; see Table 3.5) and without 
(growth controls) adding antimicrobial agents to the 50 mL conical vials, 29.8 mL of 
cation-adjusted Mueller-Hinton broth (see Media Preparation) with 150 µL of 0.5 
McFarland matched bacterial suspension (see Preparation of Inocula for Susceptibility 
Testing) were used for a total of 30 mL of approximately 7.5 * 105 CFU/mL of bacteria. 
Additionally, instead of using Mueller-Hinton agar plates, the antimicrobial-impregnated 
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plates were used (see Media Preparation). Finally, sampling time points were 0, 2, 3, 4, 6, 
and 24 hours. All other aspects of this modified study were like the Time-Kill Procedure. 
 It was thought that the subpopulations we wished to quantify may be below the 
lower limit of quantification (102 CFU/mL) for the laser colony counter. To address this, 
two comparable approaches were used. First, instead of using aliquots of 50 µL 
logarithmically plated by the spiral plater, a uniform 500 µL setting was used. Second, we 
implemented a process called microfiltration which involved taking a specific sample 
volume at each time point (Tables 3.5 - 3.8; Estimations of viable colony counts made by 
outside collaborator), passing sample through a 0.22 µm filter (Millipak® 40 filter; Merck 
KGaA, Darmstadt, Germany) using a vacuum filter apparatus (Figure 3.20), and then 
placing the filter (bacteria-side up) directly onto the antimicrobial-impregnated agar plate 
where nutrients could diffuse through the filter paper to the bacteria. In both cases, the 
plates were incubated (Figure 3.12) at 35˚C for 16-24 hours and then manually counted so 
that a colony count (CFU/mL) could be calculated based on the volume utilized for each 
sample. The lower limit of quantification associated with microfiltration ranges from 30-
300 CFU/mL, decreasing as larger sample volumes are used.282,283  
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Figure 3.20: Vacuum Filter Apparatus.  
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Table 3.6: Microfiltration Sample Volumes at Each Time Point for isolate 34 
 
Agar 
Plate 0 (hours) 2 (hours) 3 (hours) 4 (hours) 6 (hours) 
24 
(hours) 
MEM 16 
(µg/mL) 500 µL 500 µL 250 µL 100 µL 100 µL 
No 
sample 
PMB 4 
(µg/mL) 1000 µL 1000 µL 500 µL 250 µL 250 µL 
No 
sample 
 
 
 
Table 3.7: Microfiltration Sample Volumes at Each Time Point for isolate 22 
 
Agar 
Plate 0 (hours) 2 (hours) 3 (hours) 4 (hours) 6 (hours) 
24 
(hours) 
MEM 16 
(µg/mL) 1000 µL 500 µL 250 µL 250 µL 250 µL 
No 
sample 
PMB 4 
(µg/mL) 1000 µL 1000 µL 500 µL 250 µL 250 µL 
No 
sample 
 
 
 
Table 3.8: Microfiltration Sample Volumes at Each Time Point for isolate 24 
 
Agar 
Plate 0 (hours) 2 (hours) 3 (hours) 4 (hours) 6 (hours) 
24 
(hours) 
MEM 64 
(µg/mL) 1000 µL 500 µL 250 µL 100 µL 100 µL 
No 
sample 
PMB 4 
(µg/mL) 1000 µL 1000 µL 500 µL 250 µL 100 µL 500 µL 
 
 
 
Table 3.9: Microfiltration Sample Volumes at Each Time Point for isolate 44 
 
Agar 
Plate 0 (hours) 2 (hours) 3 (hours) 4 (hours) 6 (hours) 
24 
(hours) 
MEM 64 
(µg/mL) 100 µL 100 µL 
No 
sample 
No 
sample 
No 
sample 
No 
sample 
PMB 4 
(µg/mL) 1000 µL 1000 µL 500 µL 500 µL 250 µL 
No 
sample 
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Whole Genome Sequencing 
Seven bacterial isolates (E. cloacae strains 10, 17, 19, and 40. K. pneumoniae 
strains 22, 24, and 44) and two quality control strains (E. coli ATCC® 25922 and K. 
pneumoniae ATCC® BAA-1705) underwent whole genome sequencing to determine 
genotypic resistance mechanisms present in each isolate and to subsequently compare 
genotype and phenotype (MIC). 
 
Isolation, Purification, and Quantification of Bacterial DNA 
Cynthia Mattingly, a senior laboratory technician, subcultured and McFarland 
matched bacteria as previously described (see Bacterial Isolates and Preparation of Inocula 
for Susceptibility Testing). The volume of subcultured suspension required to match each 
isolate to a 0.5 McFarland standard was used proportionally to create solutions containing 
approximately 2 x 109 CFU/mL cells which were placed in 1.5 mL Eppendorf tubes 
(ThermoFisher Scientific, Waltham, MA). A centrifuge (Figure 3.21; ThermoFisher 
Scientific, Waltham, MA) was used to spin cells to pellets at 12,000 rpm for 10 minutes. 
The supernatant was extracted from the pellets and Qiagen DNA Mini Kits #51304 
(Qiagen, Hilden, Germany) were used according to manufacturer provided instructions for 
isolation of bacterial DNA.  
Specifically, Buffer AL was thoroughly mixed by manual shaking, 25 mL of 
ethanol (96-100%) was added to Buffer AW1, and 30 mL of ethanol (96-100%) was added 
to Buffer AW2. Buffer ATL was added to the pellets to a total volume of 180 µL each. 
Gentle mixing was conducted with an ErgoOne pipet (Figure 3.9). 20 µL of proteinase K 
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was added, mixed by a vortexer (Maxi-Mix I Type 16700 Mixer, Barnstead International, 
Dubuque, IA) every 20 minutes for one hour, and incubated (Figure X; Dry Bath Incubator, 
Fisher Scientific, Hampton, NH) at 56ºC overnight. 4 µL of RNase A (100 mg/mL) was 
added to each pellet, vortexed for 15 seconds, and incubated for 30 minutes at 70ºC. 200 
µL of Buffer AL was added to each tube which was vortexed every 30 minutes for 2 hours. 
200 µL of ethanol (96-100%) was added to each tube which was subsequently applied to a 
QIAamp Mini spin column and centrifuged at 6,000 xg for 1 minute. The spine column 
was placed in a clean collection tube and the used tube with filtrate was discarded. 500 µL 
of Buffer AW1 was added and centrifuged at 8,000 xg for 1 minute, again placing the 
column into a clean collection tube and discarded the filtrate and old tube. 500 µL of Buffer 
AW2 was added and centrifuged at 20,000 xg for 3 minutes, the column was placed in a 
clean collection tube, and the old tube with filtrate were discarded. Nothing was added to 
the clean collection tube and it was centrifuged at 20,000 xg for 1 minute. The column was 
placed in a clean 1.5 mL Eppendorf tube and the old tube and filtrate were discarded. 200 
µL of Buffer AE was added, the tube was incubated for 5 minutes at room temperature, 
and then the sample was centrifuged at 6,000 xg for 1 minute. DNA concentration and 
purity were determined using Nanodrop 2000 (ThermoFisher Scientific; Waltham, MA) 
with a goal 260/280 ratio between 1.7-2.0. DNA was stored at -20ºC until transport to UK 
Genomics Core Laboratory. 
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Figure 3.21: IEC Micromax RF Centrifuge. ThermoFisher Scientific, Waltham, MA. 
 
 
Figure 3.22: Dry Bath Incubator. Fisher Scientific, Hampton, NH.  
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Genome Sequencing and Resistance Mechanism Screening 
Barcoded Nextera libraries were generated by UK Genomics Core Laboratory 
using approximately 50 ng of each bacterial DNA sample in 
individual tagmentation reactions, according to the manufacturer’s instructions 
(Illumina, San Diego, CA). The tagmented DNA was purified using Zymo-Clean and 
Concentrator kit (Zymo Research Corp, Irvine, CA) and then used as a template in a PCR 
amplification using reagents from the Nextera kit. The amplified products were then 
purified using AMPure XP beads (Beckman Coulter, Indianapolis, IN). The concentration 
and sizes of the amplification products were determined using the Agilent Bioanalyzer 
(Agilent Technologies, Santa Clara, CA) and library quality was assessed via qPCR, using 
the KAPA library quantification kit (KAPA Biosystems, Wilmington, MA). Amplification 
conditions were as described in the manufacturer’s instructions. The libraries were then 
pooled in equimolar fashion to a final concentration of 4 nM in a total volume of 10 µl. 
The libraries were denatured by adding an equal volume of 0.2N NaOH and then 
neutralized by adding 980 µl of Illumina hybridization buffer. Six hundred microliters of 
the denatured libraries were used for sequencing. Sequence data (250 bp, paired-end reads) 
were acquired using the MiSeq platform (Illumina, San Diego, CA). Genome assemblies 
were generated with Newbler v2.9, in paired-end mode and using default parameters. The 
presence and absence of known resistance mechanisms for each isolate were identified by 
Grace C. Lee, a collaborator and colleague, at the University of Texas at Austin using 
BLAST against two databases, ResFinder and ARG ANNOT (Antibiotic Resistance Gene 
ANNOTation).275,284 
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Pharmacodynamic Mathematical Modeling 
The growth control and monotherapy data obtained for meropenem and polymyxin 
B from the time-kill experiments of K. pneumoniae isolates 22, 24, 34, and 44 (see Time-
kill Studies) were described using a conceptual and mathematical model (Figure 3.23; 
Equations 1 and 2). A multi-step approach was adopted to developing the final parameters 
of the mathematical model using Phoenix® 8.1 Win Nonlin® (Certara; Princeton, NJ). 
Figure 3.23: Two Population Conceptual Model of a Single Antimicrobial Agent. Each 
population (S and R) exhibits a unique growth rate constant (g), shares the same maximal 
capacity (Nmax), and compose compartment C which contains the antimicrobial 
concentration (C) with unique maximal killing rate constants (k) and half maximal killing 
rate concentrations (EC50). Reprinted with modifications.285 
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First, model selection involved consideration of the available literature and 
discussion with collaborator Jeffrey J. Campion who had worked with our lab during initial 
time-kill characterization of the four K. pneumoniae isolates listed above as well as the 
four E. cloacae isolates.274,275 A net growth equation (g; Equation 3) was chosen because 
our time-kill experimental design did not allow us to easily parse out bacteria growth (b; 
Equation 3) excluding cell death (x; Equation 3) or vice versa. Other contending 
antimicrobial activity models could have been growth inhibition (A*b) or death 
acceleration (A*x) but were not evaluated. A simple direct effect killing model (Equation 
4) was chosen because it had already been used in the literature to describe antimicrobial 
activity against microorganisms, including gram negative organisms.286,287 Three 
populations within each isolate were assumed to be present based on the subpopulation 
time-kill experiments (see Subpopulation Analysis). In summary, these populations were 
a majority population (RLS) exhibiting the phenotype measured by broth microdilution 
studies (see Minimum Inhibitory Concentrations (MICs)), a subpopulation exhibiting the 
majority polymyxin B phenotype but with much higher meropenem resistance (RHS), and 
a subpopulation exhibiting the majority meropenem phenotype but with polymyxin B 
resistance (RLR). A subpopulation exhibiting elevated meropenem resistance and 
polymyxin B resistance (RHR) could be considered if a poor fit was obtained under simpler 
assumptions, and was thought reasonable to initially exclude given the low viable colony 
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counts obtained for the other two subpopulations which were assumed to be of better 
fitness.288,289 When parameter estimate coefficients of variation exceeded 50% (i.e. the 
univariate confidence interval would include 0), then simpler models were evaluated that 
excluded the poorly estimated parameters. Any data below the lower limit of quantification 
(100 CFU/mL) were omitted from the model (see Time-Kill Procedure). Alternative 
approaches could have included modeling these data points as zero, the average of zero 
and the lower limit of quantification, or the actual lower limit of quantification, but were 
unnecessary given the large quantity of time-kill data obtained (see Appendix E). Lag-
phase data were also omitted from the model since the purpose is to understand bacterial 
growth, killing, and the emergence of resistance and not the experimentally-dependent 
delay in maximal growth rate (see Determining Initial Pharmacodynamic Model Estimates 
for Growth Rate Constants and Maximum Population Count). 
𝒈𝒈 = 𝒃𝒃 − 𝒂𝒂 (3) 
𝒌𝒌∗ = 𝒌𝒌 𝑪𝑪
𝑪𝑪+𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓
 (4) 
 
Second, a net growth rate model with an assumed maximal carrying capacity of the 
in vitro system (Nmax) was initially fit to antimicrobial-free experiments stratified by 
isolate number (Equations 5, 6, and 7) to ascertain reasonable estimates for the growth rate 
parameters of the three subpopulations and the maximum experimental population size of 
each isolate – gRLS, gRLR, gRHS, and Nmax.  
𝒅𝒅𝑹𝑹𝒅𝒅𝒅𝒅
𝒅𝒅𝒅𝒅
= �𝒈𝒈𝑹𝑹𝒅𝒅𝒅𝒅 �𝟏𝟏 −
𝑹𝑹𝒅𝒅𝒅𝒅+𝑹𝑹𝒅𝒅𝑹𝑹+𝑹𝑹𝑹𝑹𝒅𝒅
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂
��𝑹𝑹𝒅𝒅𝒅𝒅 (5) 
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𝒅𝒅𝑹𝑹𝒅𝒅𝑹𝑹
𝒅𝒅𝒅𝒅
= �𝒈𝒈𝑹𝑹𝒅𝒅𝑹𝑹 �𝟏𝟏 −
𝑹𝑹𝒅𝒅𝒅𝒅+𝑹𝑹𝒅𝒅𝑹𝑹+𝑹𝑹𝑹𝑹𝒅𝒅
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂
��𝑹𝑹𝒅𝒅𝑹𝑹 (6) 
𝒅𝒅𝑹𝑹𝑹𝑹𝒅𝒅
𝒅𝒅𝒅𝒅
= �𝒈𝒈𝑹𝑹𝑹𝑹𝒅𝒅 �𝟏𝟏 −
𝑹𝑹𝒅𝒅𝒅𝒅+𝑹𝑹𝒅𝒅𝑹𝑹+𝑹𝑹𝑹𝑹𝒅𝒅
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂
��𝑹𝑹𝑹𝑹𝒅𝒅 (7) 
 
Third, graphical analyses of the time-kill curves of each isolate established the time 
of linear decline of the initial polymyxin B susceptible and/or meropenem low-resistance 
majority population. A net effect growth model and a direct effect killing model (Equations 
1) were simultaneously fit to establish parameter estimates for the maximal killing rate of 
the corresponding antimicrobial as well as the concentration at which there was half 
maximal killing – kS and EC50S. Note: polymyxin B and meropenem containing time-kill 
experiments were fit separately during this step. Therefore, in the case of two populations, 
only “S” and “R” designations were used to denote the susceptible (or least resistant in the 
case of meropenem) majority population and the resistant (or more resistant in the case of 
meropenem) minority subpopulation rather than the three letter codes used for the growth 
rates in step two. 
Fourth, all time-kill curves, still stratified by isolate, were fit by a net effect growth 
and direct effect killing model for both the susceptible majority population (or less resistant 
in the case of meropenem) and the more resistant subpopulation which would use the 
previously fit parameter estimates and confidence intervals as initial estimates and bounds 
to ultimately fit all parameters simultaneously – gS, gR, Nmax, kS, EC50S, kR, and EC50R. 
See equations 1 and 2. 
Fifth, parameter estimates of individual isolates were assessed for plausibility by 
calculating stationary concentrations (SC; Equation 8) and growth rate doubling times (d; 
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Equation 9). The stationary concentration is the theoretical antimicrobial concentration 
where the growth rate and the killing rate are equal so no net growth or killing would result. 
The bacterial doubling time is the amount of time in minutes it takes for the bacterial 
population to double in quantity. Parameter estimate precision was assessed by ensuring 
coefficients of variation (CVs) were below 50% (in order to ensure univariate confidence 
intervals did not include zero). In the case where the EC50 CV was more than 50% and 
studied concentrations were largely above the estimate (e.g. for the more susceptible 
majority population), killing was assumed to be near maximal and equation 10 was used 
where Z represents either R or S. In the case where EC50 CV was more than 50% and 
studied concentrations were largely below the estimate (i.e. for the more resistant 
subpopulation), the Emax equation collapses into equation 11 where Z represents either R 
or S, and k’ represents the merged parameter k/EC50. Overall model fit and predictability 
was assessed by evaluating the uniformity and R2 values of the observed vs. predicted plot 
as well as the Akaike Information Criterion (AIC) for minimizing information loss when 
considering alternative non-nested models.290 
𝒅𝒅𝑪𝑪 = 𝒈𝒈
𝒌𝒌−𝒈𝒈
𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓 (8) 
𝒅𝒅 = 𝒍𝒍𝒍𝒍(𝟐𝟐)
𝒈𝒈
 (9) 
𝒅𝒅𝒅𝒅
𝒅𝒅𝒅𝒅
= �𝒈𝒈𝒅𝒅 �𝟏𝟏 −
𝒅𝒅+𝑹𝑹
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂
� − 𝒌𝒌𝒅𝒅�𝒅𝒅  (10) 
𝒅𝒅𝒅𝒅
𝒅𝒅𝒅𝒅
= �𝒈𝒈𝒅𝒅 �𝟏𝟏 −
𝒅𝒅+𝑹𝑹
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂
� − 𝒌𝒌′𝒅𝒅 ∗ 𝑪𝑪� 𝒅𝒅  (11) 
 
Sixth, an overall “composite” model was fit to all growth control and polymyxin B 
monotherapy experiments to generalize the model parameters to isolates other than the 
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individual isolates. Since all isolates had similar MICs to polymyxin B, the composite was 
fit with and without MIC normalization of the drug concentrations and EC50 parameter. 
Furthermore, all growth control and meropenem monotherapy experiments were fit to a 
composite model, but only the MIC normalized model was considered because these 
isolates exhibited drastically different MICs to meropenem and therefore expected to 
behave differently at similar concentrations of meropenem. In essence, individual isolates 
were assumed to have similar parameter estimates so all experiments were fit 
simultaneously (no longer stratified) to equations 1 and 2. The AIC values were compared 
and differences in AIC >10 (and corresponding relative likelihood) were considered 
significant enough to lend tremendous support of one model over the comparator.290 
 
Determining Initial Pharmacodynamic Model Estimates for Growth Rate Constants 
and Maximum Population Count 
 Graphical analysis of each growth control time-kill experiment of isolates 22, 24, 
34, and 44 was performed to identify regions of lag phase, log phase, stationary phase, and 
death phase (Figure 3.24). All time points identified to be within log phase were stratified 
by isolate number and by experiment type (antibiotic free agar, meropenem containing 
agar, and polymyxin B containing agar) and natural log transformed. Linear regression was 
performed on each stratum using Office 365 Excel (Microsoft, Redmond, WA) to ascertain 
initial estimates for gRLS, gRLR, and gRHS, using 95% confidence intervals as boundary 
conditions. All time points identified to be within stationary phase were stratified by isolate 
number and descriptive statistics (geometric mean with 95% confidence intervals) were 
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generated using Office 365 Excel to use as initial estimates and bounds for Nmax for each 
isolate. Only antibiotic free agar experiments were utilized for Nmax estimates since 
resistant subpopulation experiments performed on antibiotic-containing agar were 
inhibited by the abundance of susceptible majority population and would yield biased 
estimates of the experimental viable colony count capacity. In the case where resistant 
subpopulation data was too scarce to generate meaningful confidence intervals, the lower 
boundary was set to 0 and the upper boundary was set to match the upper boundary of the 
corresponding isolate gRLS since it is unlikely for the more resistant isolate to grow at a 
faster rate than the more susceptible majority population. 
 
Figure 3.24: Phases of Bacterial Growth over Time. Reprinted.291  
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Determining Initial Pharmacodynamic Model Estimates for Susceptible Population 
Killing Rate Constants 
 Graphical analysis of each meropenem or polymyxin B containing time-kill 
experiment of isolates 22, 24, 34, and 44 was performed to identify regions of initial killing 
phase, regrowth phase, stationary phase, and death phase (Figure 3.25).  
 
 
Figure 3.25: Phases of Bacterial Killing over Time. Two time-kill experiments with 
polymyxin B 0.25 mg/L against isolate 22. 
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All time points identified to be within the initial killing phase were stratified by 
isolate number and drug concentration, and subsequently natural log transformed. Linear 
regression was performed on each pooled stratum using Office 365 Excel (Microsoft, 
Redmond, WA) to ascertain pairings of drug concentration and the regression slope (mS; 
Equation 12). Note that the observed initial decline in colony count is growth rate minus 
apparent killing rate (k*; Equation 13). Therefore, the gRLS parameter estimate obtained 
from modeling growth control experiments (see Pharmacodynamic Mathematical 
Modeling) was used to transform linear regression slopes into apparent killing rates 
(Equation 12). 
𝒎𝒎𝒅𝒅 = 𝒈𝒈𝒅𝒅 − 𝒌𝒌∗𝒅𝒅 (12) 
𝒌𝒌∗𝒅𝒅 = 𝒌𝒌𝒅𝒅
𝑪𝑪
𝑪𝑪+𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝒅𝒅
  (13) 
 
All possible pairwise systems of equations for concentration-k* were subsequently 
solved (Equations 14 and 15), generating a data set of kS and EC50S estimates. 
𝒌𝒌𝟏𝟏∗𝒅𝒅 = 𝒌𝒌𝒅𝒅
𝑪𝑪𝟏𝟏
𝑪𝑪𝟏𝟏+𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝒅𝒅
  (14) 
𝒌𝒌𝟐𝟐∗𝒅𝒅 = 𝒌𝒌𝒅𝒅
𝑪𝑪𝟐𝟐
𝑪𝑪𝟐𝟐+𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝒅𝒅
  (15) 
 
Descriptive statistics (mean with 95% confidence intervals) were generated using 
Office 365 Excel to use as initial estimates and bounds for kS and EC50S for each isolate. 
Stationary concentrations (Equation 8) were calculated to assess the plausibility of these 
initial parameter estimates.  
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Determining Initial Pharmacodynamic Model Estimates for Resistant Population 
Killing Rate Constants 
 Graphical analysis of each meropenem or polymyxin B containing time-kill 
experiment of isolates 22, 24, 34, and 44 was performed to identify regions of initial killing 
phase, regrowth phase, stationary phase, and death phase (Figure 3.25), as in Determining 
Initial Pharmacodynamic Model Estimates for Susceptible Population Killing Rate 
Constants. 
All time points identified to be within the regrowth phase were stratified by isolate 
number and drug concentration, and subsequently natural log transformed. Linear 
regression was performed on each pooled stratum using Office 365 Excel (Microsoft, 
Redmond, WA) to ascertain pairings of drug concentration and the regression slope (mR; 
Equation 16). Note that the observed regrowth in colony count is growth rate minus 
apparent killing rate (k*; Equation 17). Therefore, the gRLR (polymyxin B experiments) 
or gRHS (meropenem experiments) parameter estimates obtained from modeling growth 
control experiments (see Pharmacodynamic Mathematical Modeling) were used to 
transform linear regression slopes into apparent killing rates (Equation 16). 
𝒎𝒎𝑹𝑹 = 𝒈𝒈𝑹𝑹 − 𝒌𝒌∗𝑹𝑹 (16) 
𝒌𝒌∗𝑹𝑹 = 𝒌𝒌𝑹𝑹
𝑪𝑪
𝑪𝑪+𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝑹𝑹
  (17) 
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All possible pairwise systems of equations for concentration-k* were subsequently 
solved (Equations 18 and 19), generating a data set of kR and EC50R estimates. 
𝒌𝒌𝟏𝟏∗𝑹𝑹 = 𝒌𝒌𝑹𝑹
𝑪𝑪𝟏𝟏
𝑪𝑪𝟏𝟏+𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝑹𝑹
  (18) 
𝒌𝒌𝟐𝟐∗𝑹𝑹 = 𝒌𝒌𝑹𝑹
𝑪𝑪𝟐𝟐
𝑪𝑪𝟐𝟐+𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝑹𝑹
  (19) 
 
Descriptive statistics (mean with 95% confidence intervals) were generated using 
Office 365 Excel to use as initial estimates and bounds for kR and EC50R for each isolate. 
Stationary concentrations (Equation 8) were calculated to assess the plausibility of these 
initial parameter estimates. When calculated stationary concentrations were not reasonable 
(i.e. SC < C | regrowth or SC > C | killing), then a different approach was used (see below).  
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Determining Initial Pharmacodynamic Model Estimates for Resistant Population 
Killing Rate Constants Given Unreasonable Stationary Concentrations 
 In summary, this approach assumed that stationary concentrations fell within a 
given range and then estimated lowest and highest possible k and EC50 values that could 
give such a range in stationary concentrations. The lowest stationary concentration was 
assumed to be the highest concentration of antimicrobial tested where regrowth was 
observed (i.e. the true stationary concentration must be more than this value). The highest 
stationary concentration was assumed to be the lowest concentration of antimicrobial tested 
where regrowth was not observed (i.e. the true stationary concentration of antimicrobial 
tested must be less than this value). When no concentration of antimicrobial prevented 
regrowth, then the highest observed MIC of the regrowing subpopulation was used as the 
stationary concentration (see Resistance Development to Polymyxin B) following selection 
for this isolate at concentrations 2-4x the MIC of the majority population. Higher 
concentrations may elicit an adaptive response and explain the higher MICs observed in 
Table 4.19. 
 Additionally, the lower and upper 95% univariate confidence interval values for 
gRLR or gRHS were considered rather than just the parameter estimate as in Determining 
Initial Pharmacodynamic Model Estimates for Resistant Population Killing Rate 
Constants. Next, kR was assumed to be no greater than the upper planar 95% confidence 
interval of kS since it is unlikely that the more resistant subpopulation could be killed faster 
than the more susceptible subpopulation. Finally, EC50R was assumed to be at least the 
highest antimicrobial concentration tested since the best explanation for poor stationary 
130 
 
concentrations is that the concentrations tested were well below the EC50R. Otherwise, the 
original analysis should have yielded plausible kR and EC50R combinations. 
 To summarize, all possible combinations of the assumptions above were used to 
calculate new kR and EC50R estimates. In other words, the stationary concentration was 
assumed either low or high (bounds discussed previously), the growth rate constant was 
assumed either low or high (bounds discussed previously), and either the maximum kR 
assumption was used or the minimum EC50R assumption was used generating 8 possible 
parameter estimates for kR and EC50R that generate stationary concentrations between the 
bounds assumed. The average of the lowest and highest kR and EC50R was used as an initial 
estimate with the lowest and highest values also being used as boundary conditions for the 
model. 
 
Fixed Parameters 
 Initial viable colony counts for the model were fixed as opposed to being fit as 
parameters themselves. For the susceptible population, the initial counts were measured in 
all experiments and were fixed to the measured viable colony counts at time=0. For the 
resistant subpopulation, only experiments utilizing antimicrobial containing agar measured 
the starting concentration of the resistant subpopulation. Therefore, this quantity was 
assumed constant for all other experiments. In reality, this value likely varied but because 
counts were so small (usually <50 CFU/mL), estimating this value as another parameter in 
the model yielded very high CVs and was not useful without additional experimental data 
to improve the precision of starting resistant population colony count. When MICs were 
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utilized in the model to normalize parameters between isolates, they were fixed according 
to the broth microdilution MIC results (see Minimum Inhibitory Concentrations (MICs)). 
However, given the intrinsic lack of precision of antimicrobial susceptibility testing (within 
one two-fold dilution of MIC result), MICs were also fit as parameters for the meropenem 
composite model using the MICs measured by BMD as initial estimates and using one two-
fold dilution as lower and upper limits. 
 
Full Model Initial Estimates of Parameters 
 Initial parameter estimates for the full monotherapy model (Equations 1 and 2) 
utilized the fit growth parameters (gRLS, gRHS, and RLR) of the growth control 
experiments, the fit kS and EC50S parameters of the initial monotherapy killing phase, and 
the initial parameter estimates of the resistant subpopulation (kR and EC50R) of the regrowth 
phase. Univariate 95% confidence intervals were utilized for bounds except in the cases of 
anticipated great uncertainty where planar 95% confidence intervals were used to account 
for the variability of the other parameter estimates. Specifically, the growth rates of gRHS 
and gRLR were anticipated to be uncertain since only few experiments followed this 
growth rate over time, so planar confidence intervals were utilized as bounds. Since most 
polymyxin B monotherapy concentrations utilized were well above the MIC of the 
organisms, planar confidence intervals were utilized for the maximal killing rate constant 
kS and the EC50S parameters. However, for meropenem monotherapy, the concentrations 
utilized were likely not as close to the kS parameter, so a better fitting estimate of the kS 
and EC50S relationship was anticipated. Therefore, univariate confidence intervals were 
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used for kS bounds and planar confidence intervals were utilized for the less certain EC50S 
parameter. 
 
Data Analysis 
In Vitro Susceptibility Testing 
For each isolate, MIC results from within the same experiment as well as from at 
least two replicate experiments were compared and evaluated for essential agreement 
(within one two-fold dilution).262 If MIC results did not agree, broth microdilution was 
repeated for these strains. When MIC results were not the same, but at least two replicate 
experiments were in agreement, the most common (modal) MIC was accepted. If there was 
no mode, the greater of the two results was accepted as the MIC. Additionally, MIC range, 
MIC50, and MIC90 were determined. Percent susceptible was calculated based on 
breakpoints established by CLSI (Table 3.8).268  
  
133 
 
Table 3.10: Susceptibility Breakpoints for Enterobacteriaceae 
 Susceptible Intermediate Resistant 
Amikacin ≤16 32 ≥64 
Ampicillin ≤8 16 ≥32 
Ampicillin/Sulbactam ≤8/4 16/8 ≥32/16 
Aztreonam ≤4 8 ≥16 
Cefazolin ≤2 4 ≥8 
Cefepime ≤2 4-8* ≥16 
Cefoxitin ≤8 16 ≥32 
Ceftazidime ≤4 8 ≥16 
Ceftazidime / 
avibactam ≤8/4  ≥16/4 
Ceftriaxone ≤1 2 4 
Cefuroxime ≤4 8-16 ≥32 
Ciprofloxacin ≤1 2 ≥4 
Colistin† ≤2 4 ≥8 
Ertapenem ≤0.5 1 ≥2 
Imipenem ≤1 2 ≥4 
Imipenem / 
Relebactam# ≤1 2 ≥4 
Gentamicin ≤4 8 ≥16 
Levofloxacin ≤2 4 ≥8 
Meropenem ≤1 2 ≥4 
Minocycline ≤4 8 ≥16 
Polymyxin B† ≤2 4 ≥8 
Nitrofurantoin ≤32 64 ≥128 
Piperacillin /  
tazobactam ≤16/4 32/4 - 64/4 ≥128/4 
Tetracycline ≤4 8 ≥16 
Tigecycline§ ≤2 4 ≥8 
Tobramycin ≤4 8 ≥16 
Sulfamethoxazole / 
trimethoprim ≤2/38 - ≥4/76 
*Cefepime does not have an intermediate susceptibility but instead has a susceptible dose-
dependent designation 
†Colistin and polymyxin B do not have CLSI breakpoints for Enterobacteriaceae. The 
breakpoints for Pseudomonas aeruginosa and Acinetobacter baumannii were used 
instead262 
#Imipenem/relebactam does not have CLSI breakpoints for Enterobacteriaceae. Imipenem 
breakpoints were utilized according to literature and manufacturer recommendations 
§Tigecycline does not have CLSI breakpoints for gram-negative organisms. An FDA-
approved breakpoint of ≤ 2 µg/mL was considered susceptible168  
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Time-Kill Studies 
 Plots of colony count (log10 CFU/mL) versus time were constructed for each isolate 
and antimicrobial(s) studied. Furthermore, combined plots across multiple experiments 
were generated using geometric means of the colony counts and standard deviations for 
each time point. Additionally, plots of 24-hour change in log10 CFU/mL were constructed 
using the logarithm of the geometric mean of the initial (time = 0) colony count subtracted 
from the logarithm of the geometric mean of the 24-hour colony count with un-pooled 
standard deviations. Activity was evaluated as bactericidal, bacteriostatic, or growth where 
bactericidal activity was defined as a ≥103 decrease in colony count at 24 hours, 
bacteriostatic was defined as a < 103 decrease in colony count at 24 hours, and growth was 
any positive change at 24 hours. Synergy was also evaluated for combinations, being 
defined as a ≥ 102 CFU/mL lower colony count at 24 hours when compared to the most 
active agent used alone. 
 
Subpopulation Analysis 
 A table of colony count (log10 CFU/mL) at time 0 was constructed which included 
each isolate studied in time-kill assays. Measurements from microfiltration were 
preferentially used when either microfiltration data were below the lower limit of 
quantification (102 CFU/mL) for the laser colony counter or when the laser colony counter 
data were below the lower limit of quantification. When the laser colony counter and 
microfiltration data were above 102 CFU/mL or if the microfiltration method produced too 
many colonies to count, the laser colony counter value was used. Additionally, reported 
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values were not rounded to the lower limit of quantification of microfiltration because 
higher error was accepted as a limitation for comparing colony counts that were expected 
to be so low. 
 
Whole Genome Sequencing 
 Multilocus sequence typing (MLST) on the K. pneumoniae isolates 22, 24, and 44, 
and the E. cloacae isolates 10, 17, 19, and 40 was performed by Dr. Grace C. Lee.274,275 
When coverage of all housekeeping genes was insufficient to verify novel MLST, the 
closest match was reported. Antimicrobial resistance genes were stratified by class of 
antibiotic. For β-lactam antimicrobials, the Ambler classification system (see 
Classification of β-lactamases) further stratified resistance mechanisms. Likewise, for the 
aminoglycoside modifying enzymes, acetyltransferases, phosphotransferases, and 
nucleotidyltransferases were indicated separated. Furthermore, amikacin resistance 
mechanisms were uniquely identified among the aminoglycoside stratum according to 
structural analysis of amikacin. For example, some aminoglycoside resistance mechanisms 
may not apply to amikacin due to its structure not matching the active site of the 
aminoglycoside modifying enzyme. 
 
Pharmacodynamic Mathematical Model Simulations 
 The final model parameters were used to simulate viable colony counts over time 
for every experiment. The geometric average of these simulations were plotted with the 
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geometric average of the observed data for each concentration of antimicrobial to verify 
visual goodness of fit. Plots of observed vs. predicted viable colony counts were generated 
and linear regression performed to evaluate any residual bias in the model. Stationary 
concentrations and bacterial doubling rates were also calculated. Models were compared 
using the Akaike Information Criterion (AIC) and ensuring that parameter CVs yielded 
confidence intervals that exclude zero.290 All parameter estimates, CVs, and confidence 
intervals were reported. 
 
Statistical Analyses 
 Fisher’s exact or Chi-squared analyses with a Holm-Bonferroni correction, when 
appropriate, were used to compare non-parametric antimicrobial susceptibility data such 
as broth microdilution, BD Phoenix™, Etest® and nationally reported data.292,293 However, 
statistical inferences are limited in that high sample sizes may confer statistical significance 
with a lack of clinical significance. For example, a difference in susceptibility of 62% 
compared to 60% may be statistically significant, depending on the sample size, but a 
difference in susceptibility of 100% to 98% indicating first appearance of resistance may 
be more clinically significant, regardless of statistical significance. For paired data, 
McNemar’s test was used instead of Fisher’s exact or Chi-squared. 
 Geometric means and standard deviations are most meaningful regarding time-kill 
and log-change studies due to the very high inter-experiment variability (heterogeneity) 
observed across studies. Therefore, statistical parameters describing intra-experiment 
variability (e.g. standard deviation and coefficients of variance) are a better indicator of 
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valid results in the face of dynamically growing organisms where external factors are 
difficult to control without many samples. This has been a limitation and described by 
numerous meta-analyses and review articles14,201,205,212 leading to standardized definitions 
for describing and comparing data (e.g. bactericidal activity and synergy), primarily by 
CLSI.262,264 
 Akaike Information Criterion (AIC) was determine by the Phoenix® Win Nonlin® 
software and was used to compare models. Since none of the comparator models were 
considered nested (i.e. no model contained all of the parameters of another model), the 
relative likelihood rather than the likelihood ratio test was appropriate.290 Parameter CVs 
were also considered in choosing the best model in that if the univariate confidence interval 
of a parameter contained zero, then the parameter could not be concluded significant 
enough to the model to warrant inclusion. However, it was acknowledged when this 
occurred and an explanation as to why this parameter had such a poor estimate was 
provided.  
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Chapter Four: 
 
Publications, Results, and Discussion 
Part of the research contained within this chapter has been published as 
Kulengowski, B. In vitro activity of polymyxin B and meropenem alone and in 
combination against carbapenem-resistant Enterobacteriaceae. 2016. Theses and 
Dissertations—Pharmacy. 57. Other parts of this chapter have also either been published, 
are in press, or are currently under review and the reader will be informed when this is the 
case by a lead-in paragraph disclosure. Due to the volume of this dissertation, the relevant 
background and methods were kept with the results and discussion of the manuscripts so 
that readers do not need to go back and forth between the various sections within this 
manuscript. 
In Vitro Susceptibility Testing 
Bacterial Isolates 
 Clinical isolates of 612 non-duplicate, MDR, gram-negative organisms were 
collected between November 9, 2008 and October 1, 2018 from the Clinical Microbiology 
Laboratory at the University of Kentucky Chandler Medical Center in Lexington, 
Kentucky.166 The most common gram-negative MDR species in descending order were 
Escherichia coli (27%), Pseudomonas aeruginosa (25%), Klebsiella pneumoniae (19%), 
and Enterobacter cloacae (10%). CRE numbered 164 (27%) of the MDR isolates obtained, 
and Klebsiella pneumoniae (41%), Enterobacter cloacae (30%), and Citrobacter freundii 
(8%) composed most of this group. These isolates are described in Table 4.1 and Table 4.2. 
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Table 4.1: All MDR Clinical Isolates 
 
Organism Number of Isolates Percentage 
A. baumannii/ 
calcoaceticus complex 38 6.2% 
A. xylosoxidans 1 0.2% 
Achromobacter sp. 4 0.7% 
B. cepacia 1 0.2% 
C. amalonaticus 3 0.5% 
C. farmeri 2 0.3% 
C. freundii 14 2.3% 
C. youngae 2 0.3% 
E. aerogenes 5 0.8% 
E. cloacae 62 10.1% 
E. coli 166 27.1% 
E. gergoviae 2 0.3% 
E. hormaechei 2 0.3% 
E. vulneris 1 0.2% 
Enterobacter sp. 2 0.3% 
K. oxytoca 14 2.3% 
K. ozaenae 2 0.3% 
K. pneumoniae 116 19.0% 
P. aeruginosa 153 25.0% 
P. agglomerans 4 0.7% 
P. mirabilis 5 0.8% 
P. putida 4 0.7% 
P. rettgeri 1 0.2% 
P. vulgaris 1 0.2% 
P. vulgaris/penneri 2 0.3% 
S. aureus 1 0.2% 
S. marcescens 3 0.5% 
S. paucimobilis 1 0.2% 
TOTAL 612  
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Table 4.2: Carbapenem-resistant Enterobacteriaceae Clinical Isolates 
Organism Number of Isolates Percentage 
C. amalonaticus 2 1.2% 
C. freundii 13 7.9% 
C. youngae 2 1.2% 
E. aerogenes 4 2.4% 
E. cloacae 50 30.5% 
E. coli 9 5.5% 
E. gergoviae 2 1.2% 
E. hormaechei 2 1.2% 
Enterobacter sp. 2 1.2% 
K. oxytoca 5 3.0% 
K. ozaenae 2 1.2% 
K. pneumoniae 68 41.5% 
P. rettgeri 1 0.6% 
S. marcescens 2 1.2% 
TOTAL 164  
 
Minimum Inhibitory Concentrations (MICs) 
 All isolates underwent identification and antimicrobial susceptibility testing for 
clinical purposes through the University of Kentucky Clinical Microbiology Laboratory 
using BD Phoenix™ prior to collection by our lab. This data was provided to our lab and 
the specific CRE data were subsequently verified using antimicrobial susceptibility testing 
by broth microdilution methodology, the gold standard for determination of MICs.264 The 
primary objective of antimicrobial susceptibility testing through broth microdilution was 
to characterize CRE observed in a tertiary referral U.S. academic medical center. 
Carbapenem resistance was described by the measured MIC value, and these isolates 
exhibited low to high levels of resistance (MICs ranging 4 - >128) to meropenem– the most 
commonly used carbapenem antimicrobial at the University of Kentucky Chandler Medical 
Center.262 
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The MICs for all 164 CRE isolates are shown for the 20 antimicrobials tested by 
BD Phoenix™ in Appendix A. The MIC50, MIC90, and percentage susceptible across CRE 
isolates numbering at least 30 according to CLSI guidelines for cumulative susceptibility 
reporting are shown in Appendix B.292 Since clinical isolates were continually being sent 
throughout the study from the University of Kentucky Clinical Microbiology Laboratory, 
only 125 of ultimately 164 CRE organisms underwent antimicrobial susceptibility testing 
by broth microdilution (BMD). Only 122 of these 125 met the CDC definition of CRE 
when BMD was used (see Bacterial Isolates). MICs of the antimicrobials evaluated against 
these CRE are shown in Appendix C. The MIC50, MIC90, and percentage susceptible for 
these isolates are presented in Appendix D and stratified into various comparator groups 
as manuscripts submitted for publication. Specifically, these manuscripts are: 1) Evaluation 
of an Automated System for Determining Antimicrobial Susceptibility against 
Carbapenem-resistant Enterobacteriaceae Compared to Broth Microdilution, 2) 
Antimicrobial Activity against Carbapenem-resistant Enterobacteriaceae that Produce 
Verona Integron-encoded Metallo-beta-lactamase or Klebsiella pneumoniae 
Carbapenemase, and 3) Imipenem/relebactam Activity Compared to Commonly Utilized 
Antimicrobials against Carbapenem-resistant Enterobacteriaceae from an Academic 
Medical Center as part of an investigator initiated research proposal for Merck & Co. 
(MISP #56367).  
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Evaluation of an Automated System for Determining Antimicrobial Susceptibility 
against Carbapenem-resistant Enterobacteriaceae Compared to Broth Microdilution 
To be submitted: International Journal of Antimicrobial Agents as an original article 
Authors: Zachary J. Haffler, Brandon Kulengowski, David S. Burgess 
Kulengowski contribution: Experimental design, execution, data analysis, revisions and 
editing of final manuscript 
Special acknowledgements: I thank former pharmacy student, Zachary Haffler for the 
tremendous amount of effort he has put forth as the primary author of this manuscript 
submission and his words are reproduced here with his permission.  
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Abstract 
Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly common and 
result in infections associated with significant mortality. The aim of this study is to evaluate 
the categorical agreement between the automated system BD PhoenixTM and broth 
microdilution in determining minimum inhibitory concentrations for CRE. We evaluated 
the activity of amikacin, aztreonam, cefepime, ceftazidime, ertapenem, gentamicin, 
levofloxacin, meropenem, nitrofurantoin, piperacillin-tazobactam, and tobramycin on 125 
CRE isolates collected from an academic medical center. We determined categorical 
agreement between BD PhoenixTM and broth microdilution. BD PhoenixTM significantly 
overestimated susceptibility of CRE isolates for 9 of 11 tested antimicrobials compared to 
gold-standard broth microdilution. All antimicrobials exhibited increased error rates 
compared to previous literature. BD PhoenixTM overestimates antimicrobial susceptibility 
of CRE isolates, regardless of carbapenem mechanism of resistance. A secondary testing 
method should be utilized to confirm antimicrobial susceptibility results. Further studies 
are warranted in order to validate BD PhoenixTM susceptibility testing in highly resistant 
CRE isolates.  
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Introduction 
Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with a 
mortality rate of approximately 50% and have become an increasingly prevalent global 
problem.294 As carbapenem agents are considered to be among the most potent 
antimicrobials for combating gram-negative infections, the emergence and spread of 
carbapenemases that hydrolyze these agents is a cause for alarm. According to the Center 
for Disease Control (CDC), CRE infections pose an immediate public threat that requires 
urgent and aggressive action. Though historically uncommon, CRE have been identified in 
healthcare facilities in all 50 states as of 2018.295 Nationally, it has been reported that 
approximately 10% of Klebsiella spp. bloodstream infections are caused by CRE.120 
Resistance to carbapenem agents primarily results from the horizontal transfer of 
plasmid-encoded carbapenem hydrolyzing enzymes. Molecular class A, group 2f β-
lactamases include the Klebsiella pneumoniae Carbapenemase (KPC), which has been 
associated with outbreaks of multidrug-resistant infections worldwide.43,294,296,297 
Molecular class B, groups 3a and 3b β-lactamases include the metallo-β-lactamases (MBL) 
IMP and VIM which are becoming increasingly common in the United States.43 As of 
February 2018, New Delhi metallo-β-lactamase-producing  (NDM) CRE are the most 
commonly reported CRE infections.295 Plasmids which carry the genes containing 
carbapenem hydrolyzing enzymes also carry genes which confer resistance to many other 
antimicrobial drug classes, including fluoroquinolones and aminoglycosides.298-300 
Many laboratories utilize automated identification and antimicrobial susceptibility 
systems for clinical isolates to decrease the time and labor required to determine 
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susceptibility results for hospitalized patients. Inaccuracies in these systems could result in 
potentially devastating treatment failures for patients with CRE infections. Due to the 
significant morbidity and mortality associated with CRE infections, it is vital that 
healthcare practitioners are able to assess which medications are treatment options when 
patients present with CRE infections. Previous studies have demonstrated the accuracy of 
automated systems for identification and susceptibility testing of gram-negative organisms 
when compared to the agar dilution method, broth dilution, and Etests®.301-304 Conversely, 
there is little information on the validation of automated systems to appropriately determine 
susceptibility data for highly resistant CRE isolates. The purpose of this study was to assess 
the level of categorical agreement (CA) between the BD PhoenixTM automated system and 
broth microdilution (BMD) in determining minimum inhibitory concentrations (MICs) of 
CRE at an academic medical center. 
 
Methods 
Bacterial Isolates. 125 isolates of carbapenem-resistant Enterobacteriaceae (CRE) were 
obtained from UK HealthCare Albert. B Chandler Hospital from January 1, 2012 to 
December 31, 2016. We identified organisms by their resistance to either ertapenem or 
meropenem on BD Phoenix™. Isolates were frozen and stored at -80°C for use in our 
microbiology laboratory. 
Susceptibility Testing. The MICs were obtained from BD PhoenixTM automated 
susceptibility testing (versions V6.01, V6.01A, and V6.21A) and by broth microdilution 
for all CRE isolates against amikacin, aztreonam, cefepime, ceftazidime, ertapenem, 
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gentamicin, levofloxacin, meropenem, nitrofurantoin, piperacillin-tazobactam, and 
tobramycin. This panel was selected for drugs used at our institution during routine clinical 
practice. Stock antimicrobials were prepared for microdilution according to Clinical and 
Laboratory Standards Institute (CLSI) guidelines. MICs from broth microdilution were 
determined in accordance with CLSI standardized laboratory practices utilizing the Biotek 
Instruments, Inc. BioStackTM Microplate Stacker and Precision Pipetting Systems.305 
Dilution of clinical isolates to a standard inoculum of 1.5x108 CFU/ml was performed via 
McFarland standard matching. An additional 1:200 dilution was created with cation-
adjusted Mueller Hinton broth to make a final inocula of 6x105 CFU/ml. Isolates were then 
cultured and incubated at 37°C overnight. Broth microdilution experiments were 
performed in duplicate on two separate days; the modal MIC was documented. We utilized 
Pseudomonas aeruginosa ATCC 27853TM and Escherichia coli ATCC® 25922TM as 
quality control strains. CLSI susceptibility, intermediate, and resistant breakpoints were 
utilized.268  
Subgroup Analysis. Further analysis was performed on subgroups divided according to 
isolate resistance mechanism: KPC-producing (n=71), MBL-producing (n=21), and non-
carbapenemase-producing CRE (n=27). Isolates that expressed both KPC and MBL 
enzymes were excluded from subgroup analysis. Resistance phenotypes were determined 
using a combined-disc test utilizing meropenem alone, as well as in combination with 
phenylboronic acid or ethylenediaminetetraacetic acid. Tsakris et al. evaluated phenotypic 
testing method for the detection of carbapenemase production and differentiation of KPC 
and MBL enzymes.266 
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Susceptibility Data Analysis. All data from BMD and BD PhoenixTM were reported and 
transcribed into Microsoft Excel spreadsheets for analysis. We determined categorical 
agreement between the two testing methods. Essential agreement was not evaluated 
because BD PhoenixTM has a very limited reportable MIC range for each antimicrobial 
compared to BMD. Categorical agreement was defined as identical susceptibility testing 
categories reported for both testing methods. McNemar’s test was used to assess statistical 
significance for paired, binominal data. Two-sided P-values of 0.05 or less indicated 
statistical significance. 
Error Rates and CLSI Acceptable Discrepancy Rates. We determined the rates of minor 
error (MiE), major error (ME), and very major error (VME) between broth microdilution 
and the BD PhoenixTM automated system. MiE was when one testing method categorized 
an isolate as intermediate and the other did not. ME was when BD PhoenixTM categorized 
an isolate as resistant and broth microdilution categorized the same isolate was susceptible. 
VME was when BD PhoenixTM categorized an isolate as susceptible and broth 
microdilution categorized the same isolate to be resistant. The count of MiEs, MEs, and 
VMEs were used as numerators in their respective equations to determine the error rates 
for BD PhoenixTM. The denominator was established using the appropriate population of 
isolates outlined in CLSI’s guidance on susceptibility testing criteria based on the isolates’ 
MIC value.306 Therefore, isolates for each antimicrobial were divided into three 
populations: those with MIC values greater than or equal to two dilutions above the 
intermediate MIC (≥I+2), those with MIC values between one dilution above the 
intermediate MIC and one dilution below the intermediate MIC (I+1 to I-1), and those with 
MIC values less than or equal to the two dilutions below the intermediate MIC (≤I-2).306 
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Results 
Of the 125 CRE clinical isolates collected, 14 distinct species were identified by 
the automated system BD PhoenixTM: Klebsiella pneumoniae (n=58), Enterobacter 
cloacae (n=31), Citrobacter freundii (n=9), Escherichia coli (n=7), Enterobacter 
aerogenes (n=4), Klebsiella oxytoca (n=3), Enterobacter sp. (n=2), Citrobacter 
amalonaticus (n=2), Citrobacter youngae (n=2), Enterobacter hormaechei (n=2), 
Klebsiella ozaenae (n=2), Enterobacter gergoviae (n=1), Providencia rettgeri (n=1), and 
Serratia marcescens (n=1). Table 4.3 summarizes the in vitro activity of all antimicrobials 
tested via BMD and BD PhoenixTM as percent susceptibility. BD PhoenixTM overestimated 
susceptibility for CRE isolates for 82% (9/11) of tested antimicrobials – amikacin, 
gentamicin, tobramycin, levofloxacin, nitrofurantoin, aztreonam, cefepime, ceftazidime, 
and meropenem. High levels of resistance to ertapenem and piperacillin-tazobactam 
precluded detection of a statistically significant difference between broth microdilution and 
BD PhoenixTM – 2% vs. 1% and 1% vs. 3% susceptibility, respectively (Table 4.3). 
Overall categorical agreement was calculated as 76% for all organisms and 
antimicrobials tested. Categorical agreement varied greatly, even between antimicrobial 
agents of the same class, ranging from 50-95%. The highest rate of categorical agreement 
was seen in beta-lactam agents, at 79%, followed by 76%, 63%, and 61% with 
aminoglycosides, nitrofurans, and fluoroquinolones, respectively. The antimicrobials with 
the highest categorical agreement values (aztreonam, ertapenem, and piperacillin-
tazobactam) were the agents with the lowest percent susceptibility by both BD PhoenixTM 
and broth microdilution (Table 4.3). MIC values determined from both testing methods for 
all isolates and antimicrobials are listed in the Appendix A and Appendix C. 
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The susceptibility results for KPC-producing isolates, MBL-producing isolates, and 
non-carbapenemase-producing CRE isolates are summarized in Table 4.4, Table 4.5, and 
Table 4.6. In isolates producing KPC, susceptibility was overestimated by BD PhoenixTM 
for cefepime, levofloxacin, aztreonam, and nitrofurantoin with an average categorical 
agreement of 75% [range 44-99%] (Table 4.4). BD PhoenixTM also significantly 
overestimated susceptibility for MBL-producing isolates for meropenem, aztreonam, and 
nitrofurantoin (Table 4.5). In isolates where carbapenemase enzymes were not detected, a 
significant overestimation of susceptibility by BD PhoenixTM was detected only for 
levofloxacin (Table 4.6). 
All tested antimicrobials showed increased error rates in at least one category – 
VME, ME, or MiE. Only ertapenem exhibited VME rates as low as previously observed 
evaluations of automated susceptibility testing methods. Only amikacin, cefepime, 
nitrofurantoin, and tobramycin exhibited low ME error rates. Finally, only 4 of 11 
antimicrobials demonstrated relatively low MiE rates – aztreonam, ertapenem, gentamicin, 
and piperacillin-tazobactam. Table 4.7 reports the calculated error rates for broth 
microdilution vs. BD PhoenixTM. No agent exhibited consistently low rates of error per BD 
PhoenixTM when compared against broth microdilution for CRE isolates. 
 
Discussion 
Our study demonstrated that BD PhoenixTM overestimates susceptibility for CRE 
compared to gold-standard broth microdilution for 9/11 (82%) tested antimicrobials. The 
differences in susceptibility were found to be statistically significant, despite previous 
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literature validating the utilization of the BD PhoenixTM automated system for gram-
negative bacilli by repeated testing.301-304,307,308 In 2002, Endimiani et al. evaluated BD 
PhoenixTM against broth microdilution for the identification and susceptibility testing of 
136 non-fermenting gram-negative isolates. They concluded the automated system 
correctly measured the susceptibility of antipseudomonal drugs with a reported categorical 
agreement of 93.1%.303 The present study reports an overall categorical agreement of 76%, 
but there were antimicrobials with categorical agreement considerably higher than the 
average: aztreonam, ertapenem, and piperacillin-tazobactam. However, this observation 
may best be explained by observed high levels of resistance to these drugs (98-99%). 
For all drugs tested, we observed increased error rates when compared to rates 
previously described for automated susceptibility testing, with 10/11 (91%) drugs yielding 
an elevated rate of VME within at least a single intermediate range-demarcated 
subpopulation. The rates of error found for each antimicrobial agent stratified by 
population are outlined in Table 5. According to CLSI in vitro susceptibility testing criteria, 
of greatest concern are the discrepancies that occur with MICs greater than or equal to 
twofold concentrations above (≥I+2) or below (≤I-2) the intermediate MIC.306 Our study 
found rates of MiE, ME, and VME considerably greater than observed previous studies. In 
2002, Steward et al. assessed the accuracy of five antimicrobial testing methods – agar 
dilution, disk diffusion, Etest®, MicroScan WalkAway, and Vitek – in Enterobacteriaceae 
and Pseudomonas isolates using imipenem and meropenem. For Enterobacteriaceae, the 
number of MEs across all testing methods ranged from 0 to 1 for imipenem and 0 to 2 for 
meropenem, and a ME rate ranging from 0 to 2.3%. Despite these comparatively lower 
error rates, the authors concluded testing susceptibilities of carbapenems with automated 
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systems resulted in high rates of ME and variability, requiring a second verification testing 
method for these agents.309 The present study supports this conclusion. 
There is a paucity of data on the validation of automated systems to appropriately 
determine susceptibility data for highly resistant isolates. Endimiani et al. included a small 
number of resistant isolates producing extended spectrum β-lactamases (n=5) and MBLs 
(n=4) in their study evaluating BD PhoenixTM, though separate susceptibility data for 
resistant isolates was not reported.303 Ours is the largest study evaluating the BD PhoenixTM 
automated susceptibility testing method for multiple drug classes against highly-resistant 
CRE isolates. Our results are consistent with a previous study by Zhao et al. in 2017 which 
evaluated three automated susceptibility testing methods against their reference method, 
agar dilution. Seventy-five CRE isolates were run against four agents: amikacin, 
ciprofloxacin, gentamicin, and levofloxacin. The resulting rates of minor, major, and VME 
were 3.11%, 2.44%, and 4.33%, respectively.308 Our rates of error are markedly greater 
than that observed by Zhao and colleagues. Even with comparatively lower error rates, the 
authors arrived at the conclusion that clinical laboratories should seek a second, 
independent method for determining susceptibility data for CRE isolates when using 
aminoglycosides and fluoroquinolones. Our study arrives at the same conclusion given the 
greater rates of MiE, ME, and VME. 
Subgroup analyses demonstrated similar patterns of elevated error rates associated 
with BD PhoenixTM, despite smaller population sizes in the subgroups resulting in fewer 
statistically significant results (see Table 4.4, Table 4.5, and Table 4.6). Furthermore, for 
some agents, it was not possible to conclude that the results were different due to the high 
levels of resistance, or in the case of amikacin, susceptibility.  
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Limitations of the present study include that our study isolates were taken from a 
single referral medical center. Therefore, data from other centers should be reported to 
determine external validity. Furthermore, because the susceptibility results from BD 
PhoenixTM were provided to the research laboratory independent of this project, there were 
a small number of isolates and agents for which BD PhoenixTM susceptibility data did not 
exist (0.51% of susceptibility data). In the event of these absences, the MIC value was 
omitted from analysis. Additionally, isolates collected were tested via BD PhoenixTM 
during the course of routine clinical practice. The isolates were then frozen and broth 
microdilution was performed at a later date, potentially providing an explanation for 
differentiation in MIC results. A limitation is also the absence of repeat susceptibility 
testing using the BD PhoenixTM system. However, in routine patient care, BD PhoenixTM 
susceptibility results are typically not repeated before being reported to clinicians. 
Repeated testing is performed using Etest® if an organism is ertapenem resistant and 
meropenem susceptible to verify the result, which is then reported. If CREs are identified, 
all carbapenem susceptibility reporting changes to document resistance. All MIC values 
are still reported. Therefore, the study design remains applicable to current clinical practice, 
with repeated testing performed by broth microdilution permitting more accurate reference 
MIC determination for each organism. Lastly, the BD PhoenixTM system was used to 
identify which isolates were carbapenem resistant for study inclusion. This was almost 
entirely determined by resistance to ertapenem, the most sensitive marker for 
carbapenemase production. This may have excluded isolates susceptible to ertapenem by 
BD PhoenixTM and resistant by BMD. This may further explain why ertapenem exhibited 
lower very major error rates relative to the other study antimicrobials.  
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The automated system BD PhoenixTM significantly overestimated susceptibility for 
CRE isolates compared to the gold-standard, BMD. This phenomenon was still observed 
when stratifying isolates by mechanism of carbapenem resistance. When compared to 
previous evaluations of automated susceptibility testing, BD PhoenixTM was associated 
with comparably elevated error rates for all tested antimicrobials, and only ertapenem 
exhibited low rates of VME. We agree with previous conclusions that secondary 
susceptibility testing methods should be utilized to verify antimicrobial activity against 
CRE. Further data is needed to assess the ability of BD PhoenixTM to accurately determine 
the MIC of highly resistant CRE isolates.  
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Table 4.3: Antimicrobial Susceptibility for CRE Isolates Using BMD and Phoenix by Drug 
Class (n=125) 
Susceptibility breakpoints determined by CLSI.268 
  
Antimicrobial 
Broth 
Microdilution 
Susceptibility 
BD Phoenix™ 
Susceptibility p-value 
Categorical 
Agreement 
Aminoglycosides  
Amikacin 84% 93% 0.021 91% 
Gentamicin 35% 42% 0.002 66% 
Tobramycin 16% 31% 0.001 71% 
β-Lactam/ β-
lactamase inhibitors  
Piperacillin-
tazobactam 1% 3% 0.125 95% 
Carbapenems  
Ertapenem 2% 1% 1 94% 
Meropenem 18% 37% 0.002 50% 
Cephalosporins  
Cefepime 5% 20% 0.0001 68% 
Ceftazidime 1% 6% 0.03 85% 
Fluoroquinolones  
Levofloxacin 15% 33% 0.001 61% 
Monobactams  
Aztreonam 2% 12% 0.003 94% 
Nitrofurans  
Nitrofurantoin 16% 36% 0.0002 63% 
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Table 4.4: Antimicrobial Susceptibility for KPC-producing CRE Isolates Using BMD and 
Phoenix by Drug Class (n=71) 
Susceptibility breakpoints determined by CLSI.268 
Antimicrobial 
Broth 
Microdilution 
Susceptibility 
BD Phoenix™ 
Susceptibility p-value 
Categorical 
Agreement 
Aminoglycosides  
Amikacin 82% 89% 0.1306 89% 
Gentamicin 25% 39% 0.5023 56% 
Tobramycin 15% 30% 0.9609 73% 
β-Lactam/ β-
lactamase inhibitors  
Piperacillin-
tazobactam 0% 0% 1 99% 
Carbapenems  
Ertapenem 0% 0% 1 94% 
Meropenem 6% 46% 0.0817 44% 
Cephalosporins  
Cefepime 25% 5% 0.0005 65% 
Ceftazidime 0% 0% 0.1310 85% 
Fluoroquinolones  
Levofloxacin 6% 32% 0.0002 62% 
Monobactams  
Aztreonam 0% 14% 0.0094 96% 
Nitrofurans  
Nitrofurantoin 18% 35% 0.0095 61% 
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Table 4.5: Antimicrobial Susceptibility for MBL-producing CRE Isolates Using BMD and 
Phoenix by Drug Class (n=21) 
Susceptibility breakpoints determined by CLSI.268 
  
Antimicrobial 
Broth 
Microdilution 
Susceptibility 
BD Phoenix™ 
Susceptibility p-value 
Categorical 
Agreement 
Aminoglycosides  
Amikacin 90% 100% 0.4795 90% 
Gentamicin 14% 33% 0.1336 71% 
Tobramycin 0% 5% 1 86% 
β-Lactam/ β-
lactamase inhibitors  
Piperacillin-
tazobactam 0% 0% 1 100% 
Carbapenems  
Ertapenem 0% 0% 1 100% 
Meropenem 0% 19% 0.0455 71% 
Cephalosporins  
Cefepime 0% 0% 1 95% 
Ceftazidime 0% 0% 1 100% 
Fluoroquinolones  
Levofloxacin 57% 33% 0.1820 48% 
Monobactams  
Aztreonam 0% 48% 0.0044 52% 
Nitrofurans  
Nitrofurantoin 10% 43% 0.0233 57% 
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Table 4.6: Antimicrobial Susceptibility for Non-carbapenemase-producing CRE Isolates 
Using BMD and Phoenix by Drug Class (n=27) 
Susceptibility breakpoints determined by CLSI.268 
 
 
 
 
Antimicrobial 
Broth 
Microdilution 
Susceptibility 
BD Phoenix™ 
Susceptibility p-value 
Categorical 
Agreement 
Aminoglycosides  
Amikacin 100% 100% 1 100% 
Gentamicin 33% 52% 0.0736 81% 
Tobramycin 33% 52% 0.0771 56% 
β-Lactam/ β-
lactamase inhibitors  
Piperacillin-
tazobactam 0% 15% 0.3711 74% 
Carbapenems  
Ertapenem 7% 0% 1 85% 
Meropenem 67% 22% 0.0817 44% 
Cephalosporins  
Cefepime 4% 15% 0.0736 78% 
Ceftazidime 4% 7% 0.1336 89% 
Fluoroquinolones  
Levofloxacin 7% 33% 0.0455 63% 
Monobactams  
Aztreonam 7% 11% 0.2482 81% 
Nitrofurans  
Nitrofurantoin 19% 30% 1 81% 
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Table 4.7: Error Rates for BMD vs. Phoenix™
I – Intermediate MIC 
*Piperacillin-tazobactam has a lower and higher intermediate MIC range 
Numbers in MIC range category column correspond to number of 2-fold serial dilutions 
  
Antimicrobial MIC Range Category Minor Errors 
Major 
Errors 
Very 
Major 
Errors 
Amikacin 
≥I+2 0%  100% 
I+1 to I-1 44% 0% 2% 
≤I-2 0% 13%  
Gentamicin 
≥I+2 2%  20% 
I+1 to I-1 35% 11% 16% 
≤I-2 4% 4%  
Tobramycin 
≥I+2 4%  11% 
I+1 to I-1 29% 0% 14% 
≤I-2 6% 11%  
Levofloxacin 
≥I+2 4%  27% 
I+1 to I-1 22% 11% 30% 
≤I-2 15% 31%  
Nitrofurantoin 
≥I+2 13%  10% 
I+1 to I-1 30% 2% 13% 
≤I-2 13% 0%  
Aztreonam 
≥I+2 1%  10% 
I+1 to I-1 0% 0% 67% 
≤I-2 0% 100%  
Cefepime 
≥I+2 8%  14% 
I+1 to I-1 83% 0% 0% 
≤I-2 0% 0%  
Ceftazidime 
≥I+2 6%  5% 
I+1 to I-1 0% 33% 33% 
≤I-2 0% 0%  
Piperacillin-
tazobactam* 
≥IHigh+2 2%  2% 
IHigh+1 to ILow-1 25% 25% 25% 
≤ILow-2 0% 0%  
Ertapenem 
≥I+2 3%  1% 
I+1 to I-1 33% 17% 0% 
≤I-2 0% 100%  
Meropenem 
≥I+2 7%  39% 
I+1 to I-1 31% 12% 12% 
≤I-2 6% 63%  
159 
 
Polymyxin B Etest® Compared to Gold-standard Broth Microdilution in 
Carbapenem-resistant Enterobacteriaceae Exhibiting a Wide Range of Polymyxin B 
MICs 
Published: Clinical Microbiology and Infection. 2019. 25(1): 92-95 
Authors: Brandon Kulengowski, Julie A. Ribes, David S. Burgess 
Kulengowski contribution: Experimental design, execution, data analysis, revisions and 
editing of final manuscript 
  
160 
 
Abstract 
Objectives: Polymyxins have been revitalized to combat carbapenem-resistant 
Enterobacteriaceae (CRE). However, evaluating the activity of these agents by traditional 
broth dilution methods is not practical for busy clinical laboratories. We compared 
polymyxin B (PMB) activity utilizing two quantitative susceptibility testing methods, 
Etest® and broth microdilution (BMD), against CRE isolates from patients at an academic 
medical center. 
Methods: PMB activity against 70 CRE clinical isolates was determined by Etest® 
according to manufacturer and by BMD according to CLSI guidelines. P. aeruginosa 
ATCC® 27853 and E. coli NCTC 13846 served as quality control strains. The EUCAST 
colistin susceptibility breakpoint of Enterobacteriaceae (≤2 mg/L) was used. Essential 
agreement was isolates with an MIC within 1 log2 dilution over total isolates. Categorical 
agreement was number of isolates in the same susceptibility category (susceptible or 
resistant) over total isolates. Major and very major error rates were calculated using number 
of susceptible and number of resistant isolates, respectively, as the denominator. 
McNemar’s test was used for determining a difference in susceptibility between methods. 
Results: CRE isolates were primarily Klebsiella spp. (49%) and Enterobacter spp. (36%). 
PMB susceptibility was significantly higher by Etest® compared to BMD (97% vs. 77%; 
P=0.0001). Categorical agreement was 80%, but essential agreement was low (10%). False 
non-susceptibility was never observed by Etest® (BMD reference), but the very major 
errors were high (88%).  
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Conclusions: Etest® reporting of false susceptibility may result in inappropriate antibiotic 
utilization and treatment failure clinically. We do not recommend using Etest® for PMB 
susceptibility testing for routine patient care. 
 
Introduction 
 The polymyxins are an older class of antimicrobials from the 1950s reemerging for 
the treatment of multidrug resistant infections such as those caused by carbapenem-
resistant Enterobacteriaceae (CRE).131 Infections caused by CRE are reported worldwide 
and led to significant mortality, often requiring antimicrobial combinations for effective 
treatment.274 Polymyxin B (PMB) and colistin (CST) cause significant neurotoxicity and 
nephrotoxicity, and so their use was sparse until the era of CRE infections.310 As a result, 
these older agents are usually not available on standard susceptibility testing panels of 
automated systems such as Vitek®, MicroScan®, and Phoenix™. Hence, many clinical 
laboratories have utilized Etest® strips as a rapid alternative given traditional laboratory-
prepared broth dilution methods are too laborious for routine use in clinical laboratories.  
There exist, however, several concerns with in vitro susceptibility testing of PMB 
and CST. Principally, there are conflicting data reported in the literature regarding proper 
antimicrobial susceptibility testing procedures.267 There have also been disputes regarding 
the most appropriate reference standard for comparison as well as many limitations in 
modern studies around testing populations that fully represent the spectrum of polymyxin 
MICs (very susceptible to very resistant).311 Heteroresistance within bacterial isolates 
renders obtaining reproducible susceptibility information difficult as well.140 Lastly, even 
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if MIC information is obtained, one value may not appropriately describe populations that 
exhibits heteroresistance. 
 CLSI and EUCAST have jointly released a recommendation regarding the use of 
broth microdilution (BMD) as the reference standard, but these organizations have been 
unable to recommend other methods (e.g. agar dilution, disk diffusion, and gradient 
diffusion) until new study data have been generated.267 The aim of this study was to 
compare Etest® to broth microdilution using the new CLSI/EUCAST standards in a CRE 
population.267 
 
Methods 
Bacterial isolates. 70 non-duplicate clinical isolates that were non-susceptible to any of 
the carbapenems were collected from a tertiary academic medical center during 2010 to 
2016. Isolates were stored at -80˚C in 10% glycerol stocks and subcultured twice before 
testing. Pseudomonas aeruginosa ATCC 27853 and Escherichia coli NCTC 13846 served 
as susceptible (0.5 – 2 mg/L) and non-susceptible (4 – 8 mg/L) controls, respectively. 
Antimicrobial Powder. Polymyxin B sulfate was obtained from Sigma-Aldrich (St. Louis, 
MO). Certificates of analysis were used to determine potency of antimicrobials. 
Broth microdilution. BMD was conducted in duplicate on at least 2 separate occasions 
according to CLSI guidelines using cation-adjusted Mueller-Hinton broth (BBL-Becton 
Dickinson, Sparks, MD).267,312 The modal MIC was accepted, or a third replicate 
experiment was conducted for discordant MICs near the breakpoint (e.g. 1, 2, and 4 mg/L) 
or for MICs greater than 1 log2 dilution apart. The higher MIC was accepted for other cases 
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where there was no mode (e.g. one experiment measuring 0.25 mg/L and a second 
measuring 0.5 mg/L would be reported as 0.5 mg/L).  
Etest®. Polymyxin B Etest® (bioMérieux Inc., Durham, NC) on Mueller-Hinton agar 
(BBL-Becton Dickinson, Sparks, MD) was performed according to manufacturer’s 
protocol on at least 2 separate occasions. A similar approach as BMD MIC interpretation 
was taken for Etest® results.  
Analysis. All Etest® intermediate MICs were first rounded up to the nearest MIC 
measurable by BMD (e.g. 0.75 was rounded to 1, 3 was rounded to 4, etc.). Descriptive 
statistics were calculated for BMD and Etest® – percentage susceptible (%S) using 
EUCAST susceptibility breakpoints for colistin in Enterobacteriaceae, MIC50, MIC90, and 
MIC range. Comparative statistics were calculated for BMD and Etest®. The rate of 
essential agreement (EA) was defined as the ratio of the percentage of isolates with a BMD 
and Etest® MIC within 1 log2 dilution to the total number of isolates (n=70). The rate of 
categorical agreement (CA) for the test systems was defined as the ratio percentage of 
isolates with the same susceptibility category (susceptible vs. resistant) reported by both 
methods to the total number of isolates (n=70). The rate of major errors (MEs) was defined 
as the ratio percentage of isolates reported resistant by Etest® but susceptible by BMD to 
the number of isolates susceptible by BMD. Very major error (VME) rate was defined as 
the ratio percentage of isolates reported susceptible by Etest® but resistant by BMD to the 
number of resistant isolates by BMD.270 MIC distributions were determined for each test 
method (Figure 4.1). Etest® MIC vs. BMD MIC data were plotted (Figure 4.2). McNemar’s 
test was utilized to compare paired susceptibility data between testing methods. 
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Results 
Isolates were predominately Klebsiella spp. (34/70; 49%), followed by Enterobacter spp. 
(25/70; 36%), Escherichia coli (5/70; 7%), Citrobacter spp. (5/70; 7%), and Providencia 
rettgeri (1/70; 1%). PMB susceptibility, MIC50/MIC90, MIC range, EA, CA, and error rates 
are presented in Table 4.8. Overall susceptibility measured by Etest® was significantly 
higher than susceptibility measured by BMD (P=0.0001). BMD isolates generally 
exhibited a wider range of MICs (Figure 4.1 and Figure 4.2), supported also by comparing 
the MIC50/MIC90 ratios (Table 4.8). The categorical discordance between BMD and Etest® 
was exclusively very major errors. Roughly 90% isolates with PMB MICs >2 mg/L by 
BMD were reported as ≤2 mg/L by Etest® (Table 4.8). Etest® correlated poorly with BMD, 
generally overestimating the MIC when BMD MICs were <0.5 mg/L, but underestimating 
the MIC when BMD MICs were >1 mg/L (Figure 4.2). For BMD, P. aeruginosa 27853 
ranged 0.5 – 1 mg/L. E. coli NCTC 13846 ranged 4 – 8 mg/L. For Etest®, P. aeruginosa 
27853 measured 0.5 mg/L. E. coli NCTC 13846 measured 4 mg/L. 
 
Discussion 
Summary of principal findings 
In a sizeable sampling (n=70) of CRE clinical isolates consisting primarily of Klebsiella 
spp. and Enterobacter spp., we found considerable discordance between Etest® and BMD 
(EA 10%, CA 80%, VME 88%). Most importantly, Etest® poorly predicted the polymyxin 
B MIC for isolates exhibiting elevated PMB MICs by BMD when utilizing the 
recommendations of CLSI/EUCAST for BMD susceptibility testing.267 
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Findings of the present study relative to previous studies 
A recent review of polymyxin susceptibility testing has analyzed susceptibility studies for 
PMB and CST.313 Although CST has been studied frequently, only two other studies have 
evaluated PMB in a CRE population comparing Etest® to BMD as a reference, but with 
different conclusions regarding which method was more sensitive to polymyxin 
resistance.314,315 Other insights have come from Rojas et al. who used colistin Etest® to 
compare with polymyxin B broth microdilution.316 Lat et al. found PMB Etest® 
overestimates resistance relative to BMD whereas the other two studies were consistent 
with the present findings – PMB Etest® underestimates resistance. Percent susceptible was 
grossly similar, ranging 64-87% vs. present study 77%. Interestingly, very major error rates 
for PMB have ranged from 14 to 35% whereas we report the highest VME to date of 88%. 
The highest reported CST VME rate was 46%.317 A Chi-squared comparison between 
Rojas et al. VME rate (35%, n=25) vs. the present study (88%, n=16) was P=0.001.316 
Discrepancies between our data and previous findings could be explained by the rigor with 
which PMB MICs were ascertained or interpreted because skip wells are frequent.318 Other 
explanations include differences in regional resistance mechanisms (e.g. presence of mcr-
1). Chew et al. found mcr-1 in a majority of resistant isolates whereas Rojas et al. found 
none. We did not test for mcr-1, and other polymyxin resistance mechanisms are not as 
easy understood, but they are considered to involve the PhoPQ regulatory system.314 
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Strengths and limitations of the study 
Strengths of the present study include the use of clinical isolates from a tertiary academic 
medical center where patients come from all over the state, a varied representation of MICs 
across the susceptible-resistant spectrum, use of standardized laboratory methods 
performed in duplicate on at least two different days, and literature support of findings 
from other laboratory groups. Limitations of the present study include that the population 
is exclusively CRE organisms, limited quantities of isolates with polymyxin B MICs >2 
mg/L (n=16), single-center, lack of genetic data regarding the mechanisms of resistance to 
carbapenems or polymyxin B, and unavailability of clinical outcomes data. Additionally, 
this study is limited in its ability to ascertain assay variability with only duplicate, seldom 
triplicate MIC measurements. The dearth of pharmacokinetic/pharmacodynamic and 
clinical outcomes data for establishing a polymyxin B susceptibility breakpoint limited this 
study to using the susceptibility breakpoint for colistin. Finally, this study lacked sufficient 
quantities of individual species of CRE to perform sufficiently powered species subgroup 
analyses. 
 
Understanding possible mechanism 
We propose that the mechanism behind the discrepancy we and others have observed 
between PMB Etest® and BMD may be explained if BMD is more sensitive to 
heteroresistant subpopulation growth than Etest®. For example, if a few colonies are 
growing inside the Etest® zone of inhibition but are not close enough to the Etest® strip to 
confound the interpretation, then this may suggest the presence of heteroresistance but at 
too small of a quantity to reliably alter the Etest® interpretation. Consider also when these 
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heteroresistant colonies are instead in one of the microtiter wells. They may grow in such 
an environment to turn the wells turbid and result in an elevated PMB MIC. Differences in 
heteroresistance rate would then explain very major error differences between our study 
and previous studies. To date, no study has been published that describes such a 
mechanism, and so additional data are needed. 
 
Implications for practice and future research  
Although BMD is considered the standard by CLSI/EUCAST,267 alternative antimicrobial 
susceptibility testing methodologies conducive to clinical laboratory workflow are and 
should continue to be explored such as automated systems, Sensititre®, and others.313 
However, our data do not support the continued use of Etest® strips for determining PMB 
MICs in CRE populations.  
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Table 4.8: Comparison of BMD and Etest® for Polymyxin B against 70 CRE Clinical 
Isolates 
 Polymyxin B BMD Polymyxin B Etest® P-value 
%S 77% 97% 0.0001 
MICR50 0.125 0.5  
MICR90 32 1  
MIC range ≤0.06 – >64 0.125 – 1024  
EA 10%  
CA 80%  
VME 88%  
ME 0%  
%S – susceptible percentage; MICx – The lowest concentration of antimicrobial at which 
X% of isolates were inhibited; EA – Essential Agreement; CA – Categorical Agreement; 
VME – Very Major Error; ME – Major Error 
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Figure 4.1: Comparison of Broth Microdilution and Etest® MIC Distributions of Polymyxin B against 70 Carbapenem-resistant 
Enterobacteriaceae. MIC – minimum inhibitory concentration. BMD – Broth microdilution. BMD measurable range 0.125 – 64. Etest® 
MIC values rounded up to nearest measurable MIC by BMD. 
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Figure 4.2: Minimum Inhibitory Concentrations by Etest® and Gold-standard Broth Microdilution. BMD – broth microdilution. N=70 
CRE clinical isolates. Black line indicates equivalent MIC measurements between testing methods. Grey line indicates ±1 log2 dilution 
agreement between testing methods. Note that any one circle may represent multiple overlapping data points.
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Abstract 
Background: Metallo-beta-lactamase- (MBL-) producing carbapenem-resistant 
Enterobacteriaceae (CRE) are becoming more prevalent in the United States. Identifying 
differences in resistance phenotypes will help clinicians determine appropriate 
antimicrobial therapy against organisms that produce MBLs. With genotypic rapid 
diagnostics, carbapenemase phenotype is often known before susceptibility data. 
Objectives: To ascertain differences in antimicrobial activity among KPC- and VIM-
producing CRE. 
Methods: Commonly utilized antimicrobials (n=16) were tested by broth microdilution 
according to CLSI guidelines against 92 carbapenemase-producing CRE. Antimicrobial 
activity was compared between VIM- (n=20) and KPC-producing (n=72) CRE using 
Fisher’s exact test.  
Results: Polymyxin B, colistin, and levofloxacin exhibited significantly higher 
susceptibility against VIM-producing CRE than KPC-producing CRE. Gentamicin and 
tobramycin, but not amikacin, exhibited significantly higher susceptibility against KPC-
producing CRE than VIM-producing CRE. 
Conclusions: Carbapenemase phenotype among CRE should direct clinician choice of 
antimicrobial agents. VIM-producing CRE in the United States were more susceptible to 
polymyxins and fluoroquinolones than KPC-producing CRE.  
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Introduction 
Carbapenem-resistant Enterobacteriaceae (CRE) are a growing problem in the 
setting of few active antimicrobial options and relatively high mortality (50%).14 A one-
size-fits-all treatment objective for CRE is naively optimistic, so an approach focused 
instead on the nuanced resistance phenotypes among CRE is ideal, particularly given the 
variability associated with CRE susceptibility profiles.205 In the U.S., Klebsiella 
pneumoniae carbapenemases (KPCs) represent the majority of CRE resistance phenotypes 
followed by New Delhi metallo-beta-lactamase (NDM) and then other metallo-beta-
lactamases (MBLs) according to the Centers for Disease Control and Prevention.79 
However, other antimicrobial resistance genes are frequently transferred on the same 
plasmids carrying carbapenemase genes which confer resistance to other antimicrobial 
agents.14 Furthermore, interpretation of antimicrobial resistance genotyping is confounded 
by inactive but present genes, since constitutive production of enzymes or other resistance 
mechanisms is often associated with a fitness cost to the organism.289 Therefore, 
phenotypic antimicrobial activity profiles are necessary to evaluate differences in CRE sub-
groups, such as CRE that produce KPCs compared to CRE that produce MBLs. 
Since a majority of CRE in the United States produce only KPC, most U.S. in vitro 
studies have focused on KPC-producing CRE. In fact, the FDA recently approved 
ceftazidime/avibactam and meropenem-vaborbactam for use against CRE, but neither 
exhibit activity against MBL producing CRE.14 Plazomicin is a novel aminoglycoside with 
activity against CRE, but methyltransferases are associated with reduced activity and were 
subsequently found to be associated with MBL production.319 In response to a call for 
additional in vitro data with MBL-producing CRE, this study aimed to evaluate differences 
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in susceptibility of commonly utilized antimicrobial against carbapenem-resistant 
Enterobacteriaceae that produce VIM.214  
 
Materials and Methods 
CRE isolates (n=92), defined as Enterobacteriaceae resistant to at least one 
carbapenem, from January 1, 2012 through January 1, 2017 were obtained from the 
University of Kentucky HealthCare System, a tertiary referral academic medical center. 
Susceptibility testing for ertapenem and meropenem were performed by the automated 
testing system, BD Phoenix™, as part of routine patient care and used to identify study 
isolates. MBL genotyping was also performed by the Verigene® system as part of routine 
patient care which identified 20 VIM producing isolates. All 92 isolates also underwent 
duplicate separate day phenotyping experiments for KPC and/or MBL production 
according to a previously published EDTA/phenylboronic acid disk diffusion protocol.266 
Subsequent susceptibility testing was performed on CRE by broth microdilution according 
to CLSI guidelines.268 Susceptibility testing was performed in duplicate on at least two 
separate days, accepting the modal MIC. If no modal MIC was identified, the higher of the 
MICs was accepted. If the accepted higher MIC was within one two-fold dilution of an 
interpretive boundary, a third experiment was performed. Antimicrobial agents (n=16) 
tested include: ertapenem, meropenem, imipenem, amikacin, gentamicin, tobramycin, 
colistin, polymyxin B, piperacillin-tazobactam, aztreonam, cefepime, ceftazidime, 
minocycline, tigecycline, levofloxacin, and nitrofurantoin. Tazobactam was tested at a 
fixed dose of 4 mg/L. All powders were obtained from Sigma-Aldrich (St. Louis, MO, 
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USA). Because susceptibility breakpoints for polymyxin B and colistin are not available 
for Enterobacteriaceae, the EUCAST susceptibility breakpoint for colistin of 2 mg/L was 
used for both antimicrobials. 
 
Results and Discussion 
 A total of 72 KPC-producing CRE and 20 VIM-producing CRE were obtained as 
clinical isolates from UK HealthCare and were confirmed by the previously mentioned 
EDTA/phenylboronic acid diffusion assay. Klebsiella pneumoniae composed most of the 
isolates (n=44; 48%), followed by Enterobacter spp. (n=32; 35%), Citrobacter spp. (n=8; 
9%), other Klebsiella spp. (n=4; 4%), Escherichia coli (n=3; 3%), and Serratia marcescens 
(n=1; 1%). As displayed in Table 4.9, KPC-producing isolates were most susceptible to 
tigecycline (83%), amikacin (81%), and the polymyxins (64%). VIM-producing isolates 
exhibited improved susceptibility to the polymyxins (95%), tigecycline (90%), and 
amikacin (90%), but only the polymyxin class was statistically significant (P=0.003). 
Levofloxacin was also significantly more active against VIM-producing CRE than KPC-
producing CRE (60% vs. 6%; p < 0.0001; Table 4.9). Gentamicin and tobramycin, but not 
amikacin, were significantly more active against KPC-producing CRE than VIM-
producing CRE (Table 4.9), but the clinical relevance of this observation is diminished by 
the overall relatively low activity of either agent (<40%). 
Differences in antimicrobial activity may be explained by differences in the 
plasmids carrying VIM compared to those carrying KPC since neither VIM nor KPC confer 
resistance to aminoglycosides, polymyxins, glycylcyclines, or fluoroquinolones on their 
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own. However, phylogenetic analysis and multilocus sequence typing was not possible 
since complete genomic data were not available on this collection of isolates. These data, 
in conjunction with clinical data, support the use of alternative agents like 
ceftazidime/avibactam and meropenem-vaborbactam whose activity against KPC-
producing isolates is reportedly higher and associated with superior clinical 
outcomes.257,320,321 However, as mentioned previously, neither of these newer agents are 
active against MBL-producing isolates like the CRE in the present study that produce VIM. 
Instead, our data suggest that amikacin, tigecycline, and the polymyxins are most active 
against these isolates, but we would recommend their use in combination, most likely with 
a carbapenem, based on other studies.322 A limitation of the present study is the data comes 
from a single center. However, the isolates in this study come from the surrounding 
Kentucky communities, and other U.S. centers combined have not reported as many VIM-
producing CRE as Kentucky according to the CDC.79 Additional data are also warranted 
with plazomicin and eravacycline, whose CRE activity is not directly impacted by MBL-
production, but other resistance genes may have been transferred on plasmids. 
Additionally, aztreonam/avibactam offers promise against MBL-producing isolates 
because aztreonam is not inhibited by MBLs and avibactam inhibits the other serine based 
carbapenemases like KPCs and some OXA-like carbapenemases.323 
 Antimicrobial susceptibility patterns vary considerably by region, so clinicians 
should be familiar with their local antibiograms.14 Furthermore, genotypic/phenotypic 
information should direct clinical decision-making as to which antimicrobials are most 
appropriate to combat infections caused by organisms like CRE, especially given the 
present findings of susceptibility differences with antimicrobials like the aminoglycosides 
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and polymyxins against VIM- and KPC-producing CRE. Specifically, the polymyxins and 
levofloxacin exhibited superior activity whereas gentamicin and tobramycin exhibited 
reduced activity against VIM-producing CRE when compared to KPC-producing CRE. 
 
Table 4.9: Cumulative Antimicrobial Susceptibility Data for Carbapenem-resistant 
Enterobacteriaceae that produce KPC or VIM 
Antimicrobial 
KPC 
(n=72) 
MIC50 / 
MIC90 
(mg/L) 
VIM 
(n=20) 
MIC50 / 
MIC90 
(mg/L) 
KPC 
(n=72) 
Susceptible 
(%) 
VIM 
(n=20) 
Susceptible 
(%) 
P-value 
AMINOGLYCOSIDES      
Amikacin 4 / 32 8 / 16 81 90 0.18 
Gentamicin 32 / 128 16 / 128 35 15 0.05 
Tobramycin 32 / 128 16 / 64 19 0 0.02 
β-LACTAM/β-
LACTAMASE INHIBITOR      
Piperacillin/tazobactam >512/4 / >512/4 
>512/4 / 
>512/4 0 0 1 
β -LACTAMS      
Imipenem 16 / 128 32 / 64 6 0 0.37 
Meropenem 32 / 128 16 / 32 6 0 0.37 
Ertapenem 64 / >128 8 / 64 0 0 1 
Cefepime 256 / >256 128 / 256 3 0 0.61 
Ceftazidime 512 / >512 >512 / >512 0 0 1 
CYCLINES      
Tigecycline 2 / 4 1 / 2 83 90 0.23 
Minocycline 16 / 64 16 / 32 17 25 0.17 
FLUOROQUINOLONES      
Levofloxacin 32 / >32 2 / 8 6 60 <0.0001 
MONOBACTAMS      
Aztreonam 512 / >512 128 / 256 0 0 1 
NITROFURANS      
Nitrofurantoin 128 / 256 64 / 256 18 10 0.2 
POLYMYXINS      
Colistin# 0.125 / >64 ≤0.06 / 0.125 64 95 0.004 
Polymyxin B# 0.25 / >64 ≤0.06 / 0.25 64 95 0.004 
Susceptibility breakpoints were determined by CLSI 2018 criteria268 
#The EUCAST 2018 colistin susceptibility breakpoint of ≤2 mg/L was used for polymyxin 
B and colistin because there is not a CLSI breakpoint established for Enterobacteriaceae281 
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Abstract 
Objectives: Carbapenem-resistant Enterobacteriaceae cause significant mortality (50%) 
and are resistant to nearly all known antimicrobial agents. Imipenem/relebactam, a novel 
beta-lactam/beta-lactamase inhibitor combination, and 16 other antimicrobials were 
evaluated against non-MBL-producing carbapenem-resistant Enterobacteriaceae (CRE) 
clinical isolates from a United States tertiary academic medical center. 
Methods: Clinical isolates (n=96) resistant to ertapenem or meropenem by BD Phoenix™ 
and negative for metallo-beta-lactamase- (MBL-) production by an EDTA/phenylboronic 
acid disk diffusion assay were identified and collected from January 2012 to January 2017. 
In vitro susceptibility by broth microdilution was performed according to CLSI guidelines 
for 17 antimicrobials. 
Results: CRE consisted primarily of K. pneumoniae (55%) and Enterobacter spp. (25%), 
followed by Citrobacter spp. (10%), E. coli (5%), and others (5%). CRE were most 
susceptible to imipenem/relebactam (100%), followed by amikacin (85%), tigecycline 
(82%), and polymyxin B/colistin (65%). The median reduction of imipenem MICs of non-
MBL-producing CRE was 16-fold, but ranged from 0.5 to >512-fold. The MIC50, MIC90, 
and MIC range of imipenem/relebactam was 0.5 mg/L, 1 mg/L, and 0.06 – 1 mg/L, 
respectively. 
Conclusions: Imipenem/relebactam exhibits excellent activity against non-MBL-
producing CRE. 
Keywords: Carbapenem-resistant Enterobacteriaceae; imipenem/relebactam; 
antimicrobial susceptibility testing; KPC; MBL  
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Introduction 
The optimal treatment for infections caused by carbapenem-resistant 
Enterobacteriaceae (CRE) is not yet established. The greatest factor contributing to this 
gap in clinical knowledge is the lack of randomized controlled trials concerning CRE, but 
there are also other confounding variables that render meta-analyses and case studies 
ineffectual for generalization such as complex and myriad possible antimicrobial 
combinations. Heterogeneity among treatment regimens and differences among CRE 
populations, even among institutions within similar geographical regions, impact clinical 
outcomes.205 As a result, in vitro and animal studies have become critically important for 
evaluating CRE treatment, for which a carbapenem in combination with a polymyxin have, 
generally, been the front-runner in the United States. However, analysis of certain 
subgroups within CRE have suggested that even this combination has pitfalls, specifically 
when carbapenem MICs exceed 8 mg/L.204 Furthermore, in an age where the importance 
of precision medicine is realized, perhaps a generalized solution to a diverse problem will 
always be unsatisfactory. 
The concern for CRE is justifiably growing as antimicrobial resistance rates 
continue to rise.11 KPC enzymes comprise the major carbapenem resistance mechanism in 
the United States, followed by NDM, OXA-48, VIM, and IMP in order of decreasing 
prevalence.324 Other resistance mechanisms such as a cephalosporinase in combination 
with a porin channel mutation or efflux gene also affect the United States.14 Therefore, it 
is critical that reports of local and regional resistance patterns continue to be published to 
best track the epidemiology of CRE and to develop optimized treatment strategies to 
combat these organisms. Most literature from the United States has been from the New 
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England area where CRE have had the greatest impact, with resistance rates reported up to 
40% in some hospitals.122 At our institution, we observe CRE rates <5%. The objective of 
this study was to first describe the CRE population reflective of a tertiary referral academic 
medical center located in southeastern United States, and then to compare the activity of a 
novel antimicrobial, imipenem/relebactam (IMI/REL), with 16 other antimicrobials. 
Relebactam is a non-beta-lactam, bicyclic diazabicyclooctanase, beta-lactamase inhibitor 
with activity against Ambler class A and C beta-lactamases. Relebactam recently 
completed phase 3 clinical studies combined with imipenem/cilastatin (ClinicalTrials.gov. 
NCT02452047). Other than Class B (i.e., metallo-beta-lactamases,) and Class D (i.e., 
OXA) inactivation of the OmpK36 porin protein has been reported to confer resistance to 
imipenem/relebactam.325 
 
Material and Methods 
CRE isolates from January 1, 2012 through January 1, 2017 were obtained from 
the University of Kentucky HealthCare System. Susceptibility testing for commonly 
utilized antimicrobials was performed by the automated testing system, BD Phoenix™, as 
part of routine patient care. CRE isolates also underwent duplicate separate day phenotypic 
experiments for Klebsiella pneumoniae carbapenemase (KPC) and/or metallo-β-lactamase 
(MBL) production according to a previously published EDTA/phenylboronic acid disk 
diffusion protocol.266 Subsequent susceptibility testing was performed on non-MBL 
producing CRE by broth microdilution according to CLSI guidelines.268 Susceptibility 
testing was performed in duplicate on at least two separate days, accepting the modal MIC. 
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If no modal MIC was identified, the higher of the MICs was accepted. If the accepted 
higher MIC was within one two-fold dilution of an interpretive boundary, a third 
experiment was performed. Antimicrobial agents tested include: imipenem/relebactam, 
ertapenem, meropenem, imipenem, amikacin, gentamicin, tobramycin, colistin, polymyxin 
B, piperacillin-tazobactam, aztreonam, cefepime, ceftazidime, minocycline, tigecycline, 
levofloxacin, and nitrofurantoin. All inhibitors were tested at a fixed dose of 4 mg/L. 
Imipenem and relebactam powders were obtained from Merck & Co., Inc (Kenilworth, NJ, 
USA). All other powders were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Because susceptibility breakpoints have yet to be determined for IMI/REL, the imipenem 
susceptibility breakpoint (1 mg/L) was utilized. 
 
Results 
In total, 500 multidrug resistant gram-negative bacteria were collected from UK 
HealthCare, with 96 Enterobacteriaceae being resistant to at least one carbapenem tested 
(meropenem or ertapenem) and lacking production of MBL (Class B) enzymes. We found 
K. pneumoniae (55%) and Enterobacter spp. (25%) to be the predominant CRE, followed 
by Citrobacter spp. (10%), E. coli (5%), other Klebsiella spp. (4%), and S. marcescens 
(1%). Patients were predominantly white, above the age of 50, and in the ICU at the time 
of culture (Table 4.10). The most active antimicrobials against CRE were IMI/REL 
(100%), amikacin (85%), tigecycline (84%), and the polymyxins (65%) (Table 4.11). For 
most isolates, relebactam significantly enhanced the activity of imipenem, but the degree 
of change in activity varied (0.5 to >512-fold reduction in MIC). The distribution of 
 
183 
 
imipenem/relebactam MICs tightly clustered around 0.25-1 mg/L whereas imipenem alone 
was approximately evenly distributed from 1-64 mg/L (Table 4.12). 
 
Discussion 
 In a large population of non-MBL CRE clinical isolates (n=96) primarily composed 
of Klebsiella spp. and Enterobacter spp., we found excellent restored activity of imipenem 
when relebactam (at a fixed concentration of 4 mg/L) was added against non-MBL 
producing CRE (from 23% to 100%; n=96). Importantly, imipenem/relebactam exhibited 
better activity than other commonly utilized antimicrobials to treat CRE, including 
amikacin (85%), tigecycline (82%), and the polymyxins (65%) (Table 4.11). Our findings 
are consistent with other reports of improved imipenem activity when relebactam is 
added.326-329 Strengths of the present study include analyzing a sizeable population of 
carbapenem-resistant Enterobacteriaceae, collecting clinical isolates from a large referral 
academic medical center, and utilizing a robust design of gold-standard broth microdilution 
for susceptibility testing in double replicate sometimes triple replicate. Limitations, like 
other reports, include that isolates primarily come from nearby communities rather than a 
multi-center or international collection of isolates and that genetic information is 
unavailable on all of these isolates.  
Carbapenem-resistant Enterobacteriaceae populations are not sufficiently 
described by nationally or internationally observed antimicrobial activity, but rather, 
regional susceptibility data needs to be reported to improve epidemiological study and 
rational therapeutic decision-making in the clinical setting. For example, we have found a 
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population of non-MBL producing CRE in the southeastern United States exhibiting 
relatively high polymyxin MICs, but for which IMI/REL activity is excellent (100%). 
 
Conclusions 
 Imipenem/relebactam exhibits excellent activity against non-MBL producing CRE. 
Our data support the continued development of imipenem/relebactam and its use against 
carbapenem-resistant Enterobacteriaceae. 
 
Table 4.10: Patient Demographics for Non-MBL-producing Carbapenem-resistant 
Enterobacteriaceae (n=96) Collected from January 2012 – January 2017 
Patient Demographics 
Age  
Mean 56 yrs 
Median 57.4 yrs 
Range 3 wks – 96 yrs 
Sex  
Male 56% 
Female 44% 
Ethnicity  
White 95% 
African-American 4% 
Asian 1% 
ICU Status  
 Any ICU visit during stay 74% 
Culture drawn in ICU 72% 
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Table 4.11: Cumulative Antimicrobial Susceptibility for Non-MBL-producing 
Carbapenem-resistant Enterobacteriaceae (n=96) 
Antimicrobial Susceptibility 
Breakpoint 
(mg/L) 
Susceptible 
(%) 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
Range 
(mg/L) 
AMINOGLYCOSIDES      
Amikacin ≤ 16 85 4 32 ≤0.5-64 
Gentamicin ≤ 4 34 32 128 ≤0.125->128 
Tobramycin ≤ 4 23 16 128 ≤0.125->128 
β-LACTAM/ 
β-LACTAMASE 
INHIBITOR 
     
Imipenem/relebactam ≤ 1/4* 100 0.5 1 0.06-1 
Piperacillin/tazobactam ≤ 16/4 0 >512 >512 32->512 
β -LACTAMS      
Imipenem ≤ 1 23 8 128 0.25->128 
Meropenem ≤ 1 21 16 128 ≤0.125->128 
Ertapenem ≤ 0.5 0 64 128 1->128 
Cefepime ≤ 2 2 256 >256 1->256 
Ceftazidime ≤ 4 0 512 >512 8->512 
CYCLINES      
Tigecycline ≤ 2 82 2 4 0.06-16 
Minocycline ≤ 4 16 16 >64 0.25->64 
FLUOROQUINOLONES      
Levofloxacin ≤ 2 5 32 >32 0.06->32 
MONOBACTAMS      
Aztreonam ≤ 4 1 512 >512 4->512 
NITROFURANS      
Nitrofurantoin ≤ 32 18 256 256 2-512 
POLYMYXINS      
Colistin ≤ 2# 65 0.25 >64 ≤0.06->64 
Polymyxin B ≤ 2# 65 0.125 >64 ≤0.06->64 
Susceptibility breakpoints were determined by CLSI 2018 criteria except for 
imipenem/relebactam where the imipenem breakpoint of ≤1 mg/L was utilized 
*CLSI Enterobacteriaceae breakpoints for imipenem were utilized (susceptible, 1 mg/L; 
intermediate, 2 mg/L; resistant, 4 mg/L)268 
#The EUCAST 2018 colistin susceptibility breakpoint of ≤2 mg/L was used for polymyxin 
B and colistin because there is not a CLSI breakpoint established for Enterobacteriaceae. 
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Table 4.12: MIC Frequency Distribution of Carbapenem-resistant Enterobacteriaceae (n=96) 
MIC (mg/L) 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 >* 
AMINOGLYCOSIDES              
Amikacin - - - 3 19 22 18 4 16 11 3 0 0 
Gentamicin - 6 8 3 0 6 10 6 6 19 19 10 3 
Tobramycin - 3 7 5 2 1 4 10 19 20 11 6 8 
BL/BLI              
Imipenem/relebactam  2 7 28 28 31 0 0 0 0 0 - - 0 
Piperacillin/tazobactam - - - 0 0 0 0 0 0 1 1 0 94 
β -LACTAMS              
Imipenem - 0 4 6 12 7 12 11 14 9 11 6 4 
Meropenem - 1 7 6 6 6 8 5 10 17 18 10 2 
Ertapenem - 0 0 0 1 2 9 13 7 13 19 23 9 
Cefepime - - 0 0 1 1 2 0 5 10 11 14 52 
Ceftazidime - - - 0 0 0 0 1 1 1 1 7 85 
CYCLINES              
Tigecycline 1 0 1 8 28 41 10 4 3 0 - - 0 
Minocycline 0 0 1 0 0 1 13 27 19 10 15 - 10 
FLUOROQUINOLONES              
Levofloxacin 2 0 1 0 1 1 4 11 15 18 - - 43 
MONOBACTAMS              
Aztreonam - - - 0 0 0 1 0 0 1 3 7 84 
NITROFURANS              
Nitrofurantoin - - - 0 0 1 0 1 5 10 14 15 50 
POLYMYXINS              
Colistin 22 24 11 1  1 3 1 4 3 7 5 - 14 
Polymyxin B 27 26 5 2 0 2 4 3 5 4 7 - 11 
BL/BLI – β-lactam/ β-lactamase inhibitor; The first number of isolates for each drug is the number of isolates less than or equal to the corresponding MIC. “>*” 
indicates the number of isolates with MICs greater than the MIC of the last column number. 
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Time-kill Studies of Meropenem and Polymyxin B against Klebsiella pneumoniae 
Isolates 22, 24, 34, and 44 
 Research contained within this subchapter was published as Kulengowski, B. In 
vitro activity of polymyxin B and meropenem alone and in combination against 
carbapenem-resistant Enterobacteriaceae. 2016. Theses and Dissertations—Pharmacy. 
57. Furthermore, this research was subsequently published in a refereed journal as 
Kulengowski B, Campion JJ, Feola DJ, Burgess DS. 2017. Effect of the meropenem MIC 
on the killing activity of meropenem and polymyxin B in combination against KPC-
producing Klebsiella pneumoniae. J Antibiot (Tokyo) 70:974-978. 
All time-kill data of 22, 24, 34, and 44 are located in Appendix E. However, in 
order to best compare antimicrobial agents within the same organism, the average time-kill 
results are displayed for each isolate at all concentrations tested in combination as well as 
the corresponding concentrations of agents used alone. Using these graphs, the killing 
activity of each antimicrobial alone and their combination can be described as growth – 
any increase in colony count (CFU/mL) from the previous time point, bacteriostatic – any 
decrease in colony count (CFU/mL) from starting inoculum that is <103 CFU/mL, and 
bactericidal –  any decrease in colony count (CFU/mL) from starting inoculum that is ≥103 
CFU/mL. It is important to distinguish between describing antimicrobial activity as 
bactericidal (or bacteriostatic) overall (which implies ≥103 CFU/mL killing compared to 
starting inoculum that persisted up to 24 hours) and describing an antimicrobial as 
exhibiting bactericidal activity for a small window of time, which is a more detailed 
description of killing activity over time. 
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Additionally, the interaction of the two antimicrobial agents can be described as 
synergistic – a ≥102 CFU/mL lower colony count of the combination at 24 hours compared 
to the more active agent (the agent with a lower colony count) alone, additive/indifferent – 
an absolute difference in colony count of < 102 CFU/mL between the combination and the 
more active agent alone, or antagonistic – a ≥102 CFU/mL higher colony count of the 
combination at 24 hours compared to the more active agent alone. In some cases, the 
interaction may not be determinable if one of the antimicrobial agents alone exhibits 
enough killing to be <104 CFU/mL at 24 hours because this is within 102 CFU/mL (unable 
to determine synergy) of the lower limit of quantification (102 CFU/mL). A plot of log 
change in colony count from 0 to 24 hours facilitates evaluation of the interaction of 
meropenem and polymyxin B, which is described later. 
 
Antimicrobial Activity in KP 34 
Figure 4.3 describes KP 34 (MICs: MEM 4 µg/mL, PMB 0.125 µg/mL) and the 
activity of polymyxin B (0.25 and 1 µg/mL), meropenem (4 and 16 µg/mL), and their 
combination at clinically relevant concentrations. Specifically, both concentrations of 
polymyxin B exhibited bactericidal activity within 1 hour, but growth was observed by 4 
hours.  
Meropenem 4 µg/mL (1 x MIC) displayed bacteriostatic activity with growth 
observed by 8 hours. Meropenem 16 µg/mL (4 x MIC) displayed bactericidal activity 
within 2 hours, but growth was observed by 24 hours. Meropenem 64 µg/mL (16 x MIC) 
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displayed bactericidal activity by 2 hours and maintained this activity throughout the 48-
hour time period of testing (Appendix E).  
All combinations tested were bactericidal by 2 hours and maintained this activity 
throughout the 48-hour time period of testing. 
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Figure 4.3: Time-kill Curves against KP 34. 
Time-kill curve of meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 34 (MICs: MEM 4 µg/mL, PMB 
0.125 µg/mL). Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 2). The lower 
limit of quantification was 102 CFU/mL. Note: all combinations resulted in killing throughout 48-hour study period. 
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Meropenem and Polymyxin B Interaction in KP 34 
 In addition to synergy, additivity/indifference, and antagonism, the definitions of 
growth, bacteriostatic, and bactericidal can be applied to further characterize the interaction 
of polymyxin B and meropenem at 24 hours. The activity of combinations with meropenem 
4 µg/mL (1 x MIC) were all bactericidal and synergistic. Combinations with meropenem 
16 µg/mL (4 x MIC) were all bactericidal, but the interaction was indeterminate because 
the activity of meropenem 16 µg/mL alone was too close to the lower limit of quantification 
to evaluate synergy among the corresponding combinations. Table 4.13 summarizes these 
results. Figure 4.4 describes the change in colony count from 0 to 24 hours for each 
antimicrobial tested alone and in combination. 
 
Table 4.13: Meropenem and Polymyxin B Interaction for KP 34 
 
 Meropenem 4 (µg/mL) 
Meropenem 16 
(µg/mL) 
Meropenem 64 
(µg/mL) 
Polymyxin B 0.25 
(µg/mL) S / B I / B Not Tested 
Polymyxin B 1 
(µg/mL) S / B I / B Not Tested 
Polymyxin B 4 
(µg/mL) Not Tested Not Tested Not Tested 
B - Bactericidal 
I - Indeterminate 
S - Synergistic 
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Figure 4.4: Twenty-four Hour Change in Colony Count against KP 34. 
24-hour change in colony count for meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 34 (MICs: MEM 
4 µg/mL, PMB 0.125 µg/mL). Data are geometric means with un-pooled standard deviations of replicate experiments (n = 2). 
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Antimicrobial Activity in KP 22 
Figure 4.5 describes KP 22 (MICs: MEM 16 µg/mL, PMB 0.06 µg/mL) and the 
activity of polymyxin B (0.25 and 1 µg/mL), meropenem (4, 16, and 64 µg/mL), and their 
combination at clinically relevant concentrations. Specifically, both concentrations of 
polymyxin B exhibited bactericidal activity within 1 hour, but growth was observed by 8 
hours instead of 4 hours as seen in KP 34.  
Meropenem 4 µg/mL (1/4 x MIC) displayed bacteriostatic activity with growth 
observed by 8 hours. Meropenem 16 µg/mL (1 x MIC) displayed bactericidal activity 
within 4 hours, but growth was observed by 8 hours. Meropenem 64 µg/mL (4 x MIC) 
displayed bactericidal activity by 2 hours and maintained this activity throughout the 48-
hour time period of testing.  
All combinations tested were bactericidal by 1 hour (compared to 2 hours observed 
in KP 34) and maintained this activity throughout the 48-hour time period of testing. 
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Figure 4.5: Time-kill Curves against KP 22. 
Time-kill curve of meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 22 (MICs: MEM 16 µg/mL, PMB 
0.06 µg/mL). Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 2 to 3). The 
lower limit of quantification was 102 CFU/mL. Note: all combinations resulted in killing throughout 48-hour study period. 
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Meropenem and Polymyxin B Interaction in KP 22 
 The activity of combinations with meropenem 4 µg/mL and 16 µg/mL (1/4 x MIC 
and 1 x MIC, respectively) were all bactericidal and synergistic. Combinations with 
meropenem 64 µg/mL (4 x MIC) were all bactericidal, but the interaction was 
indeterminate because the activity of meropenem 64 µg/mL alone was too close to the 
lower limit of quantification to evaluate synergy among the corresponding combinations. 
Table 4.14 summarizes these results. Figure 4.6 describes the change in colony count from 
0 to 24 hours for each antimicrobial tested alone and in combination. 
 
Table 4.14: Meropenem and Polymyxin B Interaction for KP 22 
 
 Meropenem 4 
(µg/mL) 
Meropenem 16 
(µg/mL) 
Meropenem 64 
(µg/mL) 
Polymyxin B 0.25 
(µg/mL) S / B S / B I / B 
Polymyxin B 1 
(µg/mL) S / B S / B I / B 
Polymyxin B 4 
(µg/mL) Not Tested Not Tested Not Tested 
B - Bactericidal 
I - Indeterminate 
S - Synergistic 
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Figure 4.6: Twenty-four Hour Change in Colony Count against KP 22. 
24-hour change in colony count for meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 22 (MICs: MEM 
16 µg/mL, PMB 0.06 µg/mL). Data are geometric means with un-pooled standard deviations of replicate experiments (n = 2 to 3). 
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Antimicrobial Activity in KP 24 
Figure 4.7 describes KP 24 (MICs: MEM 32 µg/mL, PMB 0.125 µg/mL) and the 
activity of polymyxin B (0.25 and 1 µg/mL), meropenem (4, 16, and 64 µg/mL), and their 
combination at clinically relevant concentrations. Specifically, polymyxin B 0.25 µg/mL 
(2 x MIC) exhibited bactericidal activity within 2 hours whereas polymyxin B 1 µg/mL (8 
x MIC) exhibited bactericidal activity within 1 hour, but growth was observed for both 
concentrations by 8 hours, more similar to KP 22 than KP 34.  
Meropenem 4 µg/mL (1/8 x MIC), 16 µg/mL (1/2 x MIC), and 64 µg/mL (2 x MIC) 
displayed bacteriostatic activity with growth observed by 8 hours.  
All combinations with meropenem concentrations ≥16 µg/mL (≥1/2 x MIC) were 
bactericidal by 1 hour and maintained this activity throughout the 48-hour time period of 
testing. However, both combinations with meropenem concentrations 4 µg/mL (1/8 x MIC) 
were bactericidal by 1 hour with growth observed by 8 hours.  
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Figure 4.7: Time-kill Curves against KP 24. 
Time-kill curve of meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 24 (MICs: MEM 32 µg/mL, PMB 
0.125 µg/mL). Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 2 to 3). The 
lower limit of quantification was 102 CFU/mL. Note: some combinations resulted in killing throughout 48-hour study period. 
 
199 
 
Meropenem and Polymyxin B Interaction in KP 24 
 The activity of combinations with meropenem 4 µg/mL (1/8 x MIC) were all 
additive/indifferent and growth was observed at 24 hours. In contrast, combinations with 
meropenem at 16 and 64 µg/mL (1/2 x MIC and 2 x MIC, respectively) were all bactericidal 
and synergistic. Table 4.15 summarizes these results. Figure 4.8 describes the change in 
colony count from 0 to 24 hours for each antimicrobial tested alone and in combination. 
 
Table 4.15: Meropenem and Polymyxin B Interaction for KP 24 
 
 Meropenem 4 (µg/mL) 
Meropenem 16 
(µg/mL) 
Meropenem 64 
(µg/mL) 
Polymyxin B 0.25 
(µg/mL) A / G S / B S / B 
Polymyxin B 1 
(µg/mL) A / G S / B S / B 
Polymyxin B 4 
(µg/mL) Not Tested Not Tested Not Tested 
A - Additive/Indifferent 
B - Bactericidal 
G - Growth 
S - Synergistic 
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Figure 4.8: Twenty-four Hour Change in Colony Count against KP 24. 
 24-hour change in colony count for meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 24 (MICs: MEM 
32 µg/mL, PMB 0.125 µg/mL). Data are geometric means with un-pooled standard deviations of replicate experiments (n = 2 to 3). 
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Antimicrobial Activity in KP 44 
Figure 4.9 describes KP 44 (MICs: MEM 128 µg/mL, PMB 0.06 µg/mL) and the 
activity of polymyxin B (0.25, 1, and 4 µg/mL), meropenem (4, 16, and 64 µg/mL), and 
their combination at clinically relevant concentrations. Specifically, all concentrations of 
polymyxin B exhibited bactericidal activity within 1 hour, but growth was observed by 8 
hours for polymyxin B at 0.25 and 1 µg/mL (4 x MIC and 16 x MIC, respectively) and 24 
hours for polymyxin B 4 µg/mL (64 x MIC), more similar to KP 22 and KP 24 than KP 
34.  
Meropenem 4 µg/mL (1/32 x MIC) displayed no activity, with growth observed by 
1 hour. Meropenem 16 µg/mL (1/8 x MIC) exhibited bacteriostatic activity with growth 
observed by 8 hours. Meropenem 64 µg/mL (1/2 x MIC) displayed bacteriostatic activity 
with growth observed by 24 hours.  
Combinations with polymyxin B concentrations ≥1 µg/mL (≥16 x MIC) were 
bactericidal by 1 hour whereas combinations with polymyxin B concentrations of 0.25 
µg/mL (4 x MIC) were bactericidal by 2 hours. Growth was observed by 8 hours for 
combinations with meropenem 4 µg/mL (1/32 x MIC) whereas growth was observed by 
24 hours for combinations with meropenem ≥16 µg/mL (≥1/8 x MIC). The only 
combination that maintained bactericidal activity throughout the 48-hour time period of 
testing was the combination with the highest concentrations of both antimicrobial agents – 
meropenem 64 µg/mL (1/2 x MIC) in combination with polymyxin B 4 µg/mL (64 x MIC).
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Figure 4.9: Time-kill Curves against KP 44. Time-kill curve of meropenem (MEM) and polymyxin B (PMB) alone and in 
combination against KP 44 (MICs: MEM 128 µg/mL, PMB 0.06 µg/mL). Data points are geometric means of replicate experiments (n 
= 2 to 4). The lower limit of quantification was 102 CFU/mL. 
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Meropenem and Polymyxin B Interaction in KP 44 
 The activity of meropenem 4 µg/mL (1/32 x MIC) in combination with polymyxin 
B at 0.25 or 1 µg/mL (2 x MIC and 8 x MIC, respectively) was additive/indifferent and 
growth was observed at 24 hours. However, meropenem 4 µg/mL in combination with 
polymyxin B 4 µg/mL (32 x MIC) was synergistic with bacteriostatic activity observed at 
24 hours.  
The activity of meropenem 16 µg/mL (1/8 x MIC) in combination with polymyxin 
B 0.25 µg/mL was additive/indifferent whereas in combination with polymyxin B at 1 or 
4 µg/mL was synergistic. However, at 24 hours, growth was observed for the lower two 
polymyxin B combinations and bacteriostatic activity was observed for the combination 
with polymyxin 4 µg/mL. 
 The activity of meropenem 64 µg/mL (1/2 x MIC) in combination with polymyxin 
B 0.25 was additive/indifferent with growth observed. The combination with polymyxin B 
1 µg/mL was synergistic with bacteriostatic activity. The only combination to produce 
synergistic, bactericidal activity was meropenem 64 µg/mL in combination with 
polymyxin B 4 µg/mL. 
Table 4.16 summarizes these results. Figure 4.10 describes the change in colony 
count from 0 to 24 hours for each antimicrobial tested alone and in combination. 
  
 
204 
 
Table 4.16: Meropenem and Polymyxin B Interaction for KP 44 
 
 Meropenem 4 (µg/mL) Meropenem 16 (µg/mL) Meropenem 64 (µg/mL) 
Polymyxin B 0.25 
(µg/mL) A / G A / G A / G 
Polymyxin B 1 
(µg/mL) A / G S / G S / BS 
Polymyxin B 4 
(µg/mL) S / BS S / BS S / BC 
A - Additive/Indifferent 
BC - Bactericidal 
BS - Bacteriostatic 
G - Growth 
S - Synergistic 
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Figure 4.10: Twenty-four Hour Change in Colony Count against KP 44. 
24-hour change in colony count for meropenem (MEM) and polymyxin B (PMB) alone and in combination against KP 44 (MICs: MEM 
128 µg/mL, PMB 0.06 µg/mL). Data are geometric means with un-pooled standard deviations of replicate experiments (n = 2 to 4).
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Summary of Meropenem and Polymyxin B Alone against Carbapenem-resistant K. 
pneumoniae  
Meropenem alone, at all concentrations tested, achieved bactericidal activity (≥103 
decrease in CFU/mL) within four hours for KP 34 (MEM MIC 4 µg/mL) and KP 22 (MEM 
MIC 16 µg/mL). Regrowth in these strains was observed for the two lowest (4 and 16 
µg/mL) but not the highest (64 µg/mL) meropenem exposures (Figures 4.1 and 4.2). In 
contrast, meropenem alone produced only bacteriostatic activity (< 103 decline in 
CFU/mL) in KP 24 (MEM MIC 32 µg/mL) and KP 44 (MEM MIC 128 µg/mL; Figures 
4.3 and 4.4). Regrowth for these two isolates began by 8 hours.  
Polymyxin B alone produced bactericidal activity at all concentrations tested 
against all strains within 2 hours, but regrowth occurred within 8 hours in all instances 
(Figure 4.3, Figure 4.5, Figure 4.7, and Figure 4.9).  
 
Summary of Meropenem and Polymyxin B in Combination against Carbapenem-
resistant K. pneumoniae 
The interaction of meropenem with polymyxin B in combination was characterized 
by synergism and 24-hour bactericidality as described in Time-Kill Studies. Both 
combinations of meropenem 4 µg/mL and polymyxin B (0.25 or 1 µg/mL) concentrations 
achieved synergistic activity (≥102 decrease in CFU/mL at 24 hours compared to the most 
active agent alone) against KP 34 (MEM MIC 4 µg/mL; Figure 4.4), with no regrowth over 
48 hours (Figure 4.3). Higher concentrations of meropenem alone (16 or 64 µg/mL) 
eradicated KP 34 and so synergism was indeterminate for these combinations.   
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All combinations of meropenem (4 or 16 µg/mL) and polymyxin B (0.25 or 1 
µg/mL) concentrations achieved synergistic activity against KP 22 (MEM MIC 16 µg/mL; 
Figure 4.6) with no regrowth over 48 hours (Figure 4.5), but higher concentrations of 
meropenem alone (64 µg/mL) eradicated KP 22 which rendered synergism assessment 
indeterminate. 
Meropenem 4 µg/mL in combination with polymyxin B 0.25 or 1 µg/mL produced 
additive/indifferent activity (<102 change in CFU/mL at 24 hours compared to the most 
active agent alone) against KP 24 (MEM MIC 32 µg/mL; Figure 4.8) with regrowth 
occurring by 8 hours (Figure 4.7), but all remaining combinations of meropenem 16 or 64 
µg/mL with polymyxin B 0.25 or 1 µg/mL achieved synergistic activity with no regrowth 
over 48 hours (Figure 4.7 and Figure 4.8).  
Combinations of meropenem 4, 16, or 64 µg/mL with polymyxin B 0.25 µg/mL 
displayed additive/indifferent activity against KP 44 (MEM MIC 128 µg/mL; Figure 4.10) 
with variable regrowth (Figure 4.9). Combinations with polymyxin B at 1 or 4 µg/mL 
displayed synergy, but only the highest tested concentration of meropenem (64 µg/mL) and 
polymyxin B (4 µg/mL) also prevented regrowth against KP 44 (Figure 4.9 and Figure 
4.10). 
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Discussion 
 Polymyxin B alone against polymyxin-susceptible, KPC-producing Klebsiella 
pneumoniae generally exhibited quick bactericidal activity, with rapid regrowth observed 
whereas meropenem alone generally exhibited bacteriostatic activity initially with growth 
observed as well. These results are consistent with in vitro data from other groups.212,330 
When used in combination, results were often bactericidal, synergistic, and maintained this 
activity throughout 48 hours unless resistance to meropenem was high (≥32 µg/mL) in 
which case higher levels of antimicrobial agents were shown to overcome the strains with 
elevated MICs, but such regimens may have limited feasibility in a patient where 
antimicrobial concentrations are not static but change as drug is eliminated. Therefore, 
additional in vitro or animal (or even human) models are needed to elucidate the impact of 
pharmacokinetics and the degree of meropenem resistance on the activity of meropenem 
and polymyxin B in combination against KPC-producing K. pneumoniae. 
 A 2013 meta-analysis on in vitro synergy of polymyxins and carbapenems 
highlighted that most data for comparison involves non-Enterobacteriaceae such as 
Pseudomonas aeruginosa or Acinetobacter baumannii. In fact, the authors included only 
three studies206,331,332 that evaluated polymyxin B in combination with a carbapenem 
(imipenem, doripenem, meropenem, or ertapenem) across a total of 34 unique isolates of 
K. pneumoniae, most of which were polymyxin-susceptible. Synergy rates for polymyxin 
B and a carbapenem were higher than synergy rates for colistin and a carbapenem (64% 
vs. 40%; P = 0.04), but substantial heterogeneity among these studies was present (I2 = 
51%).212 Since the publication of the meta-analysis, only one other study has compared 
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polymyxin B in combination with a carbapenem in vitro against KPC-producing Klebsiella 
pneumoniae.330 
 Among the four studies evaluating the in vitro activity of polymyxin B in 
combination with a carbapenem against KPC-producing K. pneumoniae, two evaluated 
exclusively KPC-2-producing K. pneumoniae (18 isolates total),206,330 one evaluated 
exclusively KPC-3-producing K. pneumoniae (4 isolates),332 and the last evaluated both 
KPC-2- and KPC-3-producing K. pneumoniae (8 and 6 isolates, respectively). Our study 
evaluated KPC-3-producing K. pneumoniae (4 isolates). Although KPC-2 is considered the 
ancestral enzyme, KPC-3 has also been frequently observed in the United States. KPC-3 is 
very similar to KPC-2 in both structure and phenotypic resistance expression, differing 
only by a single nucleotide polymorphism and therefore also a single amino acid 
substitution of histidine for tyrosine (H272Y).333 To date, there is no data to suggest 
distinguishing between KPC-2 or KPC-3 correlates with differences in phenotypic 
resistance or clinical outcome in meropenem and polymyxin B combinations, and so this 
difference among studies was accepted. Finally, definitions of synergy and bactericidality 
among studies were consistent except when noted. 
 
Polymyxin B or a Carbapenem Alone 
Comparing results of monotherapy was not possible among all studies because 
complete time-kill data was only provided by Lee et al.332 Data for 0 hours and 24 hours 
was provided by Bratu et al.,206 but the other studies only provided the difference from 0 
hours to 24 hours.330,331 Lee et al. studied the four KPC-3 isolates most similar to this study, 
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exhibiting polymyxin B MICs ranging from 0.125 - 0.25 µg/mL (this study: MICs 0.06 - 
0.125 µg/mL) and doripenem (DOR) MICs ranging from 16 - 32 µg/mL (this study: MEM 
MICs 4 - 128 µg/mL). Polymyxin B at 2 x MIC displayed similar killing to the present 
study, but we observed regrowth sooner (4 hours) than did Lee et al. (8 hours), despite our 
use of higher concentrations relative to the MIC (Figure 4.11 vs. Figure 4.3, Figure 4.5, 
Figure 4.7, and Figure 4.9). Concerning carbapenem therapy, the bacteriostatic activity and 
growth observed with doripenem used alone (Figure 4.11) was similar to the present study, 
despite our use of meropenem instead.332 
 
 
Figure 4.11: Time-kill Curves for Four KPC-3-producing K. pneumoniae. 
Reprinted332Abbreviations: Dor - Doripenem, Col - Colistin, PolyB - Polymyxin B 
 
211 
 
 Comparing the data provided by Bratu et al., polymyxin B alone at 0.5, 1, 2, and 4 
µg/mL remained bactericidal at 24 hours for 2, 7, 12, and 13 isolates, respectively, out of 
16 total.  Interestingly, isolates from this study had at least 4-fold lower polymyxin B MICs 
than those studied by Bratu et al. (0.06 - 0.125 µg/mL vs. 0.5 - 16 µg/mL), but we, in 
contrast, observed regrowth in all polymyxin B concentrations tested alone before 24 
hours. Comparing carbapenem therapy, imipenem (IPM) 4 µg/mL alone displayed growth 
in all 16 isolates. For the present study, the three isolates most similar to those evaluated 
by Bratu et al. (IPM MICs 8 - >32) were KP 22 (MEM MIC 16 µg/mL), KP 24 (MEM 
MIC 32 µg/mL), and KP 44 (MEM MIC 128 µg/mL). Like Bratu et al., meropenem alone 
showed growth at 4 and 16 µg/mL.206 
 
Polymyxin B and a Carbapenem in Combination 
 Lee et al. evaluated colistin or polymyxin B at 2 x MIC in combination with 
doripenem 6 µg/mL against four polymyxin-susceptible, KPC-3-producing Klebsiella 
pneumoniae (DOR MIC 16 - 32 µg/mL). Bactericidal, synergistic activity was observed 
throughout 24 hours for all isolates with some regrowth observed only at 48 hours for 1 of 
4 isolates with polymyxin B and 2 of 4 with colistin.332 Polymyxin B and meropenem 
showed similar activity against KP 22 and KP 24 (MEM MICs 16 and 32 µg/mL, 
respectively) in the present study at comparable concentrations (MEM 4 µg/mL and 16 
µg/mL). One notable difference compared to our study was that meropenem 4 µg/mL in 
combination with polymyxin B at 0.25 or 1 µg/mL (2 and 8 x MIC, respectively) did not 
maintain bactericidal or synergistic activity by 24 hours against KP 24. However, 
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meropenem concentrations ≥1 x MIC in combination with polymyxin B did retain 
bactericidal activity and a synergistic interaction. The difference between meropenem and 
doripenem in combination with polymyxin B cannot be explained with good evidence, but 
clinically, others have observed equivalent efficacy of doripenem compared to other 
carbapenems when being used in lower doses but at extended infusions.334 
 Pankey et al. evaluated polymyxin B at 1/4, 1/2, and 1 x MIC in combination with 
meropenem 1 x MIC against 14 KPC-producing Klebsiella pneumoniae (MER MIC 16 - 
>32 µg/mL, PMB MIC ≤2 for 11 of 14 isolates). Synergy was observed for 9 of 14 isolates 
for all concentrations tested with meropenem and polymyxin B. Non-synergistic isolates 
showed indifferent/additive activity, but only 1 of 5 was resistant to polymyxin B (PMB 
MIC 32 µg/mL) before study. The authors did not comment on the killing activity 
(bactericidal vs. bacteriostatic) of meropenem and polymyxin B in combination against 
these isolates. Compared to the present study, we observed a loss of synergistic activity 
between meropenem and polymyxin B related to increasing meropenem MIC. A similar 
assessment is difficult to make in the study by Pankey et al. because detection of synergy 
did not depend on meropenem MIC, but a much smaller range of carbapenem resistance 
was evaluated (MEM MIC 16 - >32 µg/mL). Similarly, carbapenem MIC did not change 
the observation of synergy in the study by Lee et al., but again, a smaller range (16 - 32 
µg/mL) of carbapenem MIC was evaluated whereas we evaluated MEM MICs 4 - 128 
µg/mL.331 
 Bratu et al. evaluated polymyxin B at 1 µg/mL and 1/2 x MIC in combination with 
imipenem 4 µg/mL against 16 KPC-2-producing Klebsiella pneumoniae that were mostly 
polymyxin-susceptible (14 of 16 isolates). Imipenem MICs were all >32 µg/mL except for 
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one isolate which had an imipenem MIC of 8 µg/mL. Data were unavailable for each isolate 
tested individually, but synergy was reported for 10 of 16 isolates with polymyxin B at 0.5 
x MIC in combination with imipenem. Interestingly, antagonism was observed in 3 of 16 
isolates. Although antagonism was not observed with polymyxin B and meropenem in the 
present study, the antagonism reported by Bratu et al. is consistent with our observed loss 
or reduction of synergy as the carbapenem MIC increases. It is important to note that a 
majority of isolates evaluated by Bratu et al. had imipenem MICs > 32 µg/mL while we 
observed loss of synergy at lower concentrations of meropenem (4 µg/mL) when 
meropenem MICs were at least 32 µg/mL. It is also interesting that synergy was still 
observed in a majority of highly carbapenem-resistant isolates (10 of 16 isolates) at 
polymyxin B concentrations close to 1 µg/mL in combination with imipenem 4 µg/mL 
when the present study required meropenem concentrations ≥ 16 µg/mL in combination 
with polymyxin B 1 µg/mL to maintain synergy.206 
 In the most recently published study, Barth et al. evaluated polymyxin B at 0.5, 1, 
and 2 µg/mL in combination with meropenem or imipenem at 4 µg/mL against two KPC-
2-producing Klebsiella pneumoniae. Both isolates had a polymyxin B MIC of 2 µg/mL and 
a meropenem MIC of 32 µg/mL but had different imipenem MICs of 8 and 32 µg/mL. 
Synergy was observed in both strains at all combinations studied which is in contrast to 
this study where polymyxin B at 0.5 and 1 µg/mL in combination with meropenem 4 
µg/mL was not synergistic for KP 24, despite having a lower polymyxin B MIC (MEM 
MIC 32 µg/mL, PMB MIC 0.125 µg/mL). Although not as directly comparable, but 
interesting, Barth et al. also evaluated two strains each of Escherichia coli and Serratia 
marcescens for which synergy was also found in all the same concentrations of polymyxin 
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B in combination with either meropenem or imipenem. This result was most surprising for 
S. marcescens which is intrinsically resistant to polymyxins. The E. coli strains had 
meropenem MICs of 64 µg/mL whereas the S. marcescens strains had meropenem MICs 
of 128 and 256 µg/mL. The polymyxin B MICs for E. coli were 2 µg/mL whereas the S. 
marcescens stains had polymyxin B MICs of 64 and >64 µg/mL. The author did 
characterize the killing of these antimicrobial agents against the strains, however their 
definition of bactericidality was different from most studies, including the present one. The 
authors assessed bactericidal activity based on a 103 CFU/mL difference between the 
colony count of the combination and the colony count of the most active agent alone, 
which, while appropriate for synergy, could actually mean that growth (as defined in this 
and most studies) occurred but to a lesser extent than the most active agent. Since only this 
difference was reported, it is not possible to compare the killing activity in the experiments 
by Barth et al. to the killing activity observed in this study.330 
 Overall, other studies evaluating polymyxin B in combination with a carbapenem 
by time-kill assay observed bactericidal activity and synergistic interaction maintained 
throughout 24 hours most of the time206,330-332 which is in agreement with our findings. 
Antagonism was rarely observed, and it was only seen in a minority of isolates with high 
carbapenem MICs (IPM MICs > 32)206 which is also similar to our findings because a 
lower extent of synergy was also observed in this study when carbapenem MICs were 
elevated (MEM MICs ≥ 32 µg/mL). A carbapenem alone exhibited similar activity in this 
study as compared to the Lee et al.332 and Bratu et al.206 Polymyxin B alone exhibited 
variable activity depending on the study. Our results were more similar to Lee et al. where 
growth was consistently observed, but at a slower rate.332 In contrast, Bratu et al. observed 
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growth in only a fraction of the isolates, depending on the concentration of polymyxin B. 
This might best be explained by variable heteroresistant subpopulations among KPC-
producing K. pneumoniae isolates,140 however this has not been well characterized and was 
not discussed by Bratu et al.206 
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Abstract 
Little is known regarding the appropriate timing and sequencing of a carbapenem and 
polymyxin in combination against CRE. Meropenem and polymyxin B were administered 
simultaneously or one agent two hours prior to the other, in vitro. The carbapenem should 
be administered prior to the polymyxin when used in combination.  
 
Keywords: Carbapenem-resistant Enterobacteriaceae, Polymyxin B, Meropenem, Time-
kill, Staggered administration  
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Introduction 
CRE are resistant to nearly all antimicrobials and are associated with staggering 
mortality (50%).14 CRE are often treated with combination therapy, but optimal therapy 
has not been established. Polymyxin B (PMB) and meropenem (MEM) are commonly 
utilized against CRE, and the meropenem MIC is known to influence their interaction.274 
The aim of this study was to determine whether the sequence of administration of MEM or 
PMB affects the efficacy of this combination against CRE with varying MEM MICs. 
 
Methods 
CRE isolates expressing KPC-2 (isolates 10 and 17) or KPC-3 (isolates 24 and 44) 
with PMB MICs 0.06-0.125 mg/L and MEM MICs 8-128 mg/L were selected for analysis. 
Whole genome sequencing was previously performed on these isolates.274,335 We 
conducted separate-day duplicate time-kill studies of clinically achievable concentrations 
by typical human dosing of PMB (0.25 and 1 mg/L) and MEM (4 and 16 mg/L) alone and 
in combination against two Enterobacter cloacae (MEM MICs: 8, and 32 mg/L) and two 
Klebsiella pneumoniae isolates (MEM MICs: 32 and 128 mg/L). MEM 64 mg/L was also 
tested alone and in combination with PMB 0.25 and 1 mg/L for the isolate with a MEM 
MIC of 128 mg/L. Sampling occurred at 0, 1, 2, 4, 8, 24, and 48 hours. For simultaneous 
administration, both antimicrobials were added at time 0. Otherwise, either PMB or MEM 
was added at time 0 and the remaining antimicrobial (MEM or PMB) was added at 2 hours. 
This 2-hour delay was selected based on maximal killing for polymyxin B monotherapy 
occurring around that time (Figure 4.12), and our working theory was that administering 
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polymyxin B first may improve the permeability of meropenem to its target site. Samples 
were diluted, plated using a spiral plater, which controlled for antimicrobial carryover, and 
enumerated by a laser colony counter.277,336 Kill curves were constructed to characterize 
the activity of staggered vs. simultaneous administration. Standard definitions of 
bactericidal activity, bacteriostatic activity (colony count less than or equal to starting 
inoculum but not bactericidal), regrowth (any increase in colony count from previous time 
point), synergy, indifference, and antagonism were utilized.336 
 
Results 
For PMB monotherapy against all isolates, bactericidal activity was observed by 2 
hours, but regrowth occurred by 8 hours (Figure 4.12). For MEM monotherapy against all 
isolates, bacteriostatic activity was observed with regrowth by 24 hours (Figure 4.12). 
Administering polymyxin B first exhibited less killing activity than simultaneous 
administration or administering meropenem first for all isolates, regardless of MEM MIC 
(Figure 4.12, Figure 4.13). Against the isolate with a MEM MIC of 8 mg/L, bactericidal 
activity was maintained throughout 48 hours only when meropenem was administered first 
(Figure 4.12, panel A). Furthermore, all combinations of meropenem administered first 
were synergistic. Synergy and bactericidal activity at 24 hours for simultaneous 
administration was only observed for the two higher meropenem combination 
concentrations (MEM 16 mg/L) (Figure 4.12, panel A). There was not a clear difference 
between administering meropenem first and simultaneous administration when the MEM 
MICs were 32 mg/L, but both exhibited more killing activity than administering polymyxin 
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B first (Figure 4.12, panels B and C; Figure 4.13). For the isolate with a MEM MIC of 128 
mg/L, only when meropenem was administered first and at the highest meropenem 
concentration (MEM 64 mg/L) was bactericidal activity maintained throughout 48 hours. 
Regrowth was observed by 8 hours for the remaining combinations against this isolate 
except for the simultaneous MEM 64 / PMB 1 mg/L and the polymyxin first MEM 64 / 
PMB 1 mg/L curves where regrowth was observed by 24 hours (Figure 4.12, panel D). 
 
Discussion 
Although we are not the first to employ staggered administration techniques with 
combination antimicrobials, this study is the first to look at the sequencing of a carbapenem 
and a polymyxin against CRE. Lewis et al. demonstrated polyene-azole antagonism when 
fluconazole was administer prior to amphotericin B in a dynamic in vitro model;337 
Zelenitsky et al. demonstrated significantly improved (six-fold) activity with simultaneous 
or beta-lactam-first staggering of ceftazidime and either ciprofloxacin or tobramycin 
against P. aeruginosa.338 Based on our data, a carbapenem should be given prior to a 
polymyxin antimicrobial when these two agents are used in combination. Polymyxins 
should not be administered first, and neither agent should be administered as monotherapy. 
However, some clinical data with A. baumannii have suggested no difference in clinical 
failure with colistin monotherapy compared to colistin combinations with meropenem, 
rifampin, or fosfomycin.339,340 Data from another clinical trial of colistin with meropenem 
against extensively drug resistant gram-negative bacilli are anxiously awaited 
(NCT01597973, ClinicalTrials.gov). 
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The mechanism explaining why polymyxin B administered first results in less 
killing activity of the combination has yet to be determined. As previously mentioned, we 
anticipated improved combination antimicrobial activity based on the idea that polymyxins 
disrupt the outer membrane of bacteria, improving permeability of other compounds.341 
Instead, polymyxin B may be decreasing bacterial growth and metabolism without 
improving beta-lactam activity on cell wall synthesis.338 Alternatively, polymyxin B may 
have increased beta-lactamase concentration in the growth media by improving the 
permeability of beta-lactamase out of viable bacterial cells or causing its release upon cell 
death. Increased extracellular beta-lactamase may result in decreased beta-lactam 
concentrations, but data suggest a 30% increase in permeability of meropenem in the 
presence of polymyxin B after accounting for increased extracellular beta-lactamase. 
However, that data involved polymyxin B administered 20 minutes prior to meropenem 
(X. Tao et al., presented at ASM Microbe 2018, Atlanta, GA, 8 June 2018). 
 
Conclusions 
Although there is not a clear benefit to administering a carbapenem first compared 
to simultaneously in isolates exhibiting carbapenem MICs of 32 mg/L, a benefit is 
observable at lower and higher carbapenem MICs (8 and 128 mg/L). Additional data are 
needed to confirm these findings and to determine optimal staggering time since only a 2-
hour delay was evaluated in the present study. Additional data are also needed to determine 
the mechanism for the decreased antimicrobial activity observed when polymyxin B was 
administered first relative to simultaneously or when meropenem was administered first. 
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Figure 4.12: Time-kill Curves of Meropenem and Polymyxin B against Carbapenem-
resistant Enterobacteriaceae. Curves represent geometric means of separate-day duplicate 
time-kill experiments conducted over 48 hours. Antibiotic concentrations in mg/L are 
subtitled above their corresponding graph. 
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Figure 4.13: Change in Colony Count after 24 Hours of Meropenem and Polymyxin B against Carbapenem-resistant 
Enterobacteriaceae. Bars represent the change in geometric mean colony counts from time 0 to time 24 hours. 
GC – Growth Control; MEM – Meropenem; PMB – Polymyxin B.
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Abstract 
Amikacin is administered with a carbapenem to treat serious infections caused by 
carbapenem-resistant Enterobacteriaceae. The varying degrees of activity of the individual 
agents corresponds to differences in activity of the two in combination. Amikacin and 
meropenem are not bactericidal against amikacin-resistant CRE. 
Keywords: carbapenem resistant Enterobacteriaceae; time kill; meropenem; polymyxin B; 
amikacin  
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Introduction 
Carbapenem-resistant Enterobacteriaceae (CRE) exhibit resistance to most 
available antimicrobial agents, cause significant mortality, and there is no current treatment 
standard. Carbapenem-containing combination regimens have been the front-running 
choice clinically, along with recently approved contenders such as ceftazidime/avibactam 
and meropenem-vaborbactam which show activity against non-metallo-beta-lactamase-
producing CRE.14 The present study aimed to evaluate the killing activity of amikacin 
(AMK) in combination with meropenem (MEM) against KPC- or VIM-producing CRE 
exhibiting moderate resistance to MEM (MICs 16-32 mg/L) and variable activity ranging 
from susceptible to resistant with AMK (MICs 8-64 mg/L). 
 
Methods 
 The selection of isolates and time-kill methodology has been previously 
described.275 In brief, CRE isolates were identified as part of routine patient care and the 
carbapenemase gene was confirmed by the Verigene® system. MICs of AMK and MEM 
were determined by broth microdilution according to CLSI guidelines and four isolates 
were chosen for further study. A VIM-producing AMK susceptible isolate (MIC 8 mg/L; 
isolate 169), a KPC-producing AMK susceptible isolate (MIC 16 mg/L; isolate 32), a KPC-
producing AMK intermediate isolate (MIC 32 mg/L; isolate 22), and a KPC-producing 
AMK resistant isolate (MIC 64 mg/L; isolate 37) were selected. The first three isolates 
exhibited MEM MICs of 16 mg/L, and the AMK resistant isolate had an MEM MIC of 32 
mg/L. Time-kill assays were performed in at least duplicate using clinically achievable 
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concentrations with typical human dosing regimens. AMK alone (8 and 16 mg/L), MEM 
alone (4 and 16 mg/L), and all possible combinations were evaluated.342,343 Standard 
definitions of bactericidal activity, bacteriostatic activity, regrowth, synergy, indifference, 
and antagonism were utilized.275 
 
Results 
 AMK and MEM, when used alone, resulted in regrowth except for the highest 
MEM concentration (16 mg/L) against the VIM-producing isolate, even though the MEM 
MICs for most isolates were 16 mg/L (Figure 4.14). All combinations maintained 
bactericidal activity against the two amikacin-susceptible CRE (isolates 169 and 32), and 
synergy was demonstrated in 5 of 8 combinations (Figure 4.14 and Figure 4.15). Synergy 
was not determinable in the remaining 3 combinations because the most active single agent 
was within 2-log CFU/mL of the lower limit of quantification of the laser colony counter. 
Against the amikacin-intermediate isolate, only the highest MEM-AMK combination 
maintained synergy and bactericidal activity (Figure 4.14 and Figure 4.15). However, no 
combination maintained bactericidal activity against the amikacin resistant strain, and none 
were synergistic (Figure 4.14 and Figure 4.15). Antagonism was never observed with any 
isolate.  
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Discussion 
 These data suggest that amikacin and meropenem are only reliably synergistic and 
bactericidal when bacterial strains are susceptible to amikacin (MICs ≤16 mg/L) and are 
exhibiting meropenem MICs of at most 16 mg/L. Previous data with polymyxins in 
combination with a carbapenem have suggested that in vitro killing activity (bactericidal 
activity and synergy) is dependent on the carbapenem MIC.274 We have not observed a 
similar relationship for amikacin in combination with meropenem against other amikacin 
susceptible isolates.275 Similar to the present study, Le et al. demonstrated synergy and 
bactericidal activity maintained in 2 of 3 KPC-3-producing amikacin intermediate isolates, 
but not in the 1 amikacin resistant isolate. Unlike our study, Le et al. did not analyze 
amikacin susceptible isolates near the CLSI susceptibility breakpoint (16 mg/L). 
Interestingly, the rate of killing was faster in the present study with maximal killing around 
2-4 hours except in the VIM-1-producing isolate where maximal killing was around 8 hours 
(Figure 4.14). In the study by Le et al., maximal killing occurred around 8-12 hours, but 
meropenem MICs were reportedly higher (≥32 mg/L).217 We have previously observed 
slower killing rates as meropenem MIC increases with no change in rates of bactericidal 
activity or synergy in carbapenem-resistant Enterobacter cloacae.275 Others have also 
reported in vitro synergy of amikacin and a carbapenem using an Etest® strip interaction 
assay against carbapenem-resistant K. pneumoniae. The improved activity of doripenem 
was found to be dependent on the susceptibility phenotypes of each drug alone since 
doripenem became significantly more active with the addition of amikacin only in 
amikacin-susceptible strains and not amikacin-resistant strains.344 Another study has 
quantified the MIC-lowering effect of amikacin on doripenem and concluded that the 
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addition of amikacin to doripenem lowers doripenem MICs by 8-16 fold against KPC-
producing K. pneumoniae.345 
 
Conclusions 
 Amikacin in combination with meropenem demonstrates not only synergy, but 
important bactericidal activity against amikacin-susceptible CRE, including VIM-
producing CRE. Additional data are needed to ascertain the mechanism of reduced rates of 
killing against VIM-producing CRE and KPC-producing CRE with elevated carbapenem 
MICs (i.e. >32 mg/L). Additional data are also warranted in other MBL-producing CRE.  
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Figure 4.14: Time Kill Curves of Meropenem and Amikacin Alone and in Combination against 
Carbapenem-resistant Enterobacteriaceae. Filled circles represent growth controls. Filled squares 
represent amikacin alone. Filled triangles represent meropenem alone. Inverted hollow triangles 
represent amikacin and meropenem in combination. Data points are geometric means of replicate 
experiments (n = 2-3). The lower limit of quantification was 102 CFU/mL. 
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Figure 4.15: Twenty-four Hour Change in Colony Count for Meropenem and Amikacin Alone and in Combination against Carbapenem-
resistant Enterobacteriaceae. Data are differences of geometric means at time points 0h and 24h with standard deviations as error bars 
of replicate experiments (n=2-3). 
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Abstract 
Carbapenem resistant Enterobacteriaceae (CRE) are a growing threat worldwide. 
Infections caused by these organisms have exhibited high rates of mortality (50%) for 
which there is no standard of care and a dearth of clinical trials. Most in vitro data on CRE 
focus on Klebsiella pneumoniae, but it is known that effective therapy may depend on 
species or even strain. To address this, meropenem, amikacin, and polymyxin B alone and 
in combination were evaluated by time kill against four carbapenem-producing 
Enterobacter cloacae clinical isolates representing a range of meropenem 
nonsusceptibility (2-32 mg/L) and resistance mechanisms (KPC 2 and/or VIM 1). As 
meropenem minimum inhibitory concentration (MIC) increased, bactericidal activity and 
synergy were maintained for 48 hours in isolates exposed to meropenem and amikacin, but 
synergy and bactericidal activity were not maintained in all isolates exposed to meropenem 
and polymyxin B. 
Keywords: carbapenem resistant Enterobacteriaceae / time kill / meropenem / polymyxin 
B / amikacin 
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Introduction 
Most antimicrobial agents have limited activity against carbapenem resistant 
Enterobacteriaceae (CRE).14 Therefore, infections caused by these organisms typically 
require treatment with two or more antimicrobial agents.203,346 Most commonly, a 
carbapenem in combination with a polymyxin (colistin or polymyxin B) is administered, 
but mortality remains relatively high.14 Aminoglycosides are also a viable option for 
combination therapy, but have highly variable in vitro activity ranging from 2 to 80%, and 
very limited clinical experience.14,347,348 However, we have observed amikacin (AMK) 
susceptibility as high as 95% at our tertiary academic medical center. Furthermore, 
carbapenem MICs of K. pneumoniae ≥16 mg/L have been associated with higher mortality 
in carbapenem and polymyxin combinations against K. pneumoniae, but not reported for 
carbapenem and polymyxin or amikacin combinations against E. cloacae.200 The 
aminoglycoside MIC may also contribute to the activity of aminoglycoside and 
carbapenem combinations, but most clinical experience has been with gentamicin rather 
than amikacin.349 Therefore, we investigated the in vitro killing of meropenem (MEM) 
alone and in combination with polymyxin B (PMB) or AMK against carbapenem-
producing E. cloacae with varying MICs of MEM and varying resistance mechanisms 
(KPC 2 and VIM 1). 
 
Material and Methods  
Carbapenemase-producing E. cloacae (EC) clinical isolates were identified by 
modified Hodge test as part of routine clinical care at the University of Kentucky 
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HealthCare clinical microbiology laboratory. IRB approval was obtained and the 
requirement for informed consent was waived. MIC testing for MEM, PMB, and AMK 
were performed using broth microdilution according to CLSI guidelines.262 Antimicrobial 
agents were obtained from Sigma Aldrich® (St. Louis, MO).  CLSI does not have approved 
breakpoints or epidemiological cutoff values for PMB in Enterobacteriaceae, so the 
epidemiological cutoff value of 2 mg/L for colistin was used for PMB. However, all 
isolates had polymyxin B MICs ranging 0.06-0.125 mg/L. Four AMK susceptible strains 
with low PMB MICs (EC 2, EC 8, EC 16, and EC 32; Table 4.17) representing a wide 
range of MEM MICs were selected for time kill studies and for whole genome sequencing 
(WGS) using the MiSeq platform (Illumina) by the University of Kentucky Genomics Core 
Laboratory. 
Time kill studies of MEM, AMK, and PMB alone and in combination (MEM with 
PMB and MEM with AMK) were performed over 48 hours using cation adjusted Mueller 
Hinton broth according to CLSI guidelines with a starting inocula of 106 CFU/ml for each 
isolate.350 Clinically achievable concentrations with typical human dosing regimens were 
evaluated for MEM (4 and 16 mg/L),342 AMK (8 and 16 mg/L),343 and PMB (0.25 and 1 
mg/L)351 alone and in combination. The highest combinations (MEM 16 mg/L with PMB 
1 mg/L and MEM 16 mg/L with AMK 16 mg/L) were not evaluated because of complete 
killing observed using combinations with lower concentrations. Separate day, replicate 
time kill assays were performed for each isolate, sampling at 0, 1, 2, 4, 8, 24, and 48 hours. 
Appropriately diluted aliquots were logarithmically plated onto Mueller Hinton agar using 
a spiral plater (Advanced Instruments, Norwood, MA), which controlled for antibiotic 
carryover.277 A laser colony counter (Advanced Instruments, Norwood, MA) quantified 
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samples with a lower limit of quantification of 102 CFU/mL. Central zones of inhibition 
were not observed on agar plates for single or combination antimicrobials, so it was 
assumed that antibiotic carryover of the combinations were also controlled for by the spiral 
plater and laser colony counter.277 
Bacteriostatic activity was defined as a <3 log10 CFU/mL decrease in colony count. 
Bactericidal activity was defined as a >3 log10 CFU/mL decrease in colony count. 
Regrowth was defined as an increase in colony count from a previous time point. 
Synergism was defined as a ≥ 2 log10 CFU/mL lower colony count at 24 hours compared 
to the most active agent alone. Indifference was defined as a change in colony count at 24 
hours within 2 log10 CFU/mL compared to the most active agent alone. Antagonism was 
defined as ≥ 2 log10 CFU/mL higher colony count at 24 hours compared to the most active 
agent alone.350 
Barcoded Nextera Libraries (Illumina, San Diego, CA) were generated according to 
manufacturer protocol. Following PCR, the amplified products were purified using 
AMPure XP beads (Beckman Coulter, Indianapolis, IN) where the sizes and concentrations 
of the amplification products were determined using the Agilent Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). Library quality was assessed via qPCR using the KAPA 
library quantification kit (KAPA Biosystems, Wilmington, MA). Sequence data (250 bp, 
paired end reads) were acquired using the MiSeq platform (Illumina, San Diego, CA). 
Genome assemblies were generated with Newbler v2.9, in paired end mode and using 
default parameters. The presence and absence of known resistance mechanisms for each 
isolate were identified by BLAST against two databases, ResFinder and ARG ANNOT 
(Antibiotic Resistance Gene ANNOTation) following WGS.284  
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Results 
Susceptibilities for all four strains are listed in Table 4.17. In summary, all isolates had 
low PMB MICs (MICs: 0.06 – 0.125 mg/L); all isolates were AMK susceptible (MICs: 1 
– 16 mg/L); and all isolates were meropenem nonsusceptible (MICs: 2 – 32 mg/L). Each 
isolate belonged to a unique multi locus sequence type (MLST; Table 4.17) and numerous 
antimicrobial resistance genes were identified (Table 4.18). Concerning carbapenemase 
genes, we identified blaKPC 2 alone in isolates EC 2 and EC 8, but blaVIM 1 in EC 16. We 
detected both blaKPC 2 and blaVIM 1 in the most resistant isolate, EC 32. Other beta lactamase 
genes were present in these isolates as well (Table 4.18). No polymyxin resistance genes 
were identified by either ResFinder or ARG ANNOT (e.g. mcr 1). Numerous 
aminoglycoside modifying enzyme (AME) genes were detected in each isolate, and we 
report those capable of modifying amikacin based on site of activity and presence of 
appropriate amino or hydroxyl functional groups (Table 4.18). 
Regrowth was observed by 24 hours for all monotherapy except for the highest 
meropenem concentrations tested against 2 of 4 isolates (Figure 4.16). Specifically, MEM 
alone at 4 and 16 mg/L was bacteriostatic, resulting in regrowth by 8 hours for all isolates 
except for MEM 16 mg/L with EC 2 and EC 16. For these two, bactericidal activity was 
observed by 8 hours and maintained throughout 48 hours. PMB alone at 0.25 and 1 mg/L 
was rapidly bactericidal for all isolates by 2 hours, but regrowth was observed by 8 hours 
in all instances. AMK 8 and 16 mg/L alone was bactericidal by 4 hours for the isolates with 
the lower AMK MICs (EC 2 and EC 32) but bacteriostatic for the isolates with the higher 
AMK MICs (EC 8 and EC 16). However, regrowth was observed by 24 hours for all 
isolates when AMK was used alone (Figure 4.16). 
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All combinations of MEM (4 or 16 mg/L) and AMK (8 or 16 mg/L) achieved 
bactericidal and synergistic activity against all isolates (Figure 4.17). However, synergy 
was indeterminate for MEM 16 mg/L combinations with EC 2 and EC 16 due to the 
excellent activity of MEM 16 mg/L alone. Higher meropenem MICs trended with slower 
killing activity, but bactericidal activity and synergy were maintained throughout 48 hours 
for all MEM and AMK combinations (Figure 4.16). Specifically, the isolate with the lowest 
meropenem MIC (EC 2) reached bactericidal activity by 2 hours whereas the isolates with 
the higher meropenem MICs (EC 16 and EC 32) reached bactericidal activity by 8 hours.  
Bactericidal activity and synergy were observed for most combinations of MEM (4 or 
16 mg/L) and PMB (0.25 or 1 mg/L) against each isolate, but not all for every isolate 
(Figure 4.17). All combinations of MEM (4 or 16 mg/L) and PMB (0.25 or 1 mg/L) 
achieved bactericidal activity, and synergy was observed for all MEM and PMB 
combinations against EC 2 and EC 16 (except indeterminate interaction with MEM 16 
mg/L). However, synergy was observed only for the higher concentrations of the 
combinations (MEM 4 mg/L with PMB 1 mg/L and MEM 16 with PMB 0.25 mg/L) against 
EC 8, and the combination with the highest meropenem concentration (MEM 16 with PMB 
0.25 mg/L) against the most MEM resistant isolate, EC 32 (Figure 4.17). Bactericidal 
activity among all isolates was only maintained for the higher MEM 16 with PMB 0.25 
mg/L whereas regrowth was observed by 48 hours for combinations with lower 
concentrations for all isolates (Figure 4.16). Unlike in the MEM AMK combinations, the 
rate of killing was similar among isolates, and synergistic interactions for all combinations 
were not observed, specifically when the MEM MIC was ≥8 mg/L. Additionally, 
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bactericidal activity was only maintained for isolates when the MEM concentration was at 
least 16 mg/L or the PMB concentration was at least 1 mg/L.  
 
Discussion 
Carbapenemase genes were identified in each isolate studied, contributing to 
meropenem resistance. Other extended spectrum beta lactamase genes were also detected 
concurrently with the carbapenemase genes, particularly among the isolate with the highest 
meropenem resistance (EC 32; Table 4.18). Additionally, KPC-producing E. cloacae 
exhibited lower MEM MICs – 2 and 8 mg/L – than VIM-producing E. cloacae – 16 and 
32 mg/L. The lack of detection of polymyxin B resistance genes supports MICs measured 
as 0.06 or 0.125 mg/L. Numerous genes that can modify amikacin were present in each 
isolate, but all isolates were susceptible. This study did not query gene expression levels 
for any resistance gene tested, which may have indicated silencing or upregulation of 
resistance mechanisms. Furthermore, the number of resistance genes did not correlate with 
increasing amikacin MICs given the isolate with the lowest amikacin MIC (EC 32, AMK 
MIC 1 mg/L) had all the amikacin resistance genes detected (Table 4.18). This may suggest 
differences in relative upregulation of these genes in other isolates. 
Monotherapy with meropenem, polymyxin B or amikacin against CRE that are 
amikacin susceptible with low polymyxin MICs fails to maintain bactericidal activity 
throughout 48 hours, with regrowth occurring between 2-24 hours. Combination therapy 
with either meropenem and polymyxin B or meropenem and amikacin resulted in 
synergistic interactions and, importantly, sustained bactericidal activity. The AMK MIC 
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(compared to the MEM MIC) appeared to play a less significant role in the initial rate of 
killing for meropenem amikacin combinations given the isolate most susceptible to AMK 
(EC 32, AMK MIC 1 mg/L) had the slowest rate of killing and the isolate least susceptible 
to AMK (EC 8, AMK MIC 32 mg/L) had the second fastest rate of killing measured by 4h 
bactericidal activity (Figure 4.16). The synergistic interaction was not influenced by AMK 
MIC or MEM MIC for MEM in combination with AMK. Conversely, the synergistic 
activity of MEM and PMB was impacted by increased MEM MICs (Figure 4.17), whereas 
the rate of killing was not impacted by the MEM MICs (Figure 4.16). The PMB MICs were 
essentially the same among isolates so conclusions about PMB MIC dependence of the 
interaction could not be drawn. The observed regrowth in the combinations may indicate 
selection through antimicrobial pressure for resistant subpopulations, which has been 
observed in CRE populations by others.140 Alternatively, the mechanism of resistance 
could be adaptive where environmental stimuli (e.g. polymyxin exposure) alters the outer 
membrane, conferring resistance.137,140  
Additionally, a limitation of this study is that stability data for these antimicrobials in 
such an experiment are not well described. Meropenem is more likely impacted than 
amikacin or polymyxin B given its shorter stability time clinically, but the degree to which 
meropenem has degraded over 48 hours is unknown. Therefore, it is possible that the 
decreased antimicrobial concentrations could result in regrowth at later time points. It is 
worth mentioning that a similar limitation applies to broth dilution antimicrobial 
susceptibility studies which are the gold-standard for determining MICs, so the 
concentration exposures for the first 24 hours of the present experiment mimic that of broth 
dilution exposures. In only two cases (both meropenem-polymyxin B combinations) was 
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regrowth above the point of bactericidal activity observed at 48 hours where bactericidal 
killing had been maintained at 24 hours (Figure 4.16), and this does not impact rates of 
synergy discussed previously. 
Bactericidal activity and synergy for polymyxins or aminoglycosides in combination 
with carbapenems against CRE have been described previously, but K. pneumoniae has 
typically been the representative isolate.212,217 However, interactions between antimicrobial 
agents have exhibited a degree of dependence on bacterial strain.14,195 Therefore, studies 
evaluating these antimicrobial combinations in CRE other than K. pneumoniae are 
important, and there are limited studies exploring amikacin or polymyxin B in combination 
with a carbapenem in E. cloacae. Cai et al. investigated polymyxin B combinations in four 
extensively drug resistant E. cloacae isolates harboring metallo beta lactamase enzymes 
NDM 1 or IMP 1.352 More specifically, meropenem and polymyxin B were evaluated at 64 
and 2 mg/L in combination by time kill, and bactericidal activity was only observed for 2 
of 4 isolates at 24 hours. Regrowth was observed in all isolates by 24 hours. In contrast, 
we observed sustained bactericidal activity and synergy without regrowth throughout 48 
hours when meropenem 16 was used in combination with polymyxin 0.25 mg/L for all four 
of our study isolates. However, the isolates in this study were KPC 2- and/or VIM 1- 
producing as opposed to NDM 1- or IMP 1- producing. In agreement with the present 
study, Barth et al. found polymyxin B in combination with meropenem for two KPC 2-
producing E. cloacae to be bactericidal and synergistic at concentrations as low as 4 mg/L 
of meropenem and 0.5 mg/L of polymyxin, despite the meropenem MICs being higher than 
the present study.330 Le et al. describes synergy maintained for 24 hours for four KPC 3-
producing K. pneumoniae and bactericidal activity maintained for 24 hours for two KPC 
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3-producing K. pneumoniae for amikacin in combination with meropenem, which also 
supports the present findings.217 
In contrast to the present in vitro results, a recently published open-label clinical trial 
for gram-negative bacteria suggests there is no difference in 14-day clinical failure for 
colistin monotherapy compared to colistin-meropenem combination therapy.339 However, 
a majority (77%) of isolates were Acinetobacter baumannii and the trial was not powered 
to address monotherapy versus combination therapy with other bacterial isolates. Other 
trials involving A. baumannii have also suggested similar outcomes with colistin in 
combination with either rifampin or Fosfomycin.340 However, important differences exist 
between A. baumannii and other gram-negative bacteria such as the virulence changes 
caused by shedding of lipopolysaccharide or bacterial density which may have implications 
on the antimicrobial therapy used.340 We are still awaiting additional clinical trial data of 
colistin compared to colistin-meropenem against extensively drug resistant gram-negative 
bacilli (NCT01597973, ClinicalTrials.gov). 
Novel agents with activity against KPC-producing Enterobacteriaceae have been 
approved, such as ceftazidime/avibactam and meropenem-vaborbactam, or are being 
developed (e.g. imipenem/relebactam) and may be more appropriate alternatives given data 
indicating superior cures rates.353,354 However, beta-lactamase inhibitors like avibactam, 
vaborbactam, and relebactam do not inhibit metallo-beta-lactamase (MBL) enzymes, and 
so clinicians should be aware of their local susceptibility and genetic patterns. Other 
antimicrobial agents are under development, such as cefiderocol and aztreonam-avibactam, 
which do have activity against MBL-producing CRE. Also under development, plazomicin 
 
243 
 
and eravacycline are not beta-lactam antibiotics, but rather an aminoglycoside and a 
tetracycline, respectively, showing activity against CRE clinically.353 
Conclusions 
PMB or AMK in combination with MEM has bactericidal and synergistic activity against 
AMK susceptible E. cloacae with low polymyxin B MICs that produce KPC and/or VIM. 
Sustained bactericidal activity and synergy with MEM in combination with PMB is 
dependent on the MEM MIC. Bactericidal activity and synergy are unaffected by MEM or 
AMK MICs when MEM is used in combination with AMK. Additional in vitro, animal, 
and ideally human studies are warranted to further elucidate the impact that the carbapenem 
MIC has on the activity of a carbapenem in combination with a polymyxin or an 
aminoglycoside against carbapenem resistant E. cloacae, particularly against strains with 
carbapenem MICs ≥128 mg/L. 
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Table 4.17: Antimicrobial Activity and Carbapenemase of Selected Organisms 
Isolate MLST Carbapenemase MEM MIC (mg/L) 
PMB MIC 
(mg/L) 
AMK MIC 
(mg/L) 
EC 2 88* KPC-2 2 0.06 2 
EC 8 80* KPC-2 8 0.125 16 
EC 16 273* VIM-1 16 0.125 4 
EC 32 484 KPC-2, VIM-1 32 0.06 1 
MLST – multilocus sequence type. MIC – minimum inhibitory concentration. MEM – 
meropenem. PMB – polymyxin B. AMK – amikacin.  
*Best matched MLST reported because coverage for one of the housekeeping genes was 
too low to confirm a novel MLST 
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Table 4.18: Resistance Genes 
 EC 2 EC 8 EC 16 EC 32 
β-LACTAM 
RESISTANCE     
Ambler Class A     
CARB-2     
 KPC-2     
 SHV-69     
 SHV-73     
 TEM-1A     
 TEM-1B     
 TEM-124     
 TEM-154     
Ambler Class B     
 VIM-1     
Ambler Class C     
 ACT-6     
 ACT-7     
 FOX-5     
Ambler Class D     
 OXA-9     
AMIKACIN 
RESISTANCE     
Acetyltransferase     
aac(6’)-Ib     
aac(6’)Ib-cr     
aac(6’)-IIc     
aac(3)-IVa     
aac(3)-VIa     
Phosphotransferase     
aph(3’)-IIa     
aph(3’)-Ia     
Nucleotidyltransferase     
ant(2”)-Ia     
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Figure 4.16: Time Kill Curves of Meropenem, Amikacin, and Polymyxin B Alone and in 
Combination against Carbapenemase-producing Enterobacter cloacae Strains. Data points 
are geometric means of replicate experiments (n = 2). The lower limit of quantification was 
102 CFU/mL. 
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Figure 4.17: Twenty-four Hour Change in Colony Count for Meropenem, Polymyxin B, and Amikacin Alone and in Combination 
against Carbapenemase-producing Enterobacter cloacae Strains. Data are differences of geometric means at time points 0h and 24h 
with standard deviations of replicate experiments (n=2). 
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Resistance Development to Polymyxin B 
Surviving or regrowing bacteria from time-kill studies often exhibit higher MICs 
to the antimicrobials to which they were exposed. This can be as a result of antimicrobial 
pressure which selects for resistant subpopulations or reveals adaptable or development of 
resistance.140 MICs were reevaluated for polymyxin B in all regrowing colonies for two 
time-kill studies through broth microdilution susceptibility testing because others have 
reported rapid resistance development, attributed mostly to the selection of 
subpopulations.137,140 
 For surviving colonies, the MIC to polymyxin B increased at least 256-fold (from 
0.06 - 0.125 µg/mL to 16 - >64 µg/mL) following exposure to polymyxin B alone in 
concentrations from 0.06 to 4 µg/mL (Table 4.19). 
Table 4.19: MIC Testing of Isolates Following Exposure to Polymyxin B Alone 
 PMB 0.06 µg/mL 
PMB 0.125 
µg/mL 
PMB 0.25 
µg/mL 
PMB 1 
µg/mL 
PMB 2 
µg/mL 
PMB 4 
µg/mL 
KP 34 16 64 * * >64 >64 
KP 22 >64 0.125 64 >64 >64 >64 
KP 24 64 64 32 32 >64 >64 
KP 44 64 16 32 64 >64 >64 
*Concentration not tested, but growing colonies previously observed 
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Following exposure to meropenem alone, the polymyxin B MIC of surviving 
colonies remained in essential agreement (within one two-fold dilution) of the originally 
measured MIC of the corresponding isolate (0.06 µg/mL for KP 22 and KP 44 and 0.125 
µg/mL for KP 34 and 24). This was expected given there was no antimicrobial pressure for 
the selection of subpopulations resistant to polymyxin B. However, cross-resistance or 
some other dependency relationship between meropenem and polymyxin B resistance may 
have explained a change (Table 4.20). 
 
Table 4.20: MIC Testing of Isolates Following Exposure to Meropenem Alone 
 MEM 4 µg/mL MEM 16 µg/mL MEM 64 µg/mL 
KP 34 * * § 
KP 22 0.06 0.06 § 
KP 24 ≤0.03 0.125 0.06 
KP 44 0.06 0.06 0.06 
*Concentration not tested, but growing colonies previously observed 
§No growth of colonies during time-kill studies 
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 Surviving colonies of meropenem and polymyxin B in combination were also 
evaluated for a change in polymyxin B MIC. Results were similar to exposure to polymyxin 
B alone (≥256-fold increase in MIC; Table 4.21). 
 
Table 4.21: MIC Testing of Isolates Following Exposure to Combination   
 
MEM/PMB 
4/0.25 
µg/mL 
MEM/PMB 
4/1 
µg/mL 
MEM/PMB 
16/0.25 
µg/mL 
MEM/PMB 
16/1 
µg/mL 
MEM/PMB 
64/0.25 
µg/mL 
MEM/PMB 
64/1 
µg/mL 
KP 
34 § § § § § § 
KP 
22 § § § § § § 
KP 
24 32 32 § § § § 
KP 
44 16 16 16 64 16 16 
§No growth of colonies during time-kill studies 
 
In summary, the polymyxin B MICs of isolates exposed to polymyxin B alone or 
in combination with meropenem generally increased from 0.06 or 0.125 µg/mL at baseline 
to ≥16 µg/mL in all experiments where regrowth occurred. In contrast, the polymyxin B 
MICs for regrowing bacteria exposed only to meropenem remained at 0.06 or 0.125 µg/mL 
(Table 4.19, Table 4.20, and Table 4.21). 
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Subpopulation Analysis 
To assess for the presence of subpopulations with increased MIC values relative to 
the overall population, growing bacteria were cultured onto agar plates infused with 
antimicrobials which would inhibit the growth of all colonies with MICs less than or equal 
to the antimicrobial concentration of the agar. Colonies were enumerated and then related 
to the overall population (see Subpopulation Analysis and Microfiltration). Table 4.22 
summarizes the results of the growth control subpopulation time-kill study. The lower limit 
of quantification for microfiltration has been previously estimated to be 30 CFU/mL when 
1000 µL samples were used.282,283 
 
Table 4.22: Hetero-resistant Subpopulations of Klebsiella pneumoniae Isolates 
 KP 34 KP 22 KP 24 KP 44 
MEM MIC > 16 7.2 CFU/mL 31.6 CFU/mL - - 
MEM MIC > 64 - - 6.7 CFU/mL 5.3 x 103 CFU/mL 
PMB MIC > 4 <1 CFU/mL 2 CFU/mL <1 CFU/mL 2.4 CFU/mL 
All reported values are proportionally corrected to a 106 CFU/mL overall population 
 
 
 For the isolates with meropenem MICs of 4 and 16 µg/mL, subpopulations with 
MICs > 16 µg/mL were 7 x 100 and 3 x 101 CFU/mL, respectively. For the isolates with 
meropenem MICs of 32 and 128 µg/mL, subpopulations with MICs > 64 µg/mL were 7 x 
100 and 5 x 103 CFU/mL, respectively. Surprisingly, for all isolates, subpopulations with 
polymyxin B MICs > 4 µg/mL were almost non-detectable at < 3 CFU/mL.  
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Heteroresistance 
 KP 34, 22, 24, and 44 underwent preliminary characterization of the meropenem 
and polymyxin B MICs of any heteroresistant subpopulations. Table 4.22 displays the 
exact colony counts with respect to a 106 CFU/mL total population concentration. For a 
more complete subpopulation analysis, studies with higher inocula would provide higher 
sensitivity but would reduce the internal validity of comparing observations from the 
subpopulation study to our time-kill results, which was the primary purpose. The most 
interesting result was observing subpopulations with MICs at least 32 x the MIC of the 
total population (e.g. a strain with a population MIC of 0.125 µg/mL growing on an agar 
plate with 4 µg/mL polymyxin B). Better characterization of these heteroresistance isolates 
may elucidate the cause of regrowth observed throughout our experiments when polymyxin 
B was used alone or when combination therapy failed to prevent regrowth. 
 Other studies have also described polymyxin heteroresistance.140 Among the four 
studies recently discussed, only Lee et al. reported post-exposure susceptibility testing on 
their regrowing isolates from time-kill studies. Similar to the present study, Lee et al. 
observed an increase in colistin or polymyxin B MIC from 0.125 - 0.25 µg/mL to 8 - 128 
µg/mL whereas we observed changes from 0.06 - 0.125 µg/mL to 16 - >64 µg/mL. Lee et 
al. also observed no change in doripenem MICs following polymyxin exposure whereas 
we did not look at change in meropenem MICs. However, we observed no change in 
polymyxin MICs following meropenem exposure, suggesting insignificant (if any) cross-
resistance between these antimicrobial classes. However, both studies observed polymyxin 
B and colistin MICs correlating very strongly together.332 
 
253 
 
 Meletis et al. performed more thorough subpopulation studies on 16 
carbapenemase-producing K. pneumoniae clinical isolates. In that study, subpopulations 
growing on agar plates impregnated with up to 8 µg/mL colistin had population MICs 
ranging from 1 - 4 µg/mL. Susceptibility testing on colonies growing on these agar plates 
ranged from 16 - 64 µg/mL, which was similar to both Lee et al. and our study, although 
we analyzed polymyxin B rather than colistin. The colony counts growing on agar plates 
containing colistin 8 µg/mL ranged from 3 x 100 to 4 x 103 CFU/mL whereas the colony 
counts we observed on agar plates containing 4 µg/mL polymyxin B was closer to 2 x 100 
CFU/mL. Accounting for this difference may be the difference in the MIC of the 
populations since this study analyzed strains with much lower polymyxin B/colistin MICs 
(0.06 - 0.125 µg/mL) whereas Meletis et al. analyzed strains with colistin MICs ≥ 1 µg/mL. 
In other words, more similar colony counts may be observed in our isolates if we were to 
utilize agar plates impregnated with similar proportions of polymyxin B/colistin such as 
0.5 - 1 µg/mL (approximately 4 - 8 x MIC).  
Meletis et al. noticed that about 8 of 16 isolates did not exhibit heteroresistance 
which was demonstrated by a lack of growth on agar plates with colistin concentrations 
exceeding the colistin MIC of the population.140 This observation may explain the 
differences observed between Lee et al., our study, and Bratu et al. concerning regrowth 
with regimens containing either polymyxin alone or in combination. If heteroresistance 
impairs the synergistic interaction between polymyxins and carbapenems, then a lack of 
heteroresistance would explain the complete killing or indeterminate synergy observed by 
Bratu et al. since polymyxins alone seemed to be sufficient in preventing growth at 
concentrations above the MIC.140 There may also be clinical relevance to these findings 
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such that regions where heteroresistance to polymyxins is low may demonstrate superior 
colistin/polymyxin B activity when compared to regions with abundant heteroresistance, 
confounding comparisons of polymyxin monotherapy and combination therapy. 
Conclusions 
Agar plates with lower polymyxin concentrations would better characterize the 
heteroresistance exhibited by KP 34, 22, 24, and 44, but we as well as others have observed 
wide variability in polymyxin MICs, even among the same strains.140,332 The clinical role 
of polymyxin heteroresistance is not known at this time, but it is suspected to impair the 
synergistic interaction between carbapenems and polymyxins. Finally, not all carbapenem-
producing Klebsiella pneumoniae have observable polymyxin heteroresistance.140 
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Ceftazidime/avibactam Disk Diffusion and MBL Etest® 
 Ceftazidime/avibactam is a recently approved antimicrobial for the treatment of 
CRE in the absence of MBL-production. In order to contribute to the growing knowledge 
of this novel antimicrobial agent, we evaluated the susceptibility of all CRE that we had 
collected to date (75 out of 164 isolates). 
Metallo-β-lactamase (MBL)-production information from the University of 
Kentucky Clinical Microbiology Laboratory was available for four of the 75 isolates tested 
(isolates 26, 40, 41, and 42). Since metallo β-lactamases are not inhibited by avibactam, it 
was expected that these isolates would be resistant to ceftazidime/avibactam, but only three 
of four were resistant, verified by duplicate experiments. 
Excluding the four known MBL-producers, six isolates met criteria for MBL 
testing. Three isolates were borderline susceptible to ceftazidime/avibactam with a zone of 
inhibition of 21 mm (isolates 21, 24, and 29), two isolates were resistant (isolates 53 and 
134 with zones 17 mm and 15 mm, respectively) and one isolate was intermediate (22; 
zone 20 mm). In a duplicate experiment, only the isolate testing as intermediate changed 
in interpretation with the second test and the third test being susceptible (23 mm and 24 
mm respectively; Table 4.23).  
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Table 4.23: Ceftazidime/avibactam Kirby Bauer Disk Diffusion Results 
Organism Isolate Number 
Ceftazidime / 
Avibactam Zone 
of Inhibition 
(mm) 
Interpretation 
(S/I/R) 
Citrobacter amalonaticus 36 24 S 
Citrobacter amalonaticus 91 25 S 
Citrobacter freundii 27 29 S 
Citrobacter freundii 50 22 S 
Citrobacter freundii 54 30 S 
Citrobacter freundii 101 27 S 
Citrobacter freundii 127 27 S 
Citrobacter freundii 145 31 S 
Citrobacter freundii 147 30 S 
Citrobacter youngae 136 26 S 
Enterobacter aerogenes 97 30 S 
Enterobacter cloacae 9 27 S 
Enterobacter cloacae 10 28 S 
Enterobacter cloacae 16 27 S 
Enterobacter cloacae 17 27 S 
Enterobacter cloacae 19 29 S 
Enterobacter cloacae 20 27 S 
Enterobacter cloacae 30 25 S 
Enterobacter cloacae 39 27 S 
Enterobacter cloacae* 40 17, 16 R 
Enterobacter cloacae* 41 18, 17 R 
Enterobacter cloacae 52 27 S 
Enterobacter cloacae§ 53 17, 18 R 
Enterobacter cloacae 70 29 S 
Enterobacter cloacae 96 26 S 
Enterobacter cloacae 107 24 S 
Enterobacter cloacae 121 25 S 
Enterobacter cloacae 126 28 S 
Enterobacter cloacae§ 134 15, 14 R 
Enterobacter cloacae 144 27 S 
Escherichia coli 25 30 S 
Escherichia coli 33 25 S 
Escherichia coli 103 25 S 
Enterobacter gergoviae 13 28 S 
Enterobacter gergoviae 95 32 S 
Enterobacter spp. 146 25 S 
Klebsiella oxytoca 8 35 S 
Klebsiella oxytoca 14 29 S 
Klebsiella ozaenae 128 28 S 
Klebsiella pneumoniae 7 32 S 
Klebsiella pneumoniae§ 21 21, 21 S 
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Table 4.23 (continued): Ceftazidime/avibactam Kirby Bauer Disk Diffusion Results 
Organism Isolate Number 
Ceftazidime / 
Avibactam Zone 
of Inhibition 
(mm) 
Interpretation 
(S/I/R) 
Klebsiella pneumoniae§ 22 20, 23, 24 S 
Klebsiella pneumoniae§ 24 21, 27 S 
Klebsiella pneumoniae* 26 27, 26 S 
Klebsiella pneumoniae 28 22 S 
Klebsiella pneumoniae§ 29 21, 21 S 
Klebsiella pneumoniae 31 31 S 
Klebsiella pneumoniae 32 33 S 
Klebsiella pneumoniae 34 28 S 
Klebsiella pneumoniae 35 29 S 
Klebsiella pneumoniae 37 26 S 
Klebsiella pneumoniae* 42 14, 14 R 
Klebsiella pneumoniae 43 25 S 
Klebsiella pneumoniae 44 24 S 
Klebsiella pneumoniae 45 24 S 
Klebsiella pneumoniae 46 27 S 
Klebsiella pneumoniae 47 27 S 
Klebsiella pneumoniae 48 25 S 
Klebsiella pneumoniae 49 27 S 
Klebsiella pneumoniae 51 25 S 
Klebsiella pneumoniae 55 23 S 
Klebsiella pneumoniae 69 25 S 
Klebsiella pneumoniae 77 30 S 
Klebsiella pneumoniae 93 27 S 
Klebsiella pneumoniae 98 23 S 
Klebsiella pneumoniae 99 25 S 
Klebsiella pneumoniae 105 27 S 
Klebsiella pneumoniae 116 27 S 
Klebsiella pneumoniae 119 25 S 
Klebsiella pneumoniae 123 28 S 
Klebsiella pneumoniae 129 23 S 
Klebsiella pneumoniae 130 27 S 
Klebsiella pneumoniae 142 26 S 
Klebsiella pneumoniae 143 24 S 
Klebsiella pneumoniae 152 25 S 
TOTAL 75  93% S 
*MBL identified by PCR at University of Kentucky Clinical Microbiology Laboratory 
§MBL identified by Etest® 
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MBL-production was identified in all but one isolate tested (KP 24 was 
indeterminate twice; confirmed negative by the Verigene® system). MBL-production was 
identified in two borderline susceptible isolates (21 and 29), the initially intermediate 
isolate (KP 22), and both resistant isolates (53 and 134; Table 4.11). KP 24 was 
indeterminate upon initial testing because the resulting MIC ratio was ≥ 4 without a 
phantom zone or an ellipse deformation (Chapter 3: Methods "Etest® Procedure"). Isolate 
21 was borderline negative after initial MBL testing but tested positive upon retest. All 
other isolates were interpreted as positive for both tests (Table 4.11). 
 
Table 4.24: MBL MP/MPI Etest® Results 
Isolate MP/MPI MIC (µg/mL) Interpretation 
MP/MPI MIC 
(µg/mL) Interpretation 
21 0.5 / 0.064 Negative 1.5 / 0.094 Positive 
22 > 8 / ≤ 0.032 Positive 3 / 0.032 Positive 
24 > 8 / > 2 Indeterminate > 8 / > 2 Indeterminate 
29 > 8 / ≤ 0.032 Positive > 8 / ≤ 0.032 Positive 
53 > 8 / ≤ 0.032 Positive > 8 / ≤ 0.032 Positive 
134 4 / ≤ 0.032 Positive 2 / ≤ 0.032 Positive 
Negative 
Control 
≤ 0.0125 /  
≤ 0.032 Negative 
≤ 0.0125 /  
≤ 0.032 Negative 
Positive 
Control 1.5 / ≤ 0.032 Positive 1.5 / ≤ 0.032 Positive 
Positive Control - Isolate 42 (Confirmed MBL by PCR) 
Negative Control - Klebsiella pneumoniae ATCC® 700603 
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Overall, five of the 75 CRE isolates were resistant to ceftazidime/avibactam (93% 
susceptibility across all CRE tested), and all five were associated with MBL-production. 
All four of the MBL-producing E. cloacae isolates (40, 41, 53, and 134) were resistant to 
ceftazidime/avibactam whereas one isolate (42) of the four MBL-producing K. 
pneumoniae isolates (21, 22, 29, and 42) were resistant to ceftazidime/avibactam. Divided 
by phenotypic (determined by Etest®) compared to genotypic MBL-production 
(determined by PCR or by the Verigene® system from the University of Kentucky Clinical 
Microbiology Laboratory), two of five phenotypic MBL-producing isolates were resistant 
to ceftazidime/avibactam whereas three of four genotypic MBL-producing isolates were 
resistant to ceftazidime/avibactam.  
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Discussion 
 Other large studies have evaluated the activity of ceftazidime/avibactam against 
CRE. In 2015, Castanheira et al. reported 98% susceptibility (CZA MIC ≤ 8/4 µg/mL) 
among 153 CRE isolates collected from 71 U.S. medical centers as part of the International 
Network for Optimal Resistance Monitoring (INFORM) program (P = 0.07346 when 
compared to this study). The MIC50 was 0.5 µg/mL and the MIC90 was 2 µg/mL. Non-
susceptibility was observed in two Klebsiella pneumoniae strains isolated from a Colorado 
medical center and one Proteus mirabilis strain of an unnamed source. All three CRE had 
ceftazidime/avibactam MICs > 32 µg/mL. Similar to our non-susceptible isolates, the K. 
pneumoniae isolates were found to harbor NDM-1 but the P. mirabilis isolate tested 
negative for CTX-M subgroups 1, 2, 8, 9, and 25; TEM wild type and ESBL; SHV wild 
type and ESBL; AmpC; KPC; and NDM-1 but positive only for TEM-212, a narrow-
spectrum β-lactamase inhibitor (e.g. tazobactam, clavulanic acid, sulbactam) resistant β-
lactamase.355 The authors did not discuss the P. mirabilis strain further, but TEM-212 may 
also be resistant to the β-lactamase inhibitor, avibactam, and high ceftazidime MICs (≥32 
µg/mL) have been observed in two Providencia stuartii isolates.356 However, alternative 
explanations may exist in non-β-lactamase mediated mechanisms of resistance that still 
warrant exploration. 
 By 2016, de Jonge et al. evaluated ceftazidime/avibactam against 961 meropenem-
non-susceptible Enterobacteriaceae collected from Europe, Asia/Pacific, Latin America, 
and the Middle East/Africa as part of the INFORM program. Of these, susceptibility to 
ceftazidime/avibactam was reported in 83.5%. Upon excluding MBL-producing isolates, 
97.7% susceptibility was observed among 816 isolates, which is not significantly different 
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from our study upon also excluding MBL-producing isolates (P=0.2113). A most 
interesting result, however, was the decreased susceptibility observed among 207 
carbapenemase-negative meropenem-non-susceptible Enterobacteriaceae compared to 
609 carbapenemase-positive, MBL-negative, meropenem-non-susceptible 
Enterobacteriaceae (94.7% vs. 98.7%; P=0.0009). Among those 207, AmpC, ESBL or 
both genes were identified in only 195 isolates. Among the 12 remaining isolates, 8 (67%) 
were susceptible to ceftazidime/avibactam. Although a small subgroup, this suggests that 
non-enzyme mediate resistant may play a role in ceftazidime/avibactam non-susceptibility. 
In total, the authors identified only 19 of 961 isolates for which ceftazidime/avibactam non-
susceptibility couldn't be explained by the presence of MBLs.357 Target site 
modifications358 and other MBLs not yet identified by PCR were among the most suspected 
whereas upregulation of efflux pumps were considered less likely after direct testing.359 
Finally, among 145 MBL-producing isolates, susceptibility to ceftazidime/avibactam was 
3.4% whereas in the present study, 4 of 9 MBL-producing isolates were susceptible (44%; 
P<0.0001). The implications of this are not understood, but regional differences in 
resistance patterns combined with non-β-lactamase mediated resistance provide one 
hypothesis. Further studies are warranted to better understand this observation. 
 In the U.S., the first case report of ceftazidime/avibactam resistance in a KPC-3-
producing Klebsiella pneumoniae clinical isolate was published in October 2015. The exact 
resistance mechanism in this isolate is not suspected to be related to KPC-3-production 
since the amino acid sequence encoded by blaKPC-3 in this isolate was unaltered. This adds 
to the growing evidence that there may be non-β-lactamase resistance mechanisms to 
ceftazidime/avibactam. Others have reported β-lactamase mediated ceftazidime/avibactam 
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resistance  in KPC-3 producing CRE only in the KPC-3 Ω loop.258,360,361 The clinical 
implications of these reports are that susceptibility testing of ceftazidime/avibactam may 
still be warranted, even in the setting of MBL-negative carbapenem resistance.362 Another 
question that remains to be answered is could use of ceftazidime/avibactam in combination 
prevent the emergence of resistance? 
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Modified Disk Diffusion Procedure for the Detection of MBL and KPC Enzymes 
All CRE that had been obtained at the time of experiment (n=122) underwent 
duplicate experiments to ascertain their carbapenemase phenotype (Table 4.25; see 
Modified Disk Diffusion Procedure for the Detection of MBL and KPC Enzymes). 
Additionally, some information from the University of Kentucky Clinical Microbiology 
Laboratory was available and is also displayed in Table 4.25. 
 
Table 4.25: Carbapenem-resistant Enterobacteriaceae Carbapenemase Enzyme 
Phenotype (n=122) 
Organism Isolate Number 
PCR/Verigene® MBL 
Type 
Phenotypic Disk 
Diffusion 
C. amalonaticus 36  KPC 
C. amalonaticus 91  KPC 
C. freundii 27  KPC 
C. freundii 50  KPC 
C. freundii 54  KPC 
C. freundii 101  None 
C. freundii 127  KPC 
C. freundii 135 VIM MBL 
C. freundii 145 KPC Both 
C. freundii 324  None 
C. youngae 136  KPC 
C. youngae 435 KPC MBL 
E. aerogenes 97  KPC 
E. aerogenes 179 VIM MBL 
E. aerogenes 187  KPC 
E. aerogenes 438   KPC 
E. cloacae 10  KPC 
E. cloacae 17  KPC 
E. cloacae 30  KPC 
E. cloacae 39  KPC 
E. cloacae 40 VIM MBL 
Table 4.25 (continued): Carbapenem-resistant Enterobacteriaceae Carbapenemase 
Enzyme Phenotype (n=122) 
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Organism Isolate Number 
PCR/Verigene® MBL 
Type 
Phenotypic Disk 
Diffusion 
E. cloacae 41 VIM Both 
E. cloacae 52  KPC 
E. cloacae 53 VIM MBL 
E. cloacae 70  None 
E. cloacae 96  None 
E. cloacae 107  KPC 
E. cloacae 121  KPC 
E. cloacae 126  KPC 
E. cloacae 134 VIM MBL 
E. cloacae 144  KPC 
E. cloacae 167 VIM MBL 
E. cloacae 168 KPC* Non-determinate 
E. cloacae 169 VIM MBL 
E. cloacae 171 KPC* KPC 
E. cloacae 175 VIM MBL 
E. cloacae 189 VIM MBL 
E. cloacae 200  Both 
E. cloacae 203 VIM MBL 
E. cloacae 209  KPC 
E. cloacae 266 VIM MBL 
E. cloacae 335  None 
E. cloacae 339  KPC 
E. cloacae 369  None 
E. cloacae 416 VIM MBL 
E. cloacae 476 VIM Both 
E. cloacae 515  KPC 
E. coli 33  None 
E. coli 103  KPC 
E. coli 172 VIM MBL 
E. coli 176  KPC 
E. coli 309  None 
E. coli 390  None 
E. gergoviae 95  None 
E. hormaechei 186 VIM MBL 
E. hormaechei 398 VIM MBL 
Enterobacter sp. 146  KPC 
Enterobacter sp. 210  KPC 
K. oxytoca 166  KPC 
K. oxytoca 177 KPC Both 
Table 4.25 (continued): Carbapenem-resistant Enterobacteriaceae Carbapenemase 
Enzyme Phenotype (n=122) 
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Organism Isolate Number 
PCR/Verigene® MBL 
Type 
Phenotypic Disk 
Diffusion 
K. oxytoca 330  KPC 
K. ozaenae 128  KPC 
K. ozaenae 407  KPC 
K. pneumoniae 21  KPC 
K. pneumoniae 22   KPC 
K. pneumoniae 24  KPC 
K. pneumoniae 28   KPC 
K. pneumoniae 29   KPC 
K. pneumoniae 31  KPC 
K. pneumoniae 32  KPC 
K. pneumoniae 34  KPC 
K. pneumoniae 35  KPC 
K. pneumoniae 37  KPC 
K. pneumoniae 42 VIM MBL 
K. pneumoniae 43  KPC 
K. pneumoniae 44  KPC 
K. pneumoniae 45  KPC 
K. pneumoniae 46   KPC 
K. pneumoniae 47   KPC 
K. pneumoniae 48   KPC 
K. pneumoniae 49  KPC 
K. pneumoniae 51  KPC 
K. pneumoniae 55  KPC 
K. pneumoniae 69  None 
K. pneumoniae 77  None 
K. pneumoniae 93  KPC 
K. pneumoniae 98  None 
K. pneumoniae 99  KPC 
K. pneumoniae 105  KPC 
K. pneumoniae 116  None 
K. pneumoniae 119  KPC 
K. pneumoniae 123  KPC 
K. pneumoniae 129  KPC 
K. pneumoniae 130  KPC 
K. pneumoniae 142  KPC 
K. pneumoniae 143  None 
K. pneumoniae 152  None 
K. pneumoniae 165  KPC 
K. pneumoniae 170 VIM MBL 
Table 4.25 (continued): Carbapenem-resistant Enterobacteriaceae Carbapenemase 
Enzyme Phenotype (n=122) 
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Organism Isolate Number 
PCR/Verigene® MBL 
Type 
Phenotypic Disk 
Diffusion 
K. pneumoniae 173 VIM MBL 
K. pneumoniae 174 VIM MBL 
K. pneumoniae 230  KPC 
K. pneumoniae 243  KPC 
K. pneumoniae 256  KPC 
K. pneumoniae 269  None 
K. pneumoniae 284  None 
K. pneumoniae 349  None 
K. pneumoniae 352  None 
K. pneumoniae 372  None 
K. pneumoniae 385  None 
K. pneumoniae 391  KPC 
K. pneumoniae 411 VIM MBL 
K. pneumoniae 418  None 
K. pneumoniae 423  KPC 
K. pneumoniae 445  KPC 
K. pneumoniae 446  KPC 
K. pneumoniae 449  KPC 
K. pneumoniae 452  KPC 
K. pneumoniae 466  KPC 
K. pneumoniae 482  KPC 
K. pneumoniae 492  None 
S. marcescens 514  KPC 
*VIM by PCR performed by Olga Lomovskaya (The Medicines Co., Parsippany, NJ) 
Isolates highlighted in color indicate stratification by patient 
Isolates without highlighting indicate unique patient source 
 
KPC production composed the major mechanism of resistance to carbapenem 
antimicrobials among CRE (58%; Figure 4.18), followed by MBL production (17%; Figure 
4.18). Other mechanisms of carbapenem resistance (20%; Figure 4.18) composed a 
significant proportion of CRE, but additional information was not available by chart 
review. VIM was the only MBL type identified in these isolates by the Verigene® system 
(Table 4.25; see Modified Disk Diffusion Procedure for the Detection of MBL and KPC 
Enzymes). 
 
 
267 
 
 
Figure 4.18: Carbapenemase Phenotype of All Carbapenem-resistant Enterobacteriaceae 
(n=122). 
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Pharmacodynamic Modeling 
Pharmacodynamic Model of Isolates in Meropenem Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (1) and equation (11) were utilized for a total of 6 parameters, 52 time-kill 
experiments and 93 simultaneously solved differential equations. Individually modeled 
isolates are presented in Appendix H. 
Table 4.26: Composite Model Initial Parameter Estimates for All Isolates against 
Meropenem Monotherapy 
Parameter gS gR Nmax kS EC50S k'R 
Value 2.94 1.97 9.82E+10 5.74 0.28 0.23 
Lower 
Bound 1.62 0.93 3.80E+09 3.56 0.00 0.00 
Upper 
Bound 4.26 3.01 2.00E+11 7.93 0.83 0.49 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Average 
of all 
isolate gS 
Average 
of all 
isolate gR 
Average 
of all 
isolate 
Nmax 
Average 
of all 
isolate kS 
Average 
of all 
isolate 
EC50S 
Average of 
all isolate 
k'R 
Source of 
bounds 
95% CI 
of mean 
95% CI 
of mean 
95% CI 
of mean 
95% CI 
of mean 
95% CI 
of mean 
95% CI of 
mean 
CI – Confidence interval; Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ 
(L/mg*h-1) 
 
  
 
269 
 
Table 4.27: Composite Model Final Parameter Estimates for All Isolates against 
Meropenem Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 2.87 0.28 10 2.33 3.41 
gR 1.44 0.06 4 1.32 1.57 
Nmax 6.87E+10 1.83E+10 27 3.25E+10 1.05E+11 
kS 5.55 0.34 6 4.88 6.23 
EC50S 0.14 0.03 20 0.09 0.20 
k'R 0.35 0.02 6 0.31 0.39 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1) 
 
 The theoretical stationary concentration of the more resistant subpopulation was 
approximately 30-fold higher than the more susceptible majority population. The doubling 
time of the more resistant subpopulation was approximately twice that of the more 
susceptible majority population (Table 4.28). 
Table 4.28: Composite Model Final Secondary Parameter Estimates for All Isolates 
against Meropenem Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) 0.15*MIC 0.02 12 
SCR (mg/L) 4.11*MIC 0.12 3 
dS (min) 14.48 1.39 10 
dR (min) 28.80 1.28 4 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
270 
 
 More support in the form of the Akaike score is provided to individually modeled 
isolates than parameters unifying isolates exhibiting a wide range of meropenem resistance. 
When the isolate with predicted parameters least like the others was excluding, improved 
support for the composite model was noted, but not to same degree of individually modeled 
isolates (Table 4.29). 
Table 4.29: Akaike Scores of Competing Meropenem Monotherapy Models 
 Individually 
Modeled 
Composite Model 
MIC 
Normalized* 
Composite Model 
MIC Normalized 
AIC 1200.8 1339.8 1401.7 
Relative 
Likelihood <0.0001  
Relative 
Likelihood 
 <0.0001 
Literature relative likelihood value 0.0067 corresponds to differences in AIC of 10.290 
*Isolate 34 parameters were least like the other 3 isolates and was modeled individually 
 When MICs were fit as parameters, only one isolate showed reasonable agreement 
between the predicted and observed MIC. The other isolates exhibited MICs about 2-fold 
more or less than their corresponding predicted MIC which contributes to greater support 
for individually modeled isolates over a composite model when MICs are utilized to unify 
parameters (Table 4.30). 
Table 4.30: Model Predicted MICs 
Parameter Observed Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
34 MIC 4 2.0 0.34 17 1.34 2.66 
22 MIC 16 8.1 1.40 17 5.30 10.8 
24 MIC 32 31.2 5.06 16 21.2 41.1 
44 MIC 128 255.9 39.4 15 178 333 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: MIC (mg/L)  
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 Plots of observed and predicted data appeared congruent and simulated data fit the 
observed data well (Figure 4.19, Figure 4.20, Figure 4.21, and Figure 4.22). Gross 
systematic bias of the individually fit models was not observed (Figure 4.23). The linear 
assessment of bias was appropriate based on the randomly distributed residual plot (Figure 
4.24). 
 
Figure 4.19: Predicted and Observed Time-kill Data for Meropenem against Isolate 34. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a meropenem MIC > 16 mg/L. Other data indicate 
the total colony count with the given concentration of meropenem present in the time-kill 
flask. 
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Figure 4.20: Predicted and Observed Time-kill Data for Meropenem against Isolate 22. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a meropenem MIC > 16 mg/L. Other data indicate 
the total colony count with the given concentration of meropenem present in the time-kill 
flask.  
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Figure 4.21: Predicted and Observed Time-kill Data for Meropenem against Isolate 24. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a meropenem MIC > 64 mg/L. Other data indicate 
the total colony count with the given concentration of meropenem present in the time-kill 
flask. 
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Figure 4.22: Predicted and Observed Time-kill Data for Meropenem against Isolate 44. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a meropenem MIC > 64 mg/L. Other data indicate 
the total colony count with the given concentration of meropenem present in the time-kill 
flask. 
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Figure 4.23: Individual Model Observed vs. Predicted Data for Meropenem Monotherapy. 
95% confidence intervals: slope (0.97-1.04); intercept (-0.38-0.20). 
 
 
Figure 4.24: Individual Model Residual Data for Meropenem Monotherapy.  
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Pharmacodynamic Model of Isolates in Polymyxin B Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (1) and equation (2) were utilized for a total of 6 parameters, 78 time-kill 
experiments and 141 simultaneously solved differential equations. Individually modeled 
isolates are presented in Appendix H. 
Table 4.31: Composite Model Initial Parameter Estimates for All Isolates against 
Polymyxin B Monotherapy 
Parameter gS gR Nmax kS EC50S k'R 
Value 3.06 1.06 7.45E+10 9.03 0.06 0.07 
Lower 
Bound 1.65 0.75 3.88E+10 6.39 0.00 0.02 
Upper 
Bound 4.48 1.37 1.10E+11 11.67 0.23 0.12 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Average 
of all 
isolate gS 
Average 
of all 
isolate gR 
Average 
of all 
isolate 
Nmax 
Average 
of all 
isolate kS 
Average 
of all 
isolate 
EC50S 
Average of 
all isolate 
k'R 
Source of 
bounds 
95% CI 
of mean 
95% CI 
of mean 
95% CI 
of mean 
95% CI 
of mean 
95% CI 
of mean 
95% CI of 
mean 
CI – Confidence interval; Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ 
(L/mg*h-1) 
 
Table 4.32: Composite Model Final Parameter Estimates for All Isolates against 
Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 2.85 0.27 9 2.32 3.38 
gR 1.06 0.03 3 1.00 1.12 
Nmax 6.23E+10 1.29E+10 21 3.69E+10 8.77E+10 
kS 10.15 0.74 7 8.69 11.60 
EC50S 0.06 0.01 24 0.03 0.09 
k'R 0.09 0.01 12 0.07 0.11 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1)  
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The theoretical stationary concentration of the more resistant subpopulation was 
approximately 400-fold higher than the more susceptible majority population. The 
doubling time of the more resistant subpopulation was approximately twice that of the more 
susceptible majority population (Table 4.33). 
Table 4.33: Composite Model Final Secondary Parameter Estimates for All Isolates 
against Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) 0.025 0.003 13 
SCR (mg/L) 11.0 0.98 9 
dS (min) 15.8 1.62 10 
dR (min) 36.6 1.15 3 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
More support in the form of the Akaike score is provided to the composite model 
than individually modeled isolates. Furthermore, the most support is provided to the model 
with parameters that were MIC-independent (Table 4.34). 
Table 4.34: Akaike Scores of Competing Polymyxin B Monotherapy Models 
 Individually 
Modeled Composite Model 
Composite Model 
MIC Normalized 
AIC 1968.1 1441.0 1448.0 
Relative 
Likelihood <0.0001  
Relative 
Likelihood 
 0.03 
Literature relative likelihood value 0.0067 corresponds to differences in AIC of 10.290  
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Plots of observed and predicted data appeared congruent and simulated data fit the 
observed data well (Figure 4.25, Figure 4.26, Figure 4.27, and Figure 4.28). Gross 
systematic bias of the individually fit models was not observed (Figure 4.29). The linear 
assessment of bias was appropriate based on the randomly distributed residual plot (Figure 
4.30). 
 
Figure 4.25: Composite Model Predicted and Observed Time-kill Data for Polymyxin B 
against Isolate 34. Observed data represent geometric means with standard deviations of at 
least 2 time-kill experiments except for green data which was only performed once. Note 
that some error bars are smaller than the symbol. Blue data represent the sum of both 
populations. Green data represent the subpopulation with a polymyxin B MIC > 4 mg/L. 
Other data indicate the total colony count with the given concentration of polymyxin B 
present in the time-kill flask. 
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Figure 4.26: Composite Model Predicted and Observed Time-kill Data for Polymyxin B 
against Isolate 22. Observed data represent geometric means with standard deviations of at 
least 2 time-kill experiments except for green data which was only performed once. Note 
that some error bars are smaller than the symbol. Blue data represent the sum of both 
populations. Green data represent the subpopulation with a polymyxin B MIC > 4 mg/L. 
Other data indicate the total colony count with the given concentration of polymyxin B 
present in the time-kill flask. 
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Figure 4.27: Composite Model Predicted and Observed Time-kill Data for Polymyxin B 
against Isolate 24. Observed data represent geometric means with standard deviations of at 
least 2 time-kill experiments except for green data which was only performed once. Note 
that some error bars are smaller than the symbol. Blue data represent the sum of both 
populations. Green data represent the subpopulation with a polymyxin B MIC > 4 mg/L. 
Other data indicate the total colony count with the given concentration of polymyxin B 
present in the time-kill flask. 
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Figure 4.28: Composite Model Predicted and Observed Time-kill Data for Polymyxin B 
against Isolate 44. Observed data represent geometric means with standard deviations of at 
least 2 time-kill experiments except for green data which was only performed once. Note 
that some error bars are smaller than the symbol. Blue data represent the sum of both 
populations. Green data represent the subpopulation with a polymyxin B MIC > 4 mg/L. 
Other data indicate the total colony count with the given concentration of polymyxin B 
present in the time-kill flask. 
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Figure 4.29: Composite Model Observed vs. Predicted Data for Polymyxin B 
Monotherapy. 95% confidence intervals: slope (0.98-1.04); intercept (-0.38-0.06). 
 
 
Figure 4.30: Composite Model Residual Data for Polymyxin B Monotherapy.  
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Discussion 
 In summary, a deterministic two-population model was assumed for each 
antimicrobial where a population of more susceptible bacteria exhibits unique growth and 
killing rate constants compared to a more resistant subpopulation. Additional 
subpopulations could be assumed in a deterministic model, but these more complex models 
were not evaluated after achieving good overall fit of a two-population model and lacking 
sufficient evidence to support an additional third population of organisms emerging. In 
reality, subpopulations likely exist as a continuum exhibiting variable growth rates and 
responses to antimicrobials.363 A probabilistic model where the variance of the 
antimicrobial killing rate constants are fit as a parameters364 or inclusion of a probabilistic 
mutation function to account for the step-wise mutations that may occur during the course 
of therapy may account for the variance observed in the time to regrowth of some of the 
experiments, particularly those of polymyxin B against isolate 44 (Figure H.19). A 
limitation of the current two-population model is that the average killing rate and time to 
regrowth are predicted by the model which may suggest lower concentrations than what 
are actually needed to prevent regrowth due to the variance in antimicrobial killing rate.364 
In other words, despite the deterministic nature of the present model, concentrations close 
to the theoretical “stationary concentration” may not always prevent the emergence of 
resistance in practice. However, in this large data set, admittedly involving few isolates 
(n=4), observed regrowth or killing was always predicted accurately by the deterministic 
two-population model for meropenem or polymyxin B. 
In further summary, the rate of change of colony forming units over time was 
determined by a difference of the linear bacterial growth rate and the sigmoidal 
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antimicrobial kill rate, except for the resistant subpopulation where a linear killing rate was 
observed. Concentrations around and exceeding the EC50 of the resistant subpopulation are 
required to more accurately ascertain this parameter but given that these concentrations are 
well above clinically achievable concentrations in patients, assumption of a linear killing 
rate on the resistant subpopulation yielded more precise parameters (CVs < 50%) and an 
Akaike score lending more support for the simpler linear killing model for the more 
resistant subpopulation. 
The polymyxin B MICs of isolates 34, 22, 24, and 44 were within essential 
agreement (within one two-fold dilution) as defined by CLSI.268 In this context, the 
increase in Akaike score when parameter estimates were normalized by the MIC (Table 
4.34) suggests that this normalization is not supported and instead these isolates likely have 
much closer MICs to one another than a 2-fold difference as determined by broth 
microdilution (see Broth Microdilution Susceptibility Testing). This result importantly 
highlights the well-described significant limitation of antimicrobial susceptibility testing 
methods. Specifically, MICs are associated with significant variance and they are 
reproducible only within one two-fold dilution.268 This limitation significantly hampers 
efforts to standardize and compare isolates exhibiting different resistance phenotypes to 
the tested antimicrobial agents, as exemplified in the meropenem results where isolates 
were best modeled individually rather than as an overall composite (Table 4.29). 
However, differences in the antimicrobial killing rate based on the organism MIC 
weren’t the only factors contributing to an ill-fitting composite model. Growth rate 
constants among the more susceptible majority populations of bacteria ranged 2.0-4.0 hr-1 
and growth rate constants of the more resistant subpopulations ranged 1.6-2.9 hr-1 for 
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meropenem and 0.8-1.2 hr-1 for polymyxin B (Appendix H). In general, the higher the 
antimicrobial MIC (or presumed higher MIC for the more resistant subpopulation), the 
lower the growth rate constants were for both populations. This may indicate a fitness cost 
as resistance mechanisms accrue, described in greater detail by previous literature.288,289 
Therefore, the ill-fitting meropenem composite model also suggests that if CRE with 
polymyxin B MICs much higher than 0.125 mg/L were evaluated, then a similar pattern 
may emerge. Essentially, differences in isolate fitness combined with the poor precision of 
MIC information may indicate isolate-specific models are better supported than a 
composite model in the setting of different isolate MICs. Improvements on MIC 
measurement precision and a better understanding of the factors underlying the fitness cost 
associated with additional resistance mechanisms is therefore warranted before a unifying 
model can be obtained. 
 The overall observed vs. predicted regression of the best fitting meropenem and 
polymyxin B models were good. In brief, at least 90% of the linear variation of the log-
transformed colony count is accounted for by the models (Figure H.20 and Figure 4.29). 
Upon cursory visual inspection, some data points (particularly around 105-107 CFU/mL) 
fall extremely close to the line of unity whereas others are more widely distributed around 
the line within the same region (105 – 107 CFU/mL). This is explained by the greater 
variability associated with the regrowing heteroresistant subpopulation when compared to 
the more susceptible majority population. Essentially, the initial concentration and killing 
of the more susceptible population are very tightly modeled and characterized but the 
regrowth of the subpopulation is not as well described. Additional sampling of the 
heteroresistant subpopulation during this phase of regrowth would increase the number of 
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data points in this region. Further, the 95% confidence intervals of the slopes and intercepts 
of the observed vs. predicted plots contain 1 and 0, respectively, indicating that the models 
are not differentially biased at lower versus higher colony counts and also not 
systematically biased at a higher or lower colony counts. Furthermore, this analysis utilized 
the approach suggested by Piñeiro et al. to ensure appropriate determination of bias 
whereas others have traditionally plotted predicted vs. observed and arrived at erroneous 
conclusions because underestimation of the slope and overestimation of the y-intercept 
increases as r2 values decrease.365  
In general, the proposed models of polymyxin B and meropenem against KPC-
producing K. pneumoniae suggest that, under ideal growth conditions for bacteria (i.e. 
nutrient rich environment, optimal temperature, sufficient oxygenation, etc.), meropenem 
concentrations up to 4x the measured meropenem MIC are required for bacteriostatic 
activity against the resistant subpopulation, but concentrations as low as 0.15x MIC may 
be required for bacteriostatic activity against the less resistant population (Table 4.28). This 
is supported by clinical data suggesting that regimens containing carbapenems using 
aggressive dosing strategies (e.g. meropenem 2g every 8h over a 3h infusion) are more 
effective in treating patients infected with CRE exhibiting MICs ≤8 mg/L, given that such 
regimens are predictive of carbapenem concentrations > MIC for at least 40% of the dosing 
interval.340 Regarding polymyxin B, concentrations as low as 0.025 mg/L are bacteriostatic 
against the majority population whereas concentrations as high as 11 mg/L are needed to 
prevent the resistant subpopulation from regrowing (Table 4.33). However, it is necessary 
to mention that the present model did not evaluate concentrations as high as 11 mg/L. This 
suggests that lower doses of polymyxin B should be utilized to kill the more susceptible 
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population and also minimize the risk of renal injury while another antimicrobial agent 
could be used to kill the more resistant subpopulation, perhaps alleviating the very 
aggressive doses of polymyxins currently utilized clinically.124 For both isolates, the 
growth rate of the more resistant subpopulation is approximately half that of the susceptible 
population, but the clinical implications of this observation are unknown. Again, this fits 
the present understanding of a fitness cost in exchange for higher degrees of resistance 
expression in isolates.288,289 
To the best of my knowledge, this is the first study to model meropenem and 
polymyxin B against KPC-producing Klebsiella pneumoniae exhibiting a wide range of 
meropenem MICs. However, others have modeled meropenem against isolates like 
Pseudomonas aeruginosa using a variety of modeling techniques, some of which were 
employed in the present study.286,363,364 Limitations of the present work include that 
insufficient data are available to validate the model. Although the model fits the training 
data very well, it remains to be seen how predictive this model will be of the activities of 
meropenem and polymyxin B of similar isolates. Furthermore, the definition of similar 
isolates may be nuanced by the isolate MIC, the genotype/phenotypic expression of 
resistance mechanisms, and perhaps even by the genus or species of the organism. 
Therefore, additional work is needed in this area to determine how similar in response other 
carbapenem-resistant organisms are. For example, clinically, patients infected with 
Acinetobacter baumannii seemingly respond to polymyxin monotherapy whereas patients 
infected with other carbapenem-resistant organisms may exhibit more frequent clinical 
failures, similar to what the present model might suggest in its prediction of rapid and 
consistent regrowth despite utilization of concentrations of up to 64x the MIC.251 
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Chapter Five: 
 
Conclusions and Future Work 
Part of the research contained within this chapter has been published as 
Kulengowski, B. In vitro activity of polymyxin B and meropenem alone and in 
combination against carbapenem-resistant Enterobacteriaceae. 2016. Theses and 
Dissertations—Pharmacy. 57. 
Carbapenem-resistant Enterobacteriaceae (CRE) are a growing national and 
international threat.39,94,95,120-123 Specifically, a "Call to Action" has been issued by various 
organizations (e.g. CDC, PACCARB, IDSA) hoping to raise awareness among the medical 
community as well as highlight the dwindling development of novel antimicrobial agents 
with activity against these hard-to-treat infections.12 Furthermore, the United Nations 
released a report estimating that by 2050, antimicrobial resistant infections will kill more 
people annually than cancer.366 
Compounding this issue is the wide variability in types of carbapenem resistance 
among CRE (e.g. KPC, MBL, OXA-48, and ESBL or AmpC with porin mutations) and 
the large differences observed among nations or even among hospitals within the same 
country, state, or province.14 There are few randomized, controlled clinical trials evaluating 
optimal therapy for CRE treatment, and treatment strategies may vary depending on the 
type of resistance. It has also been suggested that strain-to-strain differences or bacteria 
genotype may be more important to optimal therapeutic decision-making than MIC or 
pharmacodynamic indices alone.229 
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In order to contribute to the growing knowledge of CRE management, this study 
focused on KPC-producing carbapenem-resistant Enterobacteriaceae, the most common 
CRE in the U.S., approximately 99% of CRE cases in some regions.14 Some studies 
presented in this dissertation included VIM-producing CRE which emerged as a significant 
phenotype at UK HealthCare. In fact, the quantity of VIM-producing isolates within 
Kentucky is greater than all other states combined.79 Specifically, we evaluated the use of 
amikacin, meropenem, and polymyxin B alone and in combination because, among the 
four "typically susceptible" antimicrobial agents, fosfomycin is only approved in the U.S. 
for uncomplicated urinary tract infections;178 tigecycline is unable to reach effective serum 
concentrations for treatment of CRE bacteremia,168,367 where mortality is estimated to be 
around 50%;11 and colistin is associated with higher rates of nephrotoxicity, cumbersome 
therapeutic drug monitoring, and more difficult rational drug dosing when compared to 
polymyxin B.130,131,145 All of these agents are associated with rapid resistance development 
when used as monotherapy,14 and previous data have indicated that combination therapy, 
in particular combinations including a carbapenem, have a mortality benefit over 
monotherapy.10,68,185,199-203 
To the best of my knowledge, this study was among the first to evaluate the in vitro 
interaction of polymyxin B and amikacin in combination with meropenem across a wide 
range of carbapenem resistance, testing multiple concentrations, evaluating staggered and 
sequential administration, and for a longer duration (48 hours) than previous studies which 
have typically evaluated combinations involving colistin.201,206,207,331,368,369 Meropenem, 
amikacin, and polymyxin B alone and in combination were evaluated against KPC-
producing and VIM-producing clinical isolates, representing polymyxin-susceptible (PMB 
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MICs  < 2 µg/mL) CRE of varying meropenem resistance (MEM MICs 4 – 128 µg/mL) 
and amikacin susceptibility (AMK MICs 8 – 64 mg/L). These isolates were evaluated using 
CLSI-standardized in vitro laboratory methodology, designed and approved to minimize 
variability between laboratories to facilitate more meaningful comparisons of results.262 
The activity of novel antimicrobial agents such as ceftazidime/avibactam and 
imipenem/relebactam were evaluated and the agreement of antimicrobial susceptibility 
testing methods across a wide variety of antimicrobial agents were also compared 
according to CLSI guidelines.  Finally, pharmacodynamic mathematical modeling was 
performed on a subset of Klebsiella pneumoniae isolates to better understand the interplay 
of the selection for and emergence of resistance in the presence and absence of common 
antimicrobial agents against CRE.  
The most significant finding of this study is not simply that “susceptible” and 
“resistant” designations insufficiently describe antimicrobial activity, but rather that both 
the antimicrobial MIC as well as the specific resistance mechanisms influence optimal 
choice of therapy. The polymyxin B and meropenem time-kill studies against polymyxin 
susceptible KPC- and/or VIM-producing K. pneumoniae and E. cloacae suggest 
bactericidal activity can be attained against isolates exhibiting meropenem MICs ≤16 
mg/L—with clinically achievable serum concentrations in patients. Similarly, the amikacin 
and meropenem time-kill studies against CRE suggest bactericidal interactions occur when 
the amikacin MIC is ≤16 mg/L. A wider variation in meropenem MICs should 
subsequently be evaluated to verify if this relationship holds for isolates exhibiting 
meropenem MICs ≤8 mg/L or >32 mg/L. Also, pharmacokinetic factors such as drug 
distribution will need to be addressed when considering infection sites that are not well 
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vascularized or are known to be difficult to reach such as central nervous system infections. 
If aggressive doses of these antimicrobial agents are used, our data suggest isolates 
exhibiting meropenem MICs ≤32 mg/L may be treatable. However, accounting for the 
within-one-10-fold-dilution variability in MIC tests would suggest that aggressive dosing 
should be used for isolates exhibiting a meropenem MIC of 16 mg/L. Isolates exhibiting 
MICs greater than 16 mg/L warrant additional exploration. One possibility is to further 
assess the utilization of the novel carbapenemase inhibitor combinations (e.g. 
ceftazidime/avibactam, meropenem/vaborbactam, etc.) and their interaction with 
antimicrobials like polymyxin B and amikacin using high through-put in vitro methods 
such as those described in this dissertation. Further work could also be conducted using 
triple (or higher degree) combinations to manage these organisms, but even high 
throughput in vitro methodology will be very time consuming to parse out the interactions 
between each pair of agents, the interaction component of all three agents together, and the 
activity of the antimicrobials individually. However, what makes this latter approach most 
interesting is the analogy to HIV treatment in that triple combination therapy is the standard 
for the prevention of resistance and not simply treatment of the acute-phase of the infection. 
It should be pointed out, however, that double agent HIV treatment is becoming more 
widespread in practice and, particularly with the novel compounds, is just as effective at 
preventing resistance while minimizing patient pill burden and toxicity. These points 
should also be considered for future work with CRE in that as regimen complexity 
increases, patients will require additional IV lines which pose increased risk as well as 
possible compounding toxicity issues like renal failure. 
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The next major finding of this dissertation is that the sequence of drug 
administration matters for meropenem and polymyxin B combinations. In fact, 
administering the beta-lactam agent first exhibited as good and sometimes superior activity 
to simultaneous administration of the two agents whereas administering the polymyxin 
agent first exhibited very poor activity against CRE. To date, no other study has 
demonstrated that meropenem should be administered before polymyxin B to improve the 
combination activity against CRE. However, a lot of additional work is needed to better 
understand why the interaction is different and to take full advantage of the interaction of 
sequence, timing, antimicrobial choice, and dose. More specifically, the present 
dissertation only explored one administration time difference of 2 hours when the optimal 
administration time difference may be more or less. Furthermore, following the first 
conclusion about the antimicrobials MICs influence the interaction, these MICs may also 
influence the timing and sequence necessary to optimize killing activity. The present 
dissertation supports the notion that the sequence of administration is not dependent on the 
carbapenem MIC of the organism, but the polymyxin B MIC or the timing may play a role 
on whether the sequence of antimicrobials should be a carbapenem first versus a polymyxin 
agent first. In vitro high throughput methodology like that of this dissertation would be 
most useful for initially addressing these hypotheses, but so too would animal and 
eventually human studies since the immune system and pharmacokinetics may influence 
the sequence and timing as well. For example, the same timing in a benchtop experiment 
may not be optimal when one drug distributes to the target site considerably faster than the 
other. Carbapenem resistance phenotypes other than KPC and VIM should also be included 
in future studies to determine if the sequence/timing interaction with carbapenems and 
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polymyxins is independent of genotype, and perhaps more importantly, phenotype. Finally, 
other antimicrobial agents in combination should be evaluated, at least in vitro, based on 
the present findings because such interactions may also be impacted by sequence and 
timing. 
In the setting of current high-dose polymyxin dosing strategies exhibiting average 
free concentrations of polymyxin B around 1 m/gL, these dissertation findings suggest that 
lower polymyxin B concentrations can sufficiently kill the susceptible majority populations 
of CRE, substantiated by the model findings, and that when utilized in combination, lower 
concentration targets can exhibit equivalent killing activity as demonstrated by the time-
kill studies. This information should subsequently be tested in an in vivo animal model, but 
it suggests that clinicians may be unnecessarily utilizing high doses of antimicrobials in 
combination like polymyxin B since the monotherapy dosing strategies are typically 
implemented. Lower doses may reduce toxicity. However, higher doses may address other 
important clinical endpoints such as the prevention of the emergence of resistance either 
on therapy or at a later point in a patient’s life. Naturally, exploring this notion opens 
myriad opportunities to optimize therapeutic combinations and better characterize the 
relationship of clinical outcomes to antimicrobial dosing strategies. 
Data in this dissertation do not support particular clinical testing methodologies for 
certain antimicrobials, namely polymyxins. More specifically, the Etest® should not be 
utilized to evaluate the activity of polymyxin B or colistin in the clinic. This conclusion is 
now well supported by other labs, including major organizations like CLSI and EUCAST. 
However, this dissertation also brings to light discrepancies that warrant further 
investigation between the traditional gold-standard broth dilution techniques and the 
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clinically efficient automated system, BD Phoenix™. Therefore, numerous questions are 
raised that warrant additional investigation.  
It was previously discussed that resistance mechanism acquisition by bacteria are 
often associated with a fitness cost. Therefore, when bacteria are not under antimicrobial 
selective pressure (like when they are stored or re-subcultured prior to experimentation), 
the majority population may lose the mechanism of resistance in favor of more rapid 
growth. However, the present findings suggest that, in general, CRE tested by broth 
microdilution exhibited more resistance than the same CRE tested by BD Phoenix™ years 
prior. Since the degree of difference between testing methods was highly variable (it was 
not simply a normal distribution around, for example, 8-fold higher MICs), then attributing 
the difference only to differences in testing period or the time frozen is inappropriate. 
Instead, the data suggest a more complex explanation that warrants additional investigation 
as well as validation by other laboratories before insinuating that one testing method 
inherently produces biased results. An example of this complexity is also presented in this 
dissertation concerning the degree of heteroresistance observed with polymyxin B against 
CRE. Other laboratories have also attributed irreproducible or confounding results to 
heteroresistance observed among antimicrobials. These findings suggest that a single MIC 
report for an isolate are not sufficient for determining outcome, but instead are a guideline. 
If true, testing methodology should subsequently be developed to characterize not only the 
majority MIC measurement but also an assessment of the degree of heteroresistance or the 
uncertainty surrounding each MIC measurement. Such data could then be utilized in 
stochastic model to predict probabilities of treatment success. In other words, two isolates 
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exhibiting the same MIC but one having much more heteroresistant variability may warrant 
more aggressive treatment strategies to afford the same degree of clinical success certainty. 
In summary, data from retrospective human studies have been compelling 
regarding the advantage of combination therapy, especially those containing a carbapenem, 
for the treatment of CRE. However, questions such as which antimicrobials, at what doses, 
for how long, and are there other factors that might determine clinical outcome still remain. 
Significant limitations such as heterogeneity and correlative evidence begs for randomized 
controlled trials evaluating antimicrobial combinations head-to-head. However, cost, 
coordination, and design hurdles nearly render this undertaking infeasible, which leads to 
in vitro, animal, and retrospective studies to address these questions. So far, time-kill 
studies have identified numerous combinations of antimicrobials with high rates of 
synergy, among them are polymyxins and aminoglycosides in combination with a 
carbapenem.  
Limitations in antimicrobial susceptibility testing, such as the precision of MIC 
measurement, have been a long-standing issue for microbiologists. However, continued 
work on identifying isolate characteristics predictive of outcome and indicative of optimal 
therapy should be a continual pursuit in this field. Furthermore, as point-of-care and rapid 
diagnostic devices become available to assess patients and microorganisms for optimal 
treatment, special attention should be given to microorganisms possessing challenging-to-
treat resistance mechanisms given the often-nuanced treatment necessary to effectively 
manage such infections. Essentially, precision medicine applies to infectious diseases, and 
the concept will continue to play a larger role as more information is available at the patient 
bedside when patient care teams are making decisions.  
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Data with in vitro pharmacodynamic and animal models more closely emulating 
human pharmacokinetics and the immune system are also warranted. Using the time-kill 
and pharmacodynamic modeling data from this study, pharmacokinetic models can be 
linked using published patient data or the use of bioreactors that mimic dynamic rather than 
static drug levels. Murine models can be used to incorporate the effects of an immune 
system and other factors of a living, infected host. Previous data, although limited, can 
serve as a foundation for experimental design and for comparison once data is obtained. 
Finally, novel antimicrobial agents have just come to the market and should be 
investigated, both alone and in combination so that optimal treatment strategies can be 
developed. In particular, MBL-producing CRE are a major problem outside the U.S. but 
may easily become the predominant mechanism of resistance if judicious utilization of the 
novel carbapenemase inhibitors does not occur. Specifically, avibactam, relebactam, and 
vaborbactam show promise with inhibiting serine-based carbapenemases whereas 
plazomicin and eravacycline may demonstrate excellent activity against both KPC-
producing and MBL-producing CRE. However, historically, bacteria have always 
developed resistance to any antimicrobial introduced to humans.  
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APPENDICES 
Appendix A: 
 
Minimum Inhibitory Concentrations Determined by BD Phoenix™ 
 
 Tables A.1-A.2 provide the results of in vitro susceptibility testing performed by 
the University of Kentucky Clinical Microbiology Laboratory using BD Phoenix™. 
 The following abbreviations are used in Table A.1: AMP - Ampicillin; AMS - 
Ampicillin/Sulbactam; AZT - Aztreonam; CFZ - Cefazolin; CPM - Cefepime; FOX - 
Cefoxitin; CAZ - Ceftazidime; CAX - Ceftriaxone; CRM - Cefuroxime; ETP - Ertapenem; 
MEM - Meropenem; PTC - Piperacillin/Tazobactam. 
 The following abbreviations are used in Table A.2:  AMK - Amikacin; CIP - 
Ciprofloxacin; GEN - Gentamicin; LEV - Levofloxacin; NIT - Nitrofurantoin; TET - 
Tetracycline; TOB - Tobramycin; SXT - Sulfamethoxazole/Trimethoprim. 
  
 
 
 
 
Table A.1: Minimum Inhibitory Concentration of β-lactam Antimicrobials for University of Kentucky Carbapenem-resistant 
Enterobacteriaceae Clinical Isolates by BD Phoenix™ (n=164) 
Abbreviations: AMP - Ampicillin; AMS - Ampicillin/Sulbactam; AZT - Aztreonam; CFZ - Cefazolin; CPM - Cefepime; FOX - 
Cefoxitin; CAZ - Ceftazidime; CAX - Ceftriaxone; CRM - Cefuroxime; ETP - Ertapenem; MEM - Meropenem; PTC - 
Piperacillin/Tazobactam 
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Organism Isolate AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ERT MEM PTC 
C. amalonaticus 36 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 4 4 >64/4 
C. amalonaticus 91 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 4 >64/4 
C. freundii 6 >16 >16/8 >16 >16 8 >16 4 >32 >16 2 <=1 >64/4 
C. freundii 27 >16 >16/8 >16 >16 8 >16 8 >32 >16 2 <=1 >64/4 
C. freundii 50 >16 >16/8 >16 >16 >16 16 >16 >32 >16 4 <=1 >64/4 
C. freundii 54 >16 >16/8 >16 >16 4 >16 8 >32 >16 4 <=1 >64/4 
C. freundii 101 >16 >16/8 >16 >16 2 >16 >16 32 >16 2 <=1 >64/4 
C. freundii 127 >16 >16/8 >16 >16 2 >16 >16 >32 >16 >4 2 >64/4 
C. freundii 135 >16 >16/8 <=2 >16 >16 >16 >16 >32 >16 <=0.5 4 >64/4 
C. freundii 145 >16 >16/8 >16 >16 2 >16 >16 >32 >16 2 <=1 >64/4 
C. freundii 147 >16 >16/8 >16 >16 8 >16 >16 >32 >16 2 <=1 >64/4 
C. freundii 324 >16 >16/8 >16 >16 >16 >16 4 >32 
 
1 <=0.5 >64/4 
C. freundii 562 >16 >16/8 <=2 >16 >16 >16 >16 >32 
 
>1 4 >64/4 
C. freundii 593 >16 >16/8 >16 >16 >16 >16 >16 R 
 
>1 <=0.5 >64/4 
C. freundii 604 >16 >16/8 >16 >16 >16 >16 >16 
  
>1 <=0.5 >64/4 
C. youngae 136 >16 >16/8 >16 >16 16 >16 8 >32 >16 >4 4 >64/4 
C. youngae 435 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 8 >64/4 
E. aerogenes 97 >16 >16/8 >16 >16 2 >16 >16 >32 >16 1 <=1 >64/4 
E. aerogenes 179 >16 >16/8 <=2 >16 <=1 >16 >16 >32 >16 4 >8 >64/4 
E. aerogenes 187 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 2 <=1 >64/4 
E. aerogenes 438 >16 >16/8 >16 >16 16 >16 >16 >32 
  
8 >64/4 
E. cloacae 1 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 8 >64/4 
E. cloacae 3 >16 >16/8 >16 >16 8 >16 >16 >32 >16 >4 <=1 >64/4 
E. cloacae 4 >16 >16/8 >16 >16 4 >16 >16 >32 >16 >4 <=1 >64/4 
E. cloacae 5 >16 >16/8 >16 >16 16 >16 8 >32 >16 >4 2 >64/4 
E. cloacae 9 >16 >16/8 >16 >16 16 >16 >16 >32 >16 4 >8 >64/4 
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Organism Isolate AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ERT MEM PTC 
E. cloacae 10 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
E. cloacae 12 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
E. cloacae 15 >16 >16/8 >16 >16 4 >16 >16 >32 >16 2 <=1 >64/4 
E. cloacae 16 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 <=1 >64/4 
E. cloacae 17 >16 >16/8 >16 >16 4 >16 >16 >32 >16 >4 <=1 >64/4 
E. cloacae 19 >16 >16/8 >16 >16 8 >16 >16 >32 >16 2 <=1 >64/4 
E. cloacae 20 >16 >16/8 >16 >16 8 >16 >16 >32 >16 >4 8 >64/4 
E. cloacae 23 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 2 >64/4 
E. cloacae 30 >16 >16/8 >16 >16 
 
>16 >16 >32 >16 >4 <=1 >64/4 
E. cloacae 39 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 <=1 >64/4 
E. cloacae 40 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 4 8 >64/4 
E. cloacae 41 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 4 >8 >64/4 
E. cloacae 52 >16 >16/8 >16 >16 16 >16 8 >32 >16 >4 >8 >64/4 
E. cloacae 53 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 8 >64/4 
E. cloacae 70 >16 >16/8 >16 >16 2 >16 >16 >32 >16 2 <=1 8/4 
E. cloacae 96 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 1 >8 64/4 
E. cloacae 107 >16 >16/8 >16 >16 8 >16 8 >32 >16 >4 8 >64/4 
E. cloacae 121 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 8 >64/4 
E. cloacae 126 >16 >16/8 >16 >16 >16 >16 4 >32 >16 >4 >8 >64/4 
E. cloacae 134 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 2 8 >64/4 
E. cloacae 144 >16 >16/8 >16 >16 2 >16 16 >32 >16 >4 4 >64/4 
E. cloacae 167 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 2 4 >64/4 
E. cloacae 168 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 >8 >64/4 
E. cloacae 169 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 2 4 >64/4 
E. cloacae 171 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
E. cloacae 175 >16 >16/8 <=2 >16 >16 >16 >16 >32 >16 2 4 >64/4 
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Organism Isolate AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ERT MEM PTC 
E. cloacae 189 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 4 4 >64/4 
E. cloacae 200 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 4 <=1 >64/4 
E. cloacae 203 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
E. cloacae 209 >16 >16/8 >16 >16 >16 >16 16 >32 >16 >4 >8 >64/4 
E. cloacae 266 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 4 >64/4 
E. cloacae 335 >16 >16/8 >16 >16 >16 >16 16 >32 
 
>1 <=0.5 32/4 
E. cloacae 339 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 >8 >64/4 
E. cloacae 369 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 4 >64/4 
E. cloacae 416 >16 >16/8 <=2 >16 >16 >16 >16 >32 
 
>1 4 >64/4 
E. cloacae 476 >16 >16/8 <=2 >16 >16 >16 >16 >32 
 
1 8 >64/4 
E. cloacae 515 >16 >16/8 >16 >16 16 >16 >16 >32 
 
>1 2 >64/4 
E. cloacae 561 >16 >16/8 >16 >16 4 >16 8 >32 
 
>1 <=0.5 >64/4 
E. cloacae 599 >16 >16/8 >16 >16 8 >16 >16 >32 
  
2 >64/4 
E. cloacae 606 >16 >16/8 >16 >16 16 >16 >16 >32 
 
>1 4 >64/4 
E. cloacae 607 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 8 >64/4 
E. cloacae 608 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 >8 >64/4 
E. cloacae 611 >16 >16/8 16 >16 2 >16 16 >32 
 
>1 1 >64/4 
E. cloacae 613 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 8 >64/4 
E. cloacae 615 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 8 >64/4 
E. coli 25 >16 >16/8 4 >16 <=1 8 4 >32 >16 4 <=1 >64/4 
E. coli 33 >16 >16/8 >16 >16 8 >16 >16 >32 >16 4 <=1 >64/4 
E. coli 103 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 1 <=1 32/4 
E. coli 172 >16 >16/8 <=2 >16 >16 >16 >16 >32 >16 2 8 >64/4 
E. coli 176 >16 >16/8 >16 >16 16 16 >16 >32 >16 >4 <=1 >64/4 
E. coli 309 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 4 64/4 
E. coli 390 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
1 <=0.5 8/4 
 
 
 
 
Table A.1: Minimum Inhibitory Concentration of β-lactam Antimicrobials for University of Kentucky Carbapenem-resistant 
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Organism Isolate AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ERT MEM PTC 
E. coli 508 >16 >16/8 >16 >16 >16 16 >16 >32 
 
1 <=0.5 >64/4 
E. coli 609 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 >8 >64/4 
E. gergoviae 13 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
E. gergoviae 95 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 <=1 >64/4 
E. hormaechei 186 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
E. hormaechei 398 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 8 >64/4 
Enterobacter sp. 146 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 >8 >64/4 
Enterobacter sp. 210 >16 >16/8 >16 >16 >16 >16 16 >32 >16 >4 >8 >64/4 
K. oxytoca 8 >16 >16/8 >16 >16 <=1 8 4 16 >16 >4 <=1 >64/4 
K. oxytoca 14 >16 >16/8 >16 >16 8 8 8 >32 >16 >4 <=1 >64/4 
K. oxytoca 166 >16 >16/8 >16 >16 8 <=4 2 >32 >16 >4 8 64/4 
K. oxytoca 177 >16 >16/8 >16 >16 <=1 8 8 >32 >16 4 2 >64/4 
K. oxytoca 330 >16 >16/8 >16 >16 >16 >16 8 >32 
 
>1 8 >64/4 
K. ozaenae 128 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 <=1 >64/4 
K. ozaenae 407 >16 >16/8 >16 >16 4 16 >16 >32 
 
>1 <=0.5 >64/4 
K. pneumoniae 2 >16 >16/8 8 >16 2 <=4 4 32 >16 4 <=1 >64/4 
K. pneumoniae 7 >16 >16/8 >16 >16 >16 16 8 >32 >16 >4 8 >64/4 
K. pneumoniae 11 >16 >16/8 >16 >16 8 >16 4 >32 >16 >4 <=1 >64/4 
K. pneumoniae 18 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 <=1 >64/4 
K. pneumoniae 21 >16 >16/8 16 >16 2 >16 >16 32 >16 2 <=1 >64/4 
K. pneumoniae 22 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 <=1 >64/4 
K. pneumoniae 24 >16 >16/8 >16 >16 16 >16 >16 >32 >16 >4 2 >64/4 
K. pneumoniae 26 >16 >16/8 >16 >16 <=1 >16 >16 8 >16 >4 8 >16/4 
K. pneumoniae 28 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 29 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 31 >16 >16/8 8 >16 4 <=4 4 >32 >16 >4 <=1 >64/4 
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Organism Isolate AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ERT MEM PTC 
K. pneumoniae 32 >16 >16/8 >16 >16 >16 >16 4 >32 >16 >4 <=1 >64/4 
K. pneumoniae 34 >16 >16/8 <=2 >16 <=1 <=4 2 >32 >16 >4 <=1 >64/4 
K. pneumoniae 35 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 37 >16 >16/8 16 >16 
 
16 16 >32 >16 >4 >8 >64/4 
K. pneumoniae 42 >16 >16/8 <=2 >16 >16 >16 >16 >32 >16 2 <=1 >64/4 
K. pneumoniae 43 >16 >16/8 >16 >16 16 >16 16 >32 >16 >4 >8 >64/4 
K. pneumoniae 44 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 45 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 46 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 47 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 48 >16 >16/8 >16 >16 >16 16 >16 >32 >16 >4 <=1 >64/4 
K. pneumoniae 49 >16 >16/8 >16 >16 16 >16 16 >32 >16 >4 >8 >64/4 
K. pneumoniae 51 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 55 >16 >16/8 >16 >16 8 8 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 69 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 2 <=1 8/4 
K. pneumoniae 77 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 2 >64/4 
K. pneumoniae 93 >16 >16/8 >16 >16 >16 >16 16 >32 >16 >4 >8 >64/4 
K. pneumoniae 98 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 2 <=1 >64/4 
K. pneumoniae 99 >16 >16/8 >16 >16 8 >16 8 >32 >16 >4 8 >64/4 
K. pneumoniae 105 >16 >16/8 >16 >16 8 8 16 >32 >16 >4 >8 >64/4 
K. pneumoniae 116 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 8 >64/4 
K. pneumoniae 119 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 123 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 129 >16 >16/8 >16 >16 8 8 >16 >32 >16 >4 >8 >64/4 
K. pneumoniae 130 >16 >16/8 >16 >16 >16 8 >16 >32 >16 >4 8 >64/4 
K. pneumoniae 142 >16 >16/8 >16 >16 >16 >16 >16 >32 >16 >4 >8 >64/4 
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Organism Isolate AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ERT MEM PTC 
K. pneumoniae 143 >16 >16/8 >16 >16 <=1 >16 >16 >32 >16 4 2 >64/4 
K. pneumoniae 152 >16 >16/8 <=2 >16 16 >16 16 <=2 >16 4 <=1 >64/4 
K. pneumoniae 165 >16 >16/8 >16 >16 8 >16 16 >32 >16 >4 8 >64/4 
K. pneumoniae 170 >16 >16/8 <=2 >16 >16 >16 >16 >32 >16 4 >8 >64/4 
K. pneumoniae 173 >16 >16/8 <=2 >16 >16 >16 >16 >32 >16 2 8 >64/4 
K. pneumoniae 174 >16 >16/8 <=2 >16 >16 >16 >16 >32 >16 2 >8 >64/4 
K. pneumoniae 230 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 >8 >64/4 
K. pneumoniae 243 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 <=0.5 >64/4 
K. pneumoniae 256 >16 >16/8 >16 >16 >16 >16 16 >32 
 
>1 >8 >64/4 
K. pneumoniae 269 >16 >16/8 
 
>16 <=1 >16 >16 >32 
 
>1 <=0.5 >64/4 
K. pneumoniae 284 >16 >16/8 
 
>16 4 >16 >16 >32 
 
>1 8 >64/4 
K. pneumoniae 349 >16 >16/8 <=2 >16 <=1 >16 >16 >32 
 
>1 2 >64/4 
K. pneumoniae 352 >16 >16/8 >16 >16 >16 >16 16 >32 
 
>1 <=0.5 >64/4 
K. pneumoniae 372 >16 >16/8 >16 >16 <=1 >16 >16 >32 
 
>1 4 >64/4 
K. pneumoniae 385 >16 >16/8 >16 >16 
 
>16 >16 >32 
 
>1 1 >64/4 
K. pneumoniae 391 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 4 >64/4 
K. pneumoniae 411 >16 >16/8 <=2 >16 >16 >16 >16 >32 
 
>1 >8 >64/4 
K. pneumoniae 418 >16 >16/8 >16 >16 <=1 >16 >16 >32 
 
>1 1 >64/4 
K. pneumoniae 423 >16 >16/8 >16 >16 >16 16 >16 >32 
 
>1 4 >64/4 
K. pneumoniae 445 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 >8 >64/4 
K. pneumoniae 446 >16 >16/8   >16 <=1 >16 >16 >32 
 
>1 >8 >64/4 
K. pneumoniae 449 >16 >16/8 >16 >16 16 >16 >16 >32 
 
>1 8 >64/4 
K. pneumoniae 452 >16 >16/8 >16 >16 <=1 >16 >16 >32 
 
>1 2 >64/4 
K. pneumoniae 466 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 2 >64/4 
K. pneumoniae 482 >16 >16/8 >16 >16 <=1 >16 >16 >32 
 
>1 2 >64/4 
K. pneumoniae 492 >16 >16/8 >16 >16 <=1 >16 >16 >32 
 
>1 2 >64/4 
 
 
 
 
Table A.1: Minimum Inhibitory Concentration of β-lactam Antimicrobials for University of Kentucky Carbapenem-resistant 
Enterobacteriaceae Clinical Isolates by BD Phoenix™ (n=164) 
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Organism Isolate AMP AMS AZT CFZ CPM FOX CAZ CAX CRM ERT MEM PTC 
K. pneumoniae 536 >16 >16/8 >16 >16 4 >16 >16 >32 
 
>1 1 >64/4 
K. pneumoniae 558 >16 >16/8 >16 >16 >16 >16 16 >32 
 
>1 8 >64/4 
K. pneumoniae 605 >16 >16/8 >16 >16 2 16 >16 >32 
 
>1 8 >64/4 
K. pneumoniae 610 >16 >16/8 >16 >16 8 8 >16 >32 
 
>1 4 >64/4 
K. pneumoniae 616 >16 >16/8 <=2 >16 >16 >16 >16 >32 
 
>1 >8 >64/4 
P. rettgeri 244 >16  8/4 <=2 >16 <=1 >16 2 2 
 
>1 2 <=2/4 
S. marcescens 514 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 >8 >64/4 
S. marcescens 560 >16 >16/8 >16 >16 >16 >16 >16 >32 
 
>1 >8 >64/4 
MIC values expressed in the table are in units of mg/L 
Blank entries were not tested by University of Kentucky Microbiology Laboratory 
Some organism and antimicrobial combinations were only tested by Etest® and reported as S, I, or R
 
 
 
 
Table A.2: Minimum Inhibitory Concentration of Non-β-lactam Antimicrobials for University of Kentucky Clinical Isolates by 
BD Phoenix™ (n=164) 
Abbreviations: AMK - Amikacin; GEN - Gentamicin; TOB - Tobramycin; CIP - Ciprofloxacin; LEV - Levofloxacin; NIT - 
Nitrofurantoin; TET - Tetracycline; SXT - Sulfamethoxazole/Trimethoprim 
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Organism Isolate AMK GEN TOB CIP LEV NIT TET SXT 
C. amalonaticus 36 <=8 >8 >8 >2 >4 32 4 >2/38 
C. amalonaticus 91 <=8 >8 >8 >2 >4 64 4 >2/38 
C. freundii 6 <=8 <=2 <=2 >2 4 <=16 4 >2/38 
C. freundii 27 >32 >8 >8 >2 >4 <=16 <=2 >2/38 
C. freundii 50 <=8 >8 >8 >2 4 <=16 4 >2/38 
C. freundii 54 <=8 >8 >8 >2 >4 <=16 4 <=0.5/9.5 
C. freundii 101 <=8 8 4 >2 >4 <=16 >8 >2/38 
C. freundii 127 <=8 >8 >8 >2 >4 <=16 >8 >2/38 
C. freundii 135 <=8 <=2 8 <=0.5 <=1 <=16 <=2 >2/38 
C. freundii 145 <=8 <=2 <=2 >2 >4 <=16 4 <=0.5/9.5 
C. freundii 147 <=8 <=2 <=2 <=0.5 <=1 <=16 <=2 <=0.5/9.5 
C. freundii 324 <=8 <=2 <=2 2 <=1 <=16 <=2 >2/38 
C. freundii 562 <=8 <=2 8 <=0.5 <=1 <=16 <=2 >2/38 
C. freundii 593 <=8 >8 8 >2 >4 <=16 >8 >2/38 
C. freundii 604 <=8 >8 8 >2 >4 <=16 >8 >2/38 
C. youngae 136 <=8 <=2 <=2 >2 >4 <=16 >8 >2/38 
C. youngae 435 <=8 <=2 <=2 >2 >4 <=16 >8 <=0.5/9.5 
E. aerogenes 97 <=8 <=2 <=2 <=0.5 <=1 <=16 <=2 <=0.5/9.5 
E. aerogenes 179 <=8 8 >8 <=0.5 <=1 >64 <=2 >2/38 
E. aerogenes 187 <=8 <=2 <=2 <=0.5 <=1 >64 >8 <=0.5/9.5 
E. aerogenes 438 <=8 <=2 <=2 <=0.5 <=1 32 <=2 <=0.5/9.5 
E. cloacae 1 <=8 >8 >8 >2 >4 >64 >8 >2/38 
E. cloacae 3 <=8 >8 >8 1 <=1 64 <=2 >2/38 
E. cloacae 4 <=8 >8 >8 1 <=1 64 <=2 >2/38 
E. cloacae 5 <=8 >8 >8 <=0.5 <=1 64 <=2 >2/38 
E. cloacae 9 <=8 >8 >8 >2 >4 64 8 <=0.5/9.5 
E. cloacae 10 <=8 >8 >8 >2 >4 64 8 <=0.5/9.5 
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Organism Isolate AMK GEN TOB CIP LEV NIT TET SXT 
E. cloacae 12 <=8 >8 >8 >2 >4 64 8 <=0.5/9.5 
E. cloacae 15 <=8 8 >8 1 <=1 32 <=2 <=0.5/9.5 
E. cloacae 16 <=8 >8 >8 >2 >4 32 8 >2/38 
E. cloacae 17 <=8 >8 >8 >2 >4 64 4 >2/38 
E. cloacae 19 <=8 8 >8 1 <=1 64 <=2 <=0.5/9.5 
E. cloacae 20 <=8 >8 >8 >2 >4 64 8 <=0.5/9.5 
E. cloacae 23 <=8 >8 >8 >2 >4 64 8 <=0.5/9.5 
E. cloacae 30 <=8 >8 >8 >2 >4 >64 >8 >2/38 
E. cloacae 39 <=8 >8 >8 >2 2 32 <=2 <=0.5/9.5 
E. cloacae 40 <=8 >8 >8 >2 >4 >64 4 >2/38 
E. cloacae 41 16 >8 >8 1 <=1 64 >8 >2/38 
E. cloacae 52 <=8 8 >8 >2 >4 32 8 <=0.5/9.5 
E. cloacae 53 <=8 >8 >8 >2 >4 >64 >8 >2/38 
E. cloacae 70 <=8 >8 8 >2 >4 >64 >8 >2/38 
E. cloacae 96 <=8 <=2 <=2 <=0.5 <=1 <=16 <=2 <=0.5/9.5 
E. cloacae 107 <=8 >8 >8 >2 >4 32 4 <=0.5/9.5 
E. cloacae 121 <=8 >8 >8 1 <=1 >64 4 >2/38 
E. cloacae 126 <=8 >8 >8 >2 >4 32 8 <=0.5/9.5 
E. cloacae 134 <=8 >8 >8 1 <=1 >64 <=2 >2/38 
E. cloacae 144 <=8 >8 >8 >2 2 <=16 <=2 <=0.5/9.5 
E. cloacae 167 <=8 <=2 8 1 
 
64 <=2 >2/38 
E. cloacae 168 <=8 8 >8 >4 >4 64 8 <=0.5/9.5 
E. cloacae 169 <=8 <=2 8 1 <=1 64 <=2 >2/38 
E. cloacae 171 <=8 >8 >8 >2 >4 64 8 <=0.5/9.5 
E. cloacae 175 <=8 >8 >8 1 <=1 32 <=2 >2/38 
E. cloacae 189 <=8 <=2 8 <=0.5 <=1 64 <=2 >2/38 
E. cloacae 200 <=8 >8 >8 >2 >4 64 8 >2/38 
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BD Phoenix™ (n=164) 
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Organism Isolate AMK GEN TOB CIP LEV NIT TET SXT 
E. cloacae 203 <=8 >8 >8 1 <=1 64 <=2 >2/38 
E. cloacae 209 <=8 >8 >8 >2 >4 >64 8 <=0.5/9.5 
E. cloacae 266 <=8 >8 >8 <=0.5 <=1 64 <=2 >2/38 
E. cloacae 335 <=8 <=2 <=2 >2 >4 >64 >8 >2/38 
E. cloacae 339 <=8 >8 >8 >2 >4 >64 >8 >2/38 
E. cloacae 369 <=8 <=2 <=2 >2 4 >64 >8 <=0.5/9.5 
E. cloacae 416 <=8 >8 >8 <=0.5 <=1 64 <=2 >2/38 
E. cloacae 476 <=8 <=2 >8 <=0.5 <=1 >64 <=2 >2/38 
E. cloacae 515 <=8 4 4 >2 >4 64 8 >2/38 
E. cloacae 561 <=8 >8 >8 >2 4 32 8 >2/38 
E. cloacae 599 <=8 >8 >8 <=0.5 <=1 
 
<=2 >2/38 
E. cloacae 606 <=8 >8 >8 >2 >4 
 
<=2 >2/38 
E. cloacae 607 16 >8 >8 <=0.5 <=1 64 <=2 >2/38 
E. cloacae 608 16 >8 >8 >2 4 >64 >8 >2/38 
E. cloacae 611 <=8 >8 >8 <=0.5 <=1 64 <=2 >2/38 
E. cloacae 613 <=8 >8 >8 >2 >4 
 
>8 >2/38 
E. cloacae 615 <=8 <=2 8 1 <=1 
 
<=2 >2/38 
E. coli 25 <=8 <=2 <=2 >2 >4 <=16 >8 >2/38 
E. coli 33 <=8 >8 8 >2 >4 >64 <=2 <=0.5/9.5 
E. coli 103 <=8 <=2 >8 >2 >4 64 >8 >2/38 
E. coli 172 <=8 <=2 >8 1 <=1 <=16 <=2 >2/38 
E. coli 176 <=8 <=2 <=2 >2 >4 <=16 <=2 >2/38 
E. coli 309 <=8 <=2 <=2 >2 >4 32 >8 <=0.5/9.5 
E. coli 390 <=8 >8 8 >2 >4 <=16 >8 >2/38 
E. coli 508 <=8 >8 >8 >2 >4 <=16 >8 >2/38 
E. coli 609 <=8 >8 8 >2 >4 <=16 >8 >2/38 
E. gergoviae 13 <=8 >8 >8 >2 >4 64 8 <=0.5/9.5 
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Organism Isolate AMK GEN TOB CIP LEV NIT TET SXT 
E. gergoviae 95 <=8 <=2 <=2 <=0.5 <=1 64 >8 <=0.5/9.5 
E. hormaechei 186 <=8 >8 >8 >2 4 >64 8 >2/38 
E. hormaechei 398 <=8 >8 >8 <=0.5 <=1 64 <=2 >2/38 
Enterobacter sp. 146 <=8 >8 >8 >2 >4 64 8 <=0.5/9.5 
Enterobacter sp. 210 <=8 8 >8 >2 >4 <=16 4 <=0.5/9.5 
K. oxytoca 8 <=8 <=2 <=2 <=0.5 <=1 <=16 <=2 1/19 
K. oxytoca 14 <=8 >8 >8 2 2 <=16 4 >2/38 
K. oxytoca 166 <=8 <=2 <=2 <=0.5 <=1 32 <=2 <=0.5/9.5 
K. oxytoca 177 <=8 >8 >8 <=0.5 <=1 <=16 <=2 <=0.5/9.5 
K. oxytoca 330 <=8 8 8 >2 4 <=16 8 >2/38 
K. ozaenae 128 <=8 4 4 >2 >4 <=16 4 >2/38 
K. ozaenae 407 <=8 >8 >8 2 2 <=16 4 <=0.5/9.5 
K. pneumoniae 2 <=8 >8 >8 <=0.5 <=1 64 >8 >2/38 
K. pneumoniae 7 <=8 <=2 <=2 <=0.5 <=1 64 <=2 >2/38 
K. pneumoniae 11 <=8 <=2 <=2 <=0.5 <=1 >64 8 2/38 
K. pneumoniae 18 <=8 <=2 <=2 <=0.5 <=1 >64 8 >2/38 
K. pneumoniae 21 <=8 4 >8 1 <=1 <=16 <=2 >2/38 
K. pneumoniae 22 32 >8 >8 >2 >4 >64 >8 >2/38 
K. pneumoniae 24 <=8 8 >8 >2 >4 >64 4 <=0.5/9.5 
K. pneumoniae 26 >32 >8 >8 >2 >4 >64 <=2 >2/38 
K. pneumoniae 28 32 4 >8 >2 >4 >64 8 >2/38 
K. pneumoniae 29 32 4 >8 >2 >4 >64 4 2/38 
K. pneumoniae 31 <=8 >8 >8 <=0.5 <=1 >64 <=2 2/38 
K. pneumoniae 32 <=8 <=2 <=2 >2 4 64 8 <=0.5/9.5 
K. pneumoniae 34 <=8 <=2 <=2 <=0.5 <=1 64 <=2 <=0.5/9.5 
K. pneumoniae 35 <=8 >8 >8 >2 >4 >64 8 <=0.5/9.5 
K. pneumoniae 37 >32 >8 >8 <=0.5 <=1 32 <=2 <=0.5/9.5 
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Organism Isolate AMK GEN TOB CIP LEV NIT TET SXT 
K. pneumoniae 42 <=8 >8 >8 2 <=1 <=16 <=2 >2/38 
K. pneumoniae 43 <=8 >8 >8 >2 >4 64 4 <=0.5/9.5 
K. pneumoniae 44 <=8 >8 >8 >2 >4 >64 >8  1/19 
K. pneumoniae 45 <=8 >8 >8 >2 >4 >64 4 2/38 
K. pneumoniae 46 >32 >8 >8 >2 >4 >64 4 >2/38 
K. pneumoniae 47 >32 >8 >8 >2 >4 >64 <=2 >2/38 
K. pneumoniae 48 >32 >8 >8 >2 >4 >64 4 <=0.5/9.5 
K. pneumoniae 49 <=8 >8 >8 >2 4 32 4 <=0.5/9.5 
K. pneumoniae 51 <=8 8 8 >2 >4 64 4 <=0.5/9.5 
K. pneumoniae 55 16 <=2 >8 >2 >4 64 >8 >2/38 
K. pneumoniae 69 <=8 <=2 <=2 >2 >4 >64 >8 >2/38 
K. pneumoniae 77 <=8 >8 8 >2 4 >64 <=2 <=0.5/9.5 
K. pneumoniae 93 <=8 >8 >8 >2 >4 64 4 <=0.5/9.5 
K. pneumoniae 98 <=8 4 >8 <=0.5 <=1 <=16 >8 <=0.5/9.5 
K. pneumoniae 99 <=8 <=2 <=2 <=0.5 <=1 >64 >8 2/38 
K. pneumoniae 105 <=8 <=2 <=2 <=0.5 <=1 64 <=2 1/19 
K. pneumoniae 116 <=8 <=2 <=2 >2 >4 >64 >8 >2/38 
K. pneumoniae 119 16 >8 >8 >2 >4 >64 4 >2/38 
K. pneumoniae 123 <=8 >8 >8 >2 >4 >64 4 >2/38 
K. pneumoniae 129 16 <=2 >8 >2 >4 32 <=2 >2/38 
K. pneumoniae 130 <=8 >8 >8 1 <=1 >64 <=2 <=0.5/9.5 
K. pneumoniae 142 <=8 <=2 <=2 <=0.5 <=1 64 <=2 <=0.5/9.5 
K. pneumoniae 143 <=8 >8 8 >2 >4 >64 >8 >2/38 
K. pneumoniae 152 <=8 <=2 <=2 >2 >4 >64 >8 >2/38 
K. pneumoniae 165 <=8 >8 >8 >2 >4 64 8 <=0.5/9.5 
K. pneumoniae 170 <=8 >8 >8 >2 4 32 >8 >2/38 
K. pneumoniae 173 <=8 <=2 8 1 <=1 32 <=2 >2/38 
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Organism Isolate AMK GEN TOB CIP LEV NIT TET SXT 
K. pneumoniae 174 <=8 >8 >8 1 <=1 <=16 >8 >2/38 
K. pneumoniae 230 <=8 4 >8 >2 >4 >64 8 >2/38 
K. pneumoniae 243 <=8 <=2 <=2 >2 >4 >64 4 >2/38 
K. pneumoniae 256 <=8 8 >8 >2 >4 64 8 <=0.5/9.5 
K. pneumoniae 269 <=8 <=2 <=2 >2 >4 64 4 >2/38 
K. pneumoniae 284 <=8 <=2 <=2 >2 >4 >64 >8 >2/38 
K. pneumoniae 349 <=8 >8 8 >2 >4 >64 >8 >2/38 
K. pneumoniae 352 <=8 >8 >8 >2 >4 >64 4 >2/38 
K. pneumoniae 372 <=8 >8 >8 >2 >4 >64 >8 >2/38 
K. pneumoniae 385 <=8 <=2 <=2 >2 >4 >64 4 >2/38 
K. pneumoniae 391 <=8 <=2 <=2 >2 >4 >64 >8 >2/38 
K. pneumoniae 411 <=8 8 8 >2 >4 32 >8 >2/38 
K. pneumoniae 418 <=8 >8 8 >2 >4 >64 4 >2/38 
K. pneumoniae 423 <=8 <=2 <=2 >2 4 >64 8 >2/38 
K. pneumoniae 445 32 >8 >8 >2 >4 >64 8 >2/38 
K. pneumoniae 446 <=8 <=2 <=2 >2 >4 >64 >8 >2/38 
K. pneumoniae 449 16 >8 >8 >2 2 32 8 >2/38 
K. pneumoniae 452 <=8 <=2 <=2 >2 >4 >64 4 >2/38 
K. pneumoniae 466 <=8 <=2 <=2 >2 >4 <=16 >8 >2/38 
K. pneumoniae 482 <=8 <=2 <=2 >2 >4 >64 8 >2/38 
K. pneumoniae 492 <=8 >8 8 >2 >4 >64 >8 2/38 
K. pneumoniae 536 <=8 >8 8 >2 >4 >64 8 >2/38 
K. pneumoniae 558 <=8 <=2 <=2 <=0.5 <=1 <=16 8 <=0.5/9.5 
K. pneumoniae 605 <=8 8 >8 2 2 
 
4 <=0.5/9.5 
K. pneumoniae 610 <=8 >8 >8 <=0.5 <=1 
 
<=2 <=0.5/9.5 
K. pneumoniae 616 <=8 <=2 8 <=0.5 <=1 
 
<=2 <=0.5/9.5 
P. rettgeri 244 <=8 >8 8 >2 >4 >64 >8 >2/38 
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Organism Isolate AMK GEN TOB CIP LEV NIT TET SXT 
S. marcescens 514 <=8 <=2 <=2 >2 >4 >64 >8 
 
S. marcescens 560 <=8 <=2 <=2 >2 >4 >64 >8 
 
MIC values expressed in the table are in units of mg/L 
Blank entries were not tested by University of Kentucky Microbiology Laboratory 
Some organism and antimicrobial combinations were only tested by Etest® and reported as S, I, or R
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Appendix B: 
 
Cumulative Antimicrobial Susceptibility Summary Report from BD Phoenix™ 
 
 Tables B.1-B.3 provide the cumulative summary antimicrobial susceptibility 
results from the in vitro susceptibility testing performed by the University of Kentucky 
Clinical Microbiology Laboratory using BD Phoenix™. 
 Reports were only generated for species with testing data for ≥ 30 isolates.292 
Percentage intermediate or resistant were not included in the report. 
 The following abbreviations are used in Tables B.1-B.3: %S - percentage 
susceptible, MIC50 - Minimum Inhibitory Concentration (MIC) for 50% of isolates, MIC90 
- Minimum Inhibitory Concentration (MIC) for 90% of isolates. 
 
 
 
 
 
Table B.1: Cumulative Antimicrobial Susceptibility Summary Report for Carbapenem-resistant Enterobacteriaceae Clinical 
Isolates by the BD Phoenix™ System (n=164) 
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Antimicrobial %S MIC50 MIC90 MIC Range 
Ampicillin 0% >16 >16 >16 - >16 
Ampicillin/Sulbactam 1% >16/8 >16/8 8/4 - >16/8 
Aztreonam 11% >16 >16 <=2 - >16 
Cefazolin 0% >16 >16 >16 - >16 
Cefepime 21% >16 >16 <=1 - >16 
Cefoxitin 8% >16 >16 <=4 - >16 
Ceftazidime 7% >16 >16 2 - >16 
Ceftriaxone 1% >32 >32 2 - >32 
Cefuroxime 0% >16 >16 >16 - >16 
Ertapenem 1% >1 >4 <=0.5 - >4 
Meropenem 34% 4 >8 <=0.5 - >8 
Piperacillin/Tazobactam 2% >64/4 >64/4 <=2/4 - >64/4 
Amikacin 94% <=8 16 <=8 - >32 
Gentamicin 38% >8 >8 <=2 - >8 
Tobramycin 27% >8 >8 <=2 - >8 
Ciprofloxacin 32% >2 >2 <0.5 - >4 
Levofloxacin 36% >4 >4 <=1 - >4 
Nitrofurantoin 36% 64 >64 <=16 - >64 
Tetracycline 52% 4 >8 <=2 - >8 
Sulfamethoxazole/Trimethoprim 39% >2/38 >2/38 <=0.5/9.5 - >2/38 
MIC values expressed in the table are in units of mg/L 
 
  
 
 
 
 
 
Table B.2: Cumulative Antimicrobial Susceptibility Summary Report for Klebsiella pneumoniae Clinical Isolates by the BD 
Phoenix™ System (n=68) 
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Antimicrobial %S MIC50 MIC90 MIC Range 
Ampicillin 0% >16 >16 >16 - >16 
Ampicillin/Sulbactam 0% >16/8 >16/8 8/4 - >16/8 
Aztreonam 13% >16 >16 <=2 - >16 
Cefazolin 0% >16 >16 >16 - >16 
Cefepime 31% 16 >16 <=1 - >16 
Cefoxitin 12% >16 >16 <=4 - >16 
Ceftazidime 7% >16 >16 2 - >16 
Ceftriaxone 1% >32 >32 2 - >32 
Cefuroxime 0% >16 >16 >16 - >16 
Ertapenem 0% >1 >4 2 - >4 
Meropenem 28% <=1 >8 <=0.5 - >8 
Piperacillin/Tazobactam 1% >64/4 >64/4 8/4 - >64/4 
Amikacin 87% <=8 32 <=8 - >32 
Gentamicin 46% 8 >8 <=2 - >8 
Tobramycin 32% >8 >8 <=2 - >8 
Ciprofloxacin 26% >2 >2 <0.5 - >4 
Levofloxacin 31% >4 >4 <=1 - >4 
Nitrofurantoin 20% >64 >64 <=16 - >64 
Tetracycline 50% 4 >8 <=2 - >8 
Sulfamethoxazole/Trimethoprim 41% >2/38 >2/38 <=0.5/9.5 - >2/38 
MIC values expressed in the table are in units of mg/L 
 
 
 
 
 
Table B.3: Cumulative Antimicrobial Susceptibility Summary Report for Enterobacter cloacae Clinical Isolates by the BD 
Phoenix™ System (n=50) 
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Antimicrobial %S MIC50 MIC90 MIC Range 
Ampicillin 0% >16 >16 >16 - >16 
Ampicillin/Sulbactam 0% >16/8 >16/8 8/4 - >16/8 
Aztreonam 6% >16 >16 <=2 - >16 
Cefazolin 0% >16 >16 >16 - >16 
Cefepime 8% >16 >16 <=1 - >16 
Cefoxitin 0% >16 >16 <=4 - >16 
Ceftazidime 2% >16 >16 4 - >16 
Ceftriaxone 0% >32 >32 2 - >32 
Cefuroxime 0% >16 >16 >16 - >16 
Ertapenem 0% >1 >4 1 - >4 
Meropenem 26% 8 >8 <=0.5 - >8 
Piperacillin/Tazobactam 2% >64/4 >64/4 8/4 - 64/4 
Amikacin 100% <=8 <=8 <=8 - 16 
Gentamicin 18% >8 >8 <=2 - >8 
Tobramycin 8% >8 >8 <=2 - >8 
Ciprofloxacin 42% >2 >2 <0.5 - >4 
Levofloxacin 44% 4 >4 <=1 - >4 
Nitrofurantoin 22% 64 >64 <=16 - >64 
Tetracycline 52% 4 >8 <=2 - >8 
Sulfamethoxazole/Trimethoprim 34% >2/38 >2/38 <=0.5/9.5 - >2/38 
MIC values expressed in the table are in units of mg/L 
 
 
 
316 
Appendix C: 
 
Minimum Inhibitory Concentrations Determined by Broth Microdilution 
Susceptibility Testing, Disk Diffusion, and Etest® 
 
 Table C.1 provide the results of in vitro susceptibility testing performed by broth 
microdilution for all isolate and antimicrobial combinations except ceftazidime/avibactam 
for which Etest® or disk diffusion was utilized. 
The following abbreviations are used in Table C.1: AZT – Aztreonam; CPM – 
Cefepime; CAZ – Ceftazidime; CZA – Ceftazidime/avibactam; PTZ – 
Piperacillin/tazobactam; ERT – Ertapenem; MEM – Meropenem; IMI – Imipenem; IMR – 
Imipenem/relebactam. 
The following abbreviations are used in Table C.2:  AMK - Amikacin; GEN - 
Gentamicin; TOB - Tobramycin; CST – Colistin; PMB – Polymyxin B; MIN – 
Minocycline; TIG – Tigecycline; LEV - Levofloxacin; NIT – Nitrofurantoin.
 
 
 
 
Table C.1: Minimum Inhibitory Concentration (MIC) Values for β-lactam Antimicrobials against Carbapenem-resistant 
Enterobacteriaceae Clinical Isolates (n=122) 
Abbreviations: AZT – Aztreonam; CPM – Cefepime; CAZ – Ceftazidime; CZA – Ceftazidime/avibactam; PTZ – 
Piperacillin/tazobactam; ERT – Ertapenem; MEM – Meropenem; IMI – Imipenem; IMR – Imipenem/relebactam 
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Organism Isolate AZT CPM CAZ CZA PTZ ERT MEM IMI IMR 
C. amalonaticus 36 512 32 >512 S >512 64 16 4 1 
C. amalonaticus 91 512 >256 512 S >512 32 64 4 1 
C. freundii 27 64 4 8 S 256 4 2 2 0.5 
C. freundii 50 256 32 >512 S >512 128 64 16 0.25 
C. freundii 54 256 32 256 S 512 8 2 2 0.5 
C. freundii 101 >512 16 >512 S >512 8 2 4 1 
C. freundii 127 256 16 256 S 512 64 4 32 1 
C. freundii 135 256 128 >512 >256 >512 8 8 8 16 
C. freundii 145 128 4 256 S 512 16 8 16 8 
C. freundii 324 256 16 64 0.125 512 8 4 16 0.5 
C. youngae 136 >512 128 512 S >512 128 32 128 0.25 
C. youngae 435 512 >256 512 0.38 >512 32 16 32 32 
E. aerogenes 97 128 64 128 S 512 4 0.25 1 0.5 
E. aerogenes 179 32 32 512 >256 512 2 4 16 16 
E. aerogenes 187 512 64 >512 1.5 >512 64 32 16 0.5 
E. aerogenes 438 512 128 512 0.25 >512 16 8 4 0.25 
E. cloacae 10 512 256 128 S >512 128 64 64 0.5 
E. cloacae 17 >512 256 512 S >512 64 4 8 0.25 
E. cloacae 30 512 128 >512 S >512 128 64 8 0.5 
E. cloacae 39 512 64 >512 S >512 64 32 4 1 
E. cloacae 40 256 128 512 >256 >512 128 64 64 32 
E. cloacae 41 128 32 512 192 512 4 8 16 16 
E. cloacae 52 512 128 512 S >512 128 64 4 0.25 
E. cloacae 53 256 128 >512 >256 512 16 16 16 32 
E. cloacae 70 256 128 512 S 256 2 0.25 0.25 0.125 
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Organism Isolate AZT CPM CAZ CZA PTZ ERT MEM IMI IMR 
E. cloacae 96 256 >256 512 S 512 8 2 4 0.5 
E. cloacae 107 512 32 256 0.125 512 64 32 8 1 
E. cloacae 121 >512 64 >512 S >512 128 32 64 1 
E. cloacae 126 512 64 512 0.5 512 128 64 128 0.5 
E. cloacae 134 256 128 >512 >256 512 64 32 64 32 
E. cloacae 144 512 256 512 S >512 64 64 16 1 
E. cloacae 167 128 64 >512 >256 512 8 16 64 >32 
E. cloacae 168 256 64 512 >256 >512 32 16 32 1 
E. cloacae 169 256 128 >512 >256 512 8 16 64 >32 
E. cloacae 171 512 128 512 >256 >512 32 32 8 0.25 
E. cloacae 175 32 32 512 >256 512 4 8 32 >32 
E. cloacae 189 128 256 >512 >256 >512 8 16 32 >32 
E. cloacae 200 >512 >256 >512 4 >512 8 1 8 8 
E. cloacae 203 256 128 >512 >256 >512 4 4 32 32 
E. cloacae 209 512 64 512 0.75 >512 64 32 8 0.125 
E. cloacae 266 128 64 >512 >256 512 8 8 32 32 
E. cloacae 335 128 128 512 1 256 4 0.25 1 0.5 
E. cloacae 339 512 128 >512 1.5 >512 32 8 16 1 
E. cloacae 369 256 32 >512 1 >512 8 0.5 1 1 
E. cloacae 416 16 64 >512 >256 >512 128 32 64 >32 
E. cloacae 476 512 >256 512  >512 128 32 16 32 
E. cloacae 515 >512 32 >512  >512 16 4 16 0.5 
E. coli 33 512 64 >512 S >512 128 64 16 0.125 
E. coli 103 512 >256 >512 S >512 8 0.5 1 1 
E. coli 172 64 32 256 96 >512 8 4 16 16 
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Organism Isolate AZT CPM CAZ CZA PTZ ERT MEM IMI IMR 
E. coli 176 512 32 512 0.5 >512 32 8 2 0.25 
E. coli 309 128 >256 256 0.125 32 32 2 1 0.5 
E. coli 390 256 >256 >512 0.19 512 4 0.5 1 0.25 
E. gergoviae 95 128 >256 512 S 512 64 4 2 0.25 
E. hormaechei 186 512 128 >512 >256 >512 16 8 32 32 
E. hormaechei 398 256 256 >512 >256 >512 32 16 16 16 
Enterobacter sp. 146 512 64 512 S >512 64 32 64 1 
Enterobacter sp. 210 512 >256 128 0.5 >512 128 32 128 1 
K. oxytoca 166 64 4 32 0.094 256 16 4 64 0.5 
K. oxytoca 177 32 64 512 0.5 256 8 4 32 4 
K. oxytoca 330 256 128 128 0.75 >512 64 32 64 1 
K. ozaenae 128 256 256 256 S 512 128 128 >128 0.25 
K. ozaenae 407 128 16 512 0.5 512 32 16 16 0.5 
K. pneumoniae 21 64 2 128 0.75 256 32 2 2 0.5 
K. pneumoniae 22 512 >256 512 0.25 >512 64 16 4 0.25 
K. pneumoniae 24 512 64 >512 1.5 >512 128 64 16 1 
K. pneumoniae 28 >512 >256 >512 0.75 >512 >128 >128 >128 1 
K. pneumoniae 29 512 >256 >512 1.5 >512 128 32 32 1 
K. pneumoniae 31 32 1 256 S >512 1 0.25 0.25 0.5 
K. pneumoniae 32 512 128 512 S >512 64 16 8 0.25 
K. pneumoniae 34 256 128 16 S >512 16 16 8 0.25 
K. pneumoniae 35 >512 >256 >512 S >512 128 128 64 0.5 
K. pneumoniae 37 512 >256 512 S >512 128 32 16 0.125 
K. pneumoniae 42 64 64 >512 >256 >512 64 16 32 32 
K. pneumoniae 43 >512 >256 >512 S >512 128 64 8 0.5 
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Organism Isolate AZT CPM CAZ CZA PTZ ERT MEM IMI IMR 
K. pneumoniae 44 512 >256 512 S >512 >128 128 64 0.5 
K. pneumoniae 45 >512 >256 >512 1 >512 >128 128 64 0.25 
K. pneumoniae 46 >512 >256 512 S >512 128 64 16 1 
K. pneumoniae 47 >512 >256 512 0.5 >512 128 64 128 1 
K. pneumoniae 48 512 32 512 S >512 16 8 2 0.0625 
K. pneumoniae 49 512 >256 512 S >512 64 64 32 0.25 
K. pneumoniae 51 >512 >256 >512 S >512 128 128 32 0.25 
K. pneumoniae 55 256 256 512 S 512 64 64 4 0.125 
K. pneumoniae 69 256 >256 256 S 256 4 0.25 1 0.5 
K. pneumoniae 77 128 128 128 S >512 16 0.25 0.25 0.25 
K. pneumoniae 93 >512 >256 256 S >512 64 128 16 1 
K. pneumoniae 98 >512 32 >512 S >512 8 1 0.25 0.25 
K. pneumoniae 99 >512 >256 >512 S >512 64 32 8 1 
K. pneumoniae 105 >512 >256 >512 S >512 128 32 32 0.25 
K. pneumoniae 116 256 >256 256 S 512 8 4 1 0.5 
K. pneumoniae 119 >512 >256 >512 0.25 >512 >128 128 >128 1 
K. pneumoniae 123 >512 >256 >512 0.75 >512 >128 128 128 1 
K. pneumoniae 129 256 256 512 S >512 32 32 64 1 
K. pneumoniae 130 256 256 256 S >512 32 16 4 0.25 
K. pneumoniae 142 >512 >256 256 S >512 64 32 64 1 
K. pneumoniae 143 256 >256 256 S >512 8 1 1 0.5 
K. pneumoniae 152 4 16 128 S >512 2 <=0.125 0.5 0.25 
K. pneumoniae 165 512 64 256 0.5 >512 64 16 32 1 
K. pneumoniae 170 64 32 >512 >256 >512 8 8 32 32 
K. pneumoniae 173 16 32 512 >256 >512 8 16 16 >32 
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Organism Isolate AZT CPM CAZ CZA PTZ ERT MEM IMI IMR 
K. pneumoniae 174 64 16 512 >256 512 2 8 32 32 
K. pneumoniae 230 256 >256 512 0.75 >512 128 64 32 0.25 
K. pneumoniae 243 256 >256 512 0.38 >512 4 0.5 0.5 0.5 
K. pneumoniae 256 256 32 256 0.75 512 32 16 8 0.25 
K. pneumoniae 269 512 >256 512 0.75 >512 8 1 0.5 1 
K. pneumoniae 284 512 >256 512 2 >512 32 4 1 0.125 
K. pneumoniae 349 256 >256 >512 0.5 >512 8 1 0.5 0.5 
K. pneumoniae 352 128 >256 256 0.125 64 4 0.25 2 0.25 
K. pneumoniae 372 256 >256 512 0.38 >512 8 1 1 0.5 
K. pneumoniae 385 512 >256 >512 0.5 >512 4 0.5 0.5 0.25 
K. pneumoniae 391 256 >256 512 0.75 >512 16 8 16 0.5 
K. pneumoniae 411 32 256 >512 >256 >512 16 32 32 32 
K. pneumoniae 418 256 >256 >512 1 >512 4 0.5 1 0.5 
K. pneumoniae 423 256 >256 512 0.75 512 32 16 16 1 
K. pneumoniae 445 >512 >256 >512 2 >512 128 128 32 0.5 
K. pneumoniae 446 512 >256 512  >512 >128 >128 64 0.25 
K. pneumoniae 449 512 128 >512  >512 >128 64 8 0.0625 
K. pneumoniae 452 512 >256 >512  >512 >128 128 128 0.5 
K. pneumoniae 466 512 >256 512  >512 128 32 4 0.25 
K. pneumoniae 482 512 >256 >512  >512 128 64 4 0.125 
K. pneumoniae 492 512 >256 512  >512 8 1 0.5 0.5 
S. marcescens 514 512 128 512  512 >128 64 >128 1 
MIC values expressed in the table are in units of mg/L. Blank entries were not tested by our laboratory 
Same color highlighted isolates were identified from the same patient 
Some organism and antimicrobial combinations were only tested by disk diffusion and reported as S, I, or R
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Organism Isolate AMK GEN TOB CST PMB MIN TIG LEV NIT 
C. amalonaticus 36 16 32 128 2 2 16 2 32 256 
C. amalonaticus 91 8 128 >128 0.25 0.125 >64 2 >32 256 
C. freundii 27 2 0.25 0.5 <=0.06 <=0.06 8 1 32 64 
C. freundii 50 2 4 32 32 16 8 1 32 256 
C. freundii 54 2 32 16 <=0.06 0.125 64 2 16 8 
C. freundii 101 1 8 8 0.125 <=0.06 64 2 32 128 
C. freundii 127 16 32 32 0.125 <=0.06 16 1 32 128 
C. freundii 135 8 64 8 0.125 <=0.06 64 1 0.5 256 
C. freundii 145 1 4 8 <=0.06 0.125 32 1 16 256 
C. freundii 324 4 64 16 <=0.06 <=0.06 0.25 0.06 >32 2 
C. youngae 136 4 64 16 <=0.06 <=0.06 64 1 >32 64 
C. youngae 435 4 16 8 <=0.06 <=0.06 64 1 32 256 
E. aerogenes 97 4 32 16 <=0.06 <=0.06 4 1 16 64 
E. aerogenes 179 8 8 8 <=0.06 <=0.06 16 0.5 32 64 
E. aerogenes 187 4 16 64 <=0.06 <=0.06 8 1 32 64 
E. aerogenes 438 1 <=0.125 0.25 0.25 0.125 16 1 0.06 32 
E. cloacae 10 2 32 32 <=0.06 <=0.06 8 1 4 16 
E. cloacae 17 4 64 32 0.125 0.125 16 4 16 64 
E. cloacae 30 16 128 64 8 4 16 2 >32 256 
E. cloacae 39 1 8 16 >64 >64 4 2 1 32 
E. cloacae 40 32 128 >128 0.125 0.25 8 2 8 256 
E. cloacae 41 32 128 >128 0.125 0.125 32 2 >32 128 
E. cloacae 52 4 64 32 >64 >64 8 2 16 256 
E. cloacae 53 16 128 64 <=0.06 0.125 >64 8 8 256 
E. cloacae 70 16 64 32 0.125 <=0.06 64 2 16 256 
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Organism Isolate AMK GEN TOB CST PMB MIN TIG LEV NIT 
E. cloacae 96 4 64 32 32 32 64 2 32 256 
E. cloacae 107 4 4 16 >64 64 64 2 16 16 
E. cloacae 121 16 64 64 <=0.06 <=0.06 64 2 >32 256 
E. cloacae 126 16 32 128 >64 >64 16 2 >32 256 
E. cloacae 134 8 128 16 <=0.06 <=0.06 32 0.5 2 256 
E. cloacae 144 4 32 32 0.125 0.125 64 0.5 >32 256 
E. cloacae 167 8 0.5 8 0.125 <=0.06 4 0.5 0.5 64 
E. cloacae 168 4 4 16 >64 64 32 2 16 64 
E. cloacae 169 8 0.5 8 <=0.06 0.125 4 0.5 1 64 
E. cloacae 171 2 32 64 0.125 0.125 32 4 8 64 
E. cloacae 175 16 8 32 <=0.06 <=0.06 32 1 1 64 
E. cloacae 189 8 8 8 <=0.06 0.125 32 1 1 128 
E. cloacae 200 2 128 16 <=0.06 <=0.06 16 2 32 64 
E. cloacae 203 16 16 32 <=0.06 <=0.06 4 1 2 64 
E. cloacae 209 16 32 64 0.25 0.125 16 4 8 32 
E. cloacae 266 8 128 16 0.125 0.125 2 2 2 64 
E. cloacae 335 2 16 8 0.125 0.25 64 16 >32 256 
E. cloacae 339 16 64 32 <=0.06 <=0.06 32 4 >32 64 
E. cloacae 369 2 0.25 0.5 8 4 >64 16 16 128 
E. cloacae 416 16 16 32 0.125 0.25 16 1 0.5 64 
E. cloacae 476 8 1 32 >64 >64 16 2 0.5 128 
E. cloacae 515 1 2 4 >64 >64 16 2 32 64 
E. coli 33 16 64 16 8 4 8 2 >32 256 
E. coli 103 16 2 32 <=0.06 <=0.06 >64 2 >32 256 
E. coli 172 16 8 32 <=0.06 <=0.06 4 1 4 32 
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Organism Isolate AMK GEN TOB CST PMB MIN TIG LEV NIT 
E. coli 176 2 4 4 <=0.06 <=0.06 8 2 32 32 
E. coli 309 4 0.5 1 <=0.06 <=0.06 4 0.5 32 32 
E. coli 390 4 128 8 <=0.06 <=0.06 16 0.25 16 16 
E. gergoviae 95 1 64 32 0.125 <=0.06 64 1 8 256 
E. hormaechei 186 8 32 32 <=0.06 <=0.06 8 2 8 128 
E. hormaechei 398 16 16 16 <=0.06 <=0.06 16 2 1 128 
Enterobacter sp. 146 2 32 64 <=0.06 <=0.06 32 2 8 128 
Enterobacter sp. 210 <=0.5 <=0.125 0.5 >64 64 8 2 4 32 
K. oxytoca 166 2 16 32 0.125 0.25 8 1 4 32 
K. oxytoca 177 4 8 8 <=0.06 <=0.06 8 2 32 32 
K. oxytoca 330 2 4 2 <=0.06 <=0.06 4 1 16 32 
K. ozaenae 128 8 32 64 >64 >64 8 1 >32 256 
K. ozaenae 407 4 8 16 0.25 0.5 4 1 8 16 
K. pneumoniae 21 16 128 >128 1 0.5 8 2 >32 16 
K. pneumoniae 22 32 >128 >128 <=0.06 <=0.06 8 4 >32 256 
K. pneumoniae 24 2 4 8 0.125 0.125 4 2 >32 256 
K. pneumoniae 28 32 128 32 16 8 16 2 >32 512 
K. pneumoniae 29 32 128 64 64 64 8 2 >32 256 
K. pneumoniae 31 16 4 16 0.25 0.25 4 0.5 32 256 
K. pneumoniae 32 16 128 32 0.5 0.125 8 0.5 >32 256 
K. pneumoniae 34 1 >128 0.25 0.25 0.125 2 0.5 0.06 128 
K. pneumoniae 35 32 128 32 4 4 16 2 >32 256 
K. pneumoniae 37 64 64 >128 0.25 0.125 4 0.5 8 128 
K. pneumoniae 42 512 >128 128 8 8 32 4 >32 128 
K. pneumoniae 43 32 64 >128 0.125 <=0.06 16 2 16 128 
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Organism Isolate AMK GEN TOB CST PMB MIN TIG LEV NIT 
K. pneumoniae 44 8 32 32 0.125 <=0.06 4 2 >32 512 
K. pneumoniae 45 4 32 64 >64 >64 8 4 >32 512 
K. pneumoniae 46 64 128 >128 16 16 8 1 >32 256 
K. pneumoniae 47 64 64 >128 64 64 8 1 >32 256 
K. pneumoniae 48 32 4 32 0.125 0.125 8 1 >32 512 
K. pneumoniae 49 32 32 128 <=0.06 0.125 8 1 >32 128 
K. pneumoniae 51 1 8 16 64 32 16 2 8 512 
K. pneumoniae 55 32 0.5 16 <=0.06 0.125 4 0.5 16 64 
K. pneumoniae 69 1 0.25 0.5 0.25 0.125 64 2 32 256 
K. pneumoniae 77 2 128 128 0.125 0.125 16 0.5 8 256 
K. pneumoniae 93 8 32 64 32 8 32 2 16 256 
K. pneumoniae 98 <=0.5 2 16 0.125 <=0.06 8 1 0.25 32 
K. pneumoniae 99 2 2 8 0.125 <=0.06 32 2 8 128 
K. pneumoniae 105 4 2 16 0.125 0.125 64 1 32 64 
K. pneumoniae 116 2 0.5 0.5 0.125 <=0.06 >64 4 >32 256 
K. pneumoniae 119 32 64 >128 64 32 4 1 >32 512 
K. pneumoniae 123 2 32 128 >64 >64 8 4 >32 256 
K. pneumoniae 129 32 2 32 <=0.06 <=0.06 4 1 >32 64 
K. pneumoniae 130 4 32 16 0.125 0.125 8 2 32 128 
K. pneumoniae 142 16 4 16 0.125 0.125 >64 1 >32 64 
K. pneumoniae 143 2 64 8 <=0.06 0.125 64 1 32 256 
K. pneumoniae 152 2 4 4 0.25 0.125 >64 2 16 256 
K. pneumoniae 165 1 32 64 >64 >64 16 4 8 32 
K. pneumoniae 170 4 16 16 <=0.06 <=0.06 16 2 4 64 
K. pneumoniae 173 16 4 16 <=0.06 0.125 8 0.5 2 128 
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Organism Isolate AMK GEN TOB CST PMB MIN TIG LEV NIT 
K. pneumoniae 174 16 8 16 0.125 0.125 32 1 2 64 
K. pneumoniae 230 4 16 32 >64 64 64 16 >32 256 
K. pneumoniae 243 2 <=0.125 0.25 <=0.06 0.125 16 1 32 256 
K. pneumoniae 256 2 16 8 >64 >64 32 2 >32 64 
K. pneumoniae 269 1 8 16 8 8 8 1 >32 256 
K. pneumoniae 284 1 0.25 0.25 32 16 >64 1 32 256 
K. pneumoniae 349 1 64 4 16 16 >64 8 >32 256 
K. pneumoniae 352 16 64 16 <=0.06 <=0.06 8 2 >32 256 
K. pneumoniae 372 1 64 8 32 32 >64 4 >32 256 
K. pneumoniae 385 1 0.25 0.25 2 2 8 2 >32 256 
K. pneumoniae 391 1 <=0.125 <=0.125 32 16 16 2 8 128 
K. pneumoniae 411 8 8 8 <=0.06 0.125 8 2 8 32 
K. pneumoniae 418 1 64 8 2 0.25 4 2 >32 256 
K. pneumoniae 423 2 0.25 0.25 0.25 0.125 8 1 4 128 
K. pneumoniae 445 32 >128 128 0.25 0.125 32 1 >32 256 
K. pneumoniae 446 <=0.5 <=0.125 <=0.125 0.125 0.125 32 8 >32 256 
K. pneumoniae 449 16 8 32 0.125 <=0.06 16 2 2 128 
K. pneumoniae 452 1 0.25 0.25 0.125 0.125 32 8 >32 256 
K. pneumoniae 466 1 <=0.125 <=0.125 0.125 0.25 64 2 32 128 
K. pneumoniae 482 4 16 16 64 >64 8 2 >32 256 
K. pneumoniae 492 1 32 8 32 64 >64 2 >32 256 
S. marcescens 514 2 0.25 1 >64 >64 16 8 16 128 
MIC values expressed in the table are in units of mg/L. Blank entries were not tested by our laboratory. Inhibitors fixed at 4 mg/L 
Same color highlighted isolates were identified from the same patient 
Some organism and antimicrobial combinations were only tested by disk diffusion and reported as S, I, or R 
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Appendix D: 
 
Cumulative Antimicrobial Susceptibility Summary Report from Broth 
Microdilution 
 
 Tables D.1-D.3 provide the cumulative summary antimicrobial susceptibility 
results from the in vitro susceptibility testing performed using broth microdilution. Etest® 
and disk diffusion were utilized for ceftazidime/avibactam 
 Reports were only generated for species with testing data for ≥ 30 isolates.292 
Percentage intermediate or resistant were not included in the report. 
 The following abbreviations are used in Tables D.1-D.3: %S - percentage 
susceptible, MIC50 - Minimum Inhibitory Concentration (MIC) for 50% of isolates, MIC90 
- Minimum Inhibitory Concentration (MIC) for 90% of isolates. 
 
 
 
 
Table D.1: Cumulative Antimicrobial Susceptibility Summary Report for Carbapenem-resistant Enterobacteriaceae Clinical 
Isolates (n=122) 
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Antimicrobial %S MIC50 MIC90 MIC Range 
Aztreonam 1% 512 >512 4 - >512 
Cefepime 2% 128 >256 1 - >256 
Ceftazidime 0% 512 >512 8 - >512 
Ceftazidime/avibactam 80% <=8 >256 0.094 - >256 
 Piperacillin/tazobactam 0% >512 >512 32 - >512 
Ertapenem 0% 32 128 1 - >128 
Meropenem 17% 16 64 <=0.125 - >128 
Imipenem 18% 16 64 0.25 - >128 
Imipenem/relebactam 79% 0.5 32 0.06 - >32 
Amikacin 86% 4 32 <=0.5 - 512 
Gentamicin 31% 16 128 <=0.125 - >128 
Tobramycin 18% 16 128 <=0.125 - >128 
Colistin 70% 0.125 >64 <=0.06 - >64 
Polymyxin B 70% 0.125 64 <=0.06 - >64 
 Minocycline  16% 16 64 0.25 - >64 
Tigecycline 84% 2 4 0.06 - 16 
Levofloxacin 15% 32 >32 0.06 - >32 
Nitrofurantoin 16% 128 256 2 – 512 
MIC values expressed in the table are in units of mg/L 
Inhibitors fixed at 4 mg/L 
Unable to evaluate ceftazidime/avibactam MIC50 due to use of disk diffusion 
 
  
 
 
 
 
 
Table D.2: Cumulative Antimicrobial Susceptibility Summary Report for Klebsiella pneumoniae Clinical Isolates (n=58) 
 
329 
Antimicrobial %S MIC50 MIC90 MIC Range 
Aztreonam 2% 512 >512 4 - >512 
Cefepime 2% >256 >256 1 - >256 
Ceftazidime 0% 512 >512 16 - >512 
Ceftazidime/avibactam 90% <=8 <=8 0.125 - >256 
 Piperacillin/tazobactam 0% >512 >512 64 - >512 
Ertapenem 0% 64 >128 1 - >128 
Meropenem 24% 16 128 <=0.125 - >128 
Imipenem 26% 8 64 0.25 - >128 
Imipenem/relebactam 91% 0.5 1 0.06 - >32 
Amikacin 74% 4 32 <=0.5 - 512 
Gentamicin 36% 16 128 <=0.125 - >128 
Tobramycin 22% 16 >128 <=0.125 - >128 
Colistin 64% 0.25 64 <=0.06 - >64 
Polymyxin B 64% 0.125 64 <=0.06 - >64 
 Minocycline  16% 16 >64 2 - >64 
Tigecycline 81% 2 4 0.5 - 16 
Levofloxacin 9% >32 >32 0.06 - >32 
Nitrofurantoin 7% 256 512 16 – 512 
MIC values expressed in the table are in units of mg/L 
Inhibitors fixed at 4 mg/L 
Unable to evaluate ceftazidime/avibactam MIC50 and MIC90 due to use of disk diffusion 
 
 
 
 
Table D.3: Cumulative Antimicrobial Susceptibility Summary Report for Enterobacter cloacae Clinical Isolates (n=31) 
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Antimicrobial %S MIC50 MIC90 MIC Range 
Aztreonam 0% 256 >512 16 - >512 
Cefepime 2% 128 256 32 - >256 
Ceftazidime 0% 512 >512 128 - >512 
Ceftazidime/avibactam 55% 4 >256 0.125 - >256 
 Piperacillin/tazobactam 0% >512 >512 256 - >512 
Ertapenem 0% 32 128 2 - 128 
Meropenem 13% 16 64 0.25 - 64 
Imipenem 10% 16 64 0.25 - 128 
Imipenem/relebactam 58% 1 >32 0.125 - >32 
Amikacin 94% 8 16 1 - 32 
Gentamicin 23% 32 128 0.25 - 128 
Tobramycin 6% 32 64 0.5 - >128 
Colistin 68% 0.125 >64 <=0.06 - >64 
Polymyxin B 68% 0.125 >64 <=0.06 - >64 
 Minocycline  16% 16 64 2 - >64 
Tigecycline 77% 2 4 0.5 - 16 
Levofloxacin 32% 16 >32 0.5 - >32 
Nitrofurantoin 13% 64 256 16 – 256 
MIC values expressed in the table are in units of mg/L 
Inhibitors fixed at 4 mg/L 
Unable to evaluate ceftazidime/avibactam MIC50 and MIC90 due to use of disk diffusion 
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Appendix E: 
 
Time-kill Studies 
 
 Table E.1 contains the time-kill data for all carbapenem-resistant 
Enterobacteriaceae exposed to amikacin, meropenem, and polymyxin B alone and in 
combination. Isolates are listed alphabetically by flask code, which designates the isolate, 
concentrations of antimicrobials used, any unique container conditions, type of flask, and 
any antimicrobial containing agar. 
 Flask code is of the format: 
<Isolate_Number><Antimicrobial_1><Concentration_1><Antimicrobial_2><Concentrat
ion_2><Flask_Material><Time-kill_Type> on <Agar_Composition> 
Any antimicrobial administration delays are denoted with parentheses following 
the corresponding antimicrobial concentration and surround the time in hours from 
time=0h when the antimicrobial was added to the flask. 
Flask material “G” denotes glass flasks, all other flasks were polypropylene 
A time-kill type of “F” denotes microfiltration method, all other time-kill experiments were 
unmodified. GC – Growth Control (no antimicrobial agents present); A – Amikacin; M – 
Meropenem; P or PB – Polymyxin B. 
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Examples: “266M4P1(2)GF on PB4” uses the entire coding scheme discussed 
previously and means meropenem 4 mg/L and polymyxin B 1 mg/L in combination were 
tested against isolate 266 in glass flasks by the microfiltration method and plated on 
Mueller-Hinton agar containing polymyxin B 4 mg/L. “266GC” simply means isolate 266 
was grown in a polypropylene flask without antimicrobial agents by the traditional time-
kill methodology discussed in Time-Kill Procedure. 
 
 
 
 
 
Table E.1: Time-kill Data for Carbapenem-resistant Enterobacteriaceae 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
10A16 9/23/2014 8.12E+05 7.03E+05 1.53E+03  1.00E+02  1.00E+02 1.58E+06 1.37E+09 
10A16 9/29/2014 7.26E+05 5.86E+05 1.02E+03  1.23E+02  1.00E+02 6.26E+05 8.18E+06 
10A8 9/23/2014 1.03E+06 5.66E+05 5.36E+03  5.93E+02  1.00E+02 1.33E+07 7.15E+08 
10A8 9/29/2014 8.74E+05 5.40E+05 1.20E+04  3.47E+02  1.00E+02 6.23E+06 8.58E+06 
10GC 9/17/2014 9.18E+05 1.35E+06 1.29E+06  2.25E+08  5.25E+10 3.01E+10 2.46E+10 
10GC 10/21/2014 6.17E+05 7.58E+05 2.35E+06  2.89E+07  1.21E+11 1.10E+10 1.83E+10 
10M(2)16P0.25 9/6/2017 1.78E+06 4.70E+02 8.18E+01 0.00E+00 0.00E+00  1.43E+02 8.71E+10 7.44E+10 
10M16 9/17/2014 1.73E+06 4.89E+05 4.71E+05  1.41E+04  1.61E+04 4.55E+10 4.56E+10 
10M16 10/21/2014 8.56E+05 4.37E+05 8.19E+04  3.94E+03  7.56E+02 8.83E+10 1.85E+10 
10M16(2)P0.25 9/29/2017 1.08E+06 4.09E+01 2.04E+01  0.00E+00  0.00E+00 4.83E+10 9.93E+10 
10M16(2)P1 9/6/2017 1.32E+06 2.45E+02 1.12E+03 4.09E+01 0.00E+00  0.00E+00 1.37E+10 1.70E+09 
10M16(2)P1 9/29/2017 1.26E+06 2.04E+01 0.00E+00  0.00E+00  0.00E+00 4.43E+10 9.03E+10 
10M16A8 9/29/2014 8.73E+05 5.92E+05 9.65E+03  2.25E+02  1.00E+02 1.00E+02 1.00E+02 
10M16A8 12/9/2014 6.23E+05 3.19E+05 2.78E+04  8.79E+02  1.00E+02 1.00E+02 1.00E+02 
10M16P0.25(2) 9/26/2017 1.82E+06 1.79E+06 1.44E+05 0.00E+00 0.00E+00  0.00E+00 0.00E+00 0.00E+00 
10M16P0.25(2) 9/29/2017 9.18E+05 1.15E+06 1.36E+05  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
10M16P1 9/26/2017 2.25E+06 1.60E+06 0.00E+00 0.00E+00 4.09E+01  2.04E+01 0.00E+00 0.00E+00 
10M16P1 2/13/2018 8.49E+05 2.04E+01 0.00E+00  0.00E+00  1.23E+02 2.51E+10 6.87E+09 
10M16P1 2/26/2018 7.19E+05 2.04E+01 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
10M16P1(2) 9/26/2017 1.99E+06 1.67E+06 6.40E+04 0.00E+00 4.09E+01  0.00E+00 0.00E+00 0.00E+00 
10M16P1(2) 9/29/2017 1.06E+06 1.17E+06 1.04E+05  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
10M16PB0.25 9/23/2014 1.82E+06 1.35E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
10M16PB0.25 10/28/2014 7.97E+05 1.00E+02 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
10M4 9/17/2014 1.06E+06 1.03E+06 4.23E+05  9.67E+04  1.55E+07 6.96E+10 3.44E+10 
10M4 10/21/2014 6.48E+05 7.05E+05 1.49E+05  1.77E+04  9.67E+06 1.77E+11 2.22E+10 
10M4(2)P0.25 9/6/2017 1.81E+06 1.64E+02 4.09E+01 4.09E+01 1.43E+02  2.79E+04 1.95E+11 1.60E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
10M4(2)P0.25 9/29/2017 1.90E+06 2.45E+02 2.04E+01  2.04E+01  1.05E+04 4.92E+10 1.13E+11 
10M4(2)P1 9/6/2017 1.25E+06 4.09E+01 2.66E+02 8.18E+01 1.23E+02  1.91E+04 6.17E+10 2.41E+09 
10M4(2)P1 9/29/2017 1.33E+06 0.00E+00 0.00E+00  0.00E+00  5.70E+03 7.33E+10 6.48E+10 
10M4A16 9/29/2014 4.75E+05 4.11E+05 2.53E+03  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
10M4A16 12/9/2014 5.53E+05 3.78E+05 2.05E+04  6.34E+02  1.00E+02 1.00E+02 1.00E+02 
10M4A8 9/29/2014 6.87E+05 5.20E+05 3.50E+03  6.73E+03  1.00E+02 1.00E+02 1.00E+02 
10M4A8 12/9/2014 6.04E+05 3.94E+05 2.87E+04  6.90E+03  1.00E+02 1.00E+02 1.00E+02 
10M4P0.25(2) 9/26/2017 2.06E+06 1.76E+06 2.65E+05 0.00E+00 0.00E+00  0.00E+00 0.00E+00 0.00E+00 
10M4P0.25(2) 9/29/2017 1.10E+06 1.40E+06 2.31E+05  0.00E+00  4.70E+02 6.36E+10 8.31E+10 
10M4P0.25(2) 2/26/2018 1.13E+06 9.91E+05 1.98E+05  2.04E+01  4.50E+02 2.72E+09 3.02E+09 
10M4P1(2) 9/26/2017 1.85E+06 1.81E+06 3.64E+05 0.00E+00 2.04E+01  0.00E+00 0.00E+00 0.00E+00 
10M4P1(2) 9/29/2017 9.61E+05 1.20E+06 2.06E+05  0.00E+00  0.00E+00 3.78E+04 4.42E+10 
10M4P1(2) 2/26/2018 7.62E+05 9.50E+05 1.95E+05  0.00E+00  2.45E+02 4.11E+09 5.62E+09 
10M4PB0.25 9/23/2014 1.38E+06 5.31E+02 1.00E+02  1.00E+02  8.38E+02 2.81E+10 7.50E+10 
10M4PB0.25 10/28/2014 1.10E+06 1.00E+02 1.02E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
10M4PB0.25 12/9/2014 5.94E+05 1.98E+03 1.00E+02  1.00E+02  2.17E+04 2.57E+10 3.77E+10 
10M4PB1 9/23/2014 1.41E+06 1.00E+02 1.00E+02  1.00E+02  7.42E+03 3.15E+10 9.01E+10 
10M4PB1 10/28/2014 1.91E+05 1.00E+02 1.00E+02  1.00E+02  1.84E+02 5.52E+10 4.93E+10 
10PB0.25 9/17/2014 1.05E+06 1.43E+02 2.92E+03  8.67E+03  9.32E+05 3.88E+10 3.73E+10 
10PB0.25 10/21/2014 5.60E+05 2.66E+02 1.00E+02  1.00E+02  6.47E+04 3.42E+10 6.82E+10 
10PB1 9/17/2014 1.38E+06 1.00E+02 1.00E+02  2.13E+03  2.29E+05 4.45E+10 3.77E+10 
10PB1 10/21/2014 6.39E+05 1.00E+02 1.00E+02  1.00E+02  4.87E+04 4.90E+10 1.67E+10 
17A16 9/23/2014 2.98E+05 3.15E+05 2.68E+05  4.09E+04  1.27E+05 1.34E+11 9.83E+10 
17A16 9/29/2014 3.76E+05 5.64E+04 4.29E+04  5.68E+03  1.27E+04 5.13E+10 9.35E+10 
17A8 9/23/2014 6.44E+05 3.86E+05 6.90E+05  8.67E+06  8.79E+10 1.24E+11 1.07E+11 
17A8 9/29/2014 3.68E+05 1.17E+05 1.14E+05  1.27E+06  3.41E+08 1.57E+11 6.01E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
17GC 9/17/2014 5.38E+05 6.36E+05 1.68E+06  1.34E+08  5.50E+10 1.13E+11 6.69E+10 
17GC 10/21/2014 3.33E+05 4.15E+05 1.06E+06  1.37E+07  1.35E+11 8.99E+10 4.77E+10 
17M16 9/17/2014 8.08E+05 3.11E+05 7.19E+03  3.37E+03  1.51E+03 1.75E+11 3.25E+10 
17M16 10/21/2014 3.50E+05 2.78E+05 1.79E+04  5.33E+03  2.29E+03 5.06E+05 9.71E+10 
17M16 12/16/2014 5.10E+05 1.27E+05 5.93E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M16 1/6/2015 3.35E+05 8.14E+04 1.59E+03  1.02E+02  1.00E+02 1.57E+07 2.64E+10 
17M16 3/13/2018 5.28E+05 3.68E+04 2.86E+02  1.43E+02  6.13E+01 0.00E+00 0.00E+00 
17M16(2)P0.25 9/6/2017 7.43E+05 2.90E+03 8.18E+01 0.00E+00 0.00E+00  0.00E+00 0.00E+00 0.00E+00 
17M16(2)P0.25 9/29/2017 8.08E+05 1.21E+03 8.18E+01  0.00E+00  6.13E+01 2.40E+10 3.51E+10 
17M16(2)P0.25 2/26/2018 5.29E+05 6.17E+03 6.13E+01  0.00E+00  0.00E+00 1.23E+09 5.28E+09 
17M16(2)P1 9/6/2017 8.12E+05 3.47E+02 4.09E+01 4.09E+01 0.00E+00  0.00E+00 0.00E+00 0.00E+00 
17M16(2)P1 9/29/2017 8.00E+05 8.18E+01 0.00E+00  0.00E+00  0.00E+00 2.95E+10 7.50E+10 
17M16(2)P1 2/26/2018 4.84E+05 2.04E+02 0.00E+00  2.04E+01  2.04E+01 1.66E+03 1.33E+11 
17M16A8 9/29/2014 3.58E+05 1.02E+05 2.53E+04  4.62E+03  1.49E+03 3.68E+03 2.23E+04 
17M16A8 12/9/2014 1.25E+05 1.32E+04 7.36E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M16A8 12/16/2014 4.15E+05 6.00E+04 1.17E+03  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M16P0.25(2) 9/26/2017 1.56E+06 1.60E+04 1.04E+03 0.00E+00 0.00E+00  0.00E+00 0.00E+00 0.00E+00 
17M16P0.25(2) 9/29/2017 7.34E+05 6.60E+04 8.18E+02  2.04E+01  0.00E+00 0.00E+00 0.00E+00 
17M16P1 9/26/2017 1.05E+06 0.00E+00 0.00E+00 0.00E+00 4.09E+01  0.00E+00 2.04E+01 0.00E+00 
17M16P1 2/13/2018 5.44E+05 4.09E+01 0.00E+00  0.00E+00  0.00E+00 2.04E+01 0.00E+00 
17M16P1(2) 9/26/2017 1.65E+06 1.46E+05 5.40E+02 0.00E+00 6.13E+01  0.00E+00 0.00E+00 0.00E+00 
17M16P1(2) 9/29/2017 8.52E+05 5.00E+04 7.77E+02  2.04E+01  0.00E+00 0.00E+00 0.00E+00 
17M16PB0.25 9/23/2014 4.29E+05 1.00E+02 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M16PB0.25 10/28/2014 2.51E+05 1.92E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M4 9/17/2014 6.92E+05 5.02E+05 2.59E+04  1.10E+03  1.10E+05 3.58E+10 3.11E+10 
17M4 10/21/2014 4.29E+05 3.64E+05 4.85E+04  7.79E+03  7.97E+04 4.55E+10 9.01E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
17M4(2)P0.25 9/6/2017 1.07E+06 1.55E+03 6.13E+01 6.13E+01 2.04E+01  1.17E+04 6.21E+10 3.68E+08 
17M4(2)P0.25 9/29/2017 7.32E+05 8.79E+02 8.18E+01  4.09E+01  1.17E+04 5.16E+10 4.26E+10 
17M4(2)P1 9/6/2017 9.65E+05 3.88E+02 2.04E+01 4.09E+01 2.04E+01  6.74E+02 2.90E+10 1.86E+09 
17M4(2)P1 9/29/2017 7.32E+05 4.09E+01 2.04E+01  2.04E+01  2.62E+03 4.27E+10 8.83E+10 
17M4A16 9/29/2014 3.70E+05 4.90E+04 3.17E+04  5.13E+03  1.23E+03 1.00E+02 2.96E+03 
17M4A16 12/9/2014 1.12E+05 6.32E+03 4.91E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M4A16 12/16/2014 3.35E+05 1.72E+05 3.41E+03  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M4A8 9/29/2014 3.82E+05 1.33E+05 4.88E+04  1.72E+04  3.54E+03 1.00E+02 1.00E+02 
17M4A8 12/9/2014 1.72E+05 2.14E+04 2.60E+03  4.09E+02  1.00E+02 1.00E+02 1.00E+02 
17M4P0.25(2) 9/26/2017 1.61E+06 1.32E+06 3.72E+03 0.00E+00 0.00E+00  0.00E+00 0.00E+00 0.00E+00 
17M4P0.25(2) 9/29/2017 8.90E+05 7.52E+05 3.13E+03  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
17M4P1(2) 9/26/2017 1.67E+06 1.39E+06 2.44E+03 0.00E+00 0.00E+00  0.00E+00 0.00E+00 0.00E+00 
17M4P1(2) 9/29/2017 7.40E+05 7.20E+05 3.45E+03  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
17M4PB0.25 9/23/2014 5.67E+05 1.00E+02 1.00E+02  1.00E+02  7.89E+03 1.95E+11 1.39E+11 
17M4PB0.25 10/28/2014 2.92E+05 2.25E+02 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M4PB0.25 12/9/2014 3.80E+05 1.81E+04 5.93E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M4PB0.25 12/16/2014 3.27E+05 1.31E+03 1.00E+02  1.00E+02  1.00E+02 1.34E+05 1.58E+10 
17M4PB0.25 1/6/2015 3.13E+05 1.74E+03 1.00E+02  1.00E+02  1.00E+02 1.04E+10 8.77E+09 
17M4PB1 9/23/2014 5.78E+05 1.00E+02 1.00E+02  1.00E+02  1.00E+02 3.07E+03 5.47E+09 
17M4PB1 10/28/2014 1.60E+05 1.00E+02 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
17M4PB1 12/9/2014 4.41E+05 1.14E+03 1.00E+02  1.00E+02  1.00E+02 5.26E+05 1.54E+10 
17M4PB1 12/16/2014 4.17E+05 1.00E+02 1.00E+02  1.00E+02  1.00E+02 5.33E+05 3.80E+09 
17M4PB1 1/6/2015 3.45E+05 1.00E+02 1.00E+02  1.00E+02  1.00E+02 7.15E+04 1.90E+09 
17PB0.25 9/17/2014 5.33E+05 4.09E+03 1.00E+02  7.42E+03  5.20E+05 3.65E+11 4.88E+10 
17PB0.25 10/21/2014 3.25E+05 9.40E+02 1.00E+02  1.00E+02  2.15E+03 1.26E+11 8.51E+10 
17PB1 9/17/2014 4.46E+05 1.00E+02 1.09E+02  1.00E+02  3.70E+04 4.72E+10 6.08E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
17PB1 10/21/2014 2.82E+05 1.02E+02 1.00E+02  1.00E+02  2.98E+03 8.35E+10 7.99E+10 
19A16 9/23/2014 1.05E+06 4.11E+05 4.91E+02  1.00E+02  1.00E+02 2.86E+06 1.53E+09 
19A16 9/29/2014 4.42E+05 1.43E+03 1.00E+02  1.00E+02  1.00E+02 8.69E+05 8.18E+06 
19A8 9/23/2014 1.10E+06 2.06E+05 2.02E+03  1.84E+02  1.00E+02 2.41E+07 1.51E+09 
19A8 9/29/2014 3.06E+05 1.23E+04 1.84E+02  1.00E+02  1.00E+02 7.85E+06 6.95E+06 
19GC 9/17/2014 8.00E+05 1.22E+06 3.17E+06  6.00E+08  7.44E+10 1.13E+11 2.50E+10 
19GC 10/21/2014 6.11E+05 8.36E+05 2.26E+06  2.27E+08  7.07E+10 1.94E+11 1.09E+11 
19M16 9/17/2014 9.24E+05 5.22E+05 7.56E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M16 10/21/2014 6.75E+05 1.21E+05 2.53E+03  6.74E+02  1.00E+02 1.00E+02 1.00E+02 
19M16A8 9/29/2014 2.85E+05 2.41E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M16A8 12/9/2014 4.54E+05 1.19E+04 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M16PB0.25 9/23/2014 1.47E+06 6.39E+04 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M16PB0.25 10/28/2014 2.09E+05 1.29E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M4 9/17/2014 1.51E+06 4.87E+05 7.15E+02  1.02E+02  1.00E+02 1.16E+06 2.66E+09 
19M4 10/21/2014 7.01E+05 6.17E+05 4.72E+03  1.51E+03  1.02E+04 8.75E+10 1.71E+10 
19M4 12/16/2014 5.29E+05 4.29E+05 1.47E+03  1.29E+04  5.48E+07 3.93E+10 1.61E+10 
19M4A16 9/29/2014 4.27E+05 1.86E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M4A16 12/9/2014 3.39E+05 9.05E+03 1.84E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M4A8 9/29/2014 5.26E+05 9.88E+03 1.23E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M4A8 12/9/2014 5.01E+05 2.66E+04 3.68E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M4PB0.25 9/23/2014 1.81E+06 9.15E+04 1.43E+02  1.00E+02  1.00E+02 1.00E+02 6.78E+05 
19M4PB0.25 10/28/2014 1.00E+05 5.89E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M4PB0.25 12/9/2014 6.95E+05 5.52E+04 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M4PB1 9/23/2014 1.19E+06 3.56E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19M4PB1 10/28/2014 1.53E+05 6.13E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
19PB0.25 9/17/2014 2.25E+06 8.18E+02 1.00E+02  9.42E+03  3.80E+04 1.23E+11 1.47E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
19PB0.25 10/21/2014 6.84E+05 3.99E+03 2.45E+02  1.00E+02  8.63E+03 6.42E+10 2.38E+10 
19PB1 9/17/2014 1.27E+06 1.00E+02 1.00E+02  1.43E+02  1.63E+04 1.19E+11 2.96E+10 
19PB1 10/21/2014 7.19E+05 5.52E+02 1.00E+02  1.00E+02  6.89E+03 1.82E+11 1.56E+11 
22A16 5/29/2014 6.02E+05 4.31E+05 5.02E+05  1.23E+05  4.89E+05 1.18E+09 8.19E+10 
22A16 6/18/2014 4.47E+05 8.45E+05 2.99E+05  1.06E+06  3.84E+06 1.16E+11 1.19E+11 
22A16 5/26/2017 5.84E+05 1.45E+05 1.17E+05  2.31E+05  6.57E+05 1.18E+11 6.72E+10 
22A16M16 6/18/2014 4.67E+05 3.82E+05 4.50E+02  6.13E+01  1.00E+00 1.00E+00 1.00E+00 
22A16M16 5/26/2017 4.55E+05 7.97E+04 4.07E+03  3.07E+02  0.00E+00 0.00E+00 0.00E+00 
22A16M4 6/18/2014 4.64E+05 8.69E+05 3.77E+04  4.09E+01  1.00E+00 1.31E+07 9.03E+10 
22A16M4 5/26/2017 6.96E+05 1.08E+05 2.21E+04  2.06E+03  1.72E+03 2.31E+11 4.39E+10 
22A16M64 6/18/2014 4.73E+05 1.43E+04 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22A64 5/29/2014 6.35E+05 2.91E+04 2.49E+03  2.04E+02  1.00E+00 1.00E+00 1.00E+00 
22A64 5/26/2017 5.84E+05 1.84E+04 3.88E+02  2.04E+01  0.00E+00 0.00E+00 0.00E+00 
22A8 5/26/2017 5.13E+05 4.52E+05 3.70E+05  4.27E+07  1.07E+11 3.09E+11 6.44E+10 
22A8 2/13/2018 7.61E+05 6.87E+05 1.33E+06  1.17E+08  1.01E+11 4.28E+10 9.88E+10 
22A8M16 5/26/2017 6.10E+05 2.05E+05 2.96E+04  2.49E+03  1.14E+03 1.71E+11 6.51E+10 
22A8M16 2/13/2018 7.41E+05 7.11E+05 3.59E+04  1.10E+03  1.14E+04 7.13E+10 5.98E+10 
22A8M4 5/26/2017 6.47E+05 2.80E+05 8.99E+04  8.11E+03  6.36E+03 2.36E+11 1.19E+11 
22A8M4 2/13/2018 7.75E+05 7.08E+05 9.40E+04  1.90E+03  1.55E+04 5.70E+10 6.72E+10 
22GC 5/29/2014 6.02E+05 8.00E+05 3.14E+06  4.21E+09  1.11E+11 5.23E+10 9.93E+10 
22GC 8/23/2014 6.21E+05 9.91E+05 2.51E+06  5.15E+09  1.06E+11 6.69E+10 2.45E+09 
22GC 6/11/2015 5.07E+05  2.55E+06 6.23E+06 1.35E+08 3.21E+10  1.43E+11  
22GC on M16 6/11/2015 1.00E+00  6.00E+00 7.93E+02 8.75E+03 9.69E+04  9.69E+04  
22GC on P4 6/11/2015 1.60E+01  1.08E+02 2.54E+02 1.58E+03 3.14E+01  9.18E+03  
22M16 5/14/2014 1.64E+06 1.26E+06 2.43E+04  2.02E+03  4.09E+04 9.27E+10 4.13E+09 
22M16 5/20/2014 4.73E+05 3.52E+05 6.70E+03  1.02E+02  2.08E+03 6.68E+10 5.12E+10 
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22M16 2/13/2017 7.82E+05  1.22E+04  1.84E+02 1.64E+02 5.00E+03 2.86E+10  
22M16 on M16 2/13/2017 0.00E+00  0.00E+00  2.04E+01 8.18E+01 4.94E+03 3.19E+10  
22M16F on 
M16 2/13/2017 0.00E+00 
 0.00E+00  6.00E+00 1.54E+02 TNTC   
22M16PB0.25 5/14/2014 1.66E+06 1.08E+03 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M16PB0.25 5/20/2014 5.28E+05 1.02E+02 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M16PB1 5/14/2014 5.97E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M16PB1 5/20/2014 5.86E+05 6.13E+01 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M32 2/13/2017 8.00E+05  1.23E+03  1.23E+02 1.43E+02 6.13E+01 0.00E+00  
22M32 on M16 2/13/2017 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 0.00E+00  
22M32F on 
M16 2/13/2017 0.00E+00 
 1.00E+00  0.00E+00 0.00E+00 0.00E+00 0.00E+00  
22M4 5/14/2014 1.65E+06 1.70E+06 4.70E+04  1.68E+03  1.37E+05 1.19E+11 7.98E+10 
22M4 5/20/2014 4.93E+05 6.11E+05 3.78E+03  2.86E+02  5.23E+04 1.03E+11 1.01E+11 
22M4PB0.25 5/14/2014 1.27E+06 5.84E+03 2.04E+01  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M4PB0.25 5/20/2014 5.17E+05 2.04E+02 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M4PB1 5/14/2014 8.79E+05 2.45E+02 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M4PB1 5/20/2014 5.10E+05 2.04E+01 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M64 5/14/2014 9.34E+05 1.43E+04 2.86E+02  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M64 5/20/2014 5.28E+05 4.19E+03 8.18E+01  4.09E+01  2.04E+01 1.00E+00 1.00E+00 
22M64PB0.25 5/14/2014 1.17E+06 1.23E+02 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M64PB0.25 5/20/2014 5.88E+05 8.18E+01 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M64PB1 5/14/2014 7.68E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22M64PB1 5/20/2014 5.02E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
22PB0.06 6/10/2014 5.27E+05 9.81E+04 1.31E+05  9.39E+06  1.28E+11 7.98E+10 5.62E+10 
22PB0.06 6/18/2014 4.56E+05 4.48E+03 1.00E+03  1.12E+03  8.08E+05 1.13E+11 1.12E+11 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
22PB0.125 6/18/2014 4.93E+05 3.07E+02 2.04E+01  2.25E+02  3.00E+05 1.29E+11 6.66E+10 
22PB0.125 7/9/2014 6.91E+05 1.64E+02 1.84E+02  4.50E+02  8.58E+04 1.26E+11 8.75E+10 
22PB0.25 5/14/2014 1.34E+06 1.78E+03 1.00E+00  1.00E+00  3.94E+03 2.21E+11 2.65E+10 
22PB0.25 5/20/2014 5.01E+05 4.09E+01 2.04E+01  4.09E+01  2.23E+03 1.35E+11 9.15E+10 
22PB1 5/14/2014 1.43E+06 1.00E+00 1.00E+00  1.00E+00  2.25E+02 5.95E+10 1.04E+11 
22PB1 5/20/2014 5.53E+05 1.00E+00 2.04E+01  1.00E+00  8.18E+02 1.08E+11 1.23E+11 
22PB16 2/13/2017 5.86E+05 0.00E+00 0.00E+00  0.00E+00  6.74E+02 4.95E+09  
22PB16 on PB4 2/13/2017 0.00E+00 0.00E+00 0.00E+00  0.00E+00  0.00E+00 0.00E+00  
22PB16F on 
PB4 2/13/2017 2.29E+02 0.00E+00 1.00E+00 
 2.00E+00  5.10E+02   
22PB2 5/29/2014 6.68E+05 1.00E+00 2.04E+01  1.00E+00  2.41E+03 6.37E+10 1.21E+11 
22PB2 6/10/2014 5.64E+05 1.00E+00 1.00E+00  1.00E+00  1.37E+03 1.29E+11 8.03E+10 
22PB32 2/13/2017 6.06E+05 0.00E+00 0.00E+00  0.00E+00  0.00E+00 0.00E+00  
22PB32 on PB4 2/13/2017 0.00E+00 0.00E+00 0.00E+00  0.00E+00  0.00E+00 0.00E+00  
22PB32F on 
PB4 2/13/2017 1.90E+01 1.00E+00 0.00E+00 
 1.00E+00  0.00E+00 2.00E+00  
22PB4 5/29/2014 6.60E+05 1.00E+00 1.00E+00  1.00E+00  2.86E+02 2.11E+10 1.13E+11 
22PB4 6/10/2014 5.00E+05 1.00E+00 1.00E+00  1.00E+00  5.31E+02 2.38E+10 1.52E+11 
24A16 5/29/2014 7.00E+05 1.95E+05 1.00E+00  3.68E+02  4.29E+02 2.56E+06 9.69E+10 
24A16 6/18/2014 3.94E+05 6.91E+04 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24A16 5/26/2017 1.31E+06 6.57E+05 3.88E+02  0.00E+00  2.04E+01 3.78E+05 2.27E+09 
24A16M16 6/18/2014 3.19E+05 5.35E+04 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24A16M4 6/18/2014 3.95E+05 4.46E+04 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24A16M64 6/18/2014 3.92E+05 2.62E+03 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24A64 5/29/2014 7.14E+05 5.31E+04 1.00E+00  1.00E+00  6.13E+01 1.00E+00 1.00E+00 
24A8 5/26/2017 1.50E+06 6.62E+05 1.64E+03  0.00E+00  6.13E+01 9.39E+06 2.82E+09 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
24A8M16 5/26/2017 1.63E+06 3.86E+05 7.36E+02  1.02E+02  6.13E+01 0.00E+00 0.00E+00 
24A8M4 5/26/2017 1.53E+06 4.71E+05 1.59E+03  8.18E+01  1.23E+02 0.00E+00 0.00E+00 
24A8M64 5/26/2017 1.30E+06 1.94E+05 4.91E+02  6.13E+01  1.02E+02 0.00E+00 0.00E+00 
24GC 5/29/2014 7.17E+05 8.29E+05 1.77E+06  6.82E+07  1.45E+10 2.82E+10 2.58E+10 
24GC 8/23/2014 5.66E+05 7.22E+05 2.00E+06  8.08E+07  2.24E+10 2.60E+10 3.99E+10 
24GC 6/11/2015 1.04E+06  2.46E+06 8.59E+06 2.48E+08 5.24E+10  3.44E+11  
24GC on M64 6/11/2015 7.00E+00  5.70E+01 5.08E+02 1.01E+03 4.98E+03  3.34E+04  
24GC on P4 6/11/2015 1.00E+00  1.00E+00 1.00E+00 3.60E+01 2.00E+02  3.77E+02  
24M128 2/13/2017 5.31E+05  3.43E+03  2.45E+02 1.23E+02 4.09E+01 4.09E+01  
24M128 on M64 2/13/2017 0.00E+00  0.00E+00  2.04E+01 0.00E+00 0.00E+00 0.00E+00  
24M128F on 
M64 2/13/2017 0.00E+00 
 0.00E+00  0.00E+00 0.00E+00 0.00E+00 0.00E+00  
24M16 5/20/2014 4.53E+05 5.68E+05 1.17E+05  4.03E+03  9.81E+04 4.13E+10 1.92E+10 
24M16 6/10/2014 6.02E+05 6.34E+05 1.17E+05  2.15E+03  6.18E+03 3.10E+10 1.11E+11 
24M16(2)P0.25 9/6/2017 9.73E+05 1.18E+04 8.18E+01 6.13E+01 2.04E+01  3.07E+02 2.47E+09 1.65E+11 
24M16(2)P0.25 9/29/2017 1.16E+06 3.88E+02 5.11E+02  8.18E+01  3.74E+03 2.24E+10 1.37E+11 
24M16(2)P1 9/6/2017 8.57E+05 2.39E+03 8.18E+01 2.04E+01 0.00E+00  6.13E+01 6.13E+08 9.78E+08 
24M16(2)P1 9/29/2017 1.03E+06 3.68E+02 1.02E+02  4.09E+01  1.49E+03 1.58E+10 5.18E+10 
24M16P0.25(2) 9/26/2017 1.73E+06 1.58E+06 2.66E+05 5.40E+02 3.27E+02  6.13E+01 3.23E+05 1.33E+11 
24M16P0.25(2) 9/29/2017 1.16E+06 1.17E+06 7.88E+04  2.04E+02  6.13E+01 2.25E+02 9.02E+09 
24M16P1(2) 9/26/2017 1.71E+06 1.51E+06 1.78E+05 0.00E+00 4.09E+01  0.00E+00 1.12E+05 2.42E+05 
24M16P1(2) 9/29/2017 1.15E+06 1.15E+06 9.62E+04  4.09E+01  0.00E+00 0.00E+00 0.00E+00 
24M16P1(2) 2/26/2018 4.51E+05 5.30E+05 5.65E+04  0.00E+00  0.00E+00 1.27E+03 1.54E+10 
24M16P1(2) 3/13/2018 6.66E+05 6.46E+05 8.38E+04  2.04E+01  2.04E+01 2.14E+06 2.86E+10 
24M16PB0.25 5/20/2014 4.26E+05 1.84E+02 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24M16PB0.25 6/10/2014 6.37E+05 1.40E+05 2.17E+03  5.72E+02  8.38E+02 4.79E+10 6.00E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
24M16PB0.25 7/9/2014 7.13E+05 1.68E+03 6.13E+01  8.18E+01  1.00E+00 1.00E+00 1.00E+00 
24M16PB1 5/20/2014 4.30E+05 4.09E+01 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24M16PB1 6/10/2014 6.38E+05 4.91E+04 2.04E+01  1.00E+00  1.00E+00 2.11E+05 5.11E+10 
24M16PB1 7/9/2014 7.14E+05 2.86E+02 1.00E+00  6.13E+01  1.00E+00 1.00E+00 1.00E+00 
24M4 5/20/2014 4.46E+05 5.92E+05 4.79E+05  1.71E+04  2.07E+06 3.95E+10 5.48E+10 
24M4 6/10/2014 6.01E+05 7.29E+05 4.84E+05  1.08E+04  1.37E+03 2.79E+10 1.18E+11 
24M4(2)P0.25 9/6/2017 9.73E+05 8.34E+03 2.04E+02 1.29E+03 2.04E+01  3.45E+03 4.39E+10 1.25E+11 
24M4(2)P0.25 9/29/2017 8.31E+05 3.68E+02 3.68E+02  1.64E+02  5.31E+03 1.06E+10 1.74E+11 
24M4(2)P1 9/6/2017 1.11E+06 2.90E+03 6.13E+01 0.00E+00 0.00E+00  2.25E+02 4.70E+08 3.59E+10 
24M4(2)P1 9/29/2017 1.14E+06 1.64E+02 6.13E+01  6.13E+01  1.80E+03 3.00E+09 1.87E+10 
24M4B1 7/9/2014 8.02E+05 4.09E+01 2.04E+01  1.00E+00  3.27E+02 6.54E+08 1.61E+11 
24M4P0.25(2) 9/26/2017 2.27E+06 1.65E+06 9.83E+05 9.22E+03 7.23E+05  6.13E+08 3.11E+09 2.14E+10 
24M4P0.25(2) 9/29/2017 1.15E+06 1.26E+06 6.33E+05  1.84E+02  1.80E+05 5.70E+09 2.62E+10 
24M4P0.25(2) 2/26/2018 4.65E+05 5.97E+05 4.19E+05  5.01E+03  3.88E+02 3.70E+09 6.20E+10 
24M4P1(2) 9/26/2017 1.80E+06 1.35E+06 8.35E+05 0.00E+00 0.00E+00  0.00E+00 1.83E+06 1.03E+11 
24M4P1(2) 9/29/2017 1.08E+06 1.10E+06 7.38E+05  8.18E+01  8.18E+01 6.40E+06 4.07E+10 
24M4PB0.25 5/20/2014 4.62E+05 2.86E+02 1.00E+00  1.00E+00  1.43E+02 2.72E+10 8.07E+10 
24M4PB0.25 6/10/2014 5.61E+05 1.43E+05 4.23E+03  4.91E+02  1.01E+05 3.98E+10 2.15E+11 
24M4PB0.25 7/9/2014 8.23E+05 2.86E+02 2.04E+01  1.00E+00  6.21E+03 4.05E+10 9.07E+10 
24M4PB1 5/20/2014 4.55E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 4.93E+10 9.97E+10 
24M4PB1 6/10/2014 6.61E+05 1.04E+04 4.09E+01  1.00E+00  3.68E+02 3.84E+07 6.48E+10 
24M64 5/20/2014 4.36E+05 9.40E+04 1.05E+04  2.17E+03  1.96E+03 2.36E+11 8.95E+10 
24M64 6/10/2014 5.40E+05 3.19E+05 8.73E+03  8.79E+02  1.29E+03 8.83E+10 9.27E+10 
24M64 2/13/2017 5.29E+05  1.28E+04  3.68E+02 2.66E+02 2.45E+02 1.58E+10  
24M64 on M64 2/13/2017 0.00E+00  0.00E+00  0.00E+00 0.00E+00 4.09E+01 1.50E+10  
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
24M64F on 
M64 2/13/2017 1.00E+00 
 0.00E+00  0.00E+00 3.00E+00 2.70E+01   
24M64PB0.25 5/20/2014 4.33E+05 1.02E+02 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24M64PB0.25 6/10/2014 6.19E+05 9.76E+04 1.00E+00  1.00E+00  1.00E+00 3.88E+02 1.54E+11 
24M64PB0.25 7/9/2014 8.34E+05 5.72E+02 2.04E+01  1.00E+00  1.00E+00 4.89E+05 7.95E+10 
24M64PB1 5/20/2014 4.22E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24M64PB1 6/10/2014 5.98E+05 3.02E+03 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24M64PB1 7/9/2014 4.71E+05 2.04E+01 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
24PB0.06 6/10/2014 5.87E+05 1.10E+05 4.91E+04  8.71E+05  5.43E+09 4.00E+10 5.45E+10 
24PB0.06 6/18/2014 3.37E+05 2.78E+04 1.19E+03  1.22E+04  1.86E+06 3.66E+10 1.35E+11 
24PB0.125 6/18/2014 3.67E+05 1.00E+00 6.13E+01  1.23E+02  1.83E+04 4.96E+10 1.42E+11 
24PB0.125 7/9/2014 7.51E+05 3.70E+03 9.40E+02  5.33E+03  2.22E+05 8.15E+10 1.39E+11 
24PB0.25 5/20/2014 4.26E+05 9.69E+03 1.00E+00  1.00E+00  4.09E+02 1.12E+10 7.88E+10 
24PB0.25 6/10/2014 6.72E+05 4.69E+04 2.04E+02  1.00E+00  1.19E+03 9.95E+09 4.51E+10 
24PB1 5/20/2014 4.85E+05 8.18E+01 1.00E+00  1.00E+00  3.47E+02 4.71E+09 7.02E+10 
24PB1 6/10/2014 5.81E+05 4.01E+03 1.00E+00  1.00E+00  7.77E+02 2.06E+10 6.99E+10 
24PB16 2/13/2017 5.89E+05 4.09E+01 8.18E+01  0.00E+00  1.84E+05 6.63E+08  
24PB16 on PB4 2/13/2017 0.00E+00 0.00E+00 0.00E+00  0.00E+00  1.78E+05 4.74E+08  
24PB16F on 
PB4 2/13/2017 1.29E+03 7.80E+01 6.60E+01 
 1.61E+02  1.89E+03   
24PB2 5/29/2014 6.33E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.79E+06 7.33E+10 
24PB2 6/10/2014 6.26E+05 1.00E+00 1.00E+00  1.00E+00  3.88E+02 4.70E+08 1.10E+11 
24PB2 8/23/2014 5.37E+05 1.00E+00 1.00E+00  4.09E+01  9.40E+02 4.95E+07 1.02E+10 
24PB4 5/29/2014 7.29E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 2.08E+06 2.53E+09 
24PB4 6/10/2014 5.66E+05 1.00E+00 1.00E+00  1.00E+00  1.23E+02 7.23E+06 6.87E+10 
24PB4 8/23/2014 5.04E+05 1.00E+00 1.00E+00  1.00E+00  1.23E+02 6.66E+06 2.12E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
24PB8 2/13/2017 6.40E+05 1.02E+02 2.04E+01  2.86E+02  2.66E+05 4.19E+08  
24PB8 on PB4 2/13/2017 0.00E+00 0.00E+00 0.00E+00  8.18E+01  1.70E+05 6.87E+08  
24PB8F on PB4 2/13/2017 1.45E+03  9.00E+01  1.71E+02  2.23E+03   
29A16 7/21/2017 3.94E+05 6.57E+05 2.72E+05  4.31E+05  7.35E+07 9.20E+08 1.25E+09 
29A16M16 7/21/2017 3.64E+05 4.95E+05 3.83E+04  2.25E+02  5.04E+03 1.90E+09 1.76E+09 
29A16M4 7/21/2017 4.22E+05 8.38E+05 6.66E+04  2.17E+03  1.14E+04 3.80E+09 1.72E+09 
29A16M64 7/21/2017 8.27E+05 2.04E+03 2.86E+02  4.09E+01  0.00E+00 1.96E+03 7.97E+08 
29A8 10/18/2016 2.51E+06  2.42E+06  5.36E+09  2.22E+11 3.89E+10 7.20E+10 
29A8 7/21/2017 6.33E+05 7.90E+05 3.74E+06  5.52E+08  4.81E+09 2.72E+09 1.00E+09 
29A8M16 7/21/2017 5.05E+05 6.49E+05 4.57E+04  1.02E+03  5.31E+04 3.45E+09 1.88E+09 
29A8M4 7/21/2017 3.24E+05 1.18E+06 6.13E+04  8.38E+02  1.96E+06 8.18E+08 1.22E+10 
29A8M64 7/21/2017 5.95E+05 1.88E+04 2.45E+02  2.04E+01  6.13E+01 1.47E+09 7.93E+09 
29GC 10/18/2016 3.01E+06  1.10E+07  2.76E+09  1.33E+11 5.38E+10 6.45E+10 
29GC 7/21/2017 5.59E+05 1.48E+06 4.00E+06  9.61E+08  1.66E+10 4.65E+09 1.53E+09 
29M16 10/18/2016 2.26E+06  3.09E+03  1.19E+03  1.45E+06 3.91E+11 1.50E+11 
29M16 7/21/2017 3.12E+05 8.62E+05 2.35E+03  6.13E+02  5.40E+05 2.02E+09 2.68E+09 
29M16A8 10/18/2016 2.76E+06  1.06E+05  1.39E+03  4.99E+05 9.88E+10 1.61E+11 
29M16PB1 10/18/2016 1.93E+06  3.11E+03  3.88E+02  2.04E+01 0.00E+00 0.00E+00 
29M4 7/21/2017 4.59E+05 1.09E+06 3.84E+03  9.94E+03  3.00E+06 3.94E+10 1.78E+09 
29M64 7/21/2017 4.89E+05 2.62E+04 4.11E+03  6.13E+01  1.29E+03 1.74E+09 6.42E+09 
29PB1 10/18/2016 1.76E+06  5.43E+04  4.26E+04  1.61E+05 2.69E+11 6.82E+10 
32A16 7/21/2017 4.33E+05 2.31E+03 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32A16 2/13/2018 4.28E+05 1.04E+03 4.09E+01  6.54E+02  5.60E+04 7.45E+09 5.95E+09 
32A16 2/26/2018 3.05E+05 6.95E+02 8.18E+01  4.91E+02  2.04E+02 1.82E+06 4.07E+09 
32A16M16 7/21/2017 4.82E+05 6.13E+01 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32A16M16 2/13/2018 5.01E+05 3.27E+02 0.00E+00  6.13E+01  5.08E+03 3.58E+09 4.39E+09 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
32A16M16 2/26/2018 2.65E+05 4.70E+02 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32A16M4 7/21/2017 2.83E+05 9.20E+02 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32A16M4 2/13/2018 5.01E+05 6.74E+02 2.04E+01  1.43E+02  8.38E+04 5.15E+09 4.25E+09 
32A16M4 2/26/2018 2.78E+05 9.40E+02 2.04E+01  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32A8 7/21/2017 6.11E+05 2.70E+04 2.04E+01  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32A8 2/13/2018 4.57E+05 1.31E+04 2.04E+02  1.84E+03  3.58E+06 3.99E+10 4.83E+09 
32A8 2/26/2018 3.61E+05 3.33E+04 3.47E+02  6.57E+03  6.34E+06 4.11E+09 2.80E+09 
32A8M16 7/21/2017 7.05E+05 3.25E+04 4.09E+01  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32A8M16 2/13/2018 5.01E+05 2.22E+04 2.04E+01  4.50E+02  5.08E+05 4.20E+10 5.95E+10 
32A8M16 2/26/2018 3.51E+05 3.24E+04 2.04E+01  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32A8M4 7/21/2017 3.87E+05 3.00E+04 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32A8M4 2/13/2018 5.01E+05 2.60E+04 0.00E+00  7.97E+02  5.73E+05 4.96E+10 4.27E+10 
32A8M4 2/26/2018 3.18E+05 3.78E+04 6.13E+01  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
32GC 7/21/2017 4.44E+05 9.15E+05 2.08E+06  1.98E+09  8.32E+10 5.23E+10 3.02E+10 
32GC 2/13/2018 4.64E+05 8.19E+05 1.76E+06  1.74E+09  2.72E+10 7.42E+10 6.09E+10 
32M16 7/21/2017 5.14E+05 8.68E+04 1.39E+03  4.50E+02  1.80E+03 3.50E+07 2.86E+10 
32M16 2/13/2018 6.63E+05 2.68E+05 4.69E+03  1.88E+03  2.25E+06 7.39E+10 6.75E+10 
32M4 7/21/2017 8.35E+05 8.82E+05 7.58E+03  1.12E+03  2.35E+05 4.66E+09 2.93E+10 
32M4 2/13/2018 4.92E+05 6.72E+05 5.21E+03  2.33E+03  2.20E+06 7.92E+10 6.81E+10 
32M64 7/21/2017 8.67E+05 1.48E+04 7.15E+02  1.02E+02  0.00E+00 0.00E+00 0.00E+00 
349A8 10/18/2016 5.11E+05  8.18E+01  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
349GC 10/18/2016 1.45E+06  3.55E+06  4.79E+10  2.53E+11 1.81E+11 1.25E+11 
349M4 10/18/2016 3.07E+05  3.39E+03  4.91E+02  1.02E+02 0.00E+00 0.00E+00 
349M4A8 10/18/2016 9.17E+05  0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
349M4PB1 10/18/2016 1.45E+06  0.00E+00  0.00E+00  0.00E+00 0.00E+00 2.04E+01 
349PB1 10/18/2016 6.78E+05  1.02E+02  1.82E+03  2.19E+05 2.22E+11 1.83E+11 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
34A16 5/29/2014 1.76E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
34A16 5/26/2017 8.62E+05 0.00E+00 0.00E+00  6.13E+01  0.00E+00 1.30E+06 3.86E+09 
34A64 5/29/2014 2.86E+04 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
34A8 5/26/2017 1.04E+06 0.00E+00 0.00E+00  0.00E+00  0.00E+00 3.73E+06 7.00E+09 
34A8M16 5/26/2017 7.98E+05 0.00E+00 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
34A8M4 5/26/2017 8.24E+05 0.00E+00 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
34GC 1/26/2014 5.35E+05 1.02E+06 2.63E+06  5.07E+08  1.41E+09 4.43E+10 4.43E+11 
34GC 2/15/2014 7.44E+05 7.16E+05 4.44E+06  1.36E+10  3.42E+10 4.12E+11 3.93E+12 
34GC 3/30/2014 7.82E+05 1.53E+06 1.13E+07  3.25E+10  1.06E+11 5.43E+11 9.31E+10 
34GC 6/11/2015 8.35E+05  4.01E+06 1.14E+07 2.85E+08 5.11E+10  5.86E+11  
34GC on M16 6/11/2015 1.00E+00  0.00E+00 3.71E+02 5.09E+03 2.98E+05  2.98E+05  
34GC on P4 6/11/2015 6.00E+00  3.20E+01 1.42E+02 1.08E+03 2.02E+03  1.74E+04  
34M16 1/26/2014 7.48E+05 8.31E+04 2.19E+03  4.29E+02  1.84E+02 6.88E+03 4.53E+06 
34M16 7/9/2014 4.85E+05 5.25E+04 6.13E+01  1.43E+02  1.00E+00 2.04E+01 2.04E+01 
34M16 2/13/2017 1.14E+06  1.27E+03  2.25E+02 2.04E+02 8.18E+01 4.09E+01  
34M16 on M16 2/13/2017 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 0.00E+00  
34M16F on 
M16 2/13/2017 0.00E+00 
 0.00E+00  0.00E+00 0.00E+00 0.00E+00 0.00E+00  
34M16PB0.25 2/15/2014 5.87E+05 1.22E+04 1.33E+03  2.04E+01  1.00E+00 1.00E+00 1.00E+00 
34M16PB0.25 7/9/2014 1.21E+06 7.03E+03 7.15E+02  2.45E+02  2.04E+01 1.00E+00 1.00E+00 
34M16PB1 2/15/2014 6.72E+05 2.46E+04 2.79E+02  1.09E+02  1.00E+00 1.00E+00 1.00E+00 
34M16PB1 7/9/2014 7.14E+05 4.81E+03 1.00E+00  1.00E+00  2.04E+01 1.00E+00 2.04E+01 
34M4 1/26/2014 8.06E+05 5.94E+05 2.26E+04  1.21E+03  5.74E+03 1.06E+09 1.71E+10 
34M4 7/9/2014 1.04E+06 5.86E+05 8.73E+03  9.61E+02  5.72E+04 8.39E+10 5.76E+10 
34M4PB0.25 2/15/2014 6.02E+05 1.92E+04 1.20E+03  4.09E+01  1.00E+00 1.00E+00 1.00E+00 
34M4PB0.25 7/9/2014 8.09E+05 4.50E+04 8.58E+02  3.47E+02  1.00E+00 6.77E+03 6.21E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
34M4PB1 2/15/2014 7.34E+05 2.83E+04 2.59E+02  2.04E+01  1.00E+00 1.00E+00 1.00E+00 
34M4PB1 7/9/2014 9.91E+05 6.13E+04 8.58E+02  2.04E+01  1.00E+00 6.82E+03 7.33E+10 
34M64 1/26/2014 6.54E+05 3.39E+04 3.47E+02  6.13E+01  4.09E+01 1.43E+02 2.04E+01 
34M64 7/9/2014 7.54E+05 2.98E+04 2.25E+02  4.09E+01  1.00E+00 1.00E+00 1.00E+00 
34M8 2/13/2017 7.59E+05  2.08E+03  7.77E+02 3.47E+02 8.18E+01 2.04E+02  
34M8 on M16 2/13/2017 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 0.00E+00  
34M8F on M16 2/13/2017 0.00E+00  0.00E+00  0.00E+00 0.00E+00 0.00E+00 0.00E+00  
34PB0.06 6/10/2014 6.82E+05 6.25E+05 1.89E+06  9.20E+08  7.61E+10 1.30E+11 7.47E+10 
34PB0.06 6/18/2014 5.01E+05 6.26E+04 6.12E+03  5.87E+03  1.81E+06 9.88E+10 1.56E+11 
34PB0.06 7/9/2014 7.87E+05 1.36E+05 6.44E+04  3.79E+04  1.19E+08 2.19E+11 8.18E+10 
34PB0.125 6/18/2014 5.15E+05 2.15E+04 6.54E+02  3.88E+02  4.46E+05 6.48E+10 7.37E+10 
34PB0.125 7/9/2014 9.30E+05 4.70E+04 4.24E+03  2.76E+03  1.18E+06 8.44E+10 9.84E+10 
34PB0.25 1/26/2014 7.07E+05 2.52E+04 6.74E+02  1.92E+03  3.54E+06 4.19E+07 4.71E+10 
34PB0.25 3/30/2014 7.23E+05 3.27E+02 1.43E+02  5.93E+02  4.16E+04 7.16E+10 7.93E+09 
34PB0.25 8/23/2014 8.95E+05 3.47E+03 6.34E+02  2.92E+03  4.26E+04 7.88E+10 1.71E+10 
34PB1 1/26/2014 6.54E+05 7.07E+03 2.86E+02  4.91E+02  6.16E+05 1.18E+08 1.49E+10 
34PB1 3/30/2014 5.84E+05 1.00E+00 1.00E+00  2.66E+02  1.56E+04 1.67E+11 1.19E+10 
34PB1 8/23/2014 8.43E+05 2.21E+03 1.64E+02  4.37E+03  2.00E+04 8.59E+10 1.78E+10 
34PB16 2/13/2017 5.78E+05 2.25E+02 1.64E+02  2.04E+01  1.31E+03 5.26E+09  
34PB16 on PB4 2/13/2017 0.00E+00 2.04E+01 0.00E+00  2.04E+02  1.68E+03 3.47E+09  
34PB16F on 
PB4 2/13/2017 3.13E+02 6.00E+00 1.40E+01 
 7.70E+01  9.70E+02   
34PB2 5/29/2014 8.00E+05 6.13E+02 1.02E+02  8.99E+02  7.16E+04 1.29E+11 5.73E+10 
34PB2 6/10/2014 6.92E+05 1.00E+03 2.45E+02  1.84E+02  2.25E+04 6.13E+10 1.57E+11 
34PB32 2/13/2017 9.25E+05 4.09E+01 6.13E+01  0.00E+00  0.00E+00 1.23E+02  
34PB32 on PB4 2/13/2017 0.00E+00 0.00E+00 0.00E+00  0.00E+00  0.00E+00 6.13E+01  
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
34PB32F on 
PB4 2/13/2017 3.18E+02 4.00E+00 6.00E+00 
 3.00E+00  1.10E+01 4.60E+01  
34PB4 5/29/2014 7.79E+05 1.64E+02 6.13E+01  3.07E+02  3.09E+04 5.31E+10 1.67E+11 
34PB4 6/10/2014 6.85E+05 7.97E+02 4.09E+01  1.02E+02  8.36E+03 9.78E+10 1.96E+11 
37A16 7/21/2017 1.20E+06 1.77E+06 4.24E+06  2.86E+09  9.91E+09 5.82E+10 4.76E+10 
37A16 2/13/2018 7.79E+05 9.82E+05 3.54E+06  2.10E+10  8.11E+10 1.03E+11 1.41E+11 
37A16M16 7/21/2017 1.14E+06 3.94E+05 4.93E+03  8.18E+01  0.00E+00 3.50E+07 6.40E+09 
37A16M16 2/13/2018 6.51E+05 4.13E+05 1.42E+04  1.02E+02  8.58E+04 3.10E+10 7.45E+09 
37A16M4 7/21/2017 1.02E+06 7.29E+05 1.08E+04  8.18E+01  0.00E+00 8.71E+07 5.35E+10 
37A16M4 2/13/2018 7.66E+05 5.95E+05 1.19E+04  8.18E+01  7.56E+04 5.13E+09 3.78E+09 
37A8 7/21/2017 1.14E+06 1.20E+06 2.92E+06  1.39E+10  1.16E+10 4.86E+10 5.56E+10 
37A8 2/13/2018 7.22E+05 1.05E+06 2.97E+06  5.13E+09  1.14E+11 1.20E+11 8.91E+10 
37A8M16 7/21/2017 7.39E+05 3.25E+06 1.82E+03  6.13E+01  2.04E+01 1.77E+07 9.07E+10 
37A8M16 2/13/2018 8.11E+05 4.27E+05 9.55E+03  2.45E+02  2.68E+05 2.99E+10 4.33E+09 
37A8M4 7/21/2017 1.05E+06 1.07E+06 5.83E+03  2.25E+02  2.72E+05 5.19E+09 8.16E+10 
37A8M4 2/13/2018 7.65E+05 1.00E+06 3.76E+03  2.86E+02  1.22E+06 1.06E+11 1.11E+11 
37GC 7/21/2017 9.78E+05 1.50E+06 5.51E+06  4.43E+10  6.39E+10 1.12E+11 3.91E+10 
37GC 2/13/2018 7.23E+05 1.08E+06 2.84E+06  2.35E+10  9.23E+10 6.72E+10 6.15E+10 
37M16 7/21/2017 9.44E+05 6.44E+05 3.19E+03  1.90E+03  1.81E+06 5.33E+10 1.00E+10 
37M16 2/13/2018 7.97E+05 5.06E+05 4.46E+03  4.70E+02  5.84E+05 7.42E+09 1.13E+11 
37M4 7/21/2017 1.08E+06 9.69E+05 3.82E+03  2.35E+03  7.44E+08 4.53E+10 6.57E+10 
37M4 2/13/2018 8.77E+05 9.33E+05 1.84E+03  1.21E+03  4.55E+06 9.27E+10 7.26E+10 
40A16 9/23/2014 9.65E+05 1.57E+05 3.80E+03  9.40E+02  1.00E+02 2.70E+06 1.17E+09 
40A16 9/29/2014 4.54E+05 3.19E+05 4.33E+03  6.13E+02  3.27E+02 1.00E+05 9.20E+06 
40A16 12/16/2014 2.94E+05 1.09E+05 2.13E+04  3.23E+05  1.21E+09 6.63E+10 3.14E+10 
40A16 1/6/2015 3.78E+05 2.17E+05 8.04E+05  6.76E+07  1.08E+10 9.93E+10 3.74E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
40A8 9/23/2014 2.50E+06 5.22E+05 1.00E+05  1.13E+04  4.70E+02 1.22E+06 5.11E+10 
40A8 9/29/2014 5.33E+05 8.18E+05 1.08E+05  1.47E+03  2.86E+02 3.22E+06 3.08E+08 
40GC 9/17/2014 5.46E+05 1.51E+06 3.43E+06  4.92E+08  3.39E+10 5.76E+10 1.63E+10 
40GC 10/21/2014 5.31E+05 6.08E+05 1.78E+06  1.83E+08  4.68E+10 2.72E+10 4.29E+09 
40M16 9/17/2014 6.31E+05 1.13E+06 9.61E+04  1.35E+04  1.03E+04 1.00E+02 1.00E+02 
40M16 10/21/2014 5.36E+05 3.41E+05 1.98E+03  4.29E+02  1.00E+02 1.00E+02 1.00E+02 
40M16A8 9/29/2014 7.67E+05 3.05E+05 1.88E+03  1.10E+03  1.23E+02 1.00E+02 1.00E+02 
40M16A8 12/9/2014 3.92E+05 8.80E+04 1.66E+04  2.13E+03  1.00E+02 1.00E+02 1.00E+02 
40M16PB0.25 9/23/2014 9.40E+05 1.45E+05 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
40M16PB0.25 10/28/2014 3.39E+05 4.09E+03 7.97E+02  2.86E+02  1.00E+02 1.00E+02 1.00E+02 
40M4 9/17/2014 1.10E+06 7.38E+05 2.00E+05  1.14E+03  1.21E+05 2.41E+09 6.62E+10 
40M4 10/21/2014 6.63E+05 5.43E+05 1.32E+04  1.59E+03  4.60E+04 1.94E+10 2.82E+10 
40M4A16 9/29/2014 8.00E+05 5.76E+05 6.13E+04  1.64E+02  1.00E+02 1.00E+02 1.00E+02 
40M4A16 12/9/2014 3.86E+05 6.65E+04 6.75E+03  1.10E+05  1.64E+02 1.00E+02 1.00E+02 
40M4A8 9/29/2014 8.98E+05 6.67E+05 6.06E+03  1.02E+03  1.00E+02 1.00E+02 1.00E+02 
40M4A8 12/9/2014 4.03E+05 1.12E+05 3.35E+04  4.21E+03  1.53E+03 5.48E+03 6.51E+10 
40M4A8 12/16/2014 3.56E+05 2.21E+05 4.19E+04  1.96E+03  1.19E+03 1.00E+02 1.00E+02 
40M4PB0.25 9/23/2014 1.73E+06 3.50E+04 1.00E+02  1.00E+02  1.00E+02 3.28E+04 6.93E+09 
40M4PB0.25 10/28/2014 3.07E+05 2.15E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
40M4PB0.25 12/9/2014 4.17E+05 1.90E+04 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
40M4PB0.25 12/16/2014 3.80E+05 8.19E+03 4.70E+02  1.23E+02  1.00E+02 1.00E+02 1.00E+02 
40M4PB1 9/23/2014 1.05E+06 1.84E+03 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.61E+10 
40M4PB1 10/28/2014 1.76E+05 2.45E+02 1.00E+02  1.00E+02  1.00E+02 1.00E+02 1.00E+02 
40M4PB1 12/9/2014 4.11E+05 1.66E+04 1.00E+02  1.00E+02  1.64E+02 1.00E+02 1.00E+02 
40PB0.25 9/17/2014 6.15E+05 6.54E+02 2.45E+02  8.55E+03  1.16E+05 6.00E+10 3.79E+10 
40PB0.25 10/21/2014 4.99E+05 3.27E+04 1.00E+02  1.00E+02  6.73E+03 1.20E+10 1.89E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
40PB1 9/17/2014 9.55E+05 1.02E+02 1.00E+02  4.09E+02  4.88E+04 8.07E+10 9.40E+10 
40PB1 10/21/2014 5.68E+05 1.24E+04 1.00E+02  1.00E+02  5.11E+03 2.32E+10 9.53E+10 
44A16 5/29/2014 5.45E+05 4.61E+03 1.00E+00  4.09E+01  1.00E+00 1.00E+00 1.00E+00 
44A16 5/26/2017 5.87E+05 1.10E+05 1.06E+03  6.95E+04  8.06E+10 3.34E+11 6.72E+10 
44A64 5/29/2014 4.94E+05 8.18E+01 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44A8 5/26/2017 6.16E+05 5.53E+04 1.21E+03  1.04E+05  1.59E+10 2.42E+11 6.08E+10 
44A8M16 5/26/2017 6.02E+05 2.87E+04 1.23E+02  2.04E+01  0.00E+00 0.00E+00 0.00E+00 
44A8M4 5/26/2017 7.65E+05 1.97E+04 1.02E+02  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
44A8M64 5/26/2017 5.04E+05 7.56E+04 2.66E+02  6.13E+01  0.00E+00 0.00E+00 0.00E+00 
44GC 1/26/2014 6.71E+05 4.07E+05 1.63E+06  9.31E+07  7.23E+08 1.04E+11 8.31E+11 
44GC 2/15/2014 6.97E+05 6.86E+05 2.48E+06  1.80E+09  5.13E+10 1.04E+11 1.19E+12 
44GC 3/30/2014 5.16E+05 1.08E+06 4.29E+06  4.37E+09  3.05E+10 3.11E+11 2.01E+11 
44GC 6/11/2015 8.27E+05  4.93E+06 1.81E+07 4.32E+08 4.76E+10  5.72E+11  
44GC on M64 6/11/2015 4.39E+03  6.95E+04 2.58E+05 7.36E+06 4.29E+08  4.50E+08  
44GC on P4 6/11/2015 2.00E+00  2.50E+01 8.60E+01 4.09E+02 7.56E+02  1.08E+04  
44M128 2/13/2017 8.30E+05  2.64E+04  6.48E+03 3.92E+03 1.66E+03 1.69E+10  
44M128 on M64 2/13/2017 1.41E+04  6.64E+03  1.29E+03 4.91E+02 4.91E+02 5.00E+09  
44M128F on 
M64 2/13/2017 TNTC 
 TNTC  4.50E+02 1.89E+02 2.10E+02   
44M16 1/26/2014 7.21E+05 6.97E+05 1.73E+06  9.92E+04  2.05E+08 1.90E+10 1.22E+10 
44M16 5/20/2014 4.52E+05 7.32E+05 1.87E+06  2.14E+06  4.04E+10 5.93E+10 1.69E+10 
44M16(2)P0.25 9/6/2017 4.29E+05 3.29E+03 6.13E+02 1.64E+02 4.09E+01  6.74E+02 3.30E+10 5.07E+10 
44M16(2)P0.25 9/29/2017 7.72E+05 1.90E+03 6.74E+02  1.64E+02  3.27E+02 6.82E+09 5.47E+10 
44M16(2)P1 9/6/2017 9.11E+05 1.04E+03 1.43E+02 1.02E+02 2.04E+01  0.00E+00 2.86E+08 1.56E+11 
44M16(2)P1 9/29/2017 7.62E+05 4.50E+02 2.25E+02  0.00E+00  3.47E+02 7.47E+09 4.64E+10 
44M16P0.25(2) 9/26/2017 6.87E+05 9.13E+05 2.29E+06 2.04E+01 0.00E+00  1.29E+03 7.77E+08 1.80E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
44M16P0.25(2) 9/29/2017 7.61E+05 1.00E+06 1.80E+06  2.04E+02  4.70E+03 3.70E+10 3.70E+10 
44M16P1(2) 9/26/2017 6.16E+05 8.83E+05 2.82E+06 0.00E+00 3.59E+03  2.30E+04 2.70E+10 4.52E+10 
44M16P1(2) 9/29/2017 7.45E+05 9.24E+05 1.65E+06  8.18E+01  4.62E+03 3.15E+10 3.05E+10 
44M16PB0.25 2/15/2014 5.66E+05 5.17E+03 2.86E+02  2.04E+01  2.78E+03 5.39E+10 1.77E+12 
44M16PB0.25 3/30/2014 5.68E+05 1.00E+00 1.00E+00  6.13E+01  2.84E+03 3.61E+10 5.20E+10 
44M16PB0.25 5/14/2014 8.35E+05 1.61E+03 1.43E+02  6.13E+01  2.06E+03 1.68E+11 1.64E+10 
44M16PB1 2/15/2014 5.71E+05 1.24E+03 1.00E+00  1.00E+00  2.45E+02 2.43E+09 1.82E+12 
44M16PB1 3/30/2014 6.09E+05 1.00E+00 1.00E+00  1.00E+00  8.18E+01 2.60E+04 1.27E+11 
44M16PB1 4/19/2014 8.25E+05 6.13E+01 2.25E+02  2.04E+01  1.23E+02 2.58E+06 5.06E+11 
44M16PB1 5/14/2014 7.52E+05 1.84E+02 1.00E+00  2.04E+01  1.25E+03 2.21E+10 8.75E+09 
44M16PB1 8/23/2014 7.32E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44M16PB1G 4/19/2014 8.78E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44M16PB4 5/20/2014 4.86E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44M16PB4 7/9/2014 6.09E+05 2.04E+01 1.00E+00  1.00E+00  1.84E+02 2.10E+05 1.12E+11 
44M16PB4 8/23/2014 4.96E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 6.87E+04 1.51E+10 
44M4 1/26/2014 8.06E+05 6.80E+05 1.97E+06  5.56E+05  1.16E+09 2.71E+10 1.89E+10 
44M4 5/14/2014 1.14E+06 1.34E+06 4.97E+06  3.66E+09  9.15E+10 1.21E+11 2.26E+10 
44M4(2)P0.25 9/6/2017 4.31E+05 4.11E+03 8.38E+02 3.88E+02 4.09E+01  3.68E+02 6.56E+10 1.98E+10 
44M4(2)P0.25 9/29/2017 7.36E+05 1.10E+03 4.50E+02  1.02E+02  4.09E+02 1.28E+10 2.93E+10 
44M4(2)P1 9/6/2017 4.00E+05 1.14E+03 2.66E+02 0.00E+00 2.04E+01  1.23E+02 1.33E+09 5.32E+10 
44M4(2)P1 9/29/2017 7.32E+05 5.72E+02 1.23E+02  4.09E+01  3.68E+02 1.20E+10 4.55E+10 
44M4P0.25(2) 9/26/2017 7.26E+05 1.08E+06 3.61E+06 3.40E+02 2.43E+03  7.61E+05 2.50E+10 9.04E+09 
44M4P0.25(2) 9/29/2017 6.15E+05 9.64E+05 2.22E+06  2.66E+02  5.81E+03 7.20E+10 5.81E+10 
44M4P1(2) 9/26/2017 8.36E+05 9.41E+05 4.04E+06 0.00E+00 3.27E+03   3.53E+10 3.12E+10 
44M4P1(2) 9/29/2017 6.73E+05 9.65E+05 2.25E+06  2.25E+02  2.25E+02 1.78E+05 1.02E+11 
44M4PB0.25 2/15/2014 5.00E+05 2.58E+03 3.54E+02  6.80E+00  7.21E+02 4.19E+10 8.02E+11 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
44M4PB0.25 3/30/2014 4.47E+05 1.00E+00 1.00E+00  1.02E+02  1.80E+03 4.20E+10 6.52E+08 
44M4PB0.25 5/14/2014 9.67E+05 3.31E+03 4.50E+02  4.09E+01  4.68E+03 2.23E+11 2.62E+10 
44M4PB1 2/15/2014 5.44E+05 6.53E+03 6.13E+01  1.00E+00  6.80E+00 1.96E+04 2.76E+12 
44M4PB1 3/30/2014 4.26E+05 1.00E+00 1.00E+00  2.04E+01  1.00E+00 1.12E+04 1.28E+11 
44M4PB1 4/19/2014 1.00E+06 1.02E+02 4.09E+01  2.04E+02  4.91E+02 1.35E+10 8.07E+11 
44M4PB1 5/14/2014 7.80E+05 4.50E+02 1.64E+02  2.25E+02  1.12E+03 8.83E+10 2.98E+10 
44M4PB1 8/23/2014 8.30E+05 4.09E+01 1.00E+00  1.00E+00  1.00E+00 3.70E+07 1.89E+10 
44M4PB1G 4/19/2014 8.23E+05 2.04E+01 1.00E+00  1.43E+02  5.11E+02 1.13E+10 8.18E+06 
44M4PB4 5/20/2014 5.32E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 4.09E+01 1.00E+00 
44M4PB4 7/9/2014 8.20E+05 1.00E+00 1.00E+00  1.00E+00  1.02E+02 2.68E+05 1.27E+11 
44M4PB4 8/23/2014 9.69E+05 4.09E+01 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44M64 1/26/2014 7.36E+05 9.32E+05 6.86E+05  1.88E+05  3.63E+05 5.80E+08 2.06E+10 
44M64 5/14/2014 1.11E+06 1.38E+06 3.05E+05  4.01E+05  6.40E+05 5.77E+10 1.01E+10 
44M64 2/13/2017 8.75E+05  1.86E+05  1.27E+05 1.25E+05 2.06E+05 9.93E+10  
44M64 on M64 2/13/2017 1.66E+04  1.72E+04  1.25E+04 1.54E+04 4.70E+04 5.35E+09  
44M64(2)P0.25 9/6/2017 4.20E+05 2.17E+03 3.88E+02 1.02E+02 6.13E+01  2.04E+02 7.54E+09 1.21E+11 
44M64(2)P0.25 9/29/2017 6.58E+05 1.61E+03 4.29E+02  1.43E+02  0.00E+00 6.06E+03 9.83E+10 
44M64(2)P0.25 2/26/2018 6.30E+05 2.47E+03 6.54E+02  2.04E+02  6.13E+01 0.00E+00 0.00E+00 
44M64(2)P1 9/6/2017 5.84E+05 9.61E+02 2.04E+02 2.04E+01 2.04E+01  0.00E+00 0.00E+00 0.00E+00 
44M64(2)P1 9/29/2017 7.01E+05 7.77E+02 2.45E+02  2.04E+01  2.04E+01 6.13E+02 1.44E+04 
44M64(2)P1 2/26/2018 4.62E+05 8.18E+02 1.64E+02  2.04E+01  6.13E+01 5.63E+04 1.07E+10 
44M64F on 
M64 2/13/2017 TNTC 
        
44M64P0.25(2) 9/26/2017 8.71E+05 1.02E+06 2.10E+05 2.04E+01 2.04E+01  2.04E+01 0.00E+00 0.00E+00 
44M64P0.25(2) 9/29/2017 8.27E+05 8.12E+05 7.56E+04  1.23E+02  2.04E+01 0.00E+00 0.00E+00 
44M64P1 2/26/2018 4.86E+05 1.02E+03 2.66E+02  1.02E+02  6.13E+01 0.00E+00 0.00E+00 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
44M64P1 2/26/2018 4.68E+05 2.45E+02 0.00E+00  2.04E+01  2.04E+01 1.61E+03 6.68E+04 
44M64P1(2) 9/26/2017 1.01E+06 1.15E+06 2.66E+05 0.00E+00 2.04E+01  0.00E+00 1.00E+02 0.00E+00 
44M64P1(2) 9/29/2017 8.04E+05 3.43E+05 6.54E+04  4.09E+01  4.09E+01 0.00E+00 0.00E+00 
44M64PB0.25 2/15/2014 5.40E+05 4.30E+03 4.29E+02  6.80E+00  4.91E+02 2.10E+10 1.78E+12 
44M64PB0.25 3/30/2014 5.23E+05 1.00E+00 1.00E+00  1.00E+00  1.23E+02 3.92E+09 1.00E+10 
44M64PB0.25 5/14/2014 6.99E+05 1.84E+03 2.86E+02  1.00E+00  1.23E+02 8.58E+09 4.70E+10 
44M64PB1 2/15/2014 5.14E+05 9.53E+01 1.00E+00  6.80E+00  3.40E+01 5.07E+09 1.80E+12 
44M64PB1 3/30/2014 7.37E+04 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44M64PB1 4/19/2014 9.28E+05 6.13E+01 1.00E+00  1.00E+00  1.00E+00 2.25E+02 2.69E+05 
44M64PB1 5/14/2014 8.81E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 8.97E+04 2.06E+09 
44M64PB1 8/23/2014 5.57E+05 2.04E+01 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44M64PB1G 4/19/2014 7.32E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44M64PB4 5/20/2014 5.69E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44M64PB4 7/9/2014 6.45E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44PB0.06 6/10/2014 6.04E+05 6.95E+04 4.70E+04  1.42E+06  6.21E+10 4.91E+10 2.06E+10 
44PB0.06 6/18/2014 5.29E+05 7.15E+02 3.19E+03  2.18E+04  8.18E+05 9.18E+10 4.28E+10 
44PB0.125 6/18/2014 5.42E+05 1.64E+02 2.86E+02  1.76E+03  6.73E+04 1.61E+11 4.92E+10 
44PB0.125 7/9/2014 7.16E+05 2.00E+03 1.68E+04  2.82E+03  5.52E+04 7.37E+10 1.41E+11 
44PB0.25 1/26/2014 7.26E+05 1.29E+04 1.08E+03  2.66E+02  4.78E+06 4.45E+08 4.06E+09 
44PB0.25 3/30/2014 2.68E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+03 4.30E+10 2.43E+10 
44PB0.25 4/19/2014 8.53E+05 5.72E+02 1.23E+02  1.23E+02  9.81E+02 1.05E+10 9.97E+11 
44PB0.25 5/14/2014 8.93E+05 1.74E+03 6.74E+02  1.64E+02  2.76E+03 1.76E+11 3.44E+10 
44PB0.25G 4/19/2014 8.71E+05 3.47E+02 1.84E+02  1.84E+02  2.68E+03 8.10E+09 3.27E+09 
44PB1 1/26/2014 7.00E+05 8.86E+03 1.00E+03  1.02E+02  1.99E+06 4.94E+08 4.37E+09 
44PB1 3/30/2014 4.48E+05 1.00E+00 1.00E+00  4.09E+01  5.11E+02 8.29E+09 8.94E+10 
44PB1 4/19/2014 8.13E+05 4.09E+01 2.04E+01  2.25E+02  7.15E+02 8.23E+09 3.09E+11 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
44PB1 5/14/2014 9.82E+05 7.15E+02 1.84E+02  1.84E+02  2.55E+03 1.11E+11 1.67E+10 
44PB1G 4/19/2014 8.80E+05 8.18E+01 1.00E+00  1.00E+00  1.00E+00 2.74E+03 5.29E+10 
44PB2 5/29/2014 6.47E+05 8.18E+01 1.00E+00  1.00E+00  1.64E+02 2.27E+11 3.74E+10 
44PB2 6/10/2014 6.18E+05 8.18E+01 2.04E+02  1.00E+00  1.00E+00 1.21E+06 1.27E+10 
44PB2 8/23/2014 4.75E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 5.38E+04 2.98E+09 
44PB4 5/20/2014 5.56E+05 1.00E+00 1.00E+00  1.00E+00  1.00E+00 1.00E+00 1.00E+00 
44PB4 5/29/2014 6.53E+05 4.09E+01 1.00E+00  1.00E+00  5.72E+02 2.30E+10 3.77E+10 
44PB4 6/10/2014 5.87E+05 2.04E+01 2.04E+01  1.00E+00  2.04E+01 6.52E+05 4.00E+10 
44PB4 7/9/2014 7.75E+05 2.86E+02 1.00E+00  2.04E+01  1.02E+02 2.13E+07 3.17E+07 
44PB4 8/23/2014 1.10E+06 1.00E+00 1.00E+00  1.00E+00  1.00E+00 2.68E+07 5.87E+10 
44PB4 2/13/2017 9.48E+05 2.66E+02 6.13E+01  0.00E+00  9.81E+02 7.44E+10  
44PB4 on PB4 2/13/2017 0.00E+00 0.00E+00 0.00E+00  6.13E+01  6.54E+02 1.31E+10  
44PB4F on PB4 2/13/2017 9.20E+02 7.10E+01 8.20E+01  2.10E+02  1.12E+03   
44PB8 2/13/2017 1.02E+06 4.09E+01 0.00E+00  1.02E+02  2.04E+02 1.97E+10  
44PB8 on PB4 2/13/2017 0.00E+00 0.00E+00 0.00E+00  0.00E+00  2.04E+02 8.36E+09  
44PB8F on PB4 2/13/2017 TNTC 5.90E+01 8.90E+01  1.47E+02  1.71E+03   
45A8 5/26/2017 6.53E+05 2.70E+05 4.07E+03  2.66E+02  0.00E+00 6.79E+06 1.94E+09 
45A8M16 5/26/2017 4.99E+05 1.04E+05 2.15E+03  2.04E+02  2.00E+01 0.00E+00 0.00E+00 
45A8M4 5/26/2017 6.29E+05 7.13E+04 1.86E+03  1.02E+02  0.00E+00 0.00E+00 0.00E+00 
45A8M64 5/26/2017 9.20E+05 1.20E+04 2.40E+02  4.09E+01  0.00E+00 0.00E+00 0.00E+00 
123A8 10/18/2016 1.23E+06  2.19E+03  1.36E+04  7.45E+05 2.89E+10 1.65E+11 
123GC 10/18/2016 1.23E+06  1.61E+07  7.82E+09  1.81E+11 1.22E+11 2.70E+11 
123M16 10/18/2016 1.43E+06  1.91E+06  5.11E+08  1.37E+11 1.18E+11 1.37E+11 
123M16A8 10/18/2016 1.68E+06  7.56E+02  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
123M16PB1 10/18/2016 1.41E+06  2.54E+05  1.49E+03  6.48E+06 7.81E+10 1.44E+11 
123PB1 10/18/2016 1.43E+06  1.21E+05  7.36E+08  3.36E+10 1.25E+11 9.39E+10 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
126A8 10/18/2016 1.78E+06  5.48E+04  1.84E+03  8.65E+05 1.20E+11 4.18E+10 
126GC 10/18/2016 1.84E+06  7.68E+06  3.63E+10  2.11E+11 1.06E+11 1.24E+11 
126M16 10/18/2016 1.90E+06  4.71E+04  1.82E+03  1.57E+05 1.00E+11 1.35E+11 
126M16A8 10/18/2016 1.23E+06  3.74E+03  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
126M16PB1 10/18/2016 1.96E+06  2.35E+03  4.91E+02  8.79E+02 1.19E+11 1.08E+11 
126PB1 10/18/2016 1.78E+06  3.15E+06  6.24E+08  1.20E+11 1.99E+11 9.75E+10 
169A16 2/13/2018 6.76E+05 1.13E+06 3.67E+06  4.31E+09  1.11E+11 1.08E+10 5.06E+09 
169A16 2/26/2018 7.02E+05 3.96E+04 3.11E+03  1.25E+03  1.43E+02 1.34E+04 5.43E+10 
169A16 2/26/2018 5.43E+05 4.64E+04 2.00E+03  1.17E+03  1.23E+02 4.09E+02 1.98E+06 
169A16 3/13/2018 8.11E+05 8.37E+04 2.39E+03  9.20E+02  1.02E+02 4.09E+01 0.00E+00 
169A16M16 2/13/2018 6.72E+05 3.02E+04 3.07E+03  7.97E+02  6.13E+01 0.00E+00 0.00E+00 
169A16M16 2/26/2018 4.62E+05 3.53E+04 2.58E+03  5.52E+02  0.00E+00 0.00E+00 0.00E+00 
169A16M4 2/13/2018 5.93E+05 4.25E+04 4.84E+03  1.27E+03  8.18E+01 0.00E+00 0.00E+00 
169A16M4 2/26/2018 4.47E+05 4.31E+04 3.15E+03  7.77E+02  6.13E+01 0.00E+00 0.00E+00 
169A8 10/18/2016 8.99E+05  9.10E+04  4.09E+04  8.46E+04 2.53E+11 1.20E+11 
169A8 2/13/2018 7.23E+05 2.43E+05 3.19E+04  1.14E+04  1.92E+04 1.27E+11 2.49E+09 
169A8 2/26/2018 4.65E+06 1.66E+05 5.52E+04  1.24E+04  4.29E+03 1.21E+11 5.73E+09 
169A8M16 2/13/2018 6.17E+05 9.04E+04 1.88E+04  3.27E+03  3.88E+02 0.00E+00 0.00E+00 
169A8M16 2/26/2018 4.61E+05 1.18E+05 5.93E+04  1.22E+04  1.67E+04 7.64E+10 1.12E+10 
169A8M16 3/13/2018 7.41E+05 2.29E+05 6.74E+04  2.86E+03  8.18E+01 0.00E+00 0.00E+00 
169A8M4 10/18/2016 1.17E+06  1.41E+05  7.82E+03  7.56E+02 0.00E+00 0.00E+00 
169A8M4 2/13/2018 6.19E+05 2.11E+05 4.49E+04  8.89E+03  8.18E+02 0.00E+00 0.00E+00 
169A8M4 2/26/2018 4.60E+05 1.72E+05 4.02E+04  1.22E+04  1.52E+07 4.09E+01 1.76E+05 
169A8M4 3/13/2018 7.47E+05 3.90E+05 1.23E+05  8.34E+03  4.70E+02 2.04E+01 0.00E+00 
169GC 10/18/2016 1.41E+06  1.23E+07  7.02E+10  6.82E+10 9.58E+10 1.46E+11 
169GC 2/13/2018 8.77E+05 1.15E+06 3.63E+06  5.24E+09  2.19E+11 5.98E+10 7.55E+09 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
169GC 2/26/2018 5.49E+05 6.08E+05 1.04E+07  3.10E+08  1.31E+11 3.13E+10 3.19E+09 
169M16 2/13/2018 6.38E+05 1.45E+05 5.62E+03  1.37E+03  1.43E+02 1.29E+10 2.99E+10 
169M16 2/26/2018 4.83E+05 1.15E+05 2.92E+03  1.23E+03  2.66E+02 0.00E+00 0.00E+00 
169M16 3/13/2018 7.56E+05 1.98E+05 2.19E+03  5.52E+02  1.23E+02 0.00E+00 0.00E+00 
169M4 10/18/2016 1.31E+06  1.19E+05  4.59E+04  1.89E+10 1.16E+11 1.49E+11 
169M4 2/13/2018 1.49E+06 1.29E+06 2.34E+04  2.44E+04  7.38E+07 2.09E+10 1.69E+10 
169M4 2/26/2018 5.32E+05 5.81E+05 5.03E+03  2.98E+03  3.94E+06 1.48E+10 9.11E+09 
169M4PB1 10/18/2016 1.37E+06  1.64E+02  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
169PB1 10/18/2016 1.53E+06  2.04E+01  0.00E+00  6.74E+02 2.12E+11 8.07E+10 
256A8 10/18/2016 9.82E+05  1.25E+04  8.18E+01  0.00E+00 0.00E+00 0.00E+00 
256GC 10/18/2016 1.70E+06  1.51E+07  5.93E+10  2.13E+11 1.23E+11 1.44E+11 
256M16 10/18/2016 1.82E+06  2.06E+04  7.97E+02  1.23E+02 1.95E+11 1.34E+11 
256M16A8 10/18/2016 1.17E+06  1.76E+03  2.04E+01  0.00E+00 0.00E+00 0.00E+00 
256M16PB1 10/18/2016 1.70E+06  2.04E+01  0.00E+00  2.04E+01 1.92E+03 1.55E+11 
256PB1 10/18/2016 1.05E+06  2.17E+03  2.60E+04  7.23E+06 2.34E+11 1.21E+11 
266A8 10/18/2016 1.41E+06  5.00E+04  5.31E+04  6.10E+05 2.07E+11 2.09E+11 
266GC 10/18/2016 1.57E+06  1.68E+07  1.80E+11  1.12E+11 1.84E+11 2.22E+11 
266GC 9/6/2017 6.98E+05 1.26E+06 5.59E+06 1.24E+08 1.21E+09  8.05E+10 1.56E+11 3.05E+10 
266GC 9/26/2017 1.69E+06 2.68E+06 2.26E+07 1.59E+09 3.29E+10  1.13E+11 6.82E+10 3.14E+10 
266M16 9/6/2017 9.41E+05 1.62E+05 5.93E+02 2.66E+02 0.00E+00  0.00E+00 0.00E+00 0.00E+00 
266M16 9/26/2017 1.37E+06 2.10E+05 6.00E+02 8.18E+01 6.14E+01  4.09E+01 2.56E+01 1.02E+01 
266M16(2)P0.25 9/6/2017 1.14E+06 2.94E+03 2.86E+02 6.13E+01 4.09E+01  0.00E+00 0.00E+00 0.00E+00 
266M16(2)P1 9/6/2017 1.03E+06 1.78E+03 4.09E+02 8.18E+01 2.04E+01  1.02E+02 0.00E+00 0.00E+00 
266M16P0.25 9/26/2017 1.53E+06 3.20E+02 3.92E+01 6.13E+01 8.18E+01  0.00E+00 0.00E+00 0.00E+00 
266M16P0.25(2) 9/26/2017 1.66E+06 1.68E+05 3.00E+02 0.00E+00 0.00E+00  4.09E+01 0.00E+00 0.00E+00 
266M16P1 9/26/2017 1.56E+06 8.00E+01 0.00E+00 1.02E+02 6.13E+01  2.04E+01 0.00E+00 0.00E+00 
 
 
 
 
Table E.1: Time-kill Data for Carbapenem-resistant Enterobacteriaceae 
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Time-kill Flask Date Time (h) 0 1 2 3 4 6 8 24 48 
266M16P1(2) 9/26/2017 1.51E+06 1.64E+05 1.40E+02 0.00E+00 0.00E+00  6.13E+01 0.00E+00 0.00E+00 
266M4 10/18/2016 1.25E+06  2.49E+03  9.81E+02  3.63E+06 3.33E+11 2.39E+11 
266M4 9/6/2017 9.84E+05 7.05E+05 1.61E+03 7.77E+02 1.00E+03  2.27E+05 2.96E+11 4.73E+10 
266M4 9/26/2017 1.69E+06 1.26E+06 2.00E+03 1.93E+03 1.82E+03  1.10E+07 2.40E+10 7.16E+10 
266M4(2)P0.25 9/6/2017 8.86E+05 9.40E+03 2.04E+02 4.09E+01 6.34E+02  6.59E+03 2.17E+11 5.01E+09 
266M4(2)P1 9/6/2017 8.13E+05 1.88E+03 2.86E+02 1.02E+02 4.09E+01  4.09E+01 6.37E+10 1.01E+10 
266M4A8 10/18/2016 1.55E+06  4.42E+04  5.17E+03  2.45E+02 0.00E+00 0.00E+00 
266M4P0.25 9/26/2017 1.37E+06 3.60E+02 8.00E+01 2.04E+01 0.00E+00  0.00E+00 4.09E+01 0.00E+00 
266M4P0.25(2) 9/26/2017 1.53E+06 1.05E+06 3.28E+03 0.00E+00 0.00E+00  0.00E+00 4.09E+01 2.04E+01 
266M4P1 9/26/2017 1.70E+06 1.97E+03 4.40E+02 0.00E+00 0.00E+00  0.00E+00 6.13E+01 0.00E+00 
266M4P1(2) 9/26/2017 1.63E+06 1.20E+06 3.96E+03 0.00E+00 2.04E+01  2.04E+01 0.00E+00 0.00E+00 
266M4PB1 10/18/2016 9.40E+05  2.74E+03  1.02E+02  0.00E+00 0.00E+00 0.00E+00 
266P0.25 9/6/2017 9.95E+05 1.17E+03 4.91E+02 1.02E+02 1.43E+03  1.20E+04 6.17E+10 3.74E+10 
266P0.25 9/26/2017 1.51E+06 1.50E+03 1.52E+03 3.51E+03 3.82E+03  1.68E+05 9.47E+10 8.22E+10 
266P1 9/6/2017 1.07E+06 1.61E+03 2.04E+02 2.25E+02 4.29E+02  8.83E+04 1.06E+11 2.83E+10 
266P1 9/26/2017 1.56E+06 1.56E+03 1.74E+03 2.74E+03 3.27E+03  3.56E+04 3.65E+10 1.00E+11 
266PB1 10/18/2016 6.95E+05  1.22E+04  7.97E+04  4.09E+04 9.40E+10 1.44E+11 
369A8 10/18/2016 9.81E+05  7.56E+02  8.18E+01  0.00E+00 2.04E+01 0.00E+00 
369GC 10/18/2016 1.57E+06  5.07E+06  6.98E+10  2.91E+11 1.88E+11 1.95E+11 
369M4 10/18/2016 2.06E+06  9.23E+04  1.67E+04  4.79E+03 3.07E+02 2.04E+03 
369M4A8 10/18/2016 7.36E+05  5.31E+02  0.00E+00  0.00E+00 0.00E+00 0.00E+00 
369M4PB1 10/18/2016 1.98E+06  4.57E+04  1.57E+04  2.11E+03 6.13E+01 2.04E+01 
369PB1 10/18/2016 1.47E+06  5.50E+05  3.39E+05  4.66E+10 1.57E+11 1.20E+11 
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Appendix F: 
 
Model Input Data for Mathematical Models 
 
 Tables F.1-F.22 contain the model input data extracted from Appendix E for each 
model fit.
 
 
Table F.1: Isolate 34 Growth Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 2.63E+06 6.42 14.78 1 0 1/26/2014 
2 5.07E+08 8.71 20.04 1   
22 4.43E+10 10.65 24.51 1   
46 4.43E+11 11.65 26.82 1   
0 4.44E+06 6.65 15.31 2 0 2/15/2014 
2 1.36E+10 10.13 23.33 2   
6 3.42E+10 10.53 24.26 2   
22 4.12E+11 11.61 26.74 2   
46 3.93E+12 12.59 29.00 2   
0 1.13E+07 7.05 16.24 3 0 3/30/2014 
2 3.25E+10 10.51 24.20 3   
6 1.06E+11 11.03 25.39 3   
22 5.43E+11 11.73 27.02 3   
46 9.31E+10 10.97 25.26 3   
0 1.14E+07 7.06 16.25 4 0 6/11/2015 
1 2.85E+08 8.45 19.47 4   
3 5.11E+10 10.71 24.66 4   
21 5.86E+11 11.77 27.10 4   
0 3.71E+02 2.57 5.92 5 0 6/11/2015 
1 5.09E+03 3.71 8.54 5   
3 2.98E+05 5.47 12.60 5   
21 2.98E+05 5.47 12.60 5   
0 1.42E+02 2.15 4.96 6 0 6/11/2015 
1 1.08E+03 3.03 6.98 6   
3 2.02E+03 3.31 7.61 6   
21 1.74E+04 4.24 9.76 6   
 
 
Table F.2: Isolate 34 Meropenem Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 2.63E+06 6.42 14.78 1  1/26/2014 
2 5.07E+08 8.71 20.04 1   
22 4.43E+10 10.65 24.51 1   
46 4.43E+11 11.65 26.82 1   
0 4.44E+06 6.65 15.31 2  2/15/2014 
2 1.36E+10 10.13 23.33 2   
6 3.42E+10 10.53 24.26 2   
22 4.12E+11 11.61 26.74 2   
46 3.93E+12 12.59 29.00 2   
0 1.13E+07 7.05 16.24 3  3/30/2014 
2 3.25E+10 10.51 24.20 3   
6 1.06E+11 11.03 25.39 3   
22 5.43E+11 11.73 27.02 3   
46 9.31E+10 10.97 25.26 3   
0 1.14E+07 7.06 16.25 4  6/11/2015 
1 2.85E+08 8.45 19.47 4   
3 5.11E+10 10.71 24.66 4   
21 5.86E+11 11.77 27.10 4   
0 8.06E+05 5.91 13.60 5 4 1/26/2014 
1 5.94E+05 5.77 13.29 5   
2 2.26E+04 4.35 10.03 5   
4 1.21E+03 3.08 7.10 5   
0 7.48E+05 5.87 13.53 6 16 1/26/2014 
1 8.31E+04 4.92 11.33 6   
2 2.19E+03 3.34 7.69 6   
0 6.54E+05 5.82 13.39 7 64 1/26/2014 
1 3.39E+04 4.53 10.43 7   
2 3.47E+02 2.54 5.85 7   
0 1.04E+06 6.02 13.85 8 4 7/9/2014 
1 5.86E+05 5.77 13.28 8   
2 8.73E+03 3.94 9.07 8   
4 9.61E+02 2.98 6.87 8   
0 4.85E+05 5.69 13.09 9 16 7/9/2014 
1 5.25E+04 4.72 10.87 9   
0 7.54E+05 5.88 13.53 10 64 7/9/2014 
1 2.98E+04 4.47 10.30 10   
2 2.25E+02 2.35 5.42 10   
0 7.59E+05 5.88 13.54 11 8 2/13/2017 
2 2.08E+03 3.32 7.64 11   
0 1.14E+06 6.06 13.95 12 16 2/13/2017 
 
 
Table F.2: Isolate 34 Meropenem Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
2 1.27E+03 3.10 7.15 12   
 
 
Table F.3: Isolate 34 Polymyxin B Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 2.63E+06 6.42 14.78 1 0 1/26/2014 
22 4.43E+10 10.65 24.51 1   
46 4.43E+11 11.65 26.82 1   
0 4.44E+06 6.65 15.31 2 0 2/15/2014 
2 1.36E+10 10.13 23.33 2   
6 3.42E+10 10.53 24.26 2   
22 4.12E+11 11.61 26.74 2   
46 3.93E+12 12.59 29.00 2   
0 1.13E+07 7.05 16.24 3 0 3/30/2014 
2 3.25E+10 10.51 24.20 3   
6 1.06E+11 11.03 25.39 3   
22 5.43E+11 11.73 27.02 3   
46 9.31E+10 10.97 25.26 3   
0 1.14E+07 7.06 16.25 4 0 6/11/2015 
1 2.85E+08 8.45 19.47 4   
3 5.11E+10 10.71 24.66 4   
21 5.86E+11 11.77 27.10 4   
0 7.07E+05 5.85 13.47 5 0.25 1/24/2014 
1 2.52E+04 4.40 10.13 5   
2 6.74E+02 2.83 6.51 5   
0 6.54E+05 5.82 13.39 6 1 1/24/2014 
1 7.07E+03 3.85 8.86 6   
2 2.86E+02 2.46 5.66 6   
0 7.23E+05 5.86 13.49 7 0.25 3/30/2015 
1 3.27E+02 2.51 5.79 7   
0 8.00E+05 5.90 13.59 8 2 5/29/2014 
1 6.13E+02 2.79 6.42 8   
0 7.79E+05 5.89 13.57 9 4 5/29/2014 
1 1.64E+02 2.21 5.10 9   
0 6.92E+05 5.84 13.45 10 2 6/10/2014 
1 1.00E+03 3.00 6.91 10   
0 6.85E+05 5.84 13.44 11 4 6/10/2014 
1 7.97E+02 2.90 6.68 11   
0 5.01E+05 5.70 13.12 12 0.06 6/18/2014 
1 6.26E+04 4.80 11.04 12   
2 6.12E+03 3.79 8.72 12   
0 5.15E+05 5.71 13.15 13 0.125 6/18/2014 
1 2.15E+04 4.33 9.98 13   
2 6.54E+02 2.82 6.48 13   
0 7.87E+05 5.90 13.58 14 0.06 7/9/2014 
 
 
Table F.3: Isolate 34 Polymyxin B Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
1 1.36E+05 5.13 11.82 14   
2 6.44E+04 4.81 11.07 14   
0 9.30E+05 5.97 13.74 15 0.125 7/9/2014 
1 4.70E+04 4.67 10.76 15   
2 4.24E+03 3.63 8.35 15   
0 8.95E+05 5.95 13.70 16 0.25 8/23/2014 
1 3.47E+03 3.54 8.15 16   
2 6.34E+02 2.80 6.45 16   
0 8.43E+05 5.93 13.64 17 1 8/23/2014 
1 2.21E+03 3.34 7.70 17   
2 1.64E+02 2.21 5.10 17   
 
 
Table F.4: Isolate 34 Meropenem Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 2.63E+06 6.42 14.78 1 0 1/26/2014 
2 5.07E+08 8.71 20.04 1   
22 4.43E+10 10.65 24.51 1   
46 4.43E+11 11.65 26.82 1   
0 4.44E+06 6.65 15.31 2 0 2/15/2014 
2 1.36E+10 10.13 23.33 2   
6 3.42E+10 10.53 24.26 2   
22 4.12E+11 11.61 26.74 2   
46 3.93E+12 12.59 29.00 2   
0 1.13E+07 7.05 16.24 3 0 3/30/2014 
2 3.25E+10 10.51 24.20 3   
6 1.06E+11 11.03 25.39 3   
22 5.43E+11 11.73 27.02 3   
46 9.31E+10 10.97 25.26 3   
0 1.14E+07 7.06 16.25 4 0 6/11/2015 
1 2.85E+08 8.45 19.47 4   
3 5.11E+10 10.71 24.66 4   
21 5.86E+11 11.77 27.10 4   
0 3.71E+02 2.57 5.92 5 0 6/11/2015 
1 5.09E+03 3.71 8.54 5   
3 2.98E+05 5.47 12.60 5   
0 8.06E+05 5.91 13.60 6 4 1/26/2014 
1 5.94E+05 5.77 13.29 6   
2 2.26E+04 4.35 10.03 6   
4 1.21E+03 3.08 7.10 6   
8 5.74E+03 3.76 8.65 6   
24 1.06E+09 9.03 20.78 6   
48 1.71E+10 10.23 23.56 6   
0 7.48E+05 5.87 13.53 7 16 1/26/2014 
1 8.31E+04 4.92 11.33 7   
2 2.19E+03 3.34 7.69 7   
4 4.29E+02 2.63 6.06 7   
0 6.54E+05 5.82 13.39 8 64 1/26/2014 
1 3.39E+04 4.53 10.43 8   
2 3.47E+02 2.54 5.85 8   
0 1.04E+06 6.02 13.85 9 4 7/9/2014 
1 5.86E+05 5.77 13.28 9   
2 8.73E+03 3.94 9.07 9   
4 9.61E+02 2.98 6.87 9   
8 5.72E+04 4.76 10.95 9   
 
 
Table F.4: Isolate 34 Meropenem Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
24 8.39E+10 10.92 25.15 9   
48 5.76E+10 10.76 24.78 9   
0 4.85E+05 5.69 13.09 10 16 7/9/2014 
1 5.25E+04 4.72 10.87 10   
4 1.43E+02 2.16 4.96 10   
0 7.54E+05 5.88 13.53 11 64 7/9/2014 
1 2.98E+04 4.47 10.30 11   
2 2.25E+02 2.35 5.42 11   
0 7.59E+05 5.88 13.54 12 8 2/13/2017 
2 2.08E+03 3.32 7.64 12   
4 7.77E+02 2.89 6.66 12   
6 3.47E+02 2.54 5.85 12   
24 2.04E+02 2.31 5.32 12   
0 1.14E+06 6.06 13.95 13 16 2/13/2017 
2 1.27E+03 3.10 7.15 13   
4 2.25E+02 2.35 5.42 13   
6 2.04E+02 2.31 5.32 13   
 
 
Table F.5: Isolate 34 Polymyxin B Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 2.63E+06 6.42 14.78 1 0 1/26/2014 
22 4.43E+10 10.65 24.51 1   
46 4.43E+11 11.65 26.82 1   
0 4.44E+06 6.65 15.31 2 0 2/15/2014 
2 1.36E+10 10.13 23.33 2   
6 3.42E+10 10.53 24.26 2   
22 4.12E+11 11.61 26.74 2   
46 3.93E+12 12.59 29.00 2   
0 1.13E+07 7.05 16.24 3 0 3/30/2014 
2 3.25E+10 10.51 24.20 3   
6 1.06E+11 11.03 25.39 3   
22 5.43E+11 11.73 27.02 3   
46 9.31E+10 10.97 25.26 3   
0 1.14E+07 7.06 16.25 4 0 6/11/2015 
1 2.85E+08 8.45 19.47 4   
3 5.11E+10 10.71 24.66 4   
21 5.86E+11 11.77 27.10 4   
0 1.42E+02 2.15 4.96 5 0 6/11/2015 
1 1.08E+03 3.03 6.98 5   
3 2.02E+03 3.31 7.61 5   
21 1.74E+04 4.24 9.76 5   
0 7.07E+05 5.85 13.47 6 0.25 1/26/2014 
1 2.52E+04 4.40 10.13 6   
2 6.74E+02 2.83 6.51 6   
4 1.92E+03 3.28 7.56 6   
48 4.71E+10 10.67 24.58 6   
0 6.54E+05 5.82 13.39 7 1 1/26/2014 
1 7.07E+03 3.85 8.86 7   
2 2.86E+02 2.46 5.66 7   
4 4.91E+02 2.69 6.20 7   
48 1.49E+10 10.17 23.42 7   
0 7.23E+05 5.86 13.49 8 0.25 3/30/2015 
1 3.27E+02 2.51 5.79 8   
2 1.43E+02 2.16 4.96 8   
4 5.93E+02 2.77 6.39 8   
8 4.16E+04 4.62 10.64 8   
24 7.16E+10 10.85 24.99 8   
48 7.93E+09 9.90 22.79 8   
0 5.84E+05 5.77 13.28 9 1 3/30/2015 
4 2.66E+02 2.42 5.58 9   
 
 
Table F.5: Isolate 34 Polymyxin B Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
8 1.56E+04 4.19 9.66 9   
24 1.67E+11 11.22 25.84 9   
48 1.19E+10 10.08 23.20 9   
0 8.00E+05 5.90 13.59 10 2 5/29/2014 
1 6.13E+02 2.79 6.42 10   
2 1.02E+02 2.01 4.62 10   
4 8.99E+02 2.95 6.80 10   
8 7.16E+04 4.85 11.18 10   
24 1.29E+11 11.11 25.58 10   
48 5.73E+10 10.76 24.77 10   
0 7.79E+05 5.89 13.57 11 4 5/29/2014 
1 1.64E+02 2.21 5.10 11   
4 3.07E+02 2.49 5.73 11   
8 3.09E+04 4.49 10.34 11   
24 5.31E+10 10.73 24.70 11   
48 1.67E+11 11.22 25.84 11   
0 6.92E+05 5.84 13.45 12 2 6/10/2014 
1 1.00E+03 3.00 6.91 12   
2 2.45E+02 2.39 5.50 12   
4 1.84E+02 2.26 5.21 12   
8 2.25E+04 4.35 10.02 12   
24 6.13E+10 10.79 24.84 12   
48 1.57E+11 11.20 25.78 12   
0 6.85E+05 5.84 13.44 13 4 6/10/2014 
1 7.97E+02 2.90 6.68 13   
4 1.02E+02 2.01 4.62 13   
8 8.36E+03 3.92 9.03 13   
24 9.78E+10 10.99 25.31 13   
48 1.96E+11 11.29 26.00 13   
0 5.01E+05 5.70 13.12 14 0.06 6/18/2014 
1 6.26E+04 4.80 11.04 14   
2 6.12E+03 3.79 8.72 14   
4 5.87E+03 3.77 8.68 14   
8 1.81E+06 6.26 14.41 14   
24 9.88E+10 10.99 25.32 14   
48 1.56E+11 11.19 25.77 14   
0 5.15E+05 5.71 13.15 15 0.125 6/18/2014 
1 2.15E+04 4.33 9.98 15   
2 6.54E+02 2.82 6.48 15   
4 3.88E+02 2.59 5.96 15   
 
 
Table F.5: Isolate 34 Polymyxin B Monotherapy Model Input Data 
368 
 
Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
8 4.46E+05 5.65 13.01 15   
24 6.48E+10 10.81 24.89 15   
48 7.37E+10 10.87 25.02 15   
0 7.87E+05 5.90 13.58 16 0.06 7/9/2014 
1 1.36E+05 5.13 11.82 16   
2 6.44E+04 4.81 11.07 16   
4 3.79E+04 4.58 10.54 16   
8 1.19E+08 8.08 18.59 16   
24 2.19E+11 11.34 26.11 16   
48 8.18E+10 10.91 25.13 16   
0 9.30E+05 5.97 13.74 17 0.125 7/9/2014 
1 4.70E+04 4.67 10.76 17   
2 4.24E+03 3.63 8.35 17   
4 2.76E+03 3.44 7.92 17   
8 1.18E+06 6.07 13.98 17   
24 8.44E+10 10.93 25.16 17   
48 9.84E+10 10.99 25.31 17   
0 8.95E+05 5.95 13.70 18 0.25 8/23/2014 
1 3.47E+03 3.54 8.15 18   
2 6.34E+02 2.80 6.45 18   
4 2.92E+03 3.47 7.98 18   
8 4.26E+04 4.63 10.66 18   
24 7.88E+10 10.90 25.09 18   
48 1.71E+10 10.23 23.56 18   
0 8.43E+05 5.93 13.64 19 1 8/23/2014 
1 2.21E+03 3.34 7.70 19   
2 1.64E+02 2.21 5.10 19   
4 4.37E+03 3.64 8.38 19   
8 2.00E+04 4.30 9.90 19   
24 8.59E+10 10.93 25.18 19   
48 1.78E+10 10.25 23.60 19   
 
 
 
Table F.6: Isolate 22 Growth Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 3.14E+06 6.50 14.96 1 0 5/29/2014 
2 4.21E+09 9.62 22.16 1   
6 1.11E+11 11.05 25.43 1   
22 5.23E+10 10.72 24.68 1   
46 9.93E+10 11.00 25.32 1   
0 2.51E+06 6.40 14.74 2 0 8/23/2014 
2 5.15E+09 9.71 22.36 2   
6 1.06E+11 11.03 25.39 2   
22 6.69E+10 10.83 24.93 2   
46 2.45E+09 9.39 21.62 2   
0 6.23E+06 6.79 15.64 3 0 6/11/2015 
1 1.35E+08 8.13 18.72 3   
3 3.21E+10 10.51 24.19 3   
21 1.43E+11 11.16 25.69 3   
0 7.93E+02 2.90 6.68 4 0 6/11/2015 
1 8.75E+03 3.94 9.08 4   
3 9.69E+04 4.99 11.48 4   
0 2.54E+02 2.40 5.54 5 0 6/11/2015 
1 1.58E+03 3.20 7.37 5   
21 9.18E+03 3.96 9.12 5   
 
 
Table F.7: Isolate 22 Meropenem Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 3.14E+06 6.50 14.96 1 0 5/29/2014 
2 4.21E+09 9.62 22.16 1   
6 1.11E+11 11.05 25.43 1   
22 5.23E+10 10.72 24.68 1   
46 9.93E+10 11.00 25.32 1   
0 2.51E+06 6.40 14.74 2 0 8/23/2014 
2 5.15E+09 9.71 22.36 2   
6 1.06E+11 11.03 25.39 2   
22 6.69E+10 10.83 24.93 2   
46 2.45E+09 9.39 21.62 2   
0 6.23E+06 6.79 15.64 3 0 6/11/2015 
1 1.35E+08 8.13 18.72 3   
3 3.21E+10 10.51 24.19 3   
21 1.43E+11 11.16 25.69 3   
0 1.70E+06 6.23 14.35 4 4 5/14/2014 
1 4.70E+04 4.67 10.76 4   
0 1.26E+06 6.10 14.05 5 16 5/14/2014 
1 2.43E+04 4.39 10.10 5   
0 9.34E+05 5.97 13.75 6 64 5/14/2014 
1 1.43E+04 4.16 9.57 6   
2 2.86E+02 2.46 5.66 6   
0 6.11E+05 5.79 13.32 7 4 5/20/2014 
1 3.78E+03 3.58 8.24 7   
0 3.52E+05 5.55 12.77 8 16 5/20/2014 
1 6.70E+03 3.83 8.81 8   
0 5.28E+05 5.72 13.18 9 64 5/20/2014 
1 4.19E+03 3.62 8.34 9   
0 7.82E+05 5.89 13.57 10 16 2/13/2017 
2 1.22E+04 4.09 9.41 10   
4 1.84E+02 2.26 5.21 10   
0 8.00E+05 5.90 13.59 11 32 2/13/2017 
2 1.23E+03 3.09 7.11 11   
 
 
Table F.8: Isolate 22 Polymyxin B Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 3.14E+06 6.50 14.96 1 0 5/29/2014 
2 4.21E+09 9.62 22.16 1   
6 1.11E+11 11.05 25.43 1   
22 5.23E+10 10.72 24.68 1   
46 9.93E+10 11.00 25.32 1   
0 2.51E+06 6.40 14.74 2 0 8/23/2014 
2 5.15E+09 9.71 22.36 2   
6 1.06E+11 11.03 25.39 2   
22 6.69E+10 10.83 24.93 2   
46 2.45E+09 9.39 21.62 2   
0 6.23E+06 6.79 15.64 3 0 6/11/2015 
1 1.35E+08 8.13 18.72 3   
3 3.21E+10 10.51 24.19 3   
21 1.43E+11 11.16 25.69 3   
0 1.34E+06 6.13 14.11 4 0.25 5/14/2014 
1 1.78E+03 3.25 7.48 4   
0 5.27E+05 5.72 13.17 5 0.06 6/10/2014 
1 9.81E+04 4.99 11.49 5   
0 4.56E+05 5.66 13.03 6 0.06 6/18/2014 
1 4.48E+03 3.65 8.41 6   
0 4.93E+05 5.69 13.11 7 0.125 6/18/2014 
1 3.07E+02 2.49 5.73 7   
0 6.91E+05 5.84 13.45 8 0.125 7/9/2014 
1 1.64E+02 2.21 5.10 8   
 
 
Table F.9: Isolate 22 Meropenem Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 3.14E+06 6.50 14.96 1 0 5/29/2014 
2 4.21E+09 9.62 22.16 1   
6 1.11E+11 11.05 25.43 1   
22 5.23E+10 10.72 24.68 1   
46 9.93E+10 11.00 25.32 1   
0 2.51E+06 6.40 14.74 2 0 8/23/2014 
2 5.15E+09 9.71 22.36 2   
6 1.06E+11 11.03 25.39 2   
22 6.69E+10 10.83 24.93 2   
46 2.45E+09 9.39 21.62 2   
0 6.23E+06 6.79 15.64 3 0 6/11/2015 
1 1.35E+08 8.13 18.72 3   
3 3.21E+10 10.51 24.19 3   
21 1.43E+11 11.16 25.69 3   
0 7.93E+02 2.90 6.68 4 0 6/11/2015 
1 8.75E+03 3.94 9.08 4   
3 9.69E+04 4.99 11.48 4   
0 1.70E+06 6.23 14.35 5 4 5/14/2014 
1 4.70E+04 4.67 10.76 5   
3 1.68E+03 3.23 7.43 5   
7 1.37E+05 5.14 11.83 5   
23 1.19E+11 11.08 25.50 5   
47 7.98E+10 10.90 25.10 5   
0 1.26E+06 6.10 14.05 6 16 5/14/2014 
1 2.43E+04 4.39 10.10 6   
3 2.02E+03 3.31 7.61 6   
7 4.09E+04 4.61 10.62 6   
23 9.27E+10 10.97 25.25 6   
47 4.13E+09 9.62 22.14 6   
0 9.34E+05 5.97 13.75 7 64 5/14/2014 
1 1.43E+04 4.16 9.57 7   
2 2.86E+02 2.46 5.66 7   
0 6.11E+05 5.79 13.32 8 4 5/20/2014 
1 3.78E+03 3.58 8.24 8   
3 2.86E+02 2.46 5.66 8   
7 5.23E+04 4.72 10.86 8   
23 1.03E+11 11.01 25.36 8   
47 1.01E+11 11.00 25.34 8   
0 3.52E+05 5.55 12.77 9 16 5/20/2014 
1 6.70E+03 3.83 8.81 9   
 
 
Table F.9: Isolate 22 Meropenem Monotherapy Model Input Data 
373 
 
Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
3 1.02E+02 2.01 4.62 9   
7 2.08E+03 3.32 7.64 9   
23 6.68E+10 10.82 24.92 9   
47 5.12E+10 10.71 24.66 9   
0 5.28E+05 5.72 13.18 10 64 5/20/2014 
1 4.19E+03 3.62 8.34 10   
0 7.82E+05 5.89 13.57 11 16 2/13/2017 
2 1.22E+04 4.09 9.41 11   
4 1.84E+02 2.26 5.21 11   
6 1.64E+02 2.21 5.10 12   
8 5.00E+03 3.70 8.52 12   
24 2.86E+10 10.46 24.08 12   
4 6.00E+00 0.78 1.79 12 16 2/13/2017 
6 1.54E+02 2.19 5.04 12   
8 4.94E+03 3.69 8.51 12 16 2/13/2017 
24 3.19E+10 10.50 24.19 12   
0 8.00E+05 5.90 13.59 13 32 2/13/2017 
2 1.23E+03 3.09 7.11 13   
4 1.23E+02 2.09 4.81 13   
6 1.43E+02 2.16 4.96 13   
 
 
Table F.10: Isolate 22 Polymyxin B Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 3.14E+06 6.50 14.96 1 0 5/29/2014 
2 4.21E+09 9.62 22.16 1   
6 1.11E+11 11.05 25.43 1   
22 5.23E+10 10.72 24.68 1   
46 9.93E+10 11.00 25.32 1   
0 2.51E+06 6.40 14.74 2 0 8/23/2014 
2 5.15E+09 9.71 22.36 2   
6 1.06E+11 11.03 25.39 2   
22 6.69E+10 10.83 24.93 2   
46 2.45E+09 9.39 21.62 2   
0 6.23E+06 6.79 15.64 3 0 6/11/2015 
1 1.35E+08 8.13 18.72 3   
3 3.21E+10 10.51 24.19 3   
21 1.43E+11 11.16 25.69 3   
0 2.54E+02 2.40 5.54 4 0 6/11/2015 
1 1.58E+03 3.20 7.37 4   
21 9.18E+03 3.96 9.12 4   
0 1.34E+06 6.13 14.11 5 0.25 5/14/2014 
1 1.78E+03 3.25 7.48 5   
8 3.94E+03 3.60 8.28 5   
24 2.21E+11 11.34 26.12 5   
48 2.65E+10 10.42 24.00 5   
0 1.43E+06 6.16 14.17 6 1 5/14/2014 
8 2.25E+02 2.35 5.42 6   
24 5.95E+10 10.77 24.81 6   
48 1.04E+11 11.02 25.37 6   
0 5.01E+05 5.70 13.12 7 0.25 5/20/2014 
8 2.23E+03 3.35 7.71 7   
24 1.35E+11 11.13 25.63 7   
48 9.15E+10 10.96 25.24 7   
0 5.53E+05 5.74 13.22 8 1 5/20/2014 
8 8.18E+02 2.91 6.71 8   
24 1.08E+11 11.03 25.41 8   
48 1.23E+11 11.09 25.54 8   
0 6.68E+05 5.82 13.41 9 2 5/29/2014 
8 2.41E+03 3.38 7.79 9   
24 6.37E+10 10.80 24.88 9   
48 1.21E+11 11.08 25.52 9   
0 6.60E+05 5.82 13.40 10 4 5/29/2014 
8 2.86E+02 2.46 5.66 10   
 
 
Table F.10: Isolate 22 Polymyxin B Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
24 2.11E+10 10.32 23.77 10   
48 1.13E+11 11.05 25.45 10   
0 5.27E+05 5.72 13.17 11 0.06 6/10/2014 
1 9.81E+04 4.99 11.49 11   
0 5.64E+05 5.75 13.24 12 2 6/10/2014 
8 1.37E+03 3.14 7.22 12   
24 1.29E+11 11.11 25.58 12   
48 8.03E+10 10.90 25.11 12   
0 5.00E+05 5.70 13.12 13 4 6/10/2014 
8 5.31E+02 2.73 6.27 13   
24 2.38E+10 10.38 23.89 13   
48 1.52E+11 11.18 25.75 13   
0 4.56E+05 5.66 13.03 14 0.06 6/18/2014 
1 4.48E+03 3.65 8.41 14   
0 4.93E+05 5.69 13.11 15 0.125 6/18/2014 
1 3.07E+02 2.49 5.73 15   
4 2.25E+02 2.35 5.42 15   
8 3.00E+05 5.48 12.61 15   
24 1.29E+11 11.11 25.58 15   
48 6.66E+10 10.82 24.92 15   
0 6.91E+05 5.84 13.45 16 0.125 7/9/2014 
1 1.64E+02 2.21 5.10 16   
2 1.84E+02 2.26 5.21 16   
4 4.50E+02 2.65 6.11 16   
8 8.58E+04 4.93 11.36 16   
24 1.26E+11 11.10 25.56 16   
48 8.75E+10 10.94 25.19 16   
 
 
 
Table F.11: Isolate 24 Growth Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.77E+06 6.25 14.39 1 0 5/29/2014 
2 6.82E+07 7.83 18.04 1   
6 1.45E+10 10.16 23.40 1   
22 2.82E+10 10.45 24.06 1   
46 2.58E+10 10.41 23.97 1   
0 2.00E+06 6.30 14.51 2 0 8/23/2014 
2 8.08E+07 7.91 18.21 2   
6 2.24E+10 10.35 23.83 2   
22 2.60E+10 10.41 23.98 2   
46 3.99E+10 10.60 24.41 2   
0 2.46E+06 6.39 14.72 3 0 6/11/2015 
1 8.59E+06 6.93 15.97 3   
2 2.48E+08 8.39 19.33 3   
4 5.24E+10 10.72 24.68 3   
22 3.44E+11 11.54 26.56 3   
0 5.70E+01 1.76 4.04 4 0 6/11/2015 
1 5.08E+02 2.71 6.23 4   
2 1.01E+03 3.00 6.92 4   
4 4.98E+03 3.70 8.51 4   
22 3.34E+04 4.52 10.42 4   
2 3.60E+01 1.56 3.58 5 0 6/11/2015 
4 2.00E+02 2.30 5.30 5   
22 3.77E+02 2.58 5.93 5   
 
 
Table F.12: Isolate 24 Meropenem Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.77E+06 6.25 14.39 1 0 5/29/2014 
2 6.82E+07 7.83 18.04 1   
6 1.45E+10 10.16 23.40 1   
22 2.82E+10 10.45 24.06 1   
46 2.58E+10 10.41 23.97 1   
0 2.00E+06 6.30 14.51 2 0 8/23/2014 
2 8.08E+07 7.91 18.21 2   
6 2.24E+10 10.35 23.83 2   
22 2.60E+10 10.41 23.98 2   
46 3.99E+10 10.60 24.41 2   
0 2.46E+06 6.39 14.72 3 0 6/11/2015 
1 8.59E+06 6.93 15.97 3   
2 2.48E+08 8.39 19.33 3   
4 5.24E+10 10.72 24.68 3   
22 3.44E+11 11.54 26.56 3   
0 4.79E+05 5.68 13.08 4 4 5/20/2014 
2 1.71E+04 4.23 9.75 4   
0 5.68E+05 5.75 13.25 5 16 5/20/2014 
1 1.17E+05 5.07 11.67 5   
3 4.03E+03 3.61 8.30 5   
0 4.36E+05 5.64 12.99 6 64 5/20/2014 
1 9.40E+04 4.97 11.45 6   
2 1.05E+04 4.02 9.26 6   
4 2.17E+03 3.34 7.68 6   
0 4.84E+05 5.68 13.09 7 4 6/10/2014 
2 1.08E+04 4.03 9.29 7   
0 6.34E+05 5.80 13.36 8 16 6/10/2014 
1 1.17E+05 5.07 11.67 8   
3 2.15E+03 3.33 7.67 8   
0 5.40E+05 5.73 13.20 9 64 6/10/2014 
1 3.19E+05 5.50 12.67 9   
2 8.73E+03 3.94 9.07 9   
4 8.79E+02 2.94 6.78 9   
0 5.29E+05 5.72 13.18 10 64 2/13/2017 
2 1.28E+04 4.11 9.46 10   
4 3.68E+02 2.57 5.91 10   
0 5.31E+05 5.73 13.18 11 128 2/13/2017 
2 3.43E+03 3.54 8.14 11   
4 2.45E+02 2.39 5.50 11   
 
 
Table F.13: Isolate 24 Polymyxin B Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.77E+06 6.25 14.39 1 0 5/29/2014 
2 6.82E+07 7.83 18.04 1   
6 1.45E+10 10.16 23.40 1   
22 2.82E+10 10.45 24.06 1   
46 2.58E+10 10.41 23.97 1   
0 2.00E+06 6.30 14.51 2 0 8/23/2014 
2 8.08E+07 7.91 18.21 2   
6 2.24E+10 10.35 23.83 2   
22 2.60E+10 10.41 23.98 2   
46 3.99E+10 10.60 24.41 2   
0 2.46E+06 6.39 14.72 3 0 6/11/2015 
1 8.59E+06 6.93 15.97 3   
2 2.48E+08 8.39 19.33 3   
4 5.24E+10 10.72 24.68 3   
22 3.44E+11 11.54 26.56 3   
0 4.26E+05 5.63 12.96 4 0.25 5/20/2014 
1 9.69E+03 3.99 9.18 4   
0 5.87E+05 5.77 13.28 5 0.0625 6/10/2014 
1 1.10E+05 5.04 11.61 5   
0 6.72E+05 5.83 13.42 6 0.25 6/10/2014 
1 4.69E+04 4.67 10.76 6   
2 2.04E+02 2.31 5.32 6   
0 5.81E+05 5.76 13.27 7 1 6/10/2014 
1 4.01E+03 3.60 8.30 7   
0 3.37E+05 5.53 12.73 8 0.0625 6/18/2014 
1 2.78E+04 4.44 10.23 8   
0 7.51E+05 5.88 13.53 9 0.125 7/9/2014 
1 3.70E+03 3.57 8.22 9   
 
 
Table F.14: Isolate 24 Meropenem Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.77E+06 6.25 14.39 1 0 5/29/2014 
2 6.82E+07 7.83 18.04 1   
6 1.45E+10 10.16 23.40 1   
22 2.82E+10 10.45 24.06 1   
46 2.58E+10 10.41 23.97 1   
0 2.00E+06 6.30 14.51 2 0 8/23/2014 
2 8.08E+07 7.91 18.21 2   
6 2.24E+10 10.35 23.83 2   
22 2.60E+10 10.41 23.98 2   
46 3.99E+10 10.60 24.41 2   
0 2.46E+06 6.39 14.72 3 0 6/11/2015 
1 8.59E+06 6.93 15.97 3   
2 2.48E+08 8.39 19.33 3   
4 5.24E+10 10.72 24.68 3   
22 3.44E+11 11.54 26.56 3   
0 5.70E+01 1.76 4.04 4 0 6/11/2015 
1 5.08E+02 2.71 6.23 4   
2 1.01E+03 3.00 6.92 4   
4 4.98E+03 3.70 8.51 4   
22 3.34E+04 4.52 10.42 4   
0 4.79E+05 5.68 13.08 5 4 5/20/2014 
2 1.71E+04 4.23 9.75 5   
6 2.07E+06 6.32 14.54 5   
22 3.95E+10 10.60 24.40 5   
46 5.48E+10 10.74 24.73 5   
0 5.68E+05 5.75 13.25 6 16 5/20/2014 
1 1.17E+05 5.07 11.67 6   
3 4.03E+03 3.61 8.30 6   
7 9.81E+04 4.99 11.49 6   
23 4.13E+10 10.62 24.44 6   
47 1.92E+10 10.28 23.68 6   
0 4.36E+05 5.64 12.99 7 64 5/20/2014 
1 9.40E+04 4.97 11.45 7   
2 1.05E+04 4.02 9.26 7   
4 2.17E+03 3.34 7.68 7   
8 1.96E+03 3.29 7.58 7   
24 2.36E+11 11.37 26.19 7   
48 8.95E+10 10.95 25.22 7   
0 4.84E+05 5.68 13.09 8 4 6/10/2014 
2 1.08E+04 4.03 9.29 8   
 
 
Table F.14: Isolate 24 Meropenem Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
6 1.37E+03 3.14 7.22 8   
22 2.79E+10 10.45 24.05 8   
46 1.18E+11 11.07 25.49 8   
0 6.34E+05 5.80 13.36 9 16 6/10/2014 
1 1.17E+05 5.07 11.67 9   
3 2.15E+03 3.33 7.67 9   
7 6.18E+03 3.79 8.73 9   
23 3.10E+10 10.49 24.16 9   
47 1.11E+11 11.05 25.43 9   
0 5.40E+05 5.73 13.20 10 64 6/10/2014 
1 3.19E+05 5.50 12.67 10   
2 8.73E+03 3.94 9.07 10   
4 8.79E+02 2.94 6.78 10   
8 1.29E+03 3.11 7.16 10   
24 8.83E+10 10.95 25.20 10   
48 9.27E+10 10.97 25.25 10   
0 5.29E+05 5.72 13.18 11 64 2/13/2017 
2 1.28E+04 4.11 9.46 11   
4 3.68E+02 2.57 5.91 11   
6 2.66E+02 2.42 5.58 11   
8 2.45E+02 2.39 5.50 11   
24 1.58E+10 10.20 23.48 11   
0 5.31E+05 5.73 13.18 12 128 2/13/2017 
2 3.43E+03 3.54 8.14 12   
4 2.45E+02 2.39 5.50 12   
6 1.23E+02 2.09 4.81 12   
8 4.09E+01 1.61 3.71 13 64 2/13/2017 
24 1.50E+10 10.18 23.43 13   
6 3.00E+00 0.48 1.10 13 64 2/13/2017 
8 2.70E+01 1.43 3.30 13   
 
 
Table F.15: Isolate 24 Polymyxin B Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.77E+06 6.25 14.39 1 0 5/29/2014 
2 6.82E+07 7.83 18.04 1   
6 1.45E+10 10.16 23.40 1   
22 2.82E+10 10.45 24.06 1   
46 2.58E+10 10.41 23.97 1   
0 2.00E+06 6.30 14.51 2 0 8/23/2014 
2 8.08E+07 7.91 18.21 2   
6 2.24E+10 10.35 23.83 2   
22 2.60E+10 10.41 23.98 2   
46 3.99E+10 10.60 24.41 2   
0 2.46E+06 6.39 14.72 3 0 6/11/2015 
1 8.59E+06 6.93 15.97 3   
2 2.48E+08 8.39 19.33 3   
4 5.24E+10 10.72 24.68 3   
22 3.44E+11 11.54 26.56 3   
0 1.00E+00 0.00 0.00 4 0 6/11/2015 
2 3.60E+01 1.56 3.58 4   
4 2.00E+02 2.30 5.30 4   
22 3.77E+02 2.58 5.93 4   
0 4.26E+05 5.63 12.96 5 0.25 5/20/2014 
1 9.69E+03 3.99 9.18 5   
8 4.09E+02 2.61 6.01 5   
24 1.12E+10 10.05 23.14 5   
48 7.88E+10 10.90 25.09 5   
0 4.85E+05 5.69 13.09 6 1 5/20/2014 
8 3.47E+02 2.54 5.85 6   
24 4.71E+09 9.67 22.27 6   
48 7.02E+10 10.85 24.97 6   
0 6.33E+05 5.80 13.36 7 2 5/29/2014 
24 1.79E+06 6.25 14.40 7   
48 7.33E+10 10.87 25.02 7   
0 7.29E+05 5.86 13.50 8 4 5/29/2014 
24 2.08E+06 6.32 14.55 8   
48 2.53E+09 9.40 21.65 8   
0 5.87E+05 5.77 13.28 9 0.0625 6/10/2014 
1 1.10E+05 5.04 11.61 9   
2 4.91E+04 4.69 10.80 9   
0 6.26E+05 5.80 13.35 10 2 6/10/2014 
8 3.88E+02 2.59 5.96 10   
24 4.70E+08 8.67 19.97 10   
 
 
Table F.15: Isolate 24 Polymyxin B Monotherapy Model Input Data 
382 
 
Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
48 1.10E+11 11.04 25.42 10   
0 5.66E+05 5.75 13.25 11 4 6/10/2014 
8 1.23E+02 2.09 4.81 11   
24 7.23E+06 6.86 15.79 11   
48 6.87E+10 10.84 24.95 11   
0 6.72E+05 5.83 13.42 12 0.25 6/10/2014 
1 4.69E+04 4.67 10.76 12   
2 2.04E+02 2.31 5.32 12   
8 1.19E+03 3.08 7.08 12   
24 9.95E+09 10.00 23.02 12   
48 4.51E+10 10.65 24.53 12   
0 5.81E+05 5.76 13.27 13 1 6/10/2014 
1 4.01E+03 3.60 8.30 13   
8 7.77E+02 2.89 6.66 13   
24 2.06E+10 10.31 23.75 13   
48 6.99E+10 10.84 24.97 13   
0 3.37E+05 5.53 12.73 14 0.0625 6/18/2014 
1 2.78E+04 4.44 10.23 14   
2 1.19E+03 3.08 7.08 14   
0 3.67E+05 5.56 12.81 15 0.125 6/18/2014 
4 1.23E+02 2.09 4.81 15   
8 1.83E+04 4.26 9.81 15   
24 4.96E+10 10.70 24.63 15   
48 1.42E+11 11.15 25.68 15   
0 7.51E+05 5.88 13.53 16 0.125 7/9/2014 
1 3.70E+03 3.57 8.22 16   
2 9.40E+02 2.97 6.85 16   
4 5.33E+03 3.73 8.58 16   
8 2.22E+05 5.35 12.31 16   
24 8.15E+10 10.91 25.12 16   
48 1.39E+11 11.14 25.66 16   
0 5.37E+05 5.73 13.19 17 2 8/23/2014 
8 9.40E+02 2.97 6.85 17   
24 4.95E+07 7.69 17.72 17   
48 1.02E+10 10.01 23.05 17   
0 5.04E+05 5.70 13.13 18 4 8/23/2014 
8 1.23E+02 2.09 4.81 18   
24 6.66E+06 6.82 15.71 18   
48 2.12E+10 10.33 23.78 18   
 
 
 
Table F.16: Isolate 44 Growth Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.63E+06 6.21 14.31 1 0 1/26/2014 
2 9.31E+07 7.97 18.35 1   
6 7.23E+08 8.86 20.40 1   
22 1.04E+11 11.02 25.37 1   
46 8.31E+11 11.92 27.45 1   
0 2.48E+06 6.39 14.72 2 0 2/15/2014 
2 1.80E+09 9.26 21.31 2   
6 5.13E+10 10.71 24.66 2   
22 1.04E+11 11.02 25.37 2   
46 1.19E+12 12.08 27.81 2   
0 4.29E+06 6.63 15.27 3 0 3/30/2014 
2 4.37E+09 9.64 22.20 3   
6 3.05E+10 10.48 24.14 3   
22 3.11E+11 11.49 26.46 3   
46 2.01E+11 11.30 26.02 3   
0 4.90E+06 6.69 15.40 4 0 6/11/2015 
1 1.82E+07 7.26 16.72 4   
2 4.37E+08 8.64 19.89 4   
4 4.79E+10 10.68 24.59 4   
22 5.75E+11 11.76 27.08 4   
0 6.92E+04 4.84 11.14 5 0 6/11/2015 
1 2.57E+05 5.41 12.46 5   
2 7.41E+06 6.87 15.82 5   
4 4.27E+08 8.63 19.87 5   
22 4.47E+08 8.65 19.92 5   
0 2.51E+01 1.40 3.22 6 0 6/11/2015 
1 8.51E+01 1.93 4.44 6   
2 4.07E+02 2.61 6.01 6   
4 7.59E+02 2.88 6.63 6   
22 1.07E+04 4.03 9.28 6   
 
 
Table F.17: Isolate 44 Meropenem Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.63E+06 6.21 14.31 1 0 1/26/2014 
2 9.31E+07 7.97 18.35 1   
6 7.23E+08 8.86 20.40 1   
22 1.04E+11 11.02 25.37 1   
46 8.31E+11 11.92 27.45 1   
0 2.48E+06 6.39 14.72 2 0 2/15/2014 
2 1.80E+09 9.26 21.31 2   
6 5.13E+10 10.71 24.66 2   
22 1.04E+11 11.02 25.37 2   
46 1.19E+12 12.08 27.81 2   
0 4.29E+06 6.63 15.27 3 0 3/30/2014 
2 4.37E+09 9.64 22.20 3   
6 3.05E+10 10.48 24.14 3   
22 3.11E+11 11.49 26.46 3   
46 2.01E+11 11.30 26.02 3   
0 4.90E+06 6.69 15.40 4 0 6/11/2015 
1 1.82E+07 7.26 16.72 4   
2 4.37E+08 8.64 19.89 4   
4 4.79E+10 10.68 24.59 4   
22 5.75E+11 11.76 27.08 4   
0 6.80E+05 5.83 13.43 5 4 1/26/2014 
1 1.97E+06 6.29 14.49 5   
3 5.56E+07 7.75 17.83 5   
0 6.97E+05 5.84 13.45 6 16 1/26/2014 
1 1.73E+06 6.24 14.36 6   
0 9.32E+05 5.97 13.74 7 64 1/26/2014 
1 6.86E+05 5.84 13.44 7   
3 1.88E+05 5.27 12.14 7   
0 1.34E+06 6.13 14.11 8 4 5/14/2014 
1 4.97E+06 6.70 15.42 8   
3 3.66E+09 9.56 22.02 8   
0 1.38E+06 6.14 14.14 9 64 5/14/2014 
1 3.05E+05 5.48 12.63 9   
0 7.32E+05 5.86 13.50 10 16 5/20/2014 
1 1.87E+06 6.27 14.44 10   
3 2.14E+07 7.33 16.88 10   
1 1.86E+05 5.27 12.13 11 64 2/13/2017 
0 8.30E+05 5.92 13.63 12 128 2/13/2017 
2 2.64E+04 4.42 10.18 12   
 
 
Table F.18: Isolate 44 Polymyxin B Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.63E+06 6.21 14.31 1 0 1/26/2014 
2 9.31E+07 7.97 18.35 1   
6 7.23E+08 8.86 20.40 1   
22 1.04E+11 11.02 25.37 1   
46 8.31E+11 11.92 27.45 1   
0 2.48E+06 6.39 14.72 2 0 2/15/2014 
2 1.80E+09 9.26 21.31 2   
6 5.13E+10 10.71 24.66 2   
22 1.04E+11 11.02 25.37 2   
46 1.19E+12 12.08 27.81 2   
0 4.29E+06 6.63 15.27 3 0 3/30/2014 
2 4.37E+09 9.64 22.20 3   
6 3.05E+10 10.48 24.14 3   
22 3.11E+11 11.49 26.46 3   
46 2.01E+11 11.30 26.02 3   
0 4.90E+06 6.69 15.40 4 0 6/11/2015 
1 1.82E+07 7.26 16.72 4   
2 4.37E+08 8.64 19.89 4   
4 4.79E+10 10.68 24.59 4   
22 5.75E+11 11.76 27.08 4   
0 6.03E+05 5.78 13.31 5 0.0625 6/10/2014 
1 6.92E+04 4.84 11.14 5   
0 5.25E+05 5.72 13.17 6 0.0625 6/18/2014 
1 7.08E+02 2.85 6.56 6   
0 5.37E+05 5.73 13.19 7 0.125 6/18/2014 
1 1.62E+02 2.21 5.09 7   
0 7.08E+05 5.85 13.47 8 0.125 7/9/2014 
1 2.00E+03 3.30 7.60 8   
0 2.69E+05 5.43 12.50 9 0.25 3/30/2014 
0 8.51E+05 5.93 13.65 10 0.25 4/19/2014 
1 5.75E+02 2.76 6.36 10   
0 8.91E+05 5.95 13.70 11 0.25 5/14/2014 
1 1.74E+03 3.24 7.46 11   
0 4.47E+05 5.65 13.01 12 1 3/30/2014 
0 8.13E+05 5.91 13.61 13 1 4/19/2014 
0 9.77E+05 5.99 13.79 14 1 5/14/2014 
1 7.08E+02 2.85 6.56 14   
0 6.46E+05 5.81 13.38 15 2 5/29/2014 
0 6.17E+05 5.79 13.33 16 2 6/10/2014 
0 4.79E+05 5.68 13.08 17 2 8/23/2014 
 
 
Table F.18: Isolate 44 Polymyxin B Initial Killing Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 5.62E+05 5.75 13.24 18 4 5/20/2014 
0 6.46E+05 5.81 13.38 19 4 5/29/2014 
0 5.89E+05 5.77 13.29 20 4 6/10/2014 
0 7.76E+05 5.89 13.56 21 4 7/9/2014 
1 2.88E+02 2.46 5.66 21   
0 1.10E+06 6.04 13.91 22 4 8/23/2014 
0 9.55E+05 5.98 13.77 23 4 2/13/2017 
1 1.95E+02 2.29 5.27 23   
0 1.02E+06 6.01 13.84 24 8 2/13/2017 
 
 
Table F.19: Isolate 44 Meropenem Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.63E+06 6.21 14.31 1 0 1/26/2014 
2 9.31E+07 7.97 18.35 1   
22 1.04E+11 11.02 25.37 1   
46 8.31E+11 11.92 27.45 1   
0 2.48E+06 6.39 14.72 2 0 2/15/2014 
2 1.80E+09 9.26 21.31 2   
6 5.13E+10 10.71 24.66 2   
22 1.04E+11 11.02 25.37 2   
46 1.19E+12 12.08 27.81 2   
0 4.29E+06 6.63 15.27 3 0 3/30/2014 
2 4.37E+09 9.64 22.20 3   
6 3.05E+10 10.48 24.14 3   
22 3.11E+11 11.49 26.46 3   
46 2.01E+11 11.30 26.02 3   
0 4.90E+06 6.69 15.40 4 0 6/11/2015 
1 1.82E+07 7.26 16.72 4   
2 4.37E+08 8.64 19.89 4   
4 4.79E+10 10.68 24.59 4   
22 5.75E+11 11.76 27.08 4   
0 2.58E+05 5.41 12.46 5 0 6/11/2015 
1 7.36E+06 6.87 15.81 5   
0 6.80E+05 5.83 13.43 6 4 1/26/2014 
1 1.97E+06 6.29 14.49 6   
23 2.71E+10 10.43 24.02 6   
47 1.89E+10 10.28 23.66 6   
0 6.97E+05 5.84 13.45 7 16 1/26/2014 
1 1.73E+06 6.24 14.36 7   
23 1.90E+10 10.28 23.67 7   
47 1.22E+10 10.09 23.22 7   
0 9.32E+05 5.97 13.74 8 64 1/26/2014 
1 6.86E+05 5.84 13.44 8   
3 1.88E+05 5.27 12.14 8   
7 3.63E+05 5.56 12.80 8   
47 2.06E+10 10.31 23.75 8   
0 1.34E+06 6.13 14.11 9 4 5/14/2014 
1 4.97E+06 6.70 15.42 9   
3 3.66E+09 9.56 22.02 9   
7 9.15E+10 10.96 25.24 9   
23 1.21E+11 11.08 25.52 9   
47 2.26E+10 10.35 23.84 9   
 
 
Table F.19: Isolate 44 Meropenem Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.38E+06 6.14 14.14 10 64 5/14/2014 
1 3.05E+05 5.48 12.63 10   
3 4.01E+05 5.60 12.90 10   
7 6.40E+05 5.81 13.37 10   
23 5.77E+10 10.76 24.78 10   
47 1.01E+10 10.00 23.04 10   
0 7.32E+05 5.86 13.50 11 16 5/20/2014 
1 1.87E+06 6.27 14.44 11   
3 2.14E+07 7.33 16.88 11   
7 4.04E+10 10.61 24.42 11   
23 5.93E+10 10.77 24.81 11   
47 1.69E+10 10.23 23.55 11   
0 8.75E+05 5.94 13.68 12 64 2/13/2017 
2 1.86E+05 5.27 12.13 12   
4 1.27E+05 5.10 11.75 12   
6 1.25E+05 5.10 11.74 12   
8 2.06E+05 5.31 12.24 12   
24 9.93E+10 11.00 25.32 12 128 2/13/2017 
0 8.30E+05 5.92 13.63 13   
2 2.64E+04 4.42 10.18 13   
4 6.48E+03 3.81 8.78 13   
6 3.92E+03 3.59 8.27 13   
24 1.69E+10 10.23 23.55 13   
 
 
Table F.20: Isolate 44 Polymyxin B Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 1.63E+06 6.21 14.31 1 0 1/26/2014 
2 9.31E+07 7.97 18.35 1   
6 7.23E+08 8.86 20.40 1   
22 1.04E+11 11.02 25.37 1   
46 8.31E+11 11.92 27.45 1   
0 2.48E+06 6.39 14.72 2 0 2/15/2014 
2 1.80E+09 9.26 21.31 2   
6 5.13E+10 10.71 24.66 2   
22 1.04E+11 11.02 25.37 2   
46 1.19E+12 12.08 27.81 2   
0 4.28E+06 6.63 15.27 3 0 3/30/2014 
2 4.37E+09 9.64 22.20 3   
6 3.05E+10 10.48 24.14 3   
22 3.11E+11 11.49 26.46 3   
46 2.00E+11 11.30 26.02 3   
0 4.93E+06 6.69 15.41 4 0 6/11/2015 
1 1.81E+07 7.26 16.71 4   
2 4.32E+08 8.64 19.88 4   
4 4.76E+10 10.68 24.59 4   
22 5.72E+11 11.76 27.07 4   
0 2.50E+01 1.40 3.22 5 0 6/11/2015 
1 8.60E+01 1.93 4.45 5   
2 4.09E+02 2.61 6.01 5   
4 7.56E+02 2.88 6.63 5   
0 6.04E+05 5.78 13.31 6 0.0625 6/10/2014 
1 6.95E+04 4.84 11.15 6   
0 5.29E+05 5.72 13.18 7 0.0625 6/18/2014 
1 7.15E+02 2.85 6.57 7   
0 5.42E+05 5.73 13.20 8 0.125 6/18/2014 
1 1.64E+02 2.21 5.10 8   
2 2.86E+02 2.46 5.66 8   
4 1.76E+03 3.25 7.47 8   
8 6.73E+04 4.83 11.12 8   
24 1.61E+11 11.21 25.80 8   
48 4.92E+10 10.69 24.62 8   
0 7.16E+05 5.85 13.48 9 0.125 7/9/2014 
1 2.00E+03 3.30 7.60 9   
4 2.82E+03 3.45 7.94 9   
8 5.52E+04 4.74 10.92 9   
24 7.37E+10 10.87 25.02 9   
 
 
Table F.20: Isolate 44 Polymyxin B Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
48 1.41E+11 11.15 25.67 9   
0 2.68E+05 5.43 12.50 10 0.25 3/30/2014 
8 1.00E+03 3.00 6.91 10   
24 4.30E+10 10.63 24.48 10   
48 2.43E+10 10.39 23.91 10   
0 8.53E+05 5.93 13.66 11 0.25 4/19/2014 
1 5.72E+02 2.76 6.35 11   
4 1.23E+02 2.09 4.81 11   
8 9.81E+02 2.99 6.89 11   
24 1.05E+10 10.02 23.07 11   
48 9.97E+11 12.00 27.63 11   
0 8.93E+05 5.95 13.70 12 0.25 5/14/2014 
1 1.74E+03 3.24 7.46 12   
4 1.64E+02 2.21 5.10 12   
8 2.76E+03 3.44 7.92 12   
24 1.76E+11 11.25 25.89 12   
48 3.44E+10 10.54 24.26 12   
0 4.48E+05 5.65 13.01 13 1 3/30/2014 
8 5.11E+02 2.71 6.24 13   
24 8.29E+09 9.92 22.84 13   
48 8.94E+10 10.95 25.22 13   
0 8.13E+05 5.91 13.61 14 1 4/19/2014 
4 2.25E+02 2.35 5.42 14   
8 7.15E+02 2.85 6.57 14   
24 8.23E+09 9.92 22.83 14   
48 3.09E+11 11.49 26.46 14   
0 9.82E+05 5.99 13.80 15 1 5/14/2014 
1 7.15E+02 2.85 6.57 15   
4 1.84E+02 2.26 5.21 15   
8 2.55E+03 3.41 7.84 15   
24 1.11E+11 11.05 25.43 15   
48 1.67E+10 10.22 23.54 15   
0 6.47E+05 5.81 13.38 16 2 5/29/2014 
8 1.64E+02 2.21 5.10 16   
24 2.27E+11 11.36 26.15 16   
48 3.74E+10 10.57 24.34 16   
0 6.18E+05 5.79 13.33 17 2 6/10/2014 
2 2.04E+02 2.31 5.32 17   
24 1.21E+06 6.08 14.01 17   
48 1.27E+10 10.10 23.26 17   
 
 
Table F.20: Isolate 44 Polymyxin B Monotherapy Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 4.75E+05 5.68 13.07 18 2 8/23/2014 
24 5.38E+04 4.73 10.89 18   
48 2.98E+09 9.47 21.82 18   
0 5.56E+05 5.75 13.23 19 4 5/20/2014 
0 6.53E+05 5.81 13.39 20 4 5/29/2014 
8 5.72E+02 2.76 6.35 20   
24 2.30E+10 10.36 23.86 20   
48 3.77E+10 10.58 24.35 20   
0 5.87E+05 5.77 13.28 21 4 6/10/2014 
24 6.52E+05 5.81 13.39 21   
48 4.00E+10 10.60 24.41 21   
0 7.75E+05 5.89 13.56 22 4 7/9/2014 
1 2.86E+02 2.46 5.66 22   
8 1.02E+02 2.01 4.62 22   
24 2.13E+07 7.33 16.87 22   
48 3.17E+07 7.50 17.27 22   
0 1.10E+06 6.04 13.91 23 4 8/23/2014 
24 2.68E+07 7.43 17.10 23   
48 5.87E+10 10.77 24.80 23   
0 9.48E+05 5.98 13.76 24 4 2/13/2017 
1 1.95E+02 2.29 5.27 24   
1 7.10E+01 1.85 4.26 25 4 2/13/2017 
2 8.20E+01 1.91 4.41 25   
4 2.10E+02 2.32 5.35 25   
8 1.12E+03 3.05 7.02 25   
8 6.54E+02 2.82 6.48 25   
8 9.81E+02 2.99 6.89 25   
24 1.31E+10 10.12 23.30 25   
24 7.44E+10 10.87 25.03 25   
 
 
 
Table F.21: Meropenem Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 2.63E+06 6.42 14.78 1 0 1/26/2014 
2 5.07E+08 8.71 20.04 1   
22 4.43E+10 10.65 24.51 1   
46 4.43E+11 11.65 26.82 1   
0 4.44E+06 6.65 15.31 2 0 2/15/2014 
2 1.36E+10 10.13 23.33 2   
6 3.42E+10 10.53 24.26 2   
22 4.12E+11 11.61 26.74 2   
46 3.93E+12 12.59 29.00 2   
0 1.13E+07 7.05 16.24 3 0 3/30/2014 
2 3.25E+10 10.51 24.20 3   
6 1.06E+11 11.03 25.39 3   
22 5.43E+11 11.73 27.02 3   
46 9.31E+10 10.97 25.26 3   
0 1.14E+07 7.06 16.25 4 0 6/11/2015 
1 2.85E+08 8.45 19.47 4   
3 5.11E+10 10.71 24.66 4   
21 5.86E+11 11.77 27.10 4   
0 3.71E+02 2.57 5.92 5 0 6/11/2015 
1 5.09E+03 3.71 8.54 5   
3 2.98E+05 5.47 12.60 5   
0 8.06E+05 5.91 13.60 6 4 1/26/2014 
1 5.94E+05 5.77 13.29 6   
2 2.26E+04 4.35 10.03 6   
4 1.21E+03 3.08 7.10 6   
8 5.74E+03 3.76 8.65 6   
24 1.06E+09 9.03 20.78 6   
48 1.71E+10 10.23 23.56 6   
0 7.48E+05 5.87 13.53 7 16 1/26/2014 
1 8.31E+04 4.92 11.33 7   
2 2.19E+03 3.34 7.69 7   
4 4.29E+02 2.63 6.06 7   
0 6.54E+05 5.82 13.39 8 64 1/26/2014 
1 3.39E+04 4.53 10.43 8   
2 3.47E+02 2.54 5.85 8   
0 1.04E+06 6.02 13.85 9 4 7/9/2014 
1 5.86E+05 5.77 13.28 9   
2 8.73E+03 3.94 9.07 9   
 
 
Table F.21: Meropenem Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
4 9.61E+02 2.98 6.87 9   
8 5.72E+04 4.76 10.95 9   
24 8.39E+10 10.92 25.15 9   
48 5.76E+10 10.76 24.78 9   
0 4.85E+05 5.69 13.09 10 16 7/9/2014 
1 5.25E+04 4.72 10.87 10   
4 1.43E+02 2.16 4.96 10   
0 7.54E+05 5.88 13.53 11 64 7/9/2014 
1 2.98E+04 4.47 10.30 11   
2 2.25E+02 2.35 5.42 11   
0 7.59E+05 5.88 13.54 12 8 2/13/2017 
2 2.08E+03 3.32 7.64 12   
4 7.77E+02 2.89 6.66 12   
6 3.47E+02 2.54 5.85 12   
24 2.04E+02 2.31 5.32 12   
0 1.14E+06 6.06 13.95 13 16 2/13/2017 
2 1.27E+03 3.10 7.15 13   
4 2.25E+02 2.35 5.42 13   
6 2.04E+02 2.31 5.32 13   
0 3.14E+06 6.50 14.96 14 0 5/29/2014 
2 4.21E+09 9.62 22.16 14   
6 1.11E+11 11.05 25.43 14   
22 5.23E+10 10.72 24.68 14   
46 9.93E+10 11.00 25.32 14   
0 2.51E+06 6.40 14.74 15 0 8/23/2014 
2 5.15E+09 9.71 22.36 15   
6 1.06E+11 11.03 25.39 15   
22 6.69E+10 10.83 24.93 15   
46 2.45E+09 9.39 21.62 15   
0 6.23E+06 6.79 15.64 16 0 6/11/2015 
1 1.35E+08 8.13 18.72 16   
3 3.21E+10 10.51 24.19 16   
21 1.43E+11 11.16 25.69 16   
0 7.93E+02 2.90 6.68 17 0 6/11/2015 
1 8.75E+03 3.94 9.08 17   
3 9.69E+04 4.99 11.48 17   
0 1.70E+06 6.23 14.35 18 4 5/14/2014 
1 4.70E+04 4.67 10.76 18   
 
 
Table F.21: Meropenem Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
3 1.68E+03 3.23 7.43 18   
7 1.37E+05 5.14 11.83 18   
23 1.19E+11 11.08 25.50 18   
47 7.98E+10 10.90 25.10 18   
0 1.26E+06 6.10 14.05 19 16 5/14/2014 
1 2.43E+04 4.39 10.10 19   
3 2.02E+03 3.31 7.61 19   
7 4.09E+04 4.61 10.62 19   
23 9.27E+10 10.97 25.25 19   
47 4.13E+09 9.62 22.14 19   
0 9.34E+05 5.97 13.75 20 64 5/14/2014 
1 1.43E+04 4.16 9.57 20   
2 2.86E+02 2.46 5.66 20   
0 6.11E+05 5.79 13.32 21 4 5/20/2014 
1 3.78E+03 3.58 8.24 21   
3 2.86E+02 2.46 5.66 21   
7 5.23E+04 4.72 10.86 21   
23 1.03E+11 11.01 25.36 21   
47 1.01E+11 11.00 25.34 21   
0 3.52E+05 5.55 12.77 22 16 5/20/2014 
1 6.70E+03 3.83 8.81 22   
3 1.02E+02 2.01 4.62 22   
7 2.08E+03 3.32 7.64 22   
23 6.68E+10 10.82 24.92 22   
47 5.12E+10 10.71 24.66 22   
0 5.28E+05 5.72 13.18 23 64 5/20/2014 
1 4.19E+03 3.62 8.34 23   
0 7.82E+05 5.89 13.57 24 16 2/13/2017 
2 1.22E+04 4.09 9.41 24   
4 1.84E+02 2.26 5.21 24   
6 1.64E+02 2.21 5.10 25   
8 5.00E+03 3.70 8.52 25   
24 2.86E+10 10.46 24.08 25   
4 6.00E+00 0.78 1.79 25 16 2/13/2017 
6 1.54E+02 2.19 5.04 25   
8 4.94E+03 3.69 8.51 25 16 2/13/2017 
24 3.19E+10 10.50 24.19 25   
0 8.00E+05 5.90 13.59 26 32 2/13/2017 
 
 
Table F.21: Meropenem Composite Model Input Data 
395 
 
Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
2 1.23E+03 3.09 7.11 26   
4 1.23E+02 2.09 4.81 26   
6 1.43E+02 2.16 4.96 26   
0 1.77E+06 6.25 14.39 27 0 5/29/2014 
2 6.82E+07 7.83 18.04 27   
6 1.45E+10 10.16 23.40 27   
22 2.82E+10 10.45 24.06 27   
46 2.58E+10 10.41 23.97 27   
0 2.00E+06 6.30 14.51 28 0 8/23/2014 
2 8.08E+07 7.91 18.21 28   
6 2.24E+10 10.35 23.83 28   
22 2.60E+10 10.41 23.98 28   
46 3.99E+10 10.60 24.41 28   
0 2.46E+06 6.39 14.72 29 0 6/11/2015 
1 8.59E+06 6.93 15.97 29   
2 2.48E+08 8.39 19.33 29   
4 5.24E+10 10.72 24.68 29   
22 3.44E+11 11.54 26.56 29   
0 5.70E+01 1.76 4.04 30 0 6/11/2015 
1 5.08E+02 2.71 6.23 30   
2 1.01E+03 3.00 6.92 30   
4 4.98E+03 3.70 8.51 30   
22 3.34E+04 4.52 10.42 30   
0 4.79E+05 5.68 13.08 31 4 5/20/2014 
2 1.71E+04 4.23 9.75 31   
6 2.07E+06 6.32 14.54 31   
22 3.95E+10 10.60 24.40 31   
46 5.48E+10 10.74 24.73 31   
0 5.68E+05 5.75 13.25 32 16 5/20/2014 
1 1.17E+05 5.07 11.67 32   
3 4.03E+03 3.61 8.30 32   
7 9.81E+04 4.99 11.49 32   
23 4.13E+10 10.62 24.44 32   
47 1.92E+10 10.28 23.68 32   
0 4.36E+05 5.64 12.99 33 64 5/20/2014 
1 9.40E+04 4.97 11.45 33   
2 1.05E+04 4.02 9.26 33   
4 2.17E+03 3.34 7.68 33   
 
 
Table F.21: Meropenem Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
8 1.96E+03 3.29 7.58 33   
24 2.36E+11 11.37 26.19 33   
48 8.95E+10 10.95 25.22 33   
0 4.84E+05 5.68 13.09 34 4 6/10/2014 
2 1.08E+04 4.03 9.29 34   
6 1.37E+03 3.14 7.22 34   
22 2.79E+10 10.45 24.05 34   
46 1.18E+11 11.07 25.49 34   
0 6.34E+05 5.80 13.36 35 16 6/10/2014 
1 1.17E+05 5.07 11.67 35   
3 2.15E+03 3.33 7.67 35   
7 6.18E+03 3.79 8.73 35   
23 3.10E+10 10.49 24.16 35   
47 1.11E+11 11.05 25.43 35   
0 5.40E+05 5.73 13.20 36 64 6/10/2014 
1 3.19E+05 5.50 12.67 36   
2 8.73E+03 3.94 9.07 36   
4 8.79E+02 2.94 6.78 36   
8 1.29E+03 3.11 7.16 36   
24 8.83E+10 10.95 25.20 36   
48 9.27E+10 10.97 25.25 36   
0 5.29E+05 5.72 13.18 37 64 2/13/2017 
2 1.28E+04 4.11 9.46 37   
4 3.68E+02 2.57 5.91 37   
6 2.66E+02 2.42 5.58 37   
8 2.45E+02 2.39 5.50 37   
24 1.58E+10 10.20 23.48 37   
0 5.31E+05 5.73 13.18 38 128 2/13/2017 
2 3.43E+03 3.54 8.14 38   
4 2.45E+02 2.39 5.50 38   
6 1.23E+02 2.09 4.81 38   
8 4.09E+01 1.61 3.71 39 64 2/13/2017 
24 1.50E+10 10.18 23.43 39   
6 3.00E+00 0.48 1.10 39 64 2/13/2017 
8 2.70E+01 1.43 3.30 39   
0 1.63E+06 6.21 14.30 40 0 1/26/2014 
2 9.33E+07 7.97 18.35 40   
22 1.05E+11 11.02 25.37 40   
 
 
Table F.21: Meropenem Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
46 8.32E+11 11.92 27.45 40   
0 2.48E+06 6.39 14.72 41 0 2/15/2014 
2 1.82E+09 9.26 21.32 41   
6 5.13E+10 10.71 24.66 41   
22 1.05E+11 11.02 25.37 41   
46 1.20E+12 12.08 27.82 41   
0 4.29E+06 6.63 15.27 42 0 3/30/2014 
2 4.37E+09 9.64 22.20 42   
6 3.02E+10 10.48 24.13 42   
22 3.09E+11 11.49 26.46 42   
46 2.00E+11 11.30 26.02 42   
0 4.93E+06 6.69 15.41 43 0 6/11/2015 
1 1.82E+07 7.26 16.72 43   
2 4.37E+08 8.64 19.89 43   
4 4.79E+10 10.68 24.59 43   
22 5.75E+11 11.76 27.08 43   
0 2.58E+05 5.41 12.46 44  6/11/2015 
1 7.36E+06 6.87 15.81 44   
0 6.80E+05 5.83 13.43 45 4 1/26/2014 
1 1.97E+06 6.29 14.49 45   
23 2.71E+10 10.43 24.02 45   
47 1.89E+10 10.28 23.66 45   
0 6.97E+05 5.84 13.45 46 16 1/26/2014 
1 1.73E+06 6.24 14.36 46   
23 1.90E+10 10.28 23.67 46   
47 1.22E+10 10.09 23.22 46   
0 9.32E+05 5.97 13.74 47 64 1/26/2014 
1 6.86E+05 5.84 13.44 47   
3 1.88E+05 5.27 12.14 47   
7 3.63E+05 5.56 12.80 47   
47 2.06E+10 10.31 23.75 47   
0 1.34E+06 6.13 14.11 48 4 5/14/2014 
1 4.97E+06 6.70 15.42 48   
3 3.66E+09 9.56 22.02 48   
7 9.15E+10 10.96 25.24 48   
23 1.21E+11 11.08 25.52 48   
47 2.26E+10 10.35 23.84 48   
0 1.38E+06 6.14 14.14 49 64 5/14/2014 
 
 
Table F.21: Meropenem Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
1 3.05E+05 5.48 12.63 49   
3 4.01E+05 5.60 12.90 49   
7 6.40E+05 5.81 13.37 49   
23 5.77E+10 10.76 24.78 49   
47 1.01E+10 10.00 23.04 49   
0 7.32E+05 5.86 13.50 50 16 5/20/2014 
1 1.87E+06 6.27 14.44 50   
3 2.14E+07 7.33 16.88 50   
7 4.04E+10 10.61 24.42 50   
23 5.93E+10 10.77 24.81 50   
47 1.69E+10 10.23 23.55 50   
0 8.75E+05 5.94 13.68 51 64 2/13/2017 
2 1.86E+05 5.27 12.13 51   
4 1.27E+05 5.10 11.75 51   
6 1.25E+05 5.10 11.74 51   
8 2.06E+05 5.31 12.24 51   
24 9.93E+10 11.00 25.32 51   
0 8.30E+05 5.92 13.63 52 128 2/13/2017 
2 2.64E+04 4.42 10.18 52   
4 6.48E+03 3.81 8.78 52   
6 3.92E+03 3.59 8.27 52   
24 1.69E+10 10.23 23.55 52   
 
 
 
Table F.22: Polymyxin B Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 2.63E+06 6.42 14.78 1 0 1/26/2014 
22 4.43E+10 10.65 24.51 1 
  
46 4.43E+11 11.65 26.82 1 
  
0 4.44E+06 6.65 15.31 2 0 2/15/2014 
2 1.36E+10 10.13 23.33 2 
  
6 3.42E+10 10.53 24.26 2 
  
22 4.12E+11 11.61 26.74 2 
  
46 3.93E+12 12.59 29.00 2 
  
0 1.13E+07 7.05 16.24 3 0 3/30/2014 
2 3.25E+10 10.51 24.20 3 
  
6 1.06E+11 11.03 25.39 3 
  
22 5.43E+11 11.73 27.02 3 
  
46 9.31E+10 10.97 25.26 3 
  
0 1.14E+07 7.06 16.25 4 0 6/11/2015 
1 2.85E+08 8.45 19.47 4 
  
3 5.11E+10 10.71 24.66 4 
  
21 5.86E+11 11.77 27.10 4 
  
0 1.42E+02 2.15 4.96 5 0 6/11/2015 
1 1.08E+03 3.03 6.98 5 
  
3 2.02E+03 3.31 7.61 5 
  
21 1.74E+04 4.24 9.76 5 
  
0 7.07E+05 5.85 13.47 6 0.25 1/26/2014 
1 2.52E+04 4.40 10.13 6 
  
2 6.74E+02 2.83 6.51 6 
  
4 1.92E+03 3.28 7.56 6 
  
48 4.71E+10 10.67 24.58 6 
  
0 6.54E+05 5.82 13.39 7 1 1/26/2014 
1 7.07E+03 3.85 8.86 7 
  
2 2.86E+02 2.46 5.66 7 
  
4 4.91E+02 2.69 6.20 7 
  
48 1.49E+10 10.17 23.42 7 
  
0 7.23E+05 5.86 13.49 8 0.25 3/30/2015 
1 3.27E+02 2.51 5.79 8 
  
2 1.43E+02 2.16 4.96 8 
  
4 5.93E+02 2.77 6.39 8 
  
8 4.16E+04 4.62 10.64 8 
  
24 7.16E+10 10.85 24.99 8 
  
48 7.93E+09 9.90 22.79 8 
  
 
 
Table F.22: Polymyxin B Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 5.84E+05 5.77 13.28 9 1 3/30/2015 
4 2.66E+02 2.42 5.58 9 
  
8 1.56E+04 4.19 9.66 9 
  
24 1.67E+11 11.22 25.84 9 
  
48 1.19E+10 10.08 23.20 9 
  
0 8.00E+05 5.90 13.59 10 2 5/29/2014 
1 6.13E+02 2.79 6.42 10 
  
2 1.02E+02 2.01 4.62 10 
  
4 8.99E+02 2.95 6.80 10 
  
8 7.16E+04 4.85 11.18 10 
  
24 1.29E+11 11.11 25.58 10 
  
48 5.73E+10 10.76 24.77 10 
  
0 7.79E+05 5.89 13.57 11 4 5/29/2014 
1 1.64E+02 2.21 5.10 11 
  
4 3.07E+02 2.49 5.73 11 
  
8 3.09E+04 4.49 10.34 11 
  
24 5.31E+10 10.73 24.70 11 
  
48 1.67E+11 11.22 25.84 11 
  
0 6.92E+05 5.84 13.45 12 2 6/10/2014 
1 1.00E+03 3.00 6.91 12 
  
2 2.45E+02 2.39 5.50 12 
  
4 1.84E+02 2.26 5.21 12 
  
8 2.25E+04 4.35 10.02 12 
  
24 6.13E+10 10.79 24.84 12 
  
48 1.57E+11 11.20 25.78 12 
  
0 6.85E+05 5.84 13.44 13 4 6/10/2014 
1 7.97E+02 2.90 6.68 13 
  
4 1.02E+02 2.01 4.62 13 
  
8 8.36E+03 3.92 9.03 13 
  
24 9.78E+10 10.99 25.31 13 
  
48 1.96E+11 11.29 26.00 13 
  
0 5.01E+05 5.70 13.12 14 0.06 6/18/2014 
1 6.26E+04 4.80 11.04 14 
 
6/10/2014 
2 6.12E+03 3.79 8.72 14 
  
4 5.87E+03 3.77 8.68 14 
  
8 1.81E+06 6.26 14.41 14 
  
24 9.88E+10 10.99 25.32 14 
  
48 1.56E+11 11.19 25.77 14 
  
 
 
Table F.22: Polymyxin B Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
0 5.15E+05 5.71 13.15 15 0.125 6/18/2014 
1 2.15E+04 4.33 9.98 15 
  
2 6.54E+02 2.82 6.48 15 
  
4 3.88E+02 2.59 5.96 15 
  
8 4.46E+05 5.65 13.01 15 
  
24 6.48E+10 10.81 24.89 15 
  
48 7.37E+10 10.87 25.02 15 
  
0 7.87E+05 5.90 13.58 16 0.06 7/9/2014 
1 1.36E+05 5.13 11.82 16 
  
2 6.44E+04 4.81 11.07 16 
  
4 3.79E+04 4.58 10.54 16 
  
8 1.19E+08 8.08 18.59 16 
  
24 2.19E+11 11.34 26.11 16 
  
48 8.18E+10 10.91 25.13 16 
  
0 9.30E+05 5.97 13.74 17 0.125 7/9/2014 
1 4.70E+04 4.67 10.76 17 
  
2 4.24E+03 3.63 8.35 17 
  
4 2.76E+03 3.44 7.92 17 
  
8 1.18E+06 6.07 13.98 17 
  
24 8.44E+10 10.93 25.16 17 
  
48 9.84E+10 10.99 25.31 17 
  
0 8.95E+05 5.95 13.70 18 0.25 8/23/2014 
1 3.47E+03 3.54 8.15 18 
  
2 6.34E+02 2.80 6.45 18 
  
4 2.92E+03 3.47 7.98 18 
  
8 4.26E+04 4.63 10.66 18 
  
24 7.88E+10 10.90 25.09 18 
  
48 1.71E+10 10.23 23.56 18 
  
0 8.43E+05 5.93 13.64 19 1 8/23/2014 
1 2.21E+03 3.34 7.70 19 
  
2 1.64E+02 2.21 5.10 19 
  
4 4.37E+03 3.64 8.38 19 
  
8 2.00E+04 4.30 9.90 19 
  
24 8.59E+10 10.93 25.18 19 
  
48 1.78E+10 10.25 23.60 19 
  
0 3.14E+06 6.50 14.96 20 0 5/29/2014 
2 4.21E+09 9.62 22.16 20 
  
6 1.11E+11 11.05 25.43 20 
  
 
 
Table F.22: Polymyxin B Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
22 5.23E+10 10.72 24.68 20 
  
46 9.93E+10 11.00 25.32 20 
  
0 2.51E+06 6.40 14.74 21 0 8/23/2014 
2 5.15E+09 9.71 22.36 21 
  
6 1.06E+11 11.03 25.39 21 
  
22 6.69E+10 10.83 24.93 21 
  
46 2.45E+09 9.39 21.62 21 
  
0 6.23E+06 6.79 15.64 22 0 6/11/2015 
1 1.35E+08 8.13 18.72 22 
  
3 3.21E+10 10.51 24.19 22 
  
21 1.43E+11 11.16 25.69 22 
  
0 2.54E+02 2.40 5.54 23 0 6/11/2015 
1 1.58E+03 3.20 7.37 23 
  
21 9.18E+03 3.96 9.12 23 
  
0 1.34E+06 6.13 14.11 24 0.25 5/14/2014 
1 1.78E+03 3.25 7.48 24 
  
8 3.94E+03 3.60 8.28 24 
  
24 2.21E+11 11.34 26.12 24 
  
48 2.65E+10 10.42 24.00 24 
  
0 1.43E+06 6.16 14.17 25 1 5/14/2014 
8 2.25E+02 2.35 5.42 25 
  
24 5.95E+10 10.77 24.81 25 
  
48 1.04E+11 11.02 25.37 25 
  
0 5.01E+05 5.70 13.12 26 0.25 5/20/2014 
8 2.23E+03 3.35 7.71 26 
  
24 1.35E+11 11.13 25.63 26 
  
48 9.15E+10 10.96 25.24 26 
  
0 5.53E+05 5.74 13.22 27 1 5/20/2014 
8 8.18E+02 2.91 6.71 27 
  
24 1.08E+11 11.03 25.41 27 
  
48 1.23E+11 11.09 25.54 27 
  
0 6.68E+05 5.82 13.41 28 2 5/29/2014 
8 2.41E+03 3.38 7.79 28 
  
24 6.37E+10 10.80 24.88 28 
  
48 1.21E+11 11.08 25.52 28 
  
0 6.60E+05 5.82 13.40 29 4 5/29/2014 
8 2.86E+02 2.46 5.66 29 
  
24 2.11E+10 10.32 23.77 29 
  
 
 
Table F.22: Polymyxin B Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
48 1.13E+11 11.05 25.45 29 
  
0 5.27E+05 5.72 13.17 30 0.06 6/10/2014 
1 9.81E+04 4.99 11.49 30 
  
0 5.64E+05 5.75 13.24 31 2 6/10/2014 
8 1.37E+03 3.14 7.22 31 
  
24 1.29E+11 11.11 25.58 31 
  
48 8.03E+10 10.90 25.11 31 
  
0 5.00E+05 5.70 13.12 32 4 6/10/2014 
8 5.31E+02 2.73 6.27 32 
  
24 2.38E+10 10.38 23.89 32 
  
48 1.52E+11 11.18 25.75 32 
  
0 4.56E+05 5.66 13.03 33 0.06 6/18/2014 
1 4.48E+03 3.65 8.41 33 
  
0 4.93E+05 5.69 13.11 34 0.125 6/18/2014 
1 3.07E+02 2.49 5.73 34 
  
4 2.25E+02 2.35 5.42 34 
  
8 3.00E+05 5.48 12.61 34 
  
24 1.29E+11 11.11 25.58 34 
  
48 6.66E+10 10.82 24.92 34 
  
0 6.91E+05 5.84 13.45 35 0.125 7/9/2014 
1 1.64E+02 2.21 5.10 35 
  
2 1.84E+02 2.26 5.21 35 
  
4 4.50E+02 2.65 6.11 35 
  
8 8.58E+04 4.93 11.36 35 
  
24 1.26E+11 11.10 25.56 35 
  
48 8.75E+10 10.94 25.19 35 
  
0 1.77E+06 6.25 14.39 36 0 5/29/2014 
2 6.82E+07 7.83 18.04 36 
  
6 1.45E+10 10.16 23.40 36 
  
22 2.82E+10 10.45 24.06 36 
  
46 2.58E+10 10.41 23.97 36 
  
0 2.00E+06 6.30 14.51 37 0 8/23/2014 
2 8.08E+07 7.91 18.21 37 
  
6 2.24E+10 10.35 23.83 37 
  
22 2.60E+10 10.41 23.98 37 
  
46 3.99E+10 10.60 24.41 37 
  
0 2.46E+06 6.39 14.72 38 0 6/11/2015 
1 8.59E+06 6.93 15.97 38 
  
 
 
Table F.22: Polymyxin B Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
2 2.48E+08 8.39 19.33 38 
  
4 5.24E+10 10.72 24.68 38 
  
22 3.44E+11 11.54 26.56 38 
  
0 1.00E+00 0.00 0.00 39 0 6/11/2015 
2 3.60E+01 1.56 3.58 39 
  
4 2.00E+02 2.30 5.30 39 
  
22 3.77E+02 2.58 5.93 39 
  
0 4.26E+05 5.63 12.96 40 0.25 5/20/2014 
1 9.69E+03 3.99 9.18 40 
  
8 4.09E+02 2.61 6.01 40 
  
24 1.12E+10 10.05 23.14 40 
  
48 7.88E+10 10.90 25.09 40 
  
0 4.85E+05 5.69 13.09 41 1 5/20/2014 
8 3.47E+02 2.54 5.85 41 
  
24 4.71E+09 9.67 22.27 41 
  
48 7.02E+10 10.85 24.97 41 
  
0 6.33E+05 5.80 13.36 42 2 5/29/2014 
24 1.79E+06 6.25 14.40 42 
  
48 7.33E+10 10.87 25.02 42 
  
0 7.29E+05 5.86 13.50 43 4 5/29/2014 
24 2.08E+06 6.32 14.55 43 
  
48 2.53E+09 9.40 21.65 43 
  
0 5.87E+05 5.77 13.28 44 0.0625 6/10/2014 
1 1.10E+05 5.04 11.61 44 
  
2 4.91E+04 4.69 10.80 44 
  
0 6.26E+05 5.80 13.35 45 2 6/10/2014 
8 3.88E+02 2.59 5.96 45 
  
24 4.70E+08 8.67 19.97 45 
  
48 1.10E+11 11.04 25.42 45 
  
0 5.66E+05 5.75 13.25 46 4 6/10/2014 
8 1.23E+02 2.09 4.81 46 
  
24 7.23E+06 6.86 15.79 46 
  
48 6.87E+10 10.84 24.95 46 
  
0 6.72E+05 5.83 13.42 47 0.25 6/10/2014 
1 4.69E+04 4.67 10.76 47 
  
2 2.04E+02 2.31 5.32 47 
  
8 1.19E+03 3.08 7.08 47 
  
24 9.95E+09 10.00 23.02 47 
  
 
 
Table F.22: Polymyxin B Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
48 4.51E+10 10.65 24.53 47 
  
0 5.81E+05 5.76 13.27 48 1 6/10/2014 
1 4.01E+03 3.60 8.30 48 
  
8 7.77E+02 2.89 6.66 48 
  
24 2.06E+10 10.31 23.75 48 
  
48 6.99E+10 10.84 24.97 48 
  
0 3.37E+05 5.53 12.73 49 0.0625 6/18/2014 
1 2.78E+04 4.44 10.23 49 
  
2 1.19E+03 3.08 7.08 49 
  
0 3.67E+05 5.56 12.81 50 0.125 6/18/2014 
4 1.23E+02 2.09 4.81 50 
  
8 1.83E+04 4.26 9.81 50 
  
24 4.96E+10 10.70 24.63 50 
  
48 1.42E+11 11.15 25.68 50 
  
0 7.51E+05 5.88 13.53 51 0.125 7/9/2014 
1 3.70E+03 3.57 8.22 51 
  
2 9.40E+02 2.97 6.85 51 
  
4 5.33E+03 3.73 8.58 51 
  
8 2.22E+05 5.35 12.31 51 
  
24 8.15E+10 10.91 25.12 51 
  
48 1.39E+11 11.14 25.66 51 
  
0 5.37E+05 5.73 13.19 52 2 8/23/2014 
8 9.40E+02 2.97 6.85 52 
  
24 4.95E+07 7.69 17.72 52 
  
48 1.02E+10 10.01 23.05 52 
  
0 5.04E+05 5.70 13.13 53 4 8/23/2014 
8 1.23E+02 2.09 4.81 53 
  
24 6.66E+06 6.82 15.71 53 
  
48 2.12E+10 10.33 23.78 53 
  
0 1.63E+06 6.21 14.31 54 0 1/26/2014 
2 9.31E+07 7.97 18.35 54 
  
6 7.23E+08 8.86 20.40 54 
  
22 1.04E+11 11.02 25.37 54 
  
46 8.31E+11 11.92 27.45 54 
  
0 2.48E+06 6.39 14.72 55 0 2/15/2014 
2 1.80E+09 9.26 21.31 55 
  
6 5.13E+10 10.71 24.66 55 
  
22 1.04E+11 11.02 25.37 55 
  
 
 
Table F.22: Polymyxin B Composite Model Input Data 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
46 1.19E+12 12.08 27.81 55 
  
0 4.28E+06 6.63 15.27 56 0 3/30/2014 
2 4.37E+09 9.64 22.20 56 
  
6 3.05E+10 10.48 24.14 56 
  
22 3.11E+11 11.49 26.46 56 
  
46 2.00E+11 11.30 26.02 56 
  
0 4.93E+06 6.69 15.41 57 0 6/11/2015 
1 1.81E+07 7.26 16.71 57 
  
2 4.32E+08 8.64 19.88 57 
  
4 4.76E+10 10.68 24.59 57 
  
22 5.72E+11 11.76 27.07 57 
  
0 2.50E+01 1.40 3.22 58 0 6/11/2015 
1 8.60E+01 1.93 4.45 58 
  
2 4.09E+02 2.61 6.01 58 
  
4 7.56E+02 2.88 6.63 58 
  
0 6.04E+05 5.78 13.31 59 0.0625 6/10/2014 
1 6.95E+04 4.84 11.15 59 
  
0 5.29E+05 5.72 13.18 60 0.0625 6/18/2014 
1 7.15E+02 2.85 6.57 60 
  
0 5.42E+05 5.73 13.20 61 0.125 6/18/2014 
1 1.64E+02 2.21 5.10 61 
  
2 2.86E+02 2.46 5.66 61 
  
4 1.76E+03 3.25 7.47 61 
  
8 6.73E+04 4.83 11.12 61 
  
24 1.61E+11 11.21 25.80 61 
  
48 4.92E+10 10.69 24.62 61 
  
0 7.16E+05 5.85 13.48 62 0.125 7/9/2014 
1 2.00E+03 3.30 7.60 62 
  
4 2.82E+03 3.45 7.94 62 
  
8 5.52E+04 4.74 10.92 62 
  
24 7.37E+10 10.87 25.02 62 
  
48 1.41E+11 11.15 25.67 62 
  
0 2.68E+05 5.43 12.50 63 0.25 3/30/2014 
8 1.00E+03 3.00 6.91 63 
  
24 4.30E+10 10.63 24.48 63 
  
48 2.43E+10 10.39 23.91 63 
  
0 8.53E+05 5.93 13.66 64 0.25 4/19/2014 
1 5.72E+02 2.76 6.35 64 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
4 1.23E+02 2.09 4.81 64 
  
8 9.81E+02 2.99 6.89 64 
  
24 1.05E+10 10.02 23.07 64 
  
48 9.97E+11 12.00 27.63 64 
  
0 8.93E+05 5.95 13.70 65 0.25 5/14/2014 
1 1.74E+03 3.24 7.46 65 
  
4 1.64E+02 2.21 5.10 65 
  
8 2.76E+03 3.44 7.92 65 
  
24 1.76E+11 11.25 25.89 65 
  
48 3.44E+10 10.54 24.26 65 
  
0 4.48E+05 5.65 13.01 66 1 3/30/2014 
8 5.11E+02 2.71 6.24 66 
  
24 8.29E+09 9.92 22.84 66 
  
48 8.94E+10 10.95 25.22 66 
  
0 8.13E+05 5.91 13.61 67 1 4/19/2014 
4 2.25E+02 2.35 5.42 67 
  
8 7.15E+02 2.85 6.57 67 
  
24 8.23E+09 9.92 22.83 67 
  
48 3.09E+11 11.49 26.46 67 
  
0 9.82E+05 5.99 13.80 68 1 5/14/2014 
1 7.15E+02 2.85 6.57 68 
  
4 1.84E+02 2.26 5.21 68 
  
8 2.55E+03 3.41 7.84 68 
  
24 1.11E+11 11.05 25.43 68 
  
48 1.67E+10 10.22 23.54 68 
  
0 6.47E+05 5.81 13.38 69 2 5/29/2014 
8 1.64E+02 2.21 5.10 69 
  
24 2.27E+11 11.36 26.15 69 
  
48 3.74E+10 10.57 24.34 69 
  
0 6.18E+05 5.79 13.33 70 2 6/10/2014 
2 2.04E+02 2.31 5.32 70 
  
24 1.21E+06 6.08 14.01 70 
  
48 1.27E+10 10.10 23.26 70 
  
0 4.75E+05 5.68 13.07 71 2 8/23/2014 
24 5.38E+04 4.73 10.89 71 
  
48 2.98E+09 9.47 21.82 71 
  
0 5.56E+05 5.75 13.23 72 4 5/20/2014 
0 6.53E+05 5.81 13.39 73 4 5/29/2014 
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Adjusted 
Time 
Viable 
Count Log Ln Function 
Drug 
Concentration Date 
8 5.72E+02 2.76 6.35 73 
  
24 2.30E+10 10.36 23.86 73 
  
48 3.77E+10 10.58 24.35 73 
  
0 5.87E+05 5.77 13.28 74 4 6/10/2014 
24 6.52E+05 5.81 13.39 74 
  
48 4.00E+10 10.60 24.41 74 
  
0 7.75E+05 5.89 13.56 75 4 7/9/2014 
1 2.86E+02 2.46 5.66 75 
  
8 1.02E+02 2.01 4.62 75 
  
24 2.13E+07 7.33 16.87 75 
  
48 3.17E+07 7.50 17.27 75 
  
0 1.10E+06 6.04 13.91 76 4 8/23/2014 
24 2.68E+07 7.43 17.10 76 
  
48 5.87E+10 10.77 24.80 76 
  
0 9.48E+05 5.98 13.76 77 4 2/13/2017 
1 1.95E+02 2.29 5.27 77 
  
1 7.10E+01 1.85 4.26 78 4 2/13/2017 
2 8.20E+01 1.91 4.41 78 
  
4 2.10E+02 2.32 5.35 78 
  
8 1.12E+03 3.05 7.02 78 
  
8 6.54E+02 2.82 6.48 78 
  
8 9.81E+02 2.99 6.89 78 
  
24 1.31E+10 10.12 23.30 78 
  
24 7.44E+10 10.87 25.03 78 
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Appendix G: 
 
Win Nonlin® Code for Mathematical Models 
 
 Tables G.1-G.22 contain the Win Nonlin® code for each model. 
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MODEL 
remark  Three-Population Simple Net Effect Growth Model 
remark  Klebsiella pneumoniae 34 
remark  Growth Control Experiments with total and resistant subpopulations 
remark  6 Functions, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 8-7-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark gRHS 
remark  
remark gRLR 
remark  
remark Nmax 
 
remark - model-specific commands  
COMMANDS 
NFUN 6 
NDER 6 
NPAR 4 
PNAMES 'gRLS' 'gRHS' 'gRLR' 'Nmax' 
remark -initial estimates  
remark -gRLS and Nmax initial estimates from pooled model, gRHS and gRLR initial estimates 
from subpopulation analysis 
END 
 
remark - differential equations starting values 
START 
remark - RLS experiments 
Z(1)=2.63*10**6 
Z(2)=4.44*10**6 
Z(3)=1.13*10**7 
Z(4)=1.14*10**7 
remark - RHS experiment 
Z(5)=3.71*10**2 
remark - RLR experiment 
Z(6)=1.42*10**2 
END 
 
remark - differential equations 
DIFF 
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remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
1/26/14 
DZ(1)=(gRLS*(1-(Z(1)+Z(5)+Z(6))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
2/15/14 
DZ(2)=(gRLS*(1-(Z(2)+Z(5)+Z(6))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
3/30/14 
DZ(3)=(gRLS*(1-(Z(3)+Z(5)+Z(6))/Nmax))*Z(3) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(4)=(gRLS*(1-(Z(4)+Z(5)+Z(6))/Nmax))*Z(4) 
 
remark high-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(5)=(gRHS*(1-(Z(4)+Z(5)+Z(6))/Nmax))*Z(5) 
 
remark low-level meropenem-resistant and polymyxin B-resistant subpopulation growth 6/11/15 
DZ(6)=(gRLR*(1-(Z(4)+Z(5)+Z(6))/Nmax))*Z(6) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
F=log10(Z(6)) 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Logistic Meropenem Initial Killing Model 
remark  Klebsiella pneumoniae 34 
remark  Growth Control Experiments with MEM initial killing 
remark  12 Functions, 12 differential equations, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-19-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
 
remark - model-specific commands  
COMMANDS 
NFUN 12 
NDER 12 
NPAR 4 
PNAMES 'gRLS' 'Nmax' 'kS' 'EC50S' 
NSEC 1 
SNAM 'SC' 
END 
 
remark - differential equations starting values 
START 
remark - Growth Control Experiments 
Z(1)=2.63*10**6 
Z(2)=4.44*10**6 
Z(3)=1.13*10**7 
Z(4)=1.14*10**7 
 
remark - MEM Experiments 
Z(5)=8.06*10**5 
Z(6)=7.48*10**5 
Z(7)=6.54*10**5 
Z(8)=1.04*10**6 
Z(9)=4.85*10**5 
Z(10)=7.54*10**5 
Z(11)=7.59*10**5 
Z(12)=1.14*10**6 
END 
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remark - differential equations 
DIFF 
 
remark low-level meropenem-resistant and high-level meropenem-resistant subpopulation 
growth 1/26/14 
DZ(1)=(gRLS*(1-(Z(1))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and high-level meropenem-resistant subpopulation 
growth 2/15/14 
DZ(2)=(gRLS*(1-(Z(2))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and high-level meropenem-resistant subpopulation 
growth 3/30/14 
DZ(3)=(gRLS*(1-(Z(3))/Nmax))*Z(3) 
 
remark low-level meropenem-resistant and high-level meropenem-resistant subpopulation 
growth 6/11/15 
DZ(4)=(gRLS*(1-(Z(4))/Nmax))*Z(4) 
 
remark MEM 4 monotherapy 1/26/14 
DZ(5)=(gRLS*(1-(Z(5))/Nmax)-(kS*(4/(4+EC50S))))*Z(5) 
 
remark MEM 16 monotherapy 1/26/14 
DZ(6)=(gRLS*(1-(Z(6))/Nmax)-(kS*(16/(16+EC50S))))*Z(6) 
 
remark MEM 64 monotherapy 1/26/14 
DZ(7)=(gRLS*(1-(Z(7))/Nmax)-(kS*(64/(64+EC50S))))*Z(7) 
 
remark MEM 4 monotherapy 7/9/14 
DZ(8)=(gRLS*(1-(Z(8))/Nmax)-(kS*(4/(4+EC50S))))*Z(8) 
 
remark MEM 16 monotherapy 7/9/14 
DZ(9)=(gRLS*(1-(Z(9))/Nmax)-(kS*(16/(16+EC50S))))*Z(9) 
 
remark MEM 64 monotherapy 7/9/14 
DZ(10)=(gRLS*(1-(Z(10))/Nmax)-(kS*(64/(64+EC50S))))*Z(10) 
 
remark MEM 8 monotherapy 2/13/17 
DZ(11)=(gRLS*(1-(Z(11))/Nmax)-(kS*(8/(8+EC50S))))*Z(11) 
 
remark MEM 16 monotherapy 2/13/17 
DZ(12)=(gRLS*(1-(Z(12))/Nmax)-(kS*(16/(16+EC50S))))*Z(12) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
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FUNC 2 
F=log10(Z(2)) 
END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
F=log10(Z(6)) 
END 
FUNC 7 
F=log10(Z(7)) 
END 
FUNC 8 
F=log10(Z(8)) 
END 
FUNC 9 
F=log10(Z(9)) 
END 
FUNC 10 
F=log10(Z(10)) 
END 
FUNC 11 
F=log10(Z(11)) 
END 
FUNC 12 
F=log10(Z(12)) 
END 
 
SECONDARY 
S(1)=(kS-gRLS)/gRLS*EC50S 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Logistic Polymyxin B Initial Killing Model 
remark  Klebsiella pneumoniae 34 
remark  Growth Control Experiments with PMB initial killing 
remark  17 Functions, 17 differential equations, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-16-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
 
remark - model-specific commands  
COMMANDS 
NFUN 17 
NDER 17 
NPAR 4 
PNAMES 'gRLS' 'Nmax' 'kS' 'EC50S' 
NSEC 1 
SNAM 'SCS' 
END 
 
remark - differential equations starting values 
START 
remark - S experiments 
Z(1)=2.63*10**6 
Z(2)=4.44*10**6 
Z(3)=1.13*10**7 
Z(4)=1.14*10**7 
 
remark - PMB monotherapy experiments 
Z(5)=7.07*10**5 
Z(6)=6.54*10**5 
Z(7)=7.23*10**5 
Z(8)=8.00*10**5 
Z(9)=7.79*10**5 
Z(10)=6.92*10**5 
Z(11)=6.85*10**5 
Z(12)=5.01*10**5 
Z(13)=5.15*10**5 
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Z(14)=7.87*10**5 
Z(15)=9.30*10**5 
Z(16)=8.95*10**5 
Z(17)=8.43*10**5 
 
END 
 
remark - differential equations 
DIFF 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
1/26/14 
DZ(1)=(gRLS*(1-(Z(1))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
2/15/14 
DZ(2)=(gRLS*(1-(Z(2))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
3/30/14 
DZ(3)=(gRLS*(1-(Z(3))/Nmax))*Z(3) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(4)=(gRLS*(1-(Z(4))/Nmax))*Z(4) 
 
remark PMB 0.25 monotherapy 1/26/14 
DZ(5)=(gRLS*(1-(Z(5))/Nmax)-(kS*(0.25/(0.25+EC50S))))*Z(5) 
 
remark PMB 1 monotherapy 1/26/14 
DZ(6)=(gRLS*(1-(Z(6))/Nmax)-(kS*(1/(1+EC50S))))*Z(6) 
 
remark PMB 0.25 monotherapy 3/30/15 
DZ(7)=(gRLS*(1-(Z(7))/Nmax)-(kS*(0.25/(0.25+EC50S))))*Z(7) 
 
remark PMB 2 monotherapy 5/29/14 
DZ(8)=(gRLS*(1-(Z(8))/Nmax)-(kS*(2/(2+EC50S))))*Z(8) 
 
remark PMB 4 monotherapy 5/29/14 
DZ(9)=(gRLS*(1-(Z(9))/Nmax)-(kS*(4/(4+EC50S))))*Z(9) 
 
remark PMB 2 monotherapy 6/10/14 
DZ(10)=(gRLS*(1-(Z(10))/Nmax)-(kS*(2/(2+EC50S))))*Z(10) 
 
remark PMB 4 monotherapy 6/10/14 
DZ(11)=(gRLS*(1-(Z(11))/Nmax)-(kS*(4/(4+EC50S))))*Z(11) 
 
remark PMB 0.0625 monotherapy 6/18/14 
DZ(12)=(gRLS*(1-(Z(12))/Nmax)-(kS*(0.0625/(0.0625+EC50S))))*Z(12) 
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remark PMB 0.125 monotherapy 6/18/14 
DZ(13)=(gRLS*(1-(Z(13))/Nmax)-(kS*(0.125/(0.125+EC50S))))*Z(13) 
 
remark PMB 0.0625 monotherapy 7/9/14 
DZ(14)=(gRLS*(1-(Z(14))/Nmax)-(kS*(0.0625/(0.0625+EC50S))))*Z(14) 
 
remark PMB 0.125 monotherapy 7/9/14 
DZ(15)=(gRLS*(1-(Z(15))/Nmax)-(kS*(0.125/(0.125+EC50S))))*Z(15) 
 
remark PMB 0.25 monotherapy 8/23/14 
DZ(16)=(gRLS*(1-(Z(16))/Nmax)-(kS*(0.25/(0.25+EC50S))))*Z(16) 
 
remark PMB 1 monotherapy 8/23/14 
DZ(17)=(gRLS*(1-(Z(17))/Nmax)-(kS*(1/(1+EC50S))))*Z(17) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
F=log10(Z(6)) 
END 
FUNC 7 
F=log10(Z(7)) 
END 
FUNC 8 
F=log10(Z(8)) 
END 
FUNC 9 
F=log10(Z(9)) 
END 
FUNC 10 
F=log10(Z(10)) 
END 
FUNC 11 
F=log10(Z(11)) 
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END 
FUNC 12 
F=log10(Z(12)) 
END 
FUNC 13 
F=log10(Z(13)) 
END 
FUNC 14 
F=log10(Z(14)) 
END 
FUNC 15 
F=log10(Z(15)) 
END 
FUNC 16 
F=log10(Z(16)) 
END 
FUNC 17 
F=log10(Z(17)) 
END 
 
SECO 
SCS=(kS-gRLS)/gRLS*EC50S 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Two-Population Simple Meropenem Net Effect Model 
remark  Klebsiella pneumoniae 34 
remark  Meropenem-low-resistant and high-resistant subpopulations 
remark  13 Functions, 24 Differential Equations, 6 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-17-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
remark 
remark  kR 
 
remark - model-specific commands  
COMMANDS 
NFUN 13 
NDER 24 
NPAR 6 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'EC50S' 'kR' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
SIZE 6 
END 
 
TEMP 
R0=64.2 
END 
 
remark - differential equations starting values 
START 
Z(1)=2.63*10**6 
Z(2)=R0 
Z(3)=4.44*10**6 
Z(4)=R0 
Z(5)=1.13*10**7 
Z(6)=R0 
Z(23)=1.14*10**7 
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Z(24)=3.71*10**2 
Z(7)=8.06*10**5 
Z(8)=R0 
Z(9)=7.48*10**5 
Z(10)=R0 
Z(11)=6.54*10**5 
Z(12)=R0 
Z(13)=1.04*10**6 
Z(14)=R0 
Z(15)=4.85*10**5 
Z(16)=R0 
Z(17)=7.54*10**5 
Z(18)=R0 
Z(19)=7.59*10**5 
Z(20)=R0 
Z(21)=1.14*10**6 
Z(22)=R0 
END 
 
remark - differential equations 
DIFF 
 
remark growth control experiment 1/26/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 2/15/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 3/30/14 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
 
remark growth control experiment MEM low-resistance subpopulation 6/11/15 
DZ(23)=(gS*(1-(Z(23)+Z(24))/Nmax))*Z(23) 
 
remark    growth control experiment MEM high-resistance subpopulation 6/11/15 
DZ(24)=(gR*(1-(Z(23)+Z(24))/Nmax))*Z(24) 
 
remark meropenem 4 mg/L time-kill experiment 1/26/14 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax)-kS*(4/(4+EC50S)))*Z(7) 
DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax)-kR*4)*Z(8) 
 
remark meropenem 16 mg/L time-kill experiment 1/26/14 
DZ(9)=(gS*(1-(Z(9)+Z(10))/Nmax)-kS*(16/(16+EC50S)))*Z(9) 
DZ(10)=(gR*(1-(Z(9)+Z(10))/Nmax)-kR*16)*Z(10) 
 
remark meropenem 64 mg/L time-kill experiment 1/26/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS*(64/(64+EC50S)))*Z(11) 
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DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax)-kR*64)*Z(12) 
 
remark meropenem 4 mg/L time-kill experiment 5/14/14 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS*(4/(4+EC50S)))*Z(13) 
DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax)-kR*4)*Z(14) 
 
remark meropenem 16 mg/L time-kill experiment 5/14/14 
DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS*(16/(16+EC50S)))*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax)-kR*16)*Z(16) 
 
remark meropenem 64 mg/L time-kill experiment 5/20/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS*(64/(64+EC50S)))*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax)-kR*64)*Z(18) 
 
remark meropenem 8 mg/L time-kill experiment 2/13/14 
DZ(19)=(gS*(1-(Z(19)+Z(20))/Nmax)-kS*(8/(8+EC50S)))*Z(19) 
DZ(20)=(gR*(1-(Z(19)+Z(20))/Nmax)-kR*8)*Z(20) 
 
remark meropenem 16 mg/L time-kill experiment 2/13/14 
DZ(21)=(gS*(1-(Z(21)+Z(22))/Nmax)-kS*(16/(16+EC50S)))*Z(21) 
DZ(22)=(gR*(1-(Z(21)+Z(22))/Nmax)-kR*16)*Z(22) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(23)+Z(24)) 
END 
FUNC 5 
F=log10(Z(24)) 
END 
FUNC 6 
F=log10(Z(7)+Z(8)) 
END 
FUNC 7 
F=log10(Z(9)+Z(10)) 
END 
FUNC 8 
F=log10(Z(11)+Z(12)) 
END 
FUNC 9 
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F=log10(Z(13)+Z(14)) 
END 
FUNC 10 
F=log10(Z(15)+Z(16)) 
END 
FUNC 11 
F=log10(Z(17)+Z(18)) 
END 
FUNC 12 
F=log10(Z(19)+Z(20)+1) 
END 
FUNC 13 
F=log10(Z(21)+Z(22)) 
END 
 
 
remark - secondary parameters 
SECO 
SCS=(gS/(kS-gS))*EC50S 
SCR=gR/kR 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Two-Population Simple Polymyxin B Net Effect Model 
remark  Klebsiella pneumoniae 34 
remark  Polymyxin B-susceptible and -resistant subpopulations 
remark  19 Functions, 36 Differential Equations, 6 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-17-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
remark  
remark kR 
 
remark - model-specific commands  
COMMANDS 
NFUN 19 
NDER 36 
NPAR 6 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'EC50S' 'kR' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
SIZE 6 
END 
 
TEMP 
R0=19 
END 
 
remark - differential equations starting values 
START 
Z(1)=2.63*10**6 
Z(2)=R0 
Z(3)=2.44*10**6 
Z(4)=R0 
Z(5)=1.13*10**7 
Z(6)=R0 
Z(7)=1.14*10**7 
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Z(8)=1.42*10**2 
Z(9)=7.07*10**5 
Z(10)=R0 
Z(11)=6.54*10**5 
Z(12)=R0 
Z(13)=7.23*10**5 
Z(14)=R0 
Z(15)=5.84*10**5 
Z(16)=R0 
Z(17)=8.00*10**5 
Z(18)=R0 
Z(19)=7.79*10**5 
Z(20)=R0 
Z(21)=6.92*10**5 
Z(22)=R0 
Z(23)=6.85*10**5 
Z(24)=R0 
Z(25)=5.01*10**5 
Z(26)=R0 
Z(27)=5.15*10**5 
Z(28)=R0 
Z(29)=7.87*10**5 
Z(30)=R0 
Z(31)=9.30*10**5 
Z(32)=R0 
Z(33)=8.95*10**5 
Z(34)=R0 
Z(35)=8.43*10**5 
Z(36)=R0 
END 
 
remark - differential equations 
DIFF 
 
remark growth control experiment 1/26/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 2/15/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 3/30/14 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
 
remark growth control experiment PMB susceptible subpopulation 6/11/15 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax))*Z(7) 
 
remark growth control experiment PMB resistant subpopulation 6/11/15 
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DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax))*Z(8) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 1/26/14 
DZ(9)=(gS*(1-(Z(9)+Z(10))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(9) 
DZ(10)=(gR*(1-(Z(9)+Z(10))/Nmax)-kR*0.25)*Z(10) 
 
remark polymyxin B 1 mg/L time-kill experiment 1/26/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS*(1/(1+EC50S)))*Z(11) 
DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax)-kR*1)*Z(12) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 3/30/15 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(13) 
DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax)-kR*0.25)*Z(14) 
 
remark polymyxin B 1 mg/L time-kill experiment 3/30/15 
DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS*(1/(1+EC50S)))*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax)-kR*1)*Z(16) 
 
remark polymyxin B 2 mg/L time-kill experiment 5/29/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS*(2/(2+EC50S)))*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax)-kR*2)*Z(18) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/29/14 
DZ(19)=(gS*(1-(Z(19)+Z(20))/Nmax)-kS*(4/(4+EC50S)))*Z(19) 
DZ(20)=(gR*(1-(Z(19)+Z(20))/Nmax)-kR*4)*Z(20) 
 
remark polymyxin B 2 mg/L time-kill experiment 6/10/14 
DZ(21)=(gS*(1-(Z(21)+Z(22))/Nmax)-kS*(2/(2+EC50S)))*Z(21) 
DZ(22)=(gR*(1-(Z(21)+Z(22))/Nmax)-kR*2)*Z(22) 
 
remark polymyxin B 4 mg/L time-kill experiment 6/10/14 
DZ(23)=(gS*(1-(Z(23)+Z(24))/Nmax)-kS*(4/(4+EC50S)))*Z(23) 
DZ(24)=(gR*(1-(Z(23)+Z(24))/Nmax)-kR*4)*Z(24) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/18/14 
DZ(25)=(gS*(1-(Z(25)+Z(26))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(25) 
DZ(26)=(gR*(1-(Z(25)+Z(26))/Nmax)-kR*0.0625)*Z(26) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 6/18/14 
DZ(27)=(gS*(1-(Z(27)+Z(28))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(27) 
DZ(28)=(gR*(1-(Z(27)+Z(28))/Nmax)-kR*0.125)*Z(28) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 7/9/14 
DZ(29)=(gS*(1-(Z(29)+Z(30))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(29) 
DZ(30)=(gR*(1-(Z(29)+Z(30))/Nmax)-kR*0.0625)*Z(30) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 7/9/14 
DZ(31)=(gS*(1-(Z(31)+Z(32))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(31) 
DZ(32)=(gR*(1-(Z(31)+Z(32))/Nmax)-kR*0.125)*Z(32) 
 
 
 
Table G.5: Isolate 34 Polymyxin B Monotherapy Model Code 
426 
 
remark polymyxin B 0.25 mg/L time-kill experiment 8/23/17 
DZ(33)=(gS*(1-(Z(33)+Z(34))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(33) 
DZ(34)=(gR*(1-(Z(33)+Z(34))/Nmax)-kR*0.25)*Z(34) 
 
remark polymyxin B 1 mg/L time-kill experiment 8/23/17 
DZ(35)=(gS*(1-(Z(35)+Z(36))/Nmax)-kS*(1/(1+EC50S)))*Z(35) 
DZ(36)=(gR*(1-(Z(35)+Z(36))/Nmax)-kR*1)*Z(36) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(7)+Z(8)) 
END 
FUNC 5 
F=log10(Z(8)) 
END 
FUNC 6 
F=log10(Z(9)+Z(10)) 
END 
FUNC 7 
F=log10(Z(11)+Z(12)) 
END 
FUNC 8 
F=log10(Z(13)+Z(14)) 
END 
FUNC 9 
F=log10(Z(15)+Z(16)) 
END 
FUNC 10 
F=log10(Z(17)+Z(18)) 
END 
FUNC 11 
F=log10(Z(19)+Z(20)) 
END 
FUNC 12 
F=log10(Z(21)+Z(22)) 
END 
FUNC 13 
F=log10(Z(23)+Z(24)) 
END 
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FUNC 14 
F=log10(Z(25)+Z(26)) 
END 
FUNC 15 
F=log10(Z(27)+Z(28)) 
END 
FUNC 16 
F=log10(Z(29)+Z(30)+1) 
END 
FUNC 17 
F=log10(Z(31)+Z(32)) 
END 
FUNC 18 
F=log10(Z(33)+Z(34)) 
END 
FUNC 19 
F=log10(Z(35)+Z(36)) 
END 
 
remark - secondary parameters 
SECO 
SCS=(gS/(kS-gS))*EC50S 
SCR=gR/kR 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM
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MODEL 
remark  Three-Population Simple Net Growth Model 
remark  Klebsiella pneumoniae 22 
remark  Growth Control Experiments with total and resistant subpopulations 
remark  5 Functions, 5 differential equations 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-16-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark gRHS 
remark  
remark gRLR 
remark  
remark Nmax 
 
remark - model-specific commands  
COMMANDS 
NFUN 5 
NDER 5 
NPAR 4 
PNAMES 'gRLS' 'gRHS' 'gRLR' 'Nmax' 
remark -initial estimates  
remark -gRLS and Nmax initial estimates from pooled model, gRHS and gRLR initial estimates 
from subpopulation analysis 
END 
 
remark - differential equations starting values 
START 
remark - RLS experiments 
Z(1)=3.14*10**6 
Z(2)=2.51*10**6 
Z(3)=6.23*10**6 
remark - RHS experiment 
Z(4)=7.93*10**2 
remark - RLR experiment 
Z(5)=2.54*10**2 
END 
 
remark - differential equations 
DIFF 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
5/29/14 
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DZ(1)=(gRLS*(1-(Z(1)+Z(4)+Z(5))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
8/23/14 
DZ(2)=(gRLS*(1-(Z(2)+Z(4)+Z(5))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(3)=(gRLS*(1-(Z(3)+Z(4)+Z(5))/Nmax))*Z(3) 
 
remark high-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(4)=(gRHS*(1-(Z(3)+Z(4)+Z(5))/Nmax))*Z(4) 
 
remark low-level meropenem-resistant and polymyxin B-resistant subpopulation growth 6/11/15 
DZ(5)=(gRLR*(1-(Z(3)+Z(4)+Z(5))/Nmax))*Z(5) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Logistic Meropenem Initial Killing Model 
remark  Klebsiella pneumoniae 22 
remark  Growth Control Experiments with MEM initial killing 
remark  11 Functions, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-19-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
 
remark - model-specific commands  
COMMANDS 
NFUN 11 
NDER 11 
NPAR 4 
PNAMES 'gRLS' 'Nmax' 'kS' 'EC50S' 
NSEC 1 
SNAM 'SC' 
END 
 
remark - differential equations starting values 
START 
remark - RLS experiments 
Z(1)=3.14*10**6 
Z(2)=2.51*10**6 
Z(3)=6.23*10**6 
remark - MEM experiments 
Z(4)=1.70*10**6 
Z(5)=1.26*10**6 
Z(6)=9.34*10**5 
Z(7)=6.11*10**5 
Z(8)=3.52*10**5 
Z(9)=5.28*10**5 
Z(10)=7.82*10**5 
Z(11)=8.00*10**5 
 
END 
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remark - differential equations 
DIFF 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
5/29/14 
DZ(1)=(gRLS*(1-(Z(1))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
8/23/14 
DZ(2)=(gRLS*(1-(Z(2))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(3)=(gRLS*(1-(Z(3))/Nmax))*Z(3) 
 
remark MEM 4 monotherapy 5/14/14 
DZ(4)=(gRLS*(1-(Z(4))/Nmax)-(kS*(4/(4+EC50S))))*Z(4) 
 
remark MEM 16 monotherapy 5/14/14 
DZ(5)=(gRLS*(1-(Z(5))/Nmax)-(kS*(16/(16+EC50S))))*Z(5) 
 
remark MEM 64 monotherapy 5/14/14 
DZ(6)=(gRLS*(1-(Z(6))/Nmax)-(kS*(64/(64+EC50S))))*Z(6) 
 
remark MEM 4 monotherapy 5/20/14 
DZ(7)=(gRLS*(1-(Z(7))/Nmax)-(kS*(4/(4+EC50S))))*Z(7) 
 
remark MEM 16 monotherapy 5/20/14 
DZ(8)=(gRLS*(1-(Z(8))/Nmax)-(kS*(16/(16+EC50S))))*Z(8) 
 
 
remark MEM 64 monotherapy 5/20/14 
DZ(9)=(gRLS*(1-(Z(9))/Nmax)-(kS*(64/(64+EC50S))))*Z(9) 
 
 
remark MEM 16 monotherapy 2/13/17 
DZ(10)=(gRLS*(1-(Z(10))/Nmax)-(kS*(16/(16+EC50S))))*Z(10) 
 
 
remark MEM 32 monotherapy 2/13/17 
DZ(11)=(gRLS*(1-(Z(11))/Nmax)-(kS*(32/(32+EC50S))))*Z(11) 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
END 
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FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
F=log10(Z(6)) 
END 
FUNC 7 
F=log10(Z(7)) 
END 
FUNC 8 
F=log10(Z(8)) 
END 
FUNC 9 
F=log10(Z(9)) 
END 
FUNC 10 
F=log10(Z(10)) 
END 
FUNC 11 
F=log10(Z(11)) 
END 
 
SECONDARY 
S(1)=(kS-gRLS)/gRLS*EC50S 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Logistic Polymyxin B Initial Killing Model 
remark  Klebsiella pneumoniae 22 
remark  Growth Control Experiments with PMB initial killing 
remark  8 Functions, 8 differential equations, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-16-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
 
remark - model-specific commands  
COMMANDS 
NFUN 8 
NDER 8 
NPAR 4 
PNAMES 'gRLS' 'Nmax' 'kS' 'EC50S' 
NSEC 1 
SNAM 'SC' 
END 
 
remark - differential equations starting values 
START 
remark - RLS experiments 
Z(1)=3.14*10**6 
Z(2)=2.51*10**6 
Z(3)=6.23*10**6 
remark - RLR experiment 
Z(4)=1.34E+06 
Z(5)=5.27E+05 
Z(6)=4.56E+05 
Z(7)=4.93E+05 
Z(8)=6.91E+05 
END 
 
remark - differential equations 
DIFF 
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remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
5/29/14 
DZ(1)=(gRLS*(1-(Z(1))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
8/23/14 
DZ(2)=(gRLS*(1-(Z(2))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(3)=(gRLS*(1-(Z(3))/Nmax))*Z(3) 
 
remark PMB 0.25 monotherapy 5/14/14 
DZ(4)=(gRLS*(1-(Z(4))/Nmax)-(kS*(0.25/(0.25+EC50S))))*Z(4) 
 
remark PMB 0.0625 monotherapy 6/10/14 
DZ(5)=(gRLS*(1-(Z(5))/Nmax)-(kS*(0.0625/(0.0625+EC50S))))*Z(5) 
 
remark PMB 0.0625 monotherapy 6/18/14 
DZ(6)=(gRLS*(1-(Z(6))/Nmax)-(kS*(0.0625/(0.0625+EC50S))))*Z(6) 
 
remark PMB 0.125 monotherapy 6/18/14 
DZ(7)=(gRLS*(1-(Z(7))/Nmax)-(kS*(0.125/(0.125+EC50S))))*Z(7) 
 
remark PMB 0.125 monotherapy 7/9/14 
DZ(8)=(gRLS*(1-(Z(8))/Nmax)-(kS*(0.125/(0.125+EC50S))))*Z(8) 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
F=log10(Z(6)) 
END 
FUNC 7 
F=log10(Z(7)) 
END 
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FUNC 8 
F=log10(Z(8)) 
END 
 
SECONDARY 
S(1)=(kS-gRLS)/gRLS*EC50S 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Two-Population Simple Net Effect Model 
remark  Klebsiella pneumoniae 22 
remark  Meropenem-low-resistant and high-resistant subpopulations 
remark  13 Functions, 22 Differential Equations, 6 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-17-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
remark  
remark kR 
 
remark - model-specific commands  
COMMANDS 
NFUN 13 
NDER 22 
NPAR 6 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'EC50S' 'kR' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
SIZE 6 
END 
 
TEMP 
R0=13 
END 
 
remark - differential equations starting values 
START 
Z(1)=3.14*10**6 
Z(2)=R0 
Z(3)=2.51*10**6 
Z(4)=R0 
Z(5)=6.23*10**6 
Z(6)=7.93*10**2 
Z(7)=1.70*10**6 
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Z(8)=R0 
Z(9)=1.26*10**6 
Z(10)=R0 
Z(11)=9.34*10**5 
Z(12)=R0 
Z(13)=6.11*10**5 
Z(14)=R0 
Z(15)=3.52*10**5 
Z(16)=R0 
Z(17)=5.28*10**5 
Z(18)=R0 
Z(19)=7.82*10**5 
Z(20)=R0 
Z(21)=8.00*10**5 
Z(22)=R0 
END 
 
remark - differential equations 
DIFF 
 
remark growth control experiment 5/29/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 8/23/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 6/11/15 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
 
remark growth control experiment MEM resistant subpopulation 6/11/15 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
 
remark meropenem 4 mg/L time-kill experiment 5/14/14 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax)-kS*(4/(4+EC50S)))*Z(7) 
DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax)-kR*4)*Z(8) 
 
remark meropenem 16 mg/L time-kill experiment 5/14/14 
DZ(9)=(gS*(1-(Z(9)+Z(10))/Nmax)-kS*(16/(16+EC50S)))*Z(9) 
DZ(10)=(gR*(1-(Z(9)+Z(10))/Nmax)-kR*16)*Z(10) 
 
remark meropenem 64 mg/L time-kill experiment 5/20/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS*(64/(64+EC50S)))*Z(11) 
DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax)-kR*64)*Z(12) 
 
remark meropenem 4 mg/L time-kill experiment 5/20/14 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS*(4/(4+EC50S)))*Z(13) 
DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax)-kR*4)*Z(14) 
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remark meropenem 16 mg/L time-kill experiment 5/29/14 
DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS*(16/(16+EC50S)))*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax)-kR*16)*Z(16) 
 
remark meropenem 64 mg/L time-kill experiment 5/29/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS*(64/(64+EC50S)))*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax)-kR*64)*Z(18) 
 
remark meropenem 16 mg/L time-kill experiment 2/13/14 
DZ(19)=(gS*(1-(Z(19)+Z(20))/Nmax)-kS*(16/(16+EC50S)))*Z(19) 
 
remark meropenem 16 mg/L time-kill resistant subpopulation experiment 2/13/14 
DZ(20)=(gR*(1-(Z(19)+Z(20))/Nmax)-kR*16)*Z(20) 
 
remark meropenem 32 mg/L time-kill experiment 2/13/14 
DZ(21)=(gS*(1-(Z(21)+Z(22))/Nmax)-kS*(32/(32+EC50S)))*Z(21) 
 
remark meropenem 32 mg/L time-kill resistant subpopulation experiment 2/13/14 
DZ(22)=(gR*(1-(Z(21)+Z(22))/Nmax)-kR*32)*Z(22) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(6)) 
END 
FUNC 5 
F=log10(Z(7)+Z(8)) 
END 
FUNC 6 
F=log10(Z(9)+Z(10)) 
END 
FUNC 7 
F=log10(Z(11)+Z(12)) 
END 
FUNC 8 
F=log10(Z(13)+Z(14)) 
END 
FUNC 9 
F=log10(Z(15)+Z(16)) 
END 
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FUNC 10 
F=log10(Z(17)+Z(18)) 
END 
FUNC 11 
F=log10(Z(19)) 
END 
FUNC 12 
F=log10(Z(20)+1) 
END 
FUNC 13 
F=log10(Z(21)+Z(22)) 
END 
 
remark - secondary parameters 
SECO 
SCS=(gS/(kS-gS))*EC50S 
SCR=gR/kR 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM
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MODEL 
remark  Two-Population Simple Net Effect Model 
remark  Klebsiella pneumoniae 22 
remark  Polymyxin B-susceptible and -resistant subpopulations 
remark  16 Functions, 28 Differential Equations, 5 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-17-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark 
remark  kR 
 
remark - model-specific commands  
COMMANDS 
NFUN 16 
NDER 28 
NPAR 5 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'kR' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
SIZE 6 
END 
 
TEMP 
R0=0.63 
END 
 
remark - differential equations starting values 
START 
Z(1)=3.14*10**6 
Z(2)=R0 
Z(3)=2.51*10**6 
Z(4)=R0 
Z(5)=6.23*10**6 
Z(6)=2.54*10**2 
Z(7)=1.34*10**6 
Z(8)=R0 
Z(9)=1.43*10**6 
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Z(10)=R0 
Z(11)=5.01*10**5 
Z(12)=R0 
Z(13)=5.53*10**5 
Z(14)=R0 
Z(15)=6.68*10**5 
Z(16)=R0 
Z(17)=6.60*10**5 
Z(18)=R0 
Z(19)=5.27*10**5 
Z(20)=5.64*10**5 
Z(21)=R0 
Z(22)=5.00*10**5 
Z(23)=R0 
Z(24)=4.56*10**5 
Z(25)=4.93*10**5 
Z(26)=R0 
Z(27)=6.91*10**5 
Z(28)=R0 
END 
 
remark - differential equations 
DIFF 
 
remark growth control experiment 5/29/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 8/23/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 6/11/15 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
 
remark growth control experiment PMB resistant subpopulation 6/11/15 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 5/14/14 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax)-kS)*Z(7) 
DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax)-kR*0.25)*Z(8) 
 
remark polymyxin B 1 mg/L time-kill experiment 5/14/14 
DZ(9)=(gS*(1-(Z(9)+Z(10))/Nmax)-kS)*Z(9) 
DZ(10)=(gR*(1-(Z(9)+Z(10))/Nmax)-kR*1)*Z(10) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 5/20/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS)*Z(11) 
DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax)-kR*0.25)*Z(12) 
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remark polymyxin B 1 mg/L time-kill experiment 5/20/14 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS)*Z(13) 
DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax)-kR*1)*Z(14) 
 
remark polymyxin B 2 mg/L time-kill experiment 5/29/14 
DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS)*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax)-kR*2)*Z(16) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/29/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS)*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax)-kR*4)*Z(18) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/10/14 
DZ(19)=(gS*(1-(Z(19))/Nmax)-kS)*Z(19) 
 
remark polymyxin B 2 mg/L time-kill experiment 6/10/14 
DZ(20)=(gS*(1-(Z(20)+Z(21))/Nmax)-kS)*Z(20) 
DZ(21)=(gR*(1-(Z(20)+Z(21))/Nmax)-kR*2)*Z(21) 
 
remark polymyxin B 4 mg/L time-kill experiment 6/10/14 
DZ(22)=(gS*(1-(Z(22)+Z(23))/Nmax)-kS)*Z(22) 
DZ(23)=(gR*(1-(Z(22)+Z(23))/Nmax)-kR*4)*Z(23) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/18/14 
DZ(24)=(gS*(1-Z(24)/Nmax)-kS)*Z(24) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 6/18/14 
DZ(25)=(gS*(1-(Z(25)+Z(26))/Nmax)-kS)*Z(25) 
DZ(26)=(gR*(1-(Z(25)+Z(26))/Nmax)-kR*0.125)*Z(26) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 7/9/14 
DZ(27)=(gS*(1-(Z(27)+Z(28))/Nmax)-kS)*Z(27) 
DZ(28)=(gR*(1-(Z(27)+Z(28))/Nmax)-kR*0.125)*Z(28) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(6)) 
END 
FUNC 5 
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F=log10(Z(7)+Z(8)) 
END 
FUNC 6 
F=log10(Z(9)+Z(10)) 
END 
FUNC 7 
F=log10(Z(11)+Z(12)) 
END 
FUNC 8 
F=log10(Z(13)+Z(14)) 
END 
FUNC 9 
F=log10(Z(15)+Z(16)) 
END 
FUNC 10 
F=log10(Z(17)+Z(18)) 
END 
FUNC 11 
F=log10(Z(19)) 
END 
FUNC 12 
F=log10(Z(20)+Z(21)) 
END 
FUNC 13 
F=log10(Z(22)+Z(23)) 
END 
FUNC 14 
F=log10(Z(24)) 
END 
FUNC 15 
F=log10(Z(25)+Z(26)) 
END 
FUNC 16 
F=log10(Z(27)+Z(28)) 
END 
 
remark - secondary parameters 
SECO 
SCS=0 
SCR=gR/kR 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM
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MODEL 
remark  Three-Population Simple Net Growth Model 
remark  Klebsiella pneumoniae 24 
remark  Growth Control Experiments with total and resistant subpopulations 
remark  5 Functions, 5 differential equations, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 7-17-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark gRHS 
remark  
remark gRLR 
remark  
remark Nmax 
 
remark - model-specific commands  
COMMANDS 
NFUN 5 
NDER 5 
NPAR 4 
PNAMES 'gRLS' 'gRHS' 'gRLR' 'Nmax' 
remark -initial estimates  
remark -gRLS and Nmax initial estimates from pooled model, gRHS and gRLR initial estimates 
from subpopulation analysis 
END 
 
remark - differential equations starting values 
START 
remark - RLS experiments 
Z(1)=1.77*10**6 
Z(2)=2.00*10**6 
Z(3)=2.46*10**6 
remark - RHS experiment 
Z(4)=5.7*10**1 
remark - RLR experiment 
Z(5)=7.0*10**0 
END 
 
remark - differential equations 
DIFF 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
5/29/14 
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DZ(1)=(gRLS*(1-(Z(1)+Z(4)+Z(5))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
8/23/14 
DZ(2)=(gRLS*(1-(Z(2)+Z(4)+Z(5))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(3)=(gRLS*(1-(Z(3)+Z(4)+Z(5))/Nmax))*Z(3) 
 
remark high-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(4)=(gRHS*(1-(Z(3)+Z(4)+Z(5))/Nmax))*Z(4) 
 
remark low-level meropenem-resistant and polymyxin B-resistant subpopulation growth 6/11/15 
DZ(5)=(gRLR*(1-(Z(3)+Z(4)+Z(5))/Nmax))*Z(5) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
 
remark - end of model 
EOM 
 
 
Table G.12: Isolate 24 Meropenem Initial Killing Model Code 
446 
 
MODEL 
remark  Logistic Meropenem Initial Killing Model 
remark  Klebsiella pneumoniae 24 
remark  Growth Control Experiments with MEM initial killing 
remark  11 Functions, 11 differential equations, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Jeffrey J. Campion, Brandon Kulengowski 
remark   Model Date: 9-19-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
 
remark - model-specific commands  
COMMANDS 
NFUN 11 
NDER 11 
NPAR 4 
PNAMES 'gRLS' 'Nmax' 'kS' 'EC50S' 
NSEC 1 
SNAM 'SC' 
END 
 
remark - differential equations starting values 
START 
remark - Growth Control Experiments 
Z(1)=1.77*10**6 
Z(2)=2.00*10**6 
Z(3)=2.46*10**6 
 
remark - MEM Experiments 
Z(4)=4.79*10**5 
Z(5)=5.68*10**5 
Z(6)=4.36*10**5 
Z(7)=4.84*10**5 
Z(8)=6.34*10**5 
Z(9)=5.40*10**5 
Z(10)=5.29*10**5 
Z(11)=5.31*10**5 
END 
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remark - differential equations 
DIFF 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
5/29/14 
DZ(1)=(gRLS*(1-(Z(1))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
8/23/14 
DZ(2)=(gRLS*(1-(Z(2))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(3)=(gRLS*(1-(Z(3))/Nmax))*Z(3) 
 
remark MEM 4 monotherapy 5/20/14 
DZ(4)=(gRLS*(1-(Z(4))/Nmax)-(kS*(4/(4+EC50S))))*Z(4) 
 
remark MEM 16 monotherapy 5/20/14 
DZ(5)=(gRLS*(1-(Z(5))/Nmax)-(kS*(16/(16+EC50S))))*Z(5) 
 
remark MEM 64 monotherapy 5/20/14 
DZ(6)=(gRLS*(1-(Z(6))/Nmax)-(kS*(64/(64+EC50S))))*Z(6) 
 
remark MEM 4 monotherapy 6/10/14 
DZ(7)=(gRLS*(1-(Z(7))/Nmax)-(kS*(4/(4+EC50S))))*Z(7) 
 
remark MEM 16 monotherapy 6/10/14 
DZ(8)=(gRLS*(1-(Z(8))/Nmax)-(kS*(16/(16+EC50S))))*Z(8) 
 
 
remark MEM 64 monotherapy 6/10/14 
DZ(9)=(gRLS*(1-(Z(9))/Nmax)-(kS*(64/(64+EC50S))))*Z(9) 
 
 
remark MEM 64 monotherapy 2/13/17 
DZ(10)=(gRLS*(1-(Z(10))/Nmax)-(kS*(64/(64+EC50S))))*Z(10) 
 
 
remark MEM 128 monotherapy 2/13/17 
DZ(11)=(gRLS*(1-(Z(11))/Nmax)-(kS*(128/(128+EC50S))))*Z(11) 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
END 
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FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
F=log10(Z(6)) 
END 
FUNC 7 
F=log10(Z(7)) 
END 
FUNC 8 
F=log10(Z(8)) 
END 
FUNC 9 
F=log10(Z(9)) 
END 
FUNC 10 
F=log10(Z(10)) 
END 
FUNC 11 
F=log10(Z(11)) 
END 
 
SECONDARY 
S(1)=(kS-gRLS)/gRLS*EC50S 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Logistic Polymyxin B Initial Killing Model 
remark  Klebsiella pneumoniae 24 
remark  Growth Control Experiments with PMB initial killing 
remark  9 Functions, 9 differential equations, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-19-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
 
remark - model-specific commands  
COMMANDS 
NFUN 9 
NDER 9 
NPAR 4 
PNAMES 'gRLS' 'Nmax' 'kS' 'EC50S' 
NSEC 1 
SNAM 'SC' 
END 
 
remark - differential equations starting values 
START 
remark - Growth Control Experiments 
Z(1)=1.77*10**6 
Z(2)=2.00*10**6 
Z(3)=2.46*10**6 
 
remark - PMB Experiments 
Z(4)=4.26*10**5 
Z(5)=5.87*10**5 
Z(6)=6.72*10**5 
Z(7)=5.81*10**5 
Z(8)=3.37*10**5 
Z(9)=7.51*10**5 
END 
 
remark - differential equations 
DIFF 
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remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
5/29/14 
DZ(1)=(gRLS*(1-(Z(1))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
8/23/14 
DZ(2)=(gRLS*(1-(Z(2))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(3)=(gRLS*(1-(Z(3))/Nmax))*Z(3) 
 
remark PMB 0.25 monotherapy 5/20/14 
DZ(4)=(gRLS*(1-(Z(4))/Nmax)-(kS*(0.25/(0.25+EC50S))))*Z(4) 
 
remark PMB 0.0625 monotherapy 6/10/14 
DZ(5)=(gRLS*(1-(Z(5))/Nmax)-(kS*(0.0625/(0.0625+EC50S))))*Z(5) 
 
remark PMB 0.25 monotherapy 6/10/14 
DZ(6)=(gRLS*(1-(Z(6))/Nmax)-(kS*(0.25/(0.25+EC50S))))*Z(6) 
 
remark PMB 1 monotherapy 6/10/14 
DZ(7)=(gRLS*(1-(Z(7))/Nmax)-(kS*(1/(1+EC50S))))*Z(7) 
 
remark PMB 0.0625 monotherapy 6/18/14 
DZ(8)=(gRLS*(1-(Z(8))/Nmax)-(kS*(0.0625/(0.0625+EC50S))))*Z(8) 
 
remark PMB 0.125 monotherapy 7/9/14 
DZ(9)=(gRLS*(1-(Z(9))/Nmax)-(kS*(0.125/(0.125+EC50S))))*Z(9) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
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F=log10(Z(6)) 
END 
FUNC 7 
F=log10(Z(7)) 
END 
FUNC 8 
F=log10(Z(8)) 
END 
FUNC 9 
F=log10(Z(9)) 
END 
 
SECONDARY 
S(1)=(kS-gRLS)/gRLS*EC50S 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Two-Population Simple Net Effect Model 
remark  Klebsiella pneumoniae 24 
remark  Meropenem-low-resistant and high-resistant subpopulations 
remark  13 Functions, 23 Differential Equations, 5 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-17-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark kR 
 
remark - model-specific commands  
COMMANDS 
NFUN 13 
NDER 23 
NPAR 5 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'kR' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
SIZE 6 
END 
 
TEMP 
R0=3.27 
END 
 
remark - differential equations starting values 
START 
Z(1)=1.77*10**6 
Z(2)=R0 
Z(3)=2.00*10**6 
Z(4)=R0 
Z(5)=2.446*10**6 
Z(6)=5.7*10**1 
Z(7)=4.79*10**5 
Z(8)=R0 
Z(9)=5.68*10**5 
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Z(10)=R0 
Z(11)=4.36*10**5 
Z(12)=R0 
Z(13)=4.84*10**5 
Z(14)=R0 
Z(15)=6.34*10**5 
Z(16)=R0 
Z(17)=5.40*10**5 
Z(18)=R0 
Z(19)=5.29*10**5 
Z(20)=R0 
Z(21)=5.31*10**5 
Z(22)=R0 
Z(23)=R0 
END 
 
remark - differential equations 
DIFF 
 
remark growth control experiment 5/29/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 8/23/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 6/11/15 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
 
remark growth control experiment MEM resistant subpopulation 6/11/15 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
 
remark meropenem 4 mg/L time-kill experiment 5/20/14 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax)-kS)*Z(7) 
DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax)-kR*4)*Z(8) 
 
remark meropenem 16 mg/L time-kill experiment 5/20/14 
DZ(9)=(gS*(1-(Z(9)+Z(10))/Nmax)-kS)*Z(9) 
DZ(10)=(gR*(1-(Z(9)+Z(10))/Nmax)-kR*16)*Z(10) 
 
remark meropenem 64 mg/L time-kill experiment 5/20/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS)*Z(11) 
DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax)-kR*64)*Z(12) 
 
remark meropenem 4 mg/L time-kill experiment 6/10/14 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS)*Z(13) 
DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax)-kR*4)*Z(14) 
 
remark meropenem 16 mg/L time-kill experiment 6/10/14 
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DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS)*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax)-kR*16)*Z(16) 
 
remark meropenem 64 mg/L time-kill experiment 6/10/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS)*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax)-kR*64)*Z(18) 
 
remark meropenem 64 mg/L time-kill experiment 2/13/14 
DZ(19)=(gS*(1-(Z(19)+Z(20))/Nmax)-kS)*Z(19) 
DZ(20)=(gR*(1-(Z(19)+Z(20))/Nmax)-kR*64)*Z(20) 
 
remark meropenem 128 mg/L time-kill experiment 2/13/14 
DZ(21)=(gS*(1-(Z(21)+Z(22))/Nmax)-kS)*Z(21) 
DZ(22)=(gR*(1-(Z(21)+Z(22))/Nmax)-kR*128)*Z(22) 
 
remark meropenem 64 mg/L time-kill experiment 2/13/14 MEM resistant subpopulation MIC 
>64 mg/L 
DZ(23)=(gR*(1-(Z(19)+Z(23))/Nmax)-kR*64)*Z(23) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(6)) 
END 
FUNC 5 
F=log10(Z(7)+Z(8)) 
END 
FUNC 6 
F=log10(Z(9)+Z(10)) 
END 
FUNC 7 
F=log10(Z(11)+Z(12)) 
END 
FUNC 8 
F=log10(Z(13)+Z(14)) 
END 
FUNC 9 
F=log10(Z(15)+Z(16)) 
END 
FUNC 10 
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F=log10(Z(17)+Z(18)+1) 
END 
FUNC 11 
F=log10(Z(19)+Z(20)) 
END 
FUNC 12 
F=log10(Z(21)+Z(22)) 
END 
FUNC 13 
F=log10(Z(23)) 
END 
 
remark - secondary parameters 
SECO 
SCS=0 
SCR=gR/kR 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM
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MODEL 
remark  Two-Population Simple Net Effect Model 
remark  Klebsiella pneumoniae 24 
remark  Polymyxin B-susceptible and -resistant subpopulations 
remark  18 Functions, 34 Differential Equations, 6 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-17-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
remark  
remark kR 
 
remark - model-specific commands  
COMMANDS 
NFUN 18 
NDER 34 
NPAR 6 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'EC50S' 'kR' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
SIZE 6 
END 
 
TEMP 
R0=1 
END 
 
remark - differential equations starting values 
START 
Z(1)=1.77*10**6 
Z(2)=R0 
Z(3)=2.00*10**6 
Z(4)=R0 
Z(5)=2.46*10**6 
Z(6)=1.00*10**0 
Z(7)=4.26*10**5 
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Z(8)=R0 
Z(9)=4.85*10**5 
Z(10)=R0 
Z(11)=6.33*10**5 
Z(12)=R0 
Z(13)=7.29*10**5 
Z(14)=R0 
Z(15)=5.87*10**5 
Z(16)=R0 
Z(17)=6.26*10**5 
Z(18)=R0 
Z(19)=5.66*10**5 
Z(20)=R0 
Z(21)=6.72*10**5 
Z(22)=R0 
Z(23)=5.81*10**5 
Z(24)=R0 
Z(25)=3.37*10**5 
Z(26)=R0 
Z(27)=3.67*10**5 
Z(28)=R0 
Z(29)=7.51*10**5 
Z(30)=R0 
Z(31)=5.37*10**5 
Z(32)=R0 
Z(33)=5.04*10**5 
Z(34)=R0 
END 
 
remark - differential equations 
DIFF 
 
remark growth control experiment 5/29/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 8/23/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 6/11/15 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
 
remark growth control experiment PMB resistant subpopulation 6/11/15 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 5/20/14 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(7) 
DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax)-kR*(0.25))*Z(8) 
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remark polymyxin B 1 mg/L time-kill experiment 5/20/14 
DZ(9)=(gS*(1-(Z(9)+Z(10))/Nmax)-kS*(1/(1+EC50S)))*Z(9) 
DZ(10)=(gR*(1-(Z(9)+Z(10))/Nmax)-kR*(1))*Z(10) 
 
remark polymyxin B 2 mg/L time-kill experiment 5/29/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS*(2/(2+EC50S)))*Z(11) 
DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax)-kR*(2))*Z(12) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/29/14 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS*(4/(4+EC50S)))*Z(13) 
DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax)-kR*(4))*Z(14) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/10/14 
DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax)-kR*(0.0625))*Z(16) 
 
remark polymyxin B 2 mg/L time-kill experiment 6/10/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS*(2/(2+EC50S)))*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax)-kR*(2))*Z(18) 
 
remark polymyxin B 4 mg/L time-kill experiment 6/10/14 
DZ(19)=(gS*(1-(Z(19)+Z(20))/Nmax)-kS*(4/(4+EC50S)))*Z(19) 
DZ(20)=(gR*(1-(Z(19)+Z(20))/Nmax)-kR*(4))*Z(20) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 6/10/14 
DZ(21)=(gS*(1-(Z(21)+Z(22))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(21) 
DZ(22)=(gR*(1-(Z(21)+Z(22))/Nmax)-kR*(0.25))*Z(22) 
 
remark polymyxin B 1 mg/L time-kill experiment 6/10/14 
DZ(23)=(gS*(1-(Z(23)+Z(24))/Nmax)-kS*(1/(1+EC50S)))*Z(23) 
DZ(24)=(gR*(1-(Z(23)+Z(24))/Nmax)-kR*(1))*Z(24) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/18/14 
DZ(25)=(gS*(1-(Z(25)+Z(26))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(25) 
DZ(26)=(gR*(1-(Z(15)+Z(26))/Nmax)-kR*(0.0625))*Z(26) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 6/18/14 
DZ(27)=(gS*(1-(Z(27)+Z(28))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(27) 
DZ(28)=(gR*(1-(Z(27)+Z(28))/Nmax)-kR*(0.125))*Z(28) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 7/9/14 
DZ(29)=(gS*(1-(Z(29)+Z(30))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(29) 
DZ(30)=(gR*(1-(Z(29)+Z(30))/Nmax)-kR*(0.125))*Z(30) 
 
remark polymyxin B 2 mg/L time-kill experiment 8/23/17 
DZ(31)=(gS*(1-(Z(31)+Z(32))/Nmax)-kS*(2/(2+EC50S)))*Z(31) 
DZ(32)=(gR*(1-(Z(31)+Z(32))/Nmax)-kR*(2))*Z(32) 
 
remark polymyxin B 4 mg/L time-kill experiment 8/23/17 
DZ(33)=(gS*(1-(Z(33)+Z(34))/Nmax)-kS*(4/(4+EC50S)))*Z(33) 
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DZ(34)=(gR*(1-(Z(33)+Z(34))/Nmax)-kR*(4))*Z(34) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(6)) 
END 
FUNC 5 
F=log10(Z(7)+Z(8)) 
END 
FUNC 6 
F=log10(Z(9)+Z(10)) 
END 
FUNC 7 
F=log10(Z(11)+Z(12)) 
END 
FUNC 8 
F=log10(Z(13)+Z(14)) 
END 
FUNC 9 
F=log10(Z(15)+Z(16)) 
END 
FUNC 10 
F=log10(Z(17)+Z(18)) 
END 
FUNC 11 
F=log10(Z(19)+Z(20)) 
END 
FUNC 12 
F=log10(Z(21)+Z(22)) 
END 
FUNC 13 
F=log10(Z(23)+Z(24)) 
END 
FUNC 14 
F=log10(Z(25)+Z(26)) 
END 
FUNC 15 
F=log10(Z(27)+Z(28)) 
END 
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FUNC 16 
F=log10(Z(29)+Z(30)) 
END 
FUNC 17 
F=log10(Z(31)+Z(32)) 
END 
FUNC 18 
F=log10(Z(33)+Z(34)) 
END 
 
remark - secondary parameters 
SECO 
SCS=(gS/(kS-gS))*EC50S 
SCR=gR/kR 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Three-Population Simple Net Growth Model 
remark  Klebsiella pneumoniae 44 
remark  Growth Control Experiments with total and resistant subpopulations 6/11/15 
remark  6 Functions, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Jeffrey J. Campion, Brandon Kulengowski 
remark   Model Date: 7-17-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark gRHS 
remark  
remark gRLR 
remark  
remark Nmax 
 
remark - model-specific commands  
COMMANDS 
NFUN 6 
NDER 6 
NPAR 4 
PNAMES 'gRLS' 'gRHS' 'gRLR' 'Nmax' 
remark -initial estimates 2.6244093, 2.0018887, 1.1347168, 1.1476822E+11 
remark -gRLS and Nmax initial estimates from pooled model, gRHS and gRLR initial estimates 
from subpopulation model 
END 
 
remark - differential equations starting values 
START 
remark - RLS experiments 
Z(1)=1.63*10**6 
Z(2)=2.48*10**6 
Z(3)=4.29*10**6 
Z(4)=4.93*10**6 
remark - RHS experiment 
Z(5)=6.95*10**4 
remark - RLR experiment 
Z(6)=2.50*10**1 
END 
 
remark - differential equations 
DIFF 
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remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
1/26/14 
DZ(1)=(gRLS*(1-(Z(1)+Z(5)+Z(6))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
2/15/14 
DZ(2)=(gRLS*(1-(Z(2)+Z(5)+Z(6))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
3/30/14 
DZ(3)=(gRLS*(1-(Z(3)+Z(5)+Z(6))/Nmax))*Z(3) 
 
remark low-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(4)=(gRLS*(1-(Z(4)+Z(5)+Z(6))/Nmax))*Z(4) 
 
remark high-level meropenem-resistant and polymyxin B-susceptible subpopulation growth 
6/11/15 
DZ(5)=(gRHS*(1-(Z(4)+Z(5)+Z(6))/Nmax))*Z(5) 
 
remark low-level meropenem-resistant and polymyxin B-resistant subpopulation growth 6/11/15 
DZ(6)=(gRLR*(1-(Z(4)+Z(5)+Z(6))/Nmax))*Z(6) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
F=log10(Z(6)) 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Logistic Meropenem Initial Killing Model 
remark  Klebsiella pneumoniae 44 
remark  Growth Control Experiments with MEM initial killing 
remark  12 Functions, 12 differential equations, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Jeffrey J. Campion, Brandon Kulengowski 
remark   Model Date: 9-19-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
 
remark - model-specific commands  
COMMANDS 
NFUN 12 
NDER 12 
NPAR 4 
PNAMES 'gRLS' 'Nmax' 'kS' 'EC50S' 
NSEC 1 
SNAM 'SC' 
END 
 
remark - differential equations starting values 
START 
remark - Growth Control Experiments 
Z(1)=1.77*10**6 
Z(2)=2.00*10**6 
Z(3)=2.46*10**6 
Z(4)=4.93*10**6 
 
remark - MEM Experiments 
Z(5)=6.80*10**5 
Z(6)=6.97*10**5 
Z(7)=9.32*10**5 
Z(8)=1.34*10**6 
Z(9)=1.38*10**6 
Z(10)=7.32*10**5 
Z(11)=1.86*10**5 
Z(12)=8.30*10**5 
END 
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remark - differential equations 
DIFF 
 
remark low-level meropenem-resistant and high-level meropenem-resistant subpopulation 
growth 1/26/14 
DZ(1)=(gRLS*(1-(Z(1))/Nmax))*Z(1) 
 
remark low-level meropenem-resistant and high-level meropenem-resistant subpopulation 
growth 2/15/14 
DZ(2)=(gRLS*(1-(Z(2))/Nmax))*Z(2) 
 
remark low-level meropenem-resistant and high-level meropenem-resistant subpopulation 
growth 3/30/14 
DZ(3)=(gRLS*(1-(Z(3))/Nmax))*Z(3) 
 
remark low-level meropenem-resistant and high-level meropenem-resistant subpopulation 
growth 6/11/15 
DZ(4)=(gRLS*(1-(Z(4))/Nmax))*Z(4) 
 
remark MEM 4 monotherapy 1/26/14 
DZ(5)=(gRLS*(1-(Z(5))/Nmax)-(kS*(4/(4+EC50S))))*Z(5) 
 
remark MEM 16 monotherapy 1/26/14 
DZ(6)=(gRLS*(1-(Z(6))/Nmax)-(kS*(16/(16+EC50S))))*Z(6) 
 
remark MEM 64 monotherapy 1/26/14 
DZ(7)=(gRLS*(1-(Z(7))/Nmax)-(kS*(64/(64+EC50S))))*Z(7) 
 
remark MEM 4 monotherapy 5/14/14 
DZ(8)=(gRLS*(1-(Z(8))/Nmax)-(kS*(4/(4+EC50S))))*Z(8) 
 
remark MEM 16 monotherapy 5/14/14 
DZ(9)=(gRLS*(1-(Z(9))/Nmax)-(kS*(16/(16+EC50S))))*Z(9) 
 
remark MEM 64 monotherapy 5/20/14 
DZ(10)=(gRLS*(1-(Z(10))/Nmax)-(kS*(64/(64+EC50S))))*Z(10) 
 
remark MEM 64 monotherapy 2/13/17 
DZ(11)=(gRLS*(1-(Z(11))/Nmax)-(kS*(64/(64+EC50S))))*Z(11) 
 
remark MEM 128 monotherapy 2/13/17 
DZ(12)=(gRLS*(1-(Z(12))/Nmax)-(kS*(128/(128+EC50S))))*Z(12) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
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FUNC 2 
F=log10(Z(2)) 
END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
F=log10(Z(6)) 
END 
FUNC 7 
F=log10(Z(7)) 
END 
FUNC 8 
F=log10(Z(8)) 
END 
FUNC 9 
F=log10(Z(9)) 
END 
FUNC 10 
F=log10(Z(10)) 
END 
FUNC 11 
F=log10(Z(11)) 
END 
FUNC 12 
F=log10(Z(12)) 
END 
 
SECONDARY 
S(1)=(kS-gRLS)/gRLS*EC50S 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Logistic Polymyxin B Initial Killing Model 
remark  Klebsiella pneumoniae 44 
remark  Polymyxin B Monotherapy Initial Killing Phase 
remark  24 Functions, 24 differential equations, 4 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Jeffrey J. Campion, Brandon Kulengowski 
remark   Model Date: 7-23-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gRLS 
remark  
remark Nmax 
remark  
remark KmaxPMB 
remark  
remark EC50PMB 
 
remark - model-specific commands  
COMMANDS 
NFUN 24 
NDER 24 
NPAR 4 
PNAMES 'gRLS' 'Nmax' 'KmaxPMB' 'EC50PMB' 
remark -initial estimates 2.557385, 2.3627639E+11, 10.55, 0.041 
NSEC 1 
SNAM 'SC' 
END 
 
remark - differential equations starting values 
START 
remark ??? Growth experiments time-shifted T=0 and PMB monotherapy experiments count at 
T=0 
Z(1)=1.63E+06 
Z(2)=2.48E+06 
Z(3)=4.29E+06 
Z(4)=4.93E+06 
Z(5)=6.04E+05 
Z(6)=5.29E+05 
Z(7)=5.42E+05 
Z(8)=7.16E+05 
Z(9)=2.68E+05 
Z(10)=8.53E+05 
Z(11)=8.93E+05 
Z(12)=4.48E+05 
Z(13)=8.13E+05 
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Z(14)=9.82E+05 
Z(15)=6.47E+05 
Z(16)=6.18E+05 
Z(17)=4.75E+05 
Z(18)=5.56E+05 
Z(19)=6.53E+05 
Z(20)=5.87E+05 
Z(21)=7.75E+05 
Z(22)=1.10E+06 
Z(23)=9.48E+05 
Z(24)=1.02E+06 
END 
 
remark - differential equations 
DIFF 
remark growth control 
DZ(1)=(gRLS*(1-(Z(1))/Nmax)-(KmaxPMB*(0/(0+EC50PMB))))*Z(1) 
 
remark growth control 
DZ(2)=(gRLS*(1-(Z(2))/Nmax)-(KmaxPMB*(0/(0+EC50PMB))))*Z(2) 
 
remark growth control 
DZ(3)=(gRLS*(1-(Z(3))/Nmax)-(KmaxPMB*(0/(0+EC50PMB))))*Z(3) 
 
remark growth control 
DZ(4)=(gRLS*(1-(Z(4))/Nmax)-(KmaxPMB*(0/(0+EC50PMB))))*Z(4) 
 
remark PMB 0.0625 monotherapy 6/10/14 
DZ(5)=(gRLS*(1-(Z(5))/Nmax)-(KmaxPMB*(0.0625/(0.0625+EC50PMB))))*Z(5) 
 
remark PMB 0.0625 monotherapy 6/18/14 
DZ(6)=(gRLS*(1-(Z(6))/Nmax)-(KmaxPMB*(0.0625/(0.0625+EC50PMB))))*Z(6) 
 
remark PMB 0.125 monotherapy 6/18/14 
DZ(7)=(gRLS*(1-(Z(7))/Nmax)-(KmaxPMB*(0.125/(0.125+EC50PMB))))*Z(7) 
 
remark PMB 0.125 monotherapy 7/9/14 
DZ(8)=(gRLS*(1-(Z(8))/Nmax)-(KmaxPMB*(0.125/(0.125+EC50PMB))))*Z(8) 
 
remark PMB 0.25 monotherapy 3/30/14 
DZ(9)=(gRLS*(1-(Z(9))/Nmax)-(KmaxPMB*(0.25/(0.25+EC50PMB))))*Z(9) 
 
remark PMB 0.25 monotherapy 4/19/14 
DZ(10)=(gRLS*(1-(Z(10))/Nmax)-(KmaxPMB*(0.25/(0.25+EC50PMB))))*Z(10) 
 
remark PMB 0.25 monotherapy 5/14/14 
DZ(11)=(gRLS*(1-(Z(11))/Nmax)-(KmaxPMB*(0.25/(0.25+EC50PMB))))*Z(11) 
 
remark PMB 1 monotherapy 3/30/14 
DZ(12)=(gRLS*(1-(Z(12))/Nmax)-(KmaxPMB*(1/(1+EC50PMB))))*Z(12) 
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remark PMB 1 monotherapy 4/19/14 
DZ(13)=(gRLS*(1-(Z(13))/Nmax)-(KmaxPMB*(1/(1+EC50PMB))))*Z(13) 
 
remark PMB 1 monotherapy 5/14/14 
DZ(14)=(gRLS*(1-(Z(14))/Nmax)-(KmaxPMB*(1/(1+EC50PMB))))*Z(14) 
 
remark PMB 2 monotherapy 5/29/14 
DZ(15)=(gRLS*(1-(Z(15))/Nmax)-(KmaxPMB*(2/(2+EC50PMB))))*Z(15) 
 
remark PMB 2 monotherapy 6/10/14 
DZ(16)=(gRLS*(1-(Z(16))/Nmax)-(KmaxPMB*(2/(2+EC50PMB))))*Z(16) 
 
remark PMB 2 monotherapy 8/23/14 
DZ(17)=(gRLS*(1-(Z(17))/Nmax)-(KmaxPMB*(2/(2+EC50PMB))))*Z(17) 
 
remark PMB 4 monotherapy 5/20/14 
DZ(18)=(gRLS*(1-(Z(18))/Nmax)-(KmaxPMB*(4/(4+EC50PMB))))*Z(18) 
 
remark PMB 4 monotherapy 5/29/14 
DZ(19)=(gRLS*(1-(Z(19))/Nmax)-(KmaxPMB*(4/(4+EC50PMB))))*Z(19) 
 
remark PMB 4 monotherapy 6/10/14 
DZ(20)=(gRLS*(1-(Z(20))/Nmax)-(KmaxPMB*(4/(4+EC50PMB))))*Z(20) 
 
remark PMB 4 monotherapy 7/9/14 
DZ(21)=(gRLS*(1-(Z(21))/Nmax)-(KmaxPMB*(4/(4+EC50PMB))))*Z(21) 
 
remark PMB 4 monotherapy 8/23/14 
DZ(22)=(gRLS*(1-(Z(22))/Nmax)-(KmaxPMB*(4/(4+EC50PMB))))*Z(22) 
 
remark PMB 4 monotherapy 2/13/17 
DZ(23)=(gRLS*(1-(Z(23))/Nmax)-(KmaxPMB*(4/(4+EC50PMB))))*Z(23) 
 
remark PMB 8 monotherapy 2/13/17 
DZ(24)=(gRLS*(1-(Z(24))/Nmax)-(KmaxPMB*(8/(8+EC50PMB))))*Z(24) 
 
END 
 
SECONDARY 
remark -Stationary concentration 
S(1)=(KmaxPMB-gRLS)/gRLS*EC50PMB 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)) 
END 
FUNC 2 
F=log10(Z(2)) 
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END 
FUNC 3 
F=log10(Z(3)) 
END 
FUNC 4 
F=log10(Z(4)) 
END 
FUNC 5 
F=log10(Z(5)) 
END 
FUNC 6 
F=log10(Z(6)) 
END 
FUNC 7 
F=log10(Z(7)) 
END 
FUNC 8 
F=log10(Z(8)) 
END 
FUNC 9 
F=log10(Z(9)) 
END 
FUNC 10 
F=log10(Z(10)) 
END 
FUNC 11 
F=log10(Z(11)) 
END 
FUNC 12 
F=log10(Z(12)) 
END 
FUNC 13 
F=log10(Z(13)) 
END 
FUNC 14 
F=log10(Z(14)) 
END 
FUNC 15 
F=log10(Z(15)) 
END 
FUNC 16 
F=log10(Z(16)) 
END 
FUNC 17 
F=log10(Z(17)) 
END 
FUNC 18 
F=log10(Z(18)) 
END 
FUNC 19 
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F=log10(Z(19)) 
END 
FUNC 20 
F=log10(Z(20)) 
END 
FUNC 21 
F=log10(Z(21)) 
END 
FUNC 22 
F=log10(Z(22)) 
END 
FUNC 23 
F=log10(Z(23)) 
END 
FUNC 24 
F=log10(Z(24)) 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Two-Population Meropenem Simple Net Effect Model 
remark  Klebsiella pneumoniae 44 
remark  Meropenem-low-resistant and high-resistant subpopulations 
remark  13 Functions, 24 Differential Equations, 5 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Jeffrey J. Campion, Brandon Kulengowski 
remark   Model Date: 9-17-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
 
remark - model-specific commands  
COMMANDS 
NFUN 13 
NDER 24 
NPAR 5 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'EC50S' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
SIZE 6 
END 
 
TEMP 
R0=0.52 
END 
 
remark - differential equations starting values 
START 
Z(1)=1.63*10**6 
Z(2)=R0 
Z(3)=2.48*10**6 
Z(4)=R0 
Z(5)=4.29*10**6 
Z(6)=R0 
Z(23)=4.93*10**6 
Z(24)=2.58*10**5 
Z(7)=6.80*10**5 
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Z(8)=R0 
Z(9)=6.97*10**5 
Z(10)=R0 
Z(11)=9.32*10**5 
Z(12)=R0 
Z(13)=1.34*10**6 
Z(14)=R0 
Z(15)=1.38*10**6 
Z(16)=R0 
Z(17)=7.32*10**5 
Z(18)=R0 
Z(19)=8.75*10**5 
Z(20)=R0 
Z(21)=8.30*10**5 
Z(22)=R0 
END 
 
remark - differential equations 
DIFF 
 
remark growth control experiment 1/26/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 2/15/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 3/30/14 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
 
remark growth control experiment MEM low-resistance subpopulation 6/11/15 
DZ(23)=(gS*(1-(Z(23)+Z(24))/Nmax))*Z(23) 
 
remark    growth control experiment MEM high-resistance subpopulation 6/11/15 
DZ(24)=(gR*(1-(Z(23)+Z(24))/Nmax))*Z(24) 
 
remark meropenem 4 mg/L time-kill experiment 1/26/14 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax)-kS*(4/(4+EC50S)))*Z(7) 
DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax))*Z(8) 
 
remark meropenem 16 mg/L time-kill experiment 1/26/14 
DZ(9)=(gS*(1-(Z(9)+Z(10))/Nmax)-kS*(16/(16+EC50S)))*Z(9) 
DZ(10)=(gR*(1-(Z(9)+Z(10))/Nmax))*Z(10) 
 
remark meropenem 64 mg/L time-kill experiment 1/26/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS*(64/(64+EC50S)))*Z(11) 
DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax))*Z(12) 
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remark meropenem 4 mg/L time-kill experiment 5/14/14 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS*(4/(4+EC50S)))*Z(13) 
DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax))*Z(14) 
 
remark meropenem 64 mg/L time-kill experiment 5/14/14 
DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS*(64/(64+EC50S)))*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax))*Z(16) 
 
remark meropenem 16 mg/L time-kill experiment 5/20/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS*(16/(16+EC50S)))*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax))*Z(18) 
 
remark meropenem 64 mg/L time-kill experiment 2/13/14 
DZ(19)=(gS*(1-(Z(19)+Z(20))/Nmax)-kS*(64/(64+EC50S)))*Z(19) 
DZ(20)=(gR*(1-(Z(19)+Z(20))/Nmax))*Z(20) 
 
remark meropenem 128 mg/L time-kill experiment 2/13/14 
DZ(21)=(gS*(1-(Z(21)+Z(22))/Nmax)-kS*(128/(128+EC50S)))*Z(21) 
DZ(22)=(gR*(1-(Z(21)+Z(22))/Nmax))*Z(22) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(23)+Z(24)) 
END 
FUNC 5 
F=log10(Z(24)) 
END 
FUNC 6 
F=log10(Z(7)+Z(8)) 
END 
FUNC 7 
F=log10(Z(9)+Z(10)) 
END 
FUNC 8 
F=log10(Z(11)+Z(12)) 
END 
FUNC 9 
F=log10(Z(13)+Z(14)) 
END 
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FUNC 10 
F=log10(Z(15)+Z(16)) 
END 
FUNC 11 
F=log10(Z(17)+Z(18)) 
END 
FUNC 12 
F=log10(Z(19)+Z(20)) 
END 
FUNC 13 
F=log10(Z(21)+Z(22)) 
END 
 
 
remark - secondary parameters 
SECO 
SCS=(gS/(kS-gS))*EC50S 
SCR=0 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM 
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MODEL 
remark  Two-Population Polymyxin B Simple Net Effect Model 
remark  Klebsiella pneumoniae 44 
remark  Polymyxin B-susceptible and -resistant subpopulations 
remark  25 Functions, 43 Differential Equations, 5 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Jeffrey J. Campion, Brandon Kulengowski 
remark   Model Date: 9-6-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark  kR 
remark 
 
remark - model-specific commands  
COMMANDS 
NFUN 25 
NDER 43 
NPAR 5 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'kR' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
END 
 
TEMP 
R0=44 
END 
 
remark - differential equations starting values 
START 
Z(1)=1.63*10**6 
Z(2)=R0 
Z(3)=2.48*10**6 
Z(4)=R0 
Z(5)=4.29*10**6 
Z(6)=R0 
Z(7)=4.93*10**6 
Z(8)=2.50*10**1 
Z(9)=6.04*10**5 
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Z(10)=5.29*10**5 
Z(11)=5.42*10**5 
Z(12)=R0 
Z(13)=7.16*10**5 
Z(14)=R0 
Z(15)=2.68*10**5 
Z(16)=R0 
Z(17)=8.53*10**5 
Z(18)=R0 
Z(19)=8.93*10**5 
Z(20)=R0 
Z(21)=4.48*10**5 
Z(22)=R0 
Z(23)=8.13*10**5 
Z(24)=R0 
Z(25)=9.82*10**5 
Z(26)=R0 
Z(27)=6.47*10**5 
Z(28)=R0 
Z(29)=6.18*10**5 
Z(30)=R0 
Z(31)=4.75*10**5 
Z(32)=R0 
Z(33)=5.56*10**5 
Z(34)=6.53*10**5 
Z(35)=R0 
Z(36)=5.87*10**5 
Z(37)=R0 
Z(38)=7.75*10**5 
Z(39)=R0 
Z(40)=1.10*10**6 
Z(41)=R0 
Z(42)=9.48*10**5 
Z(43)=R0 
END 
 
remark - differential equations 
DIFF 
 
remark growth control experiment 1/26/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 2/15/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 3/30/14 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
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remark polymyxin B-susceptible subpopulation growth 6/11/15 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax))*Z(7) 
 
remark polymyxin B-resistant subpopulation growth 6/11/15 
DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax))*Z(8) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/10/14 
DZ(9)=(gS*(1-(Z(9))/Nmax)-kS)*Z(9) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/18/14 
DZ(10)=(gS*(1-(Z(10))/Nmax)-kS)*Z(10) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 6/18/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS)*Z(11) 
DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax)-kR*0.125)*Z(12) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 7/9/14 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS)*Z(13) 
DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax)-kR*0.125)*Z(14) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 3/30/14 
DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS)*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax)-kR*0.25)*Z(16) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 4/19/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS)*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax)-kR*0.25)*Z(18) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 5/14/14 
DZ(19)=(gS*(1-(Z(19)+Z(20))/Nmax)-kS)*Z(19) 
DZ(20)=(gR*(1-(Z(19)+Z(20))/Nmax)-kR*0.25)*Z(20) 
 
remark polymyxin B 1 mg/L time-kill experiment 3/30/14 
DZ(21)=(gS*(1-(Z(21)+Z(22))/Nmax)-kS)*Z(21) 
DZ(22)=(gR*(1-(Z(21)+Z(22))/Nmax)-kR*1)*Z(22) 
 
remark polymyxin B 1 mg/L time-kill experiment 4/19/14 
DZ(23)=(gS*(1-(Z(23)+Z(24))/Nmax)-kS)*Z(23) 
DZ(24)=(gR*(1-(Z(23)+Z(24))/Nmax)-kR*1)*Z(24) 
 
remark polymyxin B 1 mg/L time-kill experiment 5/14/14 
DZ(25)=(gS*(1-(Z(25)+Z(26))/Nmax)-kS)*Z(25) 
DZ(26)=(gR*(1-(Z(25)+Z(26))/Nmax)-kR*1)*Z(26) 
 
remark polymyxin B 2 mg/L time-kill experiment 5/29/14 
DZ(27)=(gS*(1-(Z(27)+Z(28))/Nmax)-kS)*Z(27) 
DZ(28)=(gR*(1-(Z(27)+Z(28))/Nmax)-kR*2)*Z(28) 
 
remark polymyxin B 2 mg/L time-kill experiment 6/10/14 
 
 
Table G.20: Isolate 44 Polymyxin B Monotherapy Model Code 
478 
 
DZ(29)=(gS*(1-(Z(29)+Z(30))/Nmax)-kS)*Z(29) 
DZ(30)=(gR*(1-(Z(29)+Z(30))/Nmax)-kR*2)*Z(30) 
 
remark polymyxin B 2 mg/L time-kill experiment 8/23/14 
DZ(31)=(gS*(1-(Z(31)+Z(32))/Nmax)-kS)*Z(31) 
DZ(32)=(gR*(1-(Z(31)+Z(32))/Nmax)-kR*2)*Z(32) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/20/14 
DZ(33)=(gS*(1-(Z(33))/Nmax)-kS)*Z(33) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/29/14 
DZ(34)=(gS*(1-(Z(34)+Z(35))/Nmax)-kS)*Z(34) 
DZ(35)=(gR*(1-(Z(34)+Z(35))/Nmax)-kR*4)*Z(35) 
 
remark polymyxin B 4 mg/L time-kill experiment 6/10/14 
DZ(36)=(gS*(1-(Z(36)+Z(37))/Nmax)-kS)*Z(36) 
DZ(37)=(gR*(1-(Z(36)+Z(37))/Nmax)-kR*4)*Z(37) 
 
remark polymyxin B 4 mg/L time-kill experiment 7/9/14 
DZ(38)=(gS*(1-(Z(38)+Z(39))/Nmax)-kS)*Z(38) 
DZ(39)=(gR*(1-(Z(38)+Z(39))/Nmax)-kR*4)*Z(39) 
 
remark polymyxin B 4 mg/L time-kill experiment 8/23/14 
DZ(40)=(gS*(1-(Z(40)+Z(41))/Nmax)-kS)*Z(40) 
DZ(41)=(gR*(1-(Z(40)+Z(41))/Nmax)-kR*4)*Z(41) 
 
remark polymyxin B-susceptible subpopulation for polymyxin B 4 mg/L time-kill experiment 
2/13/17 
DZ(42)=(gS*(1-(Z(42)+Z(43))/Nmax)-kS)*Z(42) 
 
remark polymyxin B-resistant subpopulation for polymyxin B 4 mg/L time-kill experiment 
2/13/17 
DZ(43)=(gR*(1-(Z(42)+Z(43))/Nmax)-kR*4)*Z(43) 
 
END 
 
remark - algebraic functions 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(7)) 
END 
FUNC 5 
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F=log10(Z(8)) 
END 
FUNC 6 
F=log10(Z(9)) 
END 
FUNC 7 
F=log10(Z(10)) 
END 
FUNC 8 
F=log10(Z(11)+Z(12)) 
END 
FUNC 9 
F=log10(Z(13)+Z(14)) 
END 
FUNC 10 
F=log10(Z(15)+Z(16)) 
END 
FUNC 11 
F=log10(Z(17)+Z(18)) 
END 
FUNC 12 
F=log10(Z(19)+Z(20)) 
END 
FUNC 13 
F=log10(Z(21)+Z(22)) 
END 
FUNC 14 
F=log10(Z(23)+Z(24)) 
END 
FUNC 15 
F=log10(Z(25)+Z(26)) 
END 
FUNC 16 
F=log10(Z(27)+Z(28)) 
END 
FUNC 17 
F=log10(Z(29)+Z(30)) 
END 
FUNC 18 
F=log10(Z(31)+Z(32)) 
END 
FUNC 19 
F=log10(Z(33)) 
END 
FUNC 20 
F=log10(Z(34)+Z(35)) 
END 
FUNC 21 
F=log10(Z(36)+Z(37)) 
END 
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FUNC 22 
F=log10(Z(38)+Z(39)) 
END 
FUNC 23 
F=log10(Z(40)+Z(41)) 
END 
FUNC 24 
F=log10(Z(42)) 
END 
FUNC 25 
F=log10(Z(43)) 
END 
 
remark - secondary parameters 
SECO 
SCS=0 
SCR=gR/kR 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM
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MODEL 
remark  Two-Population Meropenem Composite Simple Net Effect Model 
remark  Klebsiella pneumoniae isolates 34, 22, 24, 44 
remark  Meropenem low and high resistant subpopulations 
remark  52 Functions, 93 Differential Equations, 6 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-22-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
remark  
remark kR 
 
remark - model-specific commands  
COMMANDS 
NFUN 52 
NDER 93 
NPAR 6 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'EC50S' 'kR' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
SIZE 15 
END 
 
TEMP 
remark - initial inocula 
R034=64.2 
R022=13 
R024=3.27 
R044=0.52 
 
remark - static concentrations 
c34=4 
c22=16 
c24=32 
c44=128 
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END 
 
remark - differential equations starting values 
START 
 
remark - isolate 34 initial conditions 
 
Z(1)=2.63*10**6 
Z(2)=R034 
Z(3)=4.44*10**6 
Z(4)=R034 
Z(5)=1.13*10**7 
Z(6)=R034 
Z(23)=1.14*10**7 
Z(24)=3.71*10**2 
Z(7)=8.06*10**5 
Z(8)=R034 
Z(9)=7.48*10**5 
Z(10)=R034 
Z(11)=6.54*10**5 
Z(12)=R034 
Z(13)=1.04*10**6 
Z(14)=R034 
Z(15)=4.85*10**5 
Z(16)=R034 
Z(17)=7.54*10**5 
Z(18)=R034 
Z(19)=7.59*10**5 
Z(20)=R034 
Z(21)=1.14*10**6 
Z(22)=R034 
 
remark - isolate 22 initial conditions 
 
Z(25)=3.14*10**6 
Z(26)=R022 
Z(27)=2.51*10**6 
Z(28)=R022 
Z(29)=6.23*10**6 
Z(30)=7.93*10**2 
Z(31)=1.70*10**6 
Z(32)=R022 
Z(33)=1.26*10**6 
Z(34)=R022 
Z(35)=9.34*10**5 
Z(36)=R022 
Z(37)=6.11*10**5 
Z(38)=R022 
Z(39)=3.52*10**5 
Z(40)=R022 
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Z(41)=5.28*10**5 
Z(42)=R022 
Z(43)=7.82*10**5 
Z(44)=R022 
Z(45)=8.00*10**5 
Z(46)=R022 
 
remark - isolate 24 initial conditions 
 
Z(47)=1.77*10**6 
Z(48)=R024 
Z(49)=2.00*10**6 
Z(50)=R024 
Z(51)=2.446*10**6 
Z(52)=5.7*10**1 
Z(53)=4.79*10**5 
Z(54)=R024 
Z(55)=5.68*10**5 
Z(56)=R024 
Z(57)=4.36*10**5 
Z(58)=R024 
Z(59)=4.84*10**5 
Z(60)=R024 
Z(61)=6.34*10**5 
Z(62)=R024 
Z(63)=5.40*10**5 
Z(64)=R024 
Z(65)=5.29*10**5 
Z(66)=R024 
Z(67)=5.31*10**5 
Z(68)=R024 
Z(69)=R024 
 
remark - isolate 44 initial conditions 
 
Z(70)=1.63*10**6 
Z(71)=R044 
Z(72)=2.48*10**6 
Z(73)=R044 
Z(74)=4.29*10**6 
Z(75)=R044 
Z(76)=4.93*10**6 
Z(77)=2.58*10**5 
Z(78)=6.80*10**5 
Z(79)=R044 
Z(80)=6.97*10**5 
Z(81)=R044 
Z(82)=9.32*10**5 
Z(83)=R044 
Z(84)=1.34*10**6 
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Z(85)=R044 
Z(86)=1.38*10**6 
Z(87)=R044 
Z(88)=7.32*10**5 
Z(89)=R044 
Z(90)=8.75*10**5 
Z(91)=R044 
Z(92)=8.30*10**5 
Z(93)=R044 
 
END 
 
remark - differential equations 
DIFF 
 
remark - isolate 34 DEs 
remark - All MEM doses are normalized to 4 mg/L 
 
remark growth control experiment 1/26/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 2/15/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 3/30/14 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
 
remark growth control experiment MEM low-resistance subpopulation 6/11/15 
DZ(23)=(gS*(1-(Z(23)+Z(24))/Nmax))*Z(23) 
 
remark    growth control experiment MEM high-resistance subpopulation 6/11/15 
DZ(24)=(gR*(1-(Z(23)+Z(24))/Nmax))*Z(24) 
 
remark meropenem 4 mg/L time-kill experiment 1/26/14 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax)-kS*((4/c34)/((4/c34)+EC50S)))*Z(7) 
DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax)-kR*((4/c34)))*Z(8) 
 
remark meropenem 16 mg/L time-kill experiment 1/26/14 
DZ(9)=(gS*(1-(Z(9)+Z(10))/Nmax)-kS*((16/c34)/((16/c34)+EC50S)))*Z(9) 
DZ(10)=(gR*(1-(Z(9)+Z(10))/Nmax)-kR*((16/c34)))*Z(10) 
 
remark meropenem 64 mg/L time-kill experiment 1/26/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS*((64/c34)/((64/c34)+EC50S)))*Z(11) 
DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax)-kR*((64/c34)))*Z(12) 
 
remark meropenem 4 mg/L time-kill experiment 5/14/14 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS*((4/c34)/((4/C34)+EC50S)))*Z(13) 
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DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax)-kR*((4/c34)))*Z(14) 
 
remark meropenem 16 mg/L time-kill experiment 5/14/14 
DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS*((16/c34)/((16/C34)+EC50S)))*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax)-kR*((16/c34)))*Z(16) 
 
remark meropenem 64 mg/L time-kill experiment 5/20/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS*((64/c34)/((64/C34)+EC50S)))*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax)-kR*((64/c34)))*Z(18) 
 
remark meropenem 8 mg/L time-kill experiment 2/13/14 
DZ(19)=(gS*(1-(Z(19)+Z(20))/Nmax)-kS*((8/c34)/((8/C34)+EC50S)))*Z(19) 
DZ(20)=(gR*(1-(Z(19)+Z(20))/Nmax)-kR*((8/c34)))*Z(20) 
 
remark meropenem 16 mg/L time-kill experiment 2/13/14 
DZ(21)=(gS*(1-(Z(21)+Z(22))/Nmax)-kS*((16/c34)/((16/C34)+EC50S)))*Z(21) 
DZ(22)=(gR*(1-(Z(21)+Z(22))/Nmax)-kR*((16/c34)))*Z(22) 
 
remark - isolate 22 DEs 
remark - All MEM doses are normalized to 16 mg/L 
 
remark growth control experiment 5/29/14 
DZ(25)=(gS*(1-(Z(25)+Z(26))/Nmax))*Z(25) 
DZ(26)=(gR*(1-(Z(25)+Z(26))/Nmax))*Z(26) 
 
remark growth control experiment 8/23/14 
DZ(27)=(gS*(1-(Z(27)+Z(28))/Nmax))*Z(27) 
DZ(28)=(gR*(1-(Z(27)+Z(28))/Nmax))*Z(28) 
 
remark growth control experiment 6/11/15 
DZ(29)=(gS*(1-(Z(29)+Z(30))/Nmax))*Z(29) 
 
remark growth control experiment MEM resistant subpopulation 6/11/15 
DZ(30)=(gR*(1-(Z(29)+Z(30))/Nmax))*Z(30) 
 
remark meropenem 4 mg/L time-kill experiment 5/14/14 
DZ(31)=(gS*(1-(Z(31)+Z(32))/Nmax)-kS*((4/c22)/((4/c22)+EC50S)))*Z(31) 
DZ(32)=(gR*(1-(Z(31)+Z(32))/Nmax)-kR*((4/c22)))*Z(32) 
 
remark meropenem 16 mg/L time-kill experiment 5/14/14 
DZ(33)=(gS*(1-(Z(33)+Z(34))/Nmax)-kS*((16/c22)/((16/c22)+EC50S)))*Z(33) 
DZ(34)=(gR*(1-(Z(33)+Z(34))/Nmax)-kR*((16/c22)))*Z(34) 
 
remark meropenem 64 mg/L time-kill experiment 5/20/14 
DZ(35)=(gS*(1-(Z(35)+Z(36))/Nmax)-kS*((64/c22)/((64/c22)+EC50S)))*Z(35) 
DZ(36)=(gR*(1-(Z(35)+Z(36))/Nmax)-kR*((64/c22)))*Z(36) 
 
remark meropenem 4 mg/L time-kill experiment 5/20/14 
DZ(37)=(gS*(1-(Z(37)+Z(38))/Nmax)-kS*((4/c22)/((4/c22)+EC50S)))*Z(37) 
DZ(38)=(gR*(1-(Z(37)+Z(38))/Nmax)-kR*((4/c22)))*Z(38) 
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remark meropenem 16 mg/L time-kill experiment 5/29/14 
DZ(39)=(gS*(1-(Z(39)+Z(40))/Nmax)-kS*((16/c22)/((16/c22)+EC50S)))*Z(39) 
DZ(40)=(gR*(1-(Z(39)+Z(40))/Nmax)-kR*((16/c22)))*Z(40) 
 
remark meropenem 64 mg/L time-kill experiment 5/29/14 
DZ(41)=(gS*(1-(Z(41)+Z(42))/Nmax)-kS*((64/c22)/((64/c22)+EC50S)))*Z(41) 
DZ(42)=(gR*(1-(Z(41)+Z(42))/Nmax)-kR*((64/c22)))*Z(42) 
 
remark meropenem 16 mg/L time-kill experiment 2/13/14 
DZ(43)=(gS*(1-(Z(43)+Z(44))/Nmax)-kS*((16/c22)/((16/c22)+EC50S)))*Z(43) 
 
remark meropenem 16 mg/L time-kill resistant subpopulation experiment 2/13/14 
DZ(44)=(gR*(1-(Z(43)+Z(44))/Nmax)-kR*((16/c22)))*Z(44) 
 
remark meropenem 32 mg/L time-kill experiment 2/13/14 
DZ(45)=(gS*(1-(Z(45)+Z(46))/Nmax)-kS*((32/c22)/((32/c22)+EC50S)))*Z(45) 
 
remark meropenem 32 mg/L time-kill resistant subpopulation experiment 2/13/14 
DZ(46)=(gR*(1-(Z(45)+Z(46))/Nmax)-kR*((32/c22)))*Z(46) 
 
remark - isolate 24 DEs 
remark - All MEM doses are normalized to 32 mg/L 
 
remark growth control experiment 5/29/14 
DZ(47)=(gS*(1-(Z(47)+Z(48))/Nmax))*Z(47) 
DZ(48)=(gR*(1-(Z(47)+Z(48))/Nmax))*Z(48) 
 
remark growth control experiment 8/23/14 
DZ(49)=(gS*(1-(Z(49)+Z(50))/Nmax))*Z(49) 
DZ(50)=(gR*(1-(Z(49)+Z(50))/Nmax))*Z(50) 
 
remark growth control experiment 6/11/15 
DZ(51)=(gS*(1-(Z(51)+Z(52))/Nmax))*Z(51) 
 
remark growth control experiment MEM resistant subpopulation 6/11/15 
DZ(52)=(gR*(1-(Z(51)+Z(52))/Nmax))*Z(52) 
 
remark meropenem 4 mg/L time-kill experiment 5/20/14 
DZ(53)=(gS*(1-(Z(53)+Z(54))/Nmax)-kS*((4/c24)/((4/c24)+EC50S)))*Z(53) 
DZ(54)=(gR*(1-(Z(53)+Z(54))/Nmax)-kR*((4/c24)))*Z(54) 
 
remark meropenem 16 mg/L time-kill experiment 5/20/14 
DZ(55)=(gS*(1-(Z(55)+Z(56))/Nmax)-kS*((16/c24)/((16/c24)+EC50S)))*Z(55) 
DZ(56)=(gR*(1-(Z(55)+Z(56))/Nmax)-kR*((16/c24)))*Z(56) 
 
remark meropenem 64 mg/L time-kill experiment 5/20/14 
DZ(57)=(gS*(1-(Z(57)+Z(58))/Nmax)-kS*((64/c24)/((64/c24)+EC50S)))*Z(57) 
DZ(58)=(gR*(1-(Z(57)+Z(58))/Nmax)-kR*((64/c24)))*Z(58) 
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remark meropenem 4 mg/L time-kill experiment 6/10/14 
DZ(59)=(gS*(1-(Z(59)+Z(60))/Nmax)-kS*((4/c24)/((4/c24)+EC50S)))*Z(59) 
DZ(60)=(gR*(1-(Z(59)+Z(60))/Nmax)-kR*((4/c24)))*Z(60) 
 
remark meropenem 16 mg/L time-kill experiment 6/10/14 
DZ(61)=(gS*(1-(Z(61)+Z(62))/Nmax)-kS*((16/c24)/((16/c24)+EC50S)))*Z(61) 
DZ(62)=(gR*(1-(Z(61)+Z(62))/Nmax)-kR*((16/c24)))*Z(62) 
 
remark meropenem 64 mg/L time-kill experiment 6/10/14 
DZ(63)=(gS*(1-(Z(63)+Z(64))/Nmax)-kS*((64/c24)/((64/c24)+EC50S)))*Z(63) 
DZ(64)=(gR*(1-(Z(63)+Z(64))/Nmax)-kR*((64/c24)))*Z(64) 
 
remark meropenem 64 mg/L time-kill experiment 2/13/14 
DZ(65)=(gS*(1-(Z(65)+Z(66))/Nmax)-kS*((64/c24)/((64/c24)+EC50S)))*Z(65) 
DZ(66)=(gR*(1-(Z(65)+Z(66))/Nmax)-kR*((64/c24)))*Z(66) 
 
remark meropenem 128 mg/L time-kill experiment 2/13/14 
DZ(67)=(gS*(1-(Z(67)+Z(68))/Nmax)-kS*((128/c24)/((128/c24)+EC50S)))*Z(67) 
DZ(68)=(gR*(1-(Z(67)+Z(68))/Nmax)-kR*((128/c24)))*Z(68) 
 
remark meropenem 64 mg/L time-kill experiment 2/13/14 MEM resistant subpopulation MIC 
>64 mg/L 
DZ(69)=(gR*(1-(Z(65)+Z(69))/Nmax)-kR*((64/c24)))*Z(69) 
 
remark - isolate 44 DEs 
remark - All MEM doses are normalized to 128 mg/L 
 
remark growth control experiment 1/26/14 
DZ(70)=(gS*(1-(Z(70)+Z(71))/Nmax))*Z(70) 
DZ(71)=(gR*(1-(Z(70)+Z(71))/Nmax))*Z(71) 
 
remark growth control experiment 2/15/14 
DZ(72)=(gS*(1-(Z(72)+Z(73))/Nmax))*Z(72) 
DZ(73)=(gR*(1-(Z(72)+Z(73))/Nmax))*Z(73) 
 
remark growth control experiment 3/30/14 
DZ(74)=(gS*(1-(Z(74)+Z(75))/Nmax))*Z(74) 
DZ(75)=(gR*(1-(Z(74)+Z(75))/Nmax))*Z(75) 
 
remark growth control experiment MEM low-resistance subpopulation 6/11/15 
DZ(76)=(gS*(1-(Z(76)+Z(77))/Nmax))*Z(76) 
 
remark    growth control experiment MEM high-resistance subpopulation 6/11/15 
DZ(77)=(gR*(1-(Z(76)+Z(77))/Nmax))*Z(77) 
 
remark meropenem 4 mg/L time-kill experiment 1/26/14 
DZ(78)=(gS*(1-(Z(78)+Z(79))/Nmax)-kS*((4/c44)/((4/c44)+EC50S)))*Z(78) 
DZ(79)=(gR*(1-(Z(78)+Z(79))/Nmax)-kR*((4/c44)))*Z(79) 
 
remark meropenem 16 mg/L time-kill experiment 1/26/14 
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DZ(80)=(gS*(1-(Z(80)+Z(81))/Nmax)-kS*((16/c44)/((16/c44)+EC50S)))*Z(80) 
DZ(81)=(gR*(1-(Z(80)+Z(81))/Nmax)-kR*((16/c44)))*Z(81) 
 
remark meropenem 64 mg/L time-kill experiment 1/26/14 
DZ(82)=(gS*(1-(Z(82)+Z(83))/Nmax)-kS*((64/c44)/((64/c44)+EC50S)))*Z(82) 
DZ(83)=(gR*(1-(Z(82)+Z(83))/Nmax)-kR*((64/c44)))*Z(83) 
 
remark meropenem 4 mg/L time-kill experiment 5/14/14 
DZ(84)=(gS*(1-(Z(84)+Z(85))/Nmax)-kS*((4/c44)/((4/c44)+EC50S)))*Z(84) 
DZ(85)=(gR*(1-(Z(84)+Z(85))/Nmax)-kR*((4/c44)))*Z(85) 
 
remark meropenem 64 mg/L time-kill experiment 5/14/14 
DZ(86)=(gS*(1-(Z(86)+Z(87))/Nmax)-kS*((64/c44)/((64/c44)+EC50S)))*Z(86) 
DZ(87)=(gR*(1-(Z(86)+Z(87))/Nmax)-kR*((64/c44)))*Z(87) 
 
remark meropenem 16 mg/L time-kill experiment 5/20/14 
DZ(88)=(gS*(1-(Z(88)+Z(89))/Nmax)-kS*((16/c44)/((16/c44)+EC50S)))*Z(88) 
DZ(89)=(gR*(1-(Z(88)+Z(89))/Nmax)-kR*((16/c44)))*Z(89) 
 
remark meropenem 64 mg/L time-kill experiment 2/13/14 
DZ(90)=(gS*(1-(Z(90)+Z(91))/Nmax)-kS*((64/c44)/((64/c44)+EC50S)))*Z(90) 
DZ(91)=(gR*(1-(Z(90)+Z(91))/Nmax)-kR*((64/c44)))*Z(91) 
 
remark meropenem 128 mg/L time-kill experiment 2/13/14 
DZ(92)=(gS*(1-(Z(92)+Z(93))/Nmax)-kS*((128/c44)/((128/c44)+EC50S)))*Z(92) 
DZ(93)=(gR*(1-(Z(92)+Z(93))/Nmax)-kR*((128/c44)))*Z(93) 
 
END 
 
remark - algebraic functions 
 
remark - isolate 34 functions 
 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(23)+Z(24)) 
END 
FUNC 5 
F=log10(Z(24)) 
END 
FUNC 6 
F=log10(Z(7)+Z(8)) 
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END 
FUNC 7 
F=log10(Z(9)+Z(10)) 
END 
FUNC 8 
F=log10(Z(11)+Z(12)) 
END 
FUNC 9 
F=log10(Z(13)+Z(14)) 
END 
FUNC 10 
F=log10(Z(15)+Z(16)) 
END 
FUNC 11 
F=log10(Z(17)+Z(18)) 
END 
FUNC 12 
F=log10(Z(19)+Z(20)+1) 
END 
FUNC 13 
F=log10(Z(21)+Z(22)) 
END 
 
remark - isolate 22 functions 
 
FUNC 14 
F=log10(Z(25)+Z(26)) 
END 
FUNC 15 
F=log10(Z(27)+Z(28)) 
END 
FUNC 16 
F=log10(Z(29)+Z(30)) 
END 
FUNC 17 
F=log10(Z(30)) 
END 
FUNC 18 
F=log10(Z(31)+Z(32)) 
END 
FUNC 19 
F=log10(Z(33)+Z(34)) 
END 
FUNC 20 
F=log10(Z(35)+Z(36)) 
END 
FUNC 21 
F=log10(Z(37)+Z(38)) 
END 
FUNC 22 
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F=log10(Z(39)+Z(40)) 
END 
FUNC 23 
F=log10(Z(41)+Z(42)) 
END 
FUNC 24 
F=log10(Z(43)) 
END 
FUNC 25 
F=log10(Z(44)+1) 
END 
FUNC 26 
F=log10(Z(45)+Z(46)) 
END 
 
remark - isolate 24 functions 
 
FUNC 27 
F=log10(Z(47)+Z(48)) 
END 
FUNC 28 
F=log10(Z(49)+Z(50)) 
END 
FUNC 29 
F=log10(Z(51)+Z(52)) 
END 
FUNC 30 
F=log10(Z(52)) 
END 
FUNC 31 
F=log10(Z(53)+Z(54)) 
END 
FUNC 32 
F=log10(Z(55)+Z(56)) 
END 
FUNC 33 
F=log10(Z(57)+Z(58)) 
END 
FUNC 34 
F=log10(Z(59)+Z(60)) 
END 
FUNC 35 
F=log10(Z(61)+Z(62)) 
END 
FUNC 36 
F=log10(Z(63)+Z(64)+1) 
END 
FUNC 37 
F=log10(Z(65)+Z(66)) 
END 
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FUNC 38 
F=log10(Z(67)+Z(68)) 
END 
FUNC 39 
F=log10(Z(69)) 
END 
 
remark - isolate 44 functions 
 
FUNC 40 
F=log10(Z(70)+Z(71)) 
END 
FUNC 41 
F=log10(Z(72)+Z(73)) 
END 
FUNC 42 
F=log10(Z(74)+Z(75)) 
END 
FUNC 43 
F=log10(Z(76)+Z(77)) 
END 
FUNC 44 
F=log10(Z(77)) 
END 
FUNC 45 
F=log10(Z(78)+Z(79)) 
END 
FUNC 46 
F=log10(Z(80)+Z(81)) 
END 
FUNC 47 
F=log10(Z(82)+Z(83)) 
END 
FUNC 48 
F=log10(Z(84)+Z(85)) 
END 
FUNC 49 
F=log10(Z(86)+Z(87)) 
END 
FUNC 50 
F=log10(Z(88)+Z(89)) 
END 
FUNC 51 
F=log10(Z(90)+Z(91)) 
END 
FUNC 52 
F=log10(Z(92)+Z(93)) 
END 
 
SECO 
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SCS=gS/(kS-gS)*EC50S 
SCR=gR/kR 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM
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MODEL 
remark  Two-Population Polymyxin B Composite Simple Net Effect Model 
remark  Klebsiella pneumoniae isolates 34, 22, 24, 44 
remark  Polymyxin B-susceptible and -resistant subpopulations 
remark  78 Functions, 141 Differential Equations, 6 Parameters 
remark 
remark   ****************************************************** 
remark   Developer: Brandon Kulengowski 
remark   Model Date: 9-22-2018 
remark   Model Version: 1.0 
remark   ****************************************************** 
remark 
remark   parameters 
remark   ------------ 
remark gS 
remark  
remark gR 
remark  
remark Nmax 
remark  
remark kS 
remark  
remark EC50S 
remark  
remark kR 
 
remark - model-specific commands  
COMMANDS 
NFUN 78 
NDER 141 
NPAR 6 
PNAMES 'gS' 'gR' 'Nmax' 'kS' 'EC50S' 'kR' 
NSEC 4 
SNAMES 'SCS' 'SCR' 'dS' 'dR' 
SIZE 15 
END 
 
TEMP 
R034=19 
R022=0.63 
R024=1 
R044=44 
END 
 
remark - differential equations starting values 
START 
 
remark - isolate 34 initial conditions 
 
Z(1)=2.63*10**6 
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Z(2)=R034 
Z(3)=2.44*10**6 
Z(4)=R034 
Z(5)=1.13*10**7 
Z(6)=R034 
Z(7)=1.14*10**7 
Z(8)=1.42*10**2 
Z(9)=7.07*10**5 
Z(10)=R034 
Z(11)=6.54*10**5 
Z(12)=R034 
Z(13)=7.23*10**5 
Z(14)=R034 
Z(15)=5.84*10**5 
Z(16)=R034 
Z(17)=8.00*10**5 
Z(18)=R034 
Z(19)=7.79*10**5 
Z(20)=R034 
Z(21)=6.92*10**5 
Z(22)=R034 
Z(23)=6.85*10**5 
Z(24)=R034 
Z(25)=5.01*10**5 
Z(26)=R034 
Z(27)=5.15*10**5 
Z(28)=R034 
Z(29)=7.87*10**5 
Z(30)=R034 
Z(31)=9.30*10**5 
Z(32)=R034 
Z(33)=8.95*10**5 
Z(34)=R034 
Z(35)=8.43*10**5 
Z(36)=R034 
 
remark - isolate 22 initial conditions 
 
Z(37)=3.14*10**6 
Z(38)=R022 
Z(39)=2.51*10**6 
Z(40)=R022 
Z(41)=6.23*10**6 
Z(42)=2.54*10**2 
Z(43)=1.34*10**6 
Z(44)=R022 
Z(45)=1.43*10**6 
Z(46)=R022 
Z(47)=5.01*10**5 
Z(48)=R022 
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Z(49)=5.53*10**5 
Z(50)=R022 
Z(51)=6.68*10**5 
Z(52)=R022 
Z(53)=6.60*10**5 
Z(54)=R022 
Z(55)=5.27*10**5 
Z(56)=5.64*10**5 
Z(57)=R022 
Z(58)=5.00*10**5 
Z(59)=R022 
Z(60)=4.56*10**5 
Z(61)=4.93*10**5 
Z(62)=R022 
Z(63)=6.91*10**5 
Z(64)=R022 
 
remark - isolate 24 initial conditions 
 
Z(65)=1.77*10**6 
Z(66)=R024 
Z(67)=2.00*10**6 
Z(68)=R024 
Z(69)=2.46*10**6 
Z(70)=1.00*10**0 
Z(71)=4.26*10**5 
Z(72)=R024 
Z(73)=4.85*10**5 
Z(74)=R024 
Z(75)=6.33*10**5 
Z(76)=R024 
Z(77)=7.29*10**5 
Z(78)=R024 
Z(79)=5.87*10**5 
Z(80)=R024 
Z(81)=6.26*10**5 
Z(82)=R024 
Z(83)=5.66*10**5 
Z(84)=R024 
Z(85)=6.72*10**5 
Z(86)=R024 
Z(87)=5.81*10**5 
Z(88)=R024 
Z(89)=3.37*10**5 
Z(90)=R024 
Z(91)=3.67*10**5 
Z(92)=R024 
Z(93)=7.51*10**5 
Z(94)=R024 
Z(95)=5.37*10**5 
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Z(96)=R024 
Z(97)=5.04*10**5 
Z(98)=R024 
 
remark - isolate 44 initial conditions 
 
Z(99)=1.63*10**6 
Z(100)=R044 
Z(101)=2.48*10**6 
Z(102)=R044 
Z(103)=4.29*10**6 
Z(104)=R044 
Z(105)=4.93*10**6 
Z(106)=2.50*10**1 
Z(107)=6.04*10**5 
Z(108)=5.29*10**5 
Z(109)=5.42*10**5 
Z(110)=R044 
Z(111)=7.16*10**5 
Z(112)=R044 
Z(113)=2.68*10**5 
Z(114)=R044 
Z(115)=8.53*10**5 
Z(116)=R044 
Z(117)=8.93*10**5 
Z(118)=R044 
Z(119)=4.48*10**5 
Z(120)=R044 
Z(121)=8.13*10**5 
Z(122)=R044 
Z(123)=9.82*10**5 
Z(124)=R044 
Z(125)=6.47*10**5 
Z(126)=R044 
Z(127)=6.18*10**5 
Z(128)=R044 
Z(129)=4.75*10**5 
Z(130)=R044 
Z(131)=5.56*10**5 
Z(132)=6.53*10**5 
Z(133)=R044 
Z(134)=5.87*10**5 
Z(135)=R044 
Z(136)=7.75*10**5 
Z(137)=R044 
Z(138)=1.10*10**6 
Z(139)=R044 
Z(140)=9.48*10**5 
Z(141)=R044 
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END 
 
remark - differential equations 
DIFF 
 
remark - isolate 34 DEs 
 
remark growth control experiment 1/26/14 
DZ(1)=(gS*(1-(Z(1)+Z(2))/Nmax))*Z(1) 
DZ(2)=(gR*(1-(Z(1)+Z(2))/Nmax))*Z(2) 
 
remark growth control experiment 2/15/14 
DZ(3)=(gS*(1-(Z(3)+Z(4))/Nmax))*Z(3) 
DZ(4)=(gR*(1-(Z(3)+Z(4))/Nmax))*Z(4) 
 
remark growth control experiment 3/30/14 
DZ(5)=(gS*(1-(Z(5)+Z(6))/Nmax))*Z(5) 
DZ(6)=(gR*(1-(Z(5)+Z(6))/Nmax))*Z(6) 
 
remark growth control experiment PMB susceptible subpopulation 6/11/15 
DZ(7)=(gS*(1-(Z(7)+Z(8))/Nmax))*Z(7) 
 
remark growth control experiment PMB resistant subpopulation 6/11/15 
DZ(8)=(gR*(1-(Z(7)+Z(8))/Nmax))*Z(8) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 1/26/14 
DZ(9)=(gS*(1-(Z(9)+Z(10))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(9) 
DZ(10)=(gR*(1-(Z(9)+Z(10))/Nmax)-kR*0.25)*Z(10) 
 
remark polymyxin B 1 mg/L time-kill experiment 1/26/14 
DZ(11)=(gS*(1-(Z(11)+Z(12))/Nmax)-kS*(1/(1+EC50S)))*Z(11) 
DZ(12)=(gR*(1-(Z(11)+Z(12))/Nmax)-kR*1)*Z(12) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 3/30/15 
DZ(13)=(gS*(1-(Z(13)+Z(14))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(13) 
DZ(14)=(gR*(1-(Z(13)+Z(14))/Nmax)-kR*0.25)*Z(14) 
 
remark polymyxin B 1 mg/L time-kill experiment 3/30/15 
DZ(15)=(gS*(1-(Z(15)+Z(16))/Nmax)-kS*(1/(1+EC50S)))*Z(15) 
DZ(16)=(gR*(1-(Z(15)+Z(16))/Nmax)-kR*1)*Z(16) 
 
remark polymyxin B 2 mg/L time-kill experiment 5/29/14 
DZ(17)=(gS*(1-(Z(17)+Z(18))/Nmax)-kS*(2/(2+EC50S)))*Z(17) 
DZ(18)=(gR*(1-(Z(17)+Z(18))/Nmax)-kR*2)*Z(18) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/29/14 
DZ(19)=(gS*(1-(Z(19)+Z(20))/Nmax)-kS*(4/(4+EC50S)))*Z(19) 
DZ(20)=(gR*(1-(Z(19)+Z(20))/Nmax)-kR*4)*Z(20) 
 
remark polymyxin B 2 mg/L time-kill experiment 6/10/14 
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DZ(21)=(gS*(1-(Z(21)+Z(22))/Nmax)-kS*(2/(2+EC50S)))*Z(21) 
DZ(22)=(gR*(1-(Z(21)+Z(22))/Nmax)-kR*2)*Z(22) 
 
remark polymyxin B 4 mg/L time-kill experiment 6/10/14 
DZ(23)=(gS*(1-(Z(23)+Z(24))/Nmax)-kS*(4/(4+EC50S)))*Z(23) 
DZ(24)=(gR*(1-(Z(23)+Z(24))/Nmax)-kR*4)*Z(24) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/18/14 
DZ(25)=(gS*(1-(Z(25)+Z(26))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(25) 
DZ(26)=(gR*(1-(Z(25)+Z(26))/Nmax)-kR*0.0625)*Z(26) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 6/18/14 
DZ(27)=(gS*(1-(Z(27)+Z(28))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(27) 
DZ(28)=(gR*(1-(Z(27)+Z(28))/Nmax)-kR*0.125)*Z(28) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 7/9/14 
DZ(29)=(gS*(1-(Z(29)+Z(30))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(29) 
DZ(30)=(gR*(1-(Z(29)+Z(30))/Nmax)-kR*0.0625)*Z(30) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 7/9/14 
DZ(31)=(gS*(1-(Z(31)+Z(32))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(31) 
DZ(32)=(gR*(1-(Z(31)+Z(32))/Nmax)-kR*0.125)*Z(32) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 8/23/17 
DZ(33)=(gS*(1-(Z(33)+Z(34))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(33) 
DZ(34)=(gR*(1-(Z(33)+Z(34))/Nmax)-kR*0.25)*Z(34) 
 
remark polymyxin B 1 mg/L time-kill experiment 8/23/17 
DZ(35)=(gS*(1-(Z(35)+Z(36))/Nmax)-kS*(1/(1+EC50S)))*Z(35) 
DZ(36)=(gR*(1-(Z(35)+Z(36))/Nmax)-kR*1)*Z(36) 
 
remark - isolate 22 DEs 
 
remark growth control experiment 5/29/14 
DZ(37)=(gS*(1-(Z(37)+Z(38))/Nmax))*Z(37) 
DZ(38)=(gR*(1-(Z(37)+Z(38))/Nmax))*Z(38) 
 
remark growth control experiment 8/23/14 
DZ(39)=(gS*(1-(Z(39)+Z(40))/Nmax))*Z(39) 
DZ(40)=(gR*(1-(Z(39)+Z(40))/Nmax))*Z(40) 
 
remark growth control experiment 6/11/15 
DZ(41)=(gS*(1-(Z(41)+Z(42))/Nmax))*Z(41) 
 
remark growth control experiment PMB resistant subpopulation 6/11/15 
DZ(42)=(gR*(1-(Z(41)+Z(42))/Nmax))*Z(42) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 5/14/14 
DZ(43)=(gS*(1-(Z(43)+Z(44))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(43) 
DZ(44)=(gR*(1-(Z(43)+Z(44))/Nmax)-kR*0.25)*Z(44) 
 
 
Table G.22: Polymyxin B Composite Model Code 
499 
 
 
remark polymyxin B 1 mg/L time-kill experiment 5/14/14 
DZ(45)=(gS*(1-(Z(45)+Z(46))/Nmax)-kS*(1/(1+EC50S)))*Z(45) 
DZ(46)=(gR*(1-(Z(45)+Z(46))/Nmax)-kR*1)*Z(46) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 5/20/14 
DZ(47)=(gS*(1-(Z(47)+Z(48))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(47) 
DZ(48)=(gR*(1-(Z(47)+Z(48))/Nmax)-kR*0.25)*Z(48) 
 
remark polymyxin B 1 mg/L time-kill experiment 5/20/14 
DZ(49)=(gS*(1-(Z(49)+Z(50))/Nmax)-kS*(1/(1+EC50S)))*Z(49) 
DZ(50)=(gR*(1-(Z(49)+Z(50))/Nmax)-kR*1)*Z(50) 
 
remark polymyxin B 2 mg/L time-kill experiment 5/29/14 
DZ(51)=(gS*(1-(Z(51)+Z(52))/Nmax)-kS*(2/(2+EC50S)))*Z(51) 
DZ(52)=(gR*(1-(Z(51)+Z(52))/Nmax)-kR*2)*Z(52) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/29/14 
DZ(53)=(gS*(1-(Z(53)+Z(54))/Nmax)-kS*(4/(4+EC50S)))*Z(53) 
DZ(54)=(gR*(1-(Z(53)+Z(54))/Nmax)-kR*4)*Z(54) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/10/14 
DZ(55)=(gS*(1-(Z(55))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(55) 
 
remark polymyxin B 2 mg/L time-kill experiment 6/10/14 
DZ(56)=(gS*(1-(Z(56)+Z(57))/Nmax)-kS*(2/(2+EC50S)))*Z(56) 
DZ(57)=(gR*(1-(Z(56)+Z(57))/Nmax)-kR*2)*Z(57) 
 
remark polymyxin B 4 mg/L time-kill experiment 6/10/14 
DZ(58)=(gS*(1-(Z(58)+Z(59))/Nmax)-kS*(4/(4+EC50S)))*Z(58) 
DZ(59)=(gR*(1-(Z(58)+Z(59))/Nmax)-kR*4)*Z(59) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/18/14 
DZ(60)=(gS*(1-Z(60)/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(60) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 6/18/14 
DZ(61)=(gS*(1-(Z(61)+Z(62))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(61) 
DZ(62)=(gR*(1-(Z(61)+Z(62))/Nmax)-kR*0.125)*Z(62) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 7/9/14 
DZ(63)=(gS*(1-(Z(63)+Z(64))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(63) 
DZ(64)=(gR*(1-(Z(63)+Z(64))/Nmax)-kR*0.125)*Z(64) 
 
remark - isolate 24 DEs 
 
remark growth control experiment 5/29/14 
DZ(65)=(gS*(1-(Z(65)+Z(66))/Nmax))*Z(65) 
DZ(66)=(gR*(1-(Z(65)+Z(66))/Nmax))*Z(66) 
 
remark growth control experiment 8/23/14 
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DZ(67)=(gS*(1-(Z(67)+Z(68))/Nmax))*Z(67) 
DZ(68)=(gR*(1-(Z(67)+Z(68))/Nmax))*Z(68) 
 
remark growth control experiment 6/11/15 
DZ(69)=(gS*(1-(Z(69)+Z(70))/Nmax))*Z(69) 
 
remark growth control experiment PMB resistant subpopulation 6/11/15 
DZ(70)=(gR*(1-(Z(69)+Z(70))/Nmax))*Z(70) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 5/20/14 
DZ(71)=(gS*(1-(Z(71)+Z(72))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(71) 
DZ(72)=(gR*(1-(Z(71)+Z(72))/Nmax)-kR*0.25)*Z(72) 
 
remark polymyxin B 1 mg/L time-kill experiment 5/20/14 
DZ(73)=(gS*(1-(Z(73)+Z(74))/Nmax)-kS*(1/(1+EC50S)))*Z(73) 
DZ(74)=(gR*(1-(Z(73)+Z(74))/Nmax)-kR*1)*Z(74) 
 
remark polymyxin B 2 mg/L time-kill experiment 5/29/14 
DZ(75)=(gS*(1-(Z(75)+Z(76))/Nmax)-kS*(2/(2+EC50S)))*Z(75) 
DZ(76)=(gR*(1-(Z(75)+Z(76))/Nmax)-kR*2)*Z(76) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/29/14 
DZ(77)=(gS*(1-(Z(77)+Z(78))/Nmax)-kS*(4/(4+EC50S)))*Z(77) 
DZ(78)=(gR*(1-(Z(77)+Z(78))/Nmax)-kR*4)*Z(78) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/10/14 
DZ(79)=(gS*(1-(Z(79)+Z(80))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(79) 
DZ(80)=(gR*(1-(Z(79)+Z(80))/Nmax)-kR*0.0625)*Z(80) 
 
remark polymyxin B 2 mg/L time-kill experiment 6/10/14 
DZ(81)=(gS*(1-(Z(81)+Z(82))/Nmax)-kS*(2/(2+EC50S)))*Z(81) 
DZ(82)=(gR*(1-(Z(81)+Z(82))/Nmax)-kR*2)*Z(82) 
 
remark polymyxin B 4 mg/L time-kill experiment 6/10/14 
DZ(83)=(gS*(1-(Z(83)+Z(84))/Nmax)-kS*(4/(4+EC50S)))*Z(83) 
DZ(84)=(gR*(1-(Z(83)+Z(84))/Nmax)-kR*4)*Z(84) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 6/10/14 
DZ(85)=(gS*(1-(Z(85)+Z(86))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(85) 
DZ(86)=(gR*(1-(Z(85)+Z(86))/Nmax)-kR*0.25)*Z(86) 
 
remark polymyxin B 1 mg/L time-kill experiment 6/10/14 
DZ(87)=(gS*(1-(Z(87)+Z(88))/Nmax)-kS*(1/(1+EC50S)))*Z(87) 
DZ(88)=(gR*(1-(Z(87)+Z(88))/Nmax)-kR*1)*Z(88) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/18/14 
DZ(89)=(gS*(1-(Z(89)+Z(90))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(89) 
DZ(90)=(gR*(1-(Z(79)+Z(90))/Nmax)-kR*0.0625)*Z(90) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 6/18/14 
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DZ(91)=(gS*(1-(Z(91)+Z(92))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(91) 
DZ(92)=(gR*(1-(Z(91)+Z(92))/Nmax)-kR*0.125)*Z(92) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 7/9/14 
DZ(93)=(gS*(1-(Z(93)+Z(94))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(93) 
DZ(94)=(gR*(1-(Z(93)+Z(94))/Nmax)-kR*0.125)*Z(94) 
 
remark polymyxin B 2 mg/L time-kill experiment 8/23/17 
DZ(95)=(gS*(1-(Z(95)+Z(96))/Nmax)-kS*(2/(2+EC50S)))*Z(95) 
DZ(96)=(gR*(1-(Z(95)+Z(96))/Nmax)-kR*2)*Z(96) 
 
remark polymyxin B 4 mg/L time-kill experiment 8/23/17 
DZ(97)=(gS*(1-(Z(97)+Z(98))/Nmax)-kS*(4/(4+EC50S)))*Z(97) 
DZ(98)=(gR*(1-(Z(97)+Z(98))/Nmax)-kR*4)*Z(98) 
 
remark - isolate 44 DEs 
 
remark growth control experiment 1/26/14 
DZ(99)=(gS*(1-(Z(99)+Z(100))/Nmax))*Z(99) 
DZ(100)=(gR*(1-(Z(99)+Z(100))/Nmax))*Z(100) 
 
remark growth control experiment 2/15/14 
DZ(101)=(gS*(1-(Z(101)+Z(102))/Nmax))*Z(101) 
DZ(102)=(gR*(1-(Z(101)+Z(102))/Nmax))*Z(102) 
 
remark growth control experiment 3/30/14 
DZ(103)=(gS*(1-(Z(103)+Z(104))/Nmax))*Z(103) 
DZ(104)=(gR*(1-(Z(103)+Z(104))/Nmax))*Z(104) 
 
remark polymyxin B-susceptible subpopulation gRowth 6/11/15 
DZ(105)=(gS*(1-(Z(105)+Z(106))/Nmax))*Z(105) 
 
remark polymyxin B-resistant subpopulation gRowth 6/11/15 
DZ(106)=(gR*(1-(Z(105)+Z(106))/Nmax))*Z(106) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/10/14 
DZ(107)=(gS*(1-(Z(107))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(107) 
 
remark polymyxin B 0.0625 mg/L time-kill experiment 6/18/14 
DZ(108)=(gS*(1-(Z(108))/Nmax)-kS*(0.0625/(0.0625+EC50S)))*Z(108) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 6/18/14 
DZ(109)=(gS*(1-(Z(109)+Z(110))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(109) 
DZ(110)=(gR*(1-(Z(109)+Z(110))/Nmax)-kR*0.125)*Z(110) 
 
remark polymyxin B 0.125 mg/L time-kill experiment 7/9/14 
DZ(111)=(gS*(1-(Z(111)+Z(112))/Nmax)-kS*(0.125/(0.125+EC50S)))*Z(111) 
DZ(112)=(gR*(1-(Z(111)+Z(112))/Nmax)-kR*0.125)*Z(112) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 3/30/14 
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DZ(113)=(gS*(1-(Z(113)+Z(114))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(113) 
DZ(114)=(gR*(1-(Z(113)+Z(114))/Nmax)-kR*0.25)*Z(114) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 4/19/14 
DZ(115)=(gS*(1-(Z(115)+Z(116))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(115) 
DZ(116)=(gR*(1-(Z(115)+Z(116))/Nmax)-kR*0.25)*Z(116) 
 
remark polymyxin B 0.25 mg/L time-kill experiment 5/14/14 
DZ(117)=(gS*(1-(Z(117)+Z(118))/Nmax)-kS*(0.25/(0.25+EC50S)))*Z(117) 
DZ(118)=(gR*(1-(Z(117)+Z(118))/Nmax)-kR*0.25)*Z(118) 
 
remark polymyxin B 1 mg/L time-kill experiment 3/30/14 
DZ(119)=(gS*(1-(Z(119)+Z(120))/Nmax)-kS*(1/(1+EC50S)))*Z(119) 
DZ(120)=(gR*(1-(Z(119)+Z(120))/Nmax)-kR*1)*Z(120) 
 
remark polymyxin B 1 mg/L time-kill experiment 4/19/14 
DZ(121)=(gS*(1-(Z(121)+Z(122))/Nmax)-kS*(1/(1+EC50S)))*Z(121) 
DZ(122)=(gR*(1-(Z(121)+Z(122))/Nmax)-kR*1)*Z(122) 
 
remark polymyxin B 1 mg/L time-kill experiment 5/14/14 
DZ(123)=(gS*(1-(Z(123)+Z(124))/Nmax)-kS*(1/(1+EC50S)))*Z(123) 
DZ(124)=(gR*(1-(Z(123)+Z(124))/Nmax)-kR*1)*Z(124) 
 
remark polymyxin B 2 mg/L time-kill experiment 5/29/14 
DZ(125)=(gS*(1-(Z(125)+Z(126))/Nmax)-kS*(2/(2+EC50S)))*Z(125) 
DZ(126)=(gR*(1-(Z(125)+Z(126))/Nmax)-kR*2)*Z(126) 
 
remark polymyxin B 2 mg/L time-kill experiment 6/10/14 
DZ(127)=(gS*(1-(Z(127)+Z(128))/Nmax)-kS*(2/(2+EC50S)))*Z(127) 
DZ(128)=(gR*(1-(Z(127)+Z(128))/Nmax)-kR*2)*Z(128) 
 
remark polymyxin B 2 mg/L time-kill experiment 8/23/14 
DZ(129)=(gS*(1-(Z(129)+Z(130))/Nmax)-kS*(2/(2+EC50S)))*Z(129) 
DZ(130)=(gR*(1-(Z(129)+Z(130))/Nmax)-kR*2)*Z(130) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/20/14 
DZ(131)=(gS*(1-(Z(131))/Nmax)-kS*(4/(4+EC50S)))*Z(131) 
 
remark polymyxin B 4 mg/L time-kill experiment 5/29/14 
DZ(132)=(gS*(1-(Z(132)+Z(133))/Nmax)-kS*(4/(4+EC50S)))*Z(132) 
DZ(133)=(gR*(1-(Z(132)+Z(133))/Nmax)-kR*4)*Z(133) 
 
remark polymyxin B 4 mg/L time-kill experiment 6/10/14 
DZ(134)=(gS*(1-(Z(134)+Z(135))/Nmax)-kS*(4/(4+EC50S)))*Z(134) 
DZ(135)=(gR*(1-(Z(134)+Z(135))/Nmax)-kR*4)*Z(135) 
 
remark polymyxin B 4 mg/L time-kill experiment 7/9/14 
DZ(136)=(gS*(1-(Z(136)+Z(137))/Nmax)-kS*(4/(4+EC50S)))*Z(136) 
DZ(137)=(gR*(1-(Z(136)+Z(137))/Nmax)-kR*4)*Z(137) 
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remark polymyxin B 4 mg/L time-kill experiment 8/23/14 
DZ(138)=(gS*(1-(Z(138)+Z(139))/Nmax)-kS*(4/(4+EC50S)))*Z(138) 
DZ(139)=(gR*(1-(Z(138)+Z(139))/Nmax)-kR*4)*Z(139) 
 
remark polymyxin B-susceptible subpopulation for polymyxin B 4 mg/L time-kill experiment 
2/13/17 
DZ(140)=(gS*(1-(Z(140)+Z(141))/Nmax)-kS*(4/(4+EC50S)))*Z(140) 
 
remark polymyxin B-resistant subpopulation for polymyxin B 4 mg/L time-kill experiment 
2/13/17 
DZ(141)=(gR*(1-(Z(140)+Z(141))/Nmax)-kR*4)*Z(141) 
 
END 
 
remark - algebraic functions 
 
remark - isolate 34 functions 
 
FUNC 1 
F=log10(Z(1)+Z(2)) 
END 
FUNC 2 
F=log10(Z(3)+Z(4)) 
END 
FUNC 3 
F=log10(Z(5)+Z(6)) 
END 
FUNC 4 
F=log10(Z(7)+Z(8)) 
END 
FUNC 5 
F=log10(Z(8)) 
END 
FUNC 6 
F=log10(Z(9)+Z(10)) 
END 
FUNC 7 
F=log10(Z(11)+Z(12)) 
END 
FUNC 8 
F=log10(Z(13)+Z(14)) 
END 
FUNC 9 
F=log10(Z(15)+Z(16)) 
END 
FUNC 10 
F=log10(Z(17)+Z(18)) 
END 
FUNC 11 
F=log10(Z(19)+Z(20)) 
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END 
FUNC 12 
F=log10(Z(21)+Z(22)) 
END 
FUNC 13 
F=log10(Z(23)+Z(24)) 
END 
FUNC 14 
F=log10(Z(25)+Z(26)) 
END 
FUNC 15 
F=log10(Z(27)+Z(28)) 
END 
FUNC 16 
F=log10(Z(29)+Z(30)+1) 
END 
FUNC 17 
F=log10(Z(31)+Z(32)) 
END 
FUNC 18 
F=log10(Z(33)+Z(34)) 
END 
FUNC 19 
F=log10(Z(35)+Z(36)) 
END 
 
remark - isolate 22 functions 
 
FUNC 20 
F=log10(Z(37)+Z(38)) 
END 
FUNC 21 
F=log10(Z(39)+Z(40)) 
END 
FUNC 22 
F=log10(Z(41)+Z(42)) 
END 
FUNC 23 
F=log10(Z(42)) 
END 
FUNC 24 
F=log10(Z(43)+Z(44)) 
END 
FUNC 25 
F=log10(Z(45)+Z(46)) 
END 
FUNC 26 
F=log10(Z(47)+Z(48)) 
END 
FUNC 27 
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F=log10(Z(49)+Z(50)) 
END 
FUNC 28 
F=log10(Z(51)+Z(52)) 
END 
FUNC 29 
F=log10(Z(53)+Z(54)) 
END 
FUNC 30 
F=log10(Z(55)) 
END 
FUNC 31 
F=log10(Z(56)+Z(57)) 
END 
FUNC 32 
F=log10(Z(58)+Z(59)) 
END 
FUNC 33 
F=log10(Z(60)) 
END 
FUNC 34 
F=log10(Z(61)+Z(62)) 
END 
FUNC 35 
F=log10(Z(63)+Z(64)) 
END 
 
remark - isolate 24 functions 
 
FUNC 36 
F=log10(Z(65)+Z(66)) 
END 
FUNC 37 
F=log10(Z(67)+Z(68)) 
END 
FUNC 38 
F=log10(Z(69)+Z(70)) 
END 
FUNC 39 
F=log10(Z(70)) 
END 
FUNC 40 
F=log10(Z(71)+Z(72)) 
END 
FUNC 41 
F=log10(Z(73)+Z(74)) 
END 
FUNC 42 
F=log10(Z(75)+Z(76)) 
END 
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FUNC 43 
F=log10(Z(77)+Z(78)) 
END 
FUNC 44 
F=log10(Z(79)+Z(80)) 
END 
FUNC 45 
F=log10(Z(81)+Z(82)) 
END 
FUNC 46 
F=log10(Z(83)+Z(84)) 
END 
FUNC 47 
F=log10(Z(85)+Z(86)) 
END 
FUNC 48 
F=log10(Z(87)+Z(88)) 
END 
FUNC 49 
F=log10(Z(89)+Z(90)) 
END 
FUNC 50 
F=log10(Z(91)+Z(92)) 
END 
FUNC 51 
F=log10(Z(93)+Z(94)) 
END 
FUNC 52 
F=log10(Z(95)+Z(96)) 
END 
FUNC 53 
F=log10(Z(97)+Z(98)) 
END 
 
remark - isolate 44 functions 
 
FUNC 54 
F=log10(Z(99)+Z(100)) 
END 
FUNC 55 
F=log10(Z(101)+Z(102)) 
END 
FUNC 56 
F=log10(Z(103)+Z(104)) 
END 
FUNC 57 
F=log10(Z(105)) 
END 
FUNC 58 
F=log10(Z(106)) 
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END 
FUNC 59 
F=log10(Z(107)) 
END 
FUNC 60 
F=log10(Z(108)) 
END 
FUNC 61 
F=log10(Z(109)+Z(110)) 
END 
FUNC 62 
F=log10(Z(111)+Z(112)) 
END 
FUNC 63 
F=log10(Z(113)+Z(114)) 
END 
FUNC 64 
F=log10(Z(115)+Z(116)) 
END 
FUNC 65 
F=log10(Z(117)+Z(118)) 
END 
FUNC 66 
F=log10(Z(119)+Z(120)) 
END 
FUNC 67 
F=log10(Z(121)+Z(122)) 
END 
FUNC 68 
F=log10(Z(123)+Z(124)) 
END 
FUNC 69 
F=log10(Z(125)+Z(126)) 
END 
FUNC 70 
F=log10(Z(127)+Z(128)) 
END 
FUNC 71 
F=log10(Z(129)+Z(130)) 
END 
FUNC 72 
F=log10(Z(131)) 
END 
FUNC 73 
F=log10(Z(132)+Z(133)) 
END 
FUNC 74 
F=log10(Z(134)+Z(135)) 
END 
FUNC 75 
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F=log10(Z(136)+Z(137)) 
END 
FUNC 76 
F=log10(Z(138)+Z(139)) 
END 
FUNC 77 
F=log10(Z(140)) 
END 
FUNC 78 
F=log10(Z(141)) 
END 
 
remark - secondary parameters 
SECO 
SCS=(gS/(kS-gS))*EC50S 
SCR=gR/kR 
dS=0.6931/gS*60 
dR=0.6931/gR*60 
END 
 
remark - end of model 
EOM
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Appendix H: 
 
Pharmacodynamic Mathematical Models 
 
 Data presented here lend support for the final models discussed in 
Pharmacodynamic Modeling. Model input data for all mathematical models can be found 
in Appendix F. Phoenix® 8.1 Win Nonlin® code utilized for each model can be found in 
Appendix G. Determination of initial parameter estimates for the growth control models 
are discussed in Determining Initial Pharmacodynamic Model Estimates for Growth Rate 
Constants and Maximum Population Count.
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Pharmacodynamic Mathematical Model of Growth Experiments 
 The growth model (Equations 5, 6, and 7), initial parameter estimates, final 
parameter estimates, and fit of the growth control experiments are presented here. Growth 
model equation (5) reproduced here for easier reader reference: 
𝒅𝒅𝑹𝑹𝒅𝒅𝒅𝒅
𝒅𝒅𝒅𝒅 = �𝒈𝒈𝑹𝑹𝒅𝒅𝒅𝒅 �𝟏𝟏 −
𝑹𝑹𝒅𝒅𝒅𝒅 + 𝑹𝑹𝒅𝒅𝑹𝑹 + 𝑹𝑹𝑹𝑹𝒅𝒅
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂 ��𝑹𝑹𝒅𝒅𝒅𝒅 
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Initial Pharmacodynamic Model of Isolate 34 Growth Control Experiments 
Table H.1: Initial Parameter Estimates for 34 Growth Control Model 
Parameter gRLS gRHS gRLR Nmax 
Value 3.21 2.62 0.80 4.65E+11 
Lower 
Bound 2.26 0.00 0.00 1.04E+11 
Upper 
Bound 4.16 4.16 6.20 2.08E+12 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Linear 
regression of 
pooled growth 
control data 
Slope of single 
experiment 
meropenem 
highly resistant 
subpopulation 
data 
Linear regression 
of single 
experiment 
polymyxin 
resistant 
subpopulation 
data 
Average of 
pooled growth 
control data 
Source of 
bounds 
95% 
confidence 
interval of 
linear 
regression 
Lower bound 
can’t be <0. 
Upper bound 
likely not 
greater than 
gRLS upper 
bound 
95% confidence 
interval of linear 
regression. 
Lower bound 
can’t be <0 
95% confidence 
interval of mean 
 
Table H.2: Final Parameter Estimates for 34 Growth Control Model 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gRLS 3.43 0.28 8 2.84 4.01 
gRHS 2.39 0.31 13 1.75 3.03 
gRLR 1.37 0.28 20 0.79 1.94 
Nmax 2.34E+11 8.25E+10 35 6.31E+10 4.04E+11 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL) 
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Figure H.1: Predicted and Observed Growth Control Experiments for Isolate 34. Observed 
data represent geometric mean data of at least 2 time-kill experiments. Blue data represent 
the sum of all three populations. Red data represent the subpopulation with a meropenem 
MIC > 16 mg/L. Green data represent the subpopulation with a polymyxin B MIC > 4 
mg/L.  
0
2
4
6
8
10
12
0 4 8 12 16 20 24 28 32 36 40 44 48
Lo
g 
C
FU
/m
L
Time (h)
Obs Total
Pred Total
Obs MEM >16
Pred MEM >16
Obs PMB >4
Pred PMB >4
 
513 
 
Initial Pharmacodynamic Model of Isolate 22 Growth Control Experiments 
Table H.3: Initial Parameter Estimates for 22 Growth Control Model 
Parameter gRLS gRHS gRLR Nmax 
Value 3.23 2.4 1.83 6.22E+10 
Lower 
Bound 2.72 0.00 0.00 1.41E+10 
Upper 
Bound 3.74 3.74 3.74 1.10E+11 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Linear 
regression of 
pooled growth 
control data 
Slope of single 
experiment 
meropenem 
highly resistant 
subpopulation 
data 
Slope of single 
experiment 
polymyxin 
resistant 
subpopulation 
data 
Average of 
pooled growth 
control data 
Source of 
bounds 
95% 
confidence 
interval of 
linear 
regression 
Lower bound 
can’t be <0. 
Upper bound 
likely not 
greater than 
gRLS upper 
bound 
Lower bound 
can’t be <0. 
Upper bound 
likely not greater 
than gRLS upper 
bound 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL) 
Table H.4: Final Parameter Estimates for 22 Growth Control Model 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gRLS 3.69 0.30 8 3.05 4.34 
gRHS 2.06 0.36 18 1.30 2.83 
gRLR 1.52 0.35 23 0.79 2.26 
Nmax 5.14E+10 1.59E+10 31 1.78E+10 8.50E+10 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL) 
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Figure H.2: Predicted and Observed Growth Control Experiments for Isolate 22. Observed 
data represent geometric mean data of at least 2 time-kill experiments. Blue data represent 
the sum of all three populations. Red data represent the subpopulation with a meropenem 
MIC > 16 mg/L. Green data represent the subpopulation with a polymyxin B MIC > 4 
mg/L. 
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Initial Pharmacodynamic Model of Isolate 24 Growth Control Experiments 
Table H.5: Initial Parameter Estimates for 24 Growth Control Model 
Parameter gRLS gRHS gRLR Nmax 
Value 1.68 1.04 0.86 3.58E+10 
Lower 
Bound 0.00 0.14 0.00 1.09E+10 
Upper 
Bound 3.47 1.95 3.47 1.18E+11 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Linear 
regression of 
pooled growth 
control data 
Linear 
regression of 
meropenem 
high resistant 
subpopulation 
data 
Slope of single 
experiment 
polymyxin 
resistant 
subpopulation 
data 
Average of 
pooled growth 
control data 
Source of 
bounds 
95% 
confidence 
interval of 
linear 
regression 
95% confidence 
interval of 
linear 
regression 
Lower bound 
can’t be <0. 
Upper bound 
likely not greater 
than gRLS upper 
bound 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL) 
Table H.6: Final Parameter Estimates for 24 Growth Control Model 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gRLS 1.71 0.15 9 1.40 2.03 
gRHS 1.22 0.18 15 0.86 1.59 
gRLR 0.70 0.17 24 0.35 1.05 
Nmax 4.33E+10 2.21E+10 51 -1.94E+09 8.84E+10 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL) 
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Figure H.3: Predicted and Observed Growth Control Experiments for Isolate 24. Observed 
data represent geometric mean data of at least 2 time-kill experiments. Blue data represent 
the sum of all three populations. Red data represent the subpopulation with a meropenem 
MIC > 16 mg/L. Green data represent the subpopulation with a polymyxin B MIC > 4 
mg/L.  
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Initial Pharmacodynamic Model of Isolate 44 Growth Control Experiments 
Table H.7: Initial Parameter Estimates for 44 Growth Control Model 
Parameter gRLS gRHS gRLR Nmax 
Value 2.38 2.33 1.40 5.72E+11 
Lower 
Bound 1.56 0.00 0.21 1.04E+11 
Upper 
Bound 3.19 9.81 2.59 1.19E+12 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Linear 
regression of 
pooled growth 
control data 
Linear 
regression of 
pooled growth 
control data 
Linear regression 
of pooled growth 
control data 
Average of 
pooled growth 
control data 
Source of 
bounds 
95% 
confidence 
interval of 
linear 
regression 
95% confidence 
interval of 
linear 
regression. 
Lower bound 
can’t be <0 
95% confidence 
interval of linear 
regression 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL) 
Table H.8: Final Parameter Estimates for 44 Growth Control Model 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gRLS 2.55 0.28 11 1.97 3.13 
gRHS 2.27 0.30 13 1.65 2.88 
gRLR 1.26 0.26 21 0.73 1.80 
Nmax 1.20E+11 5.22E+10 44 1.29E+10 2.27E+11 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL) 
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Figure H.4: Predicted and Observed Growth Control Experiments for Isolate 44. Observed 
data represent geometric mean data of at least 2 time-kill experiments. Blue data represent 
the sum of all three populations. Red data represent the subpopulation with a meropenem 
MIC > 16 mg/L. Green data represent the subpopulation with a polymyxin B MIC > 4 
mg/L.  
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Pharmacodynamic Mathematical Model of the More Susceptible Population to 
Meropenem Monotherapy 
Model input data for all mathematical models can be found in Appendix F. 
Phoenix® 8.1 Win Nonlin® code utilized for each model can be found in Appendix G. 
Determination of initial parameter estimates for the meropenem low resistance models are 
discussed in Determining Initial Pharmacodynamic Model Estimates for Susceptible 
Population Killing Rate Constants. The susceptible population model (Equation 1), initial 
parameter estimates, and final parameter estimates are presented here. Susceptible model 
equation (1) reproduced here for easier reader reference: 
𝒅𝒅𝒅𝒅
𝒅𝒅𝒅𝒅 = �𝒈𝒈𝒅𝒅 �𝟏𝟏 −
𝒅𝒅 + 𝑹𝑹
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂� − 𝒌𝒌𝒅𝒅
𝑪𝑪
𝑪𝑪 + 𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝒅𝒅
� 𝒅𝒅 
Initial Killing Pharmacodynamic Model of Isolate 34 Meropenem Monotherapy 
Experiments 
Table H.9: Initial Parameter Estimates for 34 Meropenem Monotherapy 
Parameter gS Nmax kS EC50S 
Value 3.43 2.34E+11 7.56 2.28 
Lower 
Bound 2.84 6.31E+10 5.85 0 
Upper 
Bound 4.01 4.04E+11 9.28 6.57 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Growth model 
final parameter 
Growth model 
final parameter 
Average of 
pairwise kS data 
Average of 
pairwise EC50S 
data 
Source of 
bounds 
Growth model 
univariate 95% 
confidence 
interval 
Growth model 
univariate 95% 
confidence 
interval 
95% confidence 
interval of mean 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
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Table H.10: Final Parameter Estimates for 34 Meropenem Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 3.43 0.25 7 2.91 3.94 
Nmax 2.26E+11 7.01E+10 31 8.45E+10 3.68E+11 
kS 7.28 0.37 5 6.53 8.03 
EC50S 1.67 0.30 18 1.06 2.28 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
 
Initial Killing Pharmacodynamic Model of Isolate 22 Meropenem Monotherapy 
Experiments 
Table H.11: Initial Parameter Estimates for 22 Meropenem Monotherapy 
Parameter gS Nmax kS EC50S 
Value 3.69 5.14E+10 8.71 8.293 
Lower 
Bound 3.05 1.78E+10 8.44 7.075 
Upper 
Bound 4.34 8.50E+10 8.97 9.511 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Growth model 
final parameter 
Growth model 
final parameter 
Average of 
pairwise kS data 
Average of 
pairwise EC50S 
data 
Source of 
bounds 
Growth model 
univariate 95% 
confidence 
interval 
Growth model 
univariate 95% 
confidence 
interval 
95% confidence 
interval of mean 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
Table H.12: Final Parameter Estimates for 22 Meropenem Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 3.37 0.50 15 2.34 4.40 
Nmax 5.43E+10 3.00E+10 55 -6.95E+09 1.16E+11 
kS 8.44 0.99 12 6.42 10.46 
EC50S 7.08 3.00 42 0.93 13.22 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L)  
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Initial Killing Pharmacodynamic Model of Isolate 24 Meropenem Monotherapy 
Experiments 
Table H.13: Initial Parameter Estimates for 24 Meropenem Monotherapy 
Parameter gS Nmax kS EC50S 
Value 1.71 4.33E+10 3.61 0.911 
Lower 
Bound 1.40 1.94E+09 3.52 0.00 
Upper 
Bound 2.03 8.84E+10 3.69 2.43 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Growth model 
final parameter 
Growth model 
final parameter 
Average of 
pairwise kS data 
Average of 
pairwise EC50S 
data 
Source of 
bounds 
Growth model 
univariate 95% 
confidence 
interval 
Growth model 
univariate 95% 
confidence 
interval 
95% confidence 
interval of mean 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
Table H.14: Final Parameter Estimates for 24 Meropenem Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 1.99 0.15 8 1.68 2.30 
Nmax 4.03E+10 1.21E+10 30 1.58E+10 6.48E+10 
kS 3.69 0.18 5 3.33 4.05 
EC50S 0.08 0.33 420 -0.59 0.75 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
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Initial Killing Pharmacodynamic Model of Isolate 44 Meropenem Monotherapy 
Experiments 
Table H.15: Initial Parameter Estimates for 44 Meropenem Monotherapy 
Parameter gS Nmax kS EC50S 
Value 2.27 1.20E+11 6.44 29.49 
Lower 
Bound 1.65 1.29E+10 4.01 1 
Upper 
Bound 2.88 2.27E+11 8.67 64.547 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Growth model 
final parameter 
Growth model 
final parameter 
Average of 
pairwise kS data 
Average of 
pairwise EC50S 
data 
Source of 
bounds 
Growth model 
univariate 95% 
confidence 
interval 
Growth model 
univariate 95% 
confidence 
interval 
95% confidence 
interval of mean 
95% confidence 
interval of mean 
Units of g are h-1; Units of Nmax are CFU/mL; Units of k are h-1; Units of EC50 are mg/L 
 
Table H.16: Final Parameter Estimates for 44 Meropenem Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 2.49 0.31 12 1.87 3.12 
Nmax 1.16E+11 5.81E+10 49 -1.46E+09 2.34E+11 
kS 4.10 1.81 44 0.43 7.77 
EC50S 38.34 51.38 134 -65.87 142.54 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
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Pharmacodynamic Mathematical Model of the More Susceptible Population to 
Polymyxin B Monotherapy 
Model input data for all mathematical models can be found in Appendix F. 
Phoenix® 8.1 Win Nonlin® code utilized for each model can be found in Appendix G. 
Determination of initial parameter estimates for the polymyxin B susceptible models are 
discussed in Determining Initial Pharmacodynamic Model Estimates for Susceptible 
Population Killing Rate Constants. The susceptible population model (Equation 1), initial 
parameter estimates, and final parameter estimates are presented here. Susceptible model 
equation (1) reproduced here for easier reader reference: 
𝒅𝒅𝒅𝒅
𝒅𝒅𝒅𝒅 = �𝒈𝒈𝒅𝒅 �𝟏𝟏 −
𝒅𝒅 + 𝑹𝑹
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂� − 𝒌𝒌𝒅𝒅
𝑪𝑪
𝑪𝑪 + 𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝒅𝒅
� 𝒅𝒅 
Initial Killing Pharmacodynamic Model of Isolate 34 Polymyxin B Monotherapy 
Experiments 
Table H.17: Initial Parameter Estimates for 34 Polymyxin B Monotherapy 
Parameter gS Nmax kS EC50S 
Value 3.43 2.34E+11 10.60 0.235 
Lower 
Bound 2.84 6.31E+10 8.99 0.011 
Upper 
Bound 4.01 4.04E+11 12.22 0.460 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Growth model 
final parameter 
Growth model 
final parameter 
Average of 
pairwise kS data 
Average of 
pairwise EC50S 
data 
Source of 
bounds 
Growth model 
univariate 95% 
confidence 
interval 
Growth model 
univariate 95% 
confidence 
interval 
95% confidence 
interval of mean 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L)   
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Table H.18: Final Parameter Estimates for 34 Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 4.01 0.42 11 3.15 4.86 
Nmax 4.04E+11 1.60E+11 40 8.18E+10 7.27E+11 
kS 9.78 0.54 6 8.70 10.86 
EC50S 0.05 0.01 19 0.03 0.07 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
 
Initial Killing Pharmacodynamic Model of Isolate 22 Polymyxin B Monotherapy 
Experiments 
Table H.19: Initial Parameter Estimates for 22 Polymyxin B Monotherapy 
Parameter gS Nmax kS EC50S 
Value 3.69 5.14E+10 23.7 0.142 
Lower 
Bound 3.05 1.78E+10 10.39 0.004 
Upper 
Bound 4.34 8.50E+10 37.01 0.280 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Growth model 
final parameter 
Growth model 
final parameter 
Average of 
pairwise kS data 
Average of 
pairwise EC50S 
data 
Source of 
bounds 
Growth model 
univariate 95% 
confidence 
interval 
Growth model 
univariate 95% 
confidence 
interval 
95% confidence 
interval of mean 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
Table H.20: Final Parameter Estimates for 22 Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 3.66 0.39 11 2.84 4.48 
Nmax 5.24E+10 2.08E+10 40 9.01E+09 9.57E+10 
kS 14.31 2.27 16 9.59 19.03 
EC50S 0.05 0.03 49 0.00 0.11 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L)  
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Initial Killing Pharmacodynamic Model of Isolate 24 Polymyxin B Monotherapy 
Experiments 
Table H.21: Initial Parameter Estimates for 24 Polymyxin B Monotherapy 
Parameter gS Nmax kS EC50S 
Value 1.71 4.33E+10 8.82 0.039 
Lower 
Bound 1.40 1.94E+09 7.83 0.006 
Upper 
Bound 2.03 8.84E+10 9.81 0.071 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Growth model 
final parameter 
Growth model 
final parameter 
Average of 
pairwise kS data 
Average of 
pairwise EC50S 
data 
Source of 
bounds 
Growth model 
univariate 95% 
confidence 
interval 
Growth model 
univariate 95% 
confidence 
interval 
95% confidence 
interval of mean 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
Table H.22: Final Parameter Estimates for 24 Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 2.03 0.18 9 1.66 2.40 
Nmax 4.04E+10 1.39E+10 35 1.17E+10 6.92E+10 
kS 7.83 0.81 10 6.16 9.50 
EC50S 0.06 0.03 43 0.01 0.11 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
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Initial Killing Pharmacodynamic Model of Isolate 44 Polymyxin B Monotherapy 
Experiments 
Table H.23: Initial Parameter Estimates for 44 Polymyxin B Monotherapy 
Parameter gS Nmax kS EC50S 
Value 2.27 1.20E+11 10.55 0.041 
Lower 
Bound 1.65 1.29E+10 9.73 0.011 
Upper 
Bound 2.88 2.27E+11 11.36 0.108 
Type User-defined User-defined User-defined User-defined 
Source of 
estimate 
Growth model 
final parameter 
Growth model 
final parameter 
Average of 
pairwise kS data 
Average of 
pairwise EC50S 
data 
Source of 
bounds 
Growth model 
univariate 95% 
confidence 
interval 
Growth model 
univariate 95% 
confidence 
interval 
95% confidence 
interval of mean 
95% confidence 
interval of mean 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
Table H.24: Final Parameter Estimates for 44 Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 2.61 0.27 10 2.07 3.16 
Nmax 1.14E+11 4.26E+10 37 2.87E+10 2.00E+11 
kS 10.71 0.71 7 9.28 12.15 
EC50S 0.03 0.01 42 0.00 0.05 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
  
 
527 
 
Pharmacodynamic Mathematical Model of Meropenem Monotherapy 
Model input data for all mathematical models can be found in Appendix F. 
Phoenix® 8.1 Win Nonlin® code utilized for each model can be found in Appendix G. 
Determination of initial parameter estimates for the meropenem models are discussed in 
Full Model Initial Estimates of Parameters. The two population models (Equations 1 and 
2), initial parameter estimates, and final parameter estimates are presented here. 
Susceptible model equation (1) and resistant model equation (2) reproduced here for easier 
reader reference: 
𝒅𝒅𝒅𝒅
𝒅𝒅𝒅𝒅 = �𝒈𝒈𝒅𝒅 �𝟏𝟏 −
𝒅𝒅 + 𝑹𝑹
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂� − 𝒌𝒌𝒅𝒅
𝑪𝑪
𝑪𝑪 + 𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝒅𝒅
� 𝒅𝒅 
𝒅𝒅𝑹𝑹
𝒅𝒅𝒅𝒅 = �𝒈𝒈𝑹𝑹 �𝟏𝟏 −
𝒅𝒅 + 𝑹𝑹
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂� − 𝒌𝒌𝑹𝑹
𝑪𝑪
𝑪𝑪 + 𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝑹𝑹
� 𝑹𝑹 
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Pharmacodynamic Model of Isolate 34 Meropenem Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (1) and equation (11) were utilized for a total of 6 parameters, 13 time-kill 
experiments and 24 simultaneously solved differential equations. 
Table H.25: Full Model Initial Parameter Estimates for 34 Meropenem Monotherapy 
Parameter gS gR Nmax kS EC50S k'R 
Value 3.43 2.39 2.34E+11 7.28 1.67 0.548941 
Lower 
Bound 2.84 1.75 6.31E+10 6.53 0.69 0.325514 
Upper 
Bound 4.01 3.03 4.04E+11 8.03 2.65 0.772367 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Growth 
control 
model fit 
Growth 
control 
model fit 
Growth 
control 
model fit 
Net effect 
model fit 
Net effect 
model fit 
Average of 
pairwise kR 
data  
Source of 
bounds 
Univar. 
bounds 
Planar 
bounds 
Univar. 
bounds 
Planar 
bounds 
Planar 
bounds 
Lowest and 
Greatest kR 
/ EC50R 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1) 
Table H.26: Full Model Final Parameter Estimates for 34 Meropenem Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 4.01 0.50 12 3.01 5.01 
gR 2.94 0.70 24 1.55 4.34 
Nmax 1.93E+11 9.37E+10 49 4.88E+09 3.81E+11 
kS 6.53 0.56 9 5.40 7.66 
EC50S 0.94 0.42 45 0.10 1.78 
k'R 0.54 0.17 32 0.20 0.89 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1) 
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Table H.27: Full Model Final Secondary Parameter Estimates for 34 Meropenem 
Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) 1.49 0.52 35 
SCR (mg/L) 5.43 0.46 8 
dS (min) 10.4 1.29 12 
dR (min) 14.1 3.33 24 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
 
Figure H.5: Predicted and Observed Time-kill Data for Meropenem against Isolate 34. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a meropenem MIC > 16 mg/L. Other data indicate 
the total colony count with the given concentration of meropenem present in the time-kill 
flask. 
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Figure H.6: Observed vs. Predicted Data for Meropenem Monotherapy Model against 
Isolate 34.  
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Pharmacodynamic Model of Isolate 22 Meropenem Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (1) and equation (11) were utilized for a total of 6 parameters, 13 time-kill 
experiments and 22 simultaneously solved differential equations. 
Table H.28: Full Model Initial Parameter Estimates for 22 Meropenem Monotherapy 
Parameter gS gR Nmax kS EC50S k'R 
Value 3.69 2.06 5.14E+10 8.44 7.08 0.10 
Lower 
Bound 3.05 1.3 1.78E+10 6.42 0.93 0.02 
Upper 
Bound 4.34 2.83 8.5E+10 10.46 13.22 0.18 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Growth 
control 
model fit 
Growth 
control 
model fit 
Growth 
control 
model fit 
Net effect 
model fit 
Net effect 
model fit 
Average 
of 
pairwise 
kR data 
Source of 
bounds 
Univar. 
bounds 
Planar 
bounds 
Univar. 
bounds 
Planar 
bounds 
Planar 
bounds 
Lowest 
and 
Greatest 
kR / EC50R 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1) 
Table H.29: Full Model Final Parameter Estimates for 22 Meropenem Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 3.05 0.45 15 2.15 3.95 
gR 1.65 0.15 9 1.35 1.95 
Nmax 7.8E+10 3.30E+10 42 1.2E+10 1.4E+11 
kS 6.65 0.61 9 5.44 7.87 
EC50S 1.44 0.70 48 0.05 2.84 
k'R 0.05 0.01 20 0.03 0.06 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1) 
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Table H.30: Full Model Final Secondary Parameter Estimates for 22 Meropenem 
Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) 1.22 0.48 39 
SCR (mg/L) 36.0 4.07 11 
dS (min) 13.6 2.01 15 
dR (min) 25.2 2.28 9 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
 
Figure H.7: Predicted and Observed Time-kill Data for Meropenem against Isolate 22. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a meropenem MIC > 16 mg/L. Other data indicate 
the total colony count with the given concentration of meropenem present in the time-kill 
flask. 
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Figure H.8: Observed vs. Predicted Data for Meropenem Monotherapy Model against 
Isolate 22.  
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Pharmacodynamic Model of Isolate 24 Meropenem Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (10) and equation (11) were utilized for a total of 5 parameters, 13 time-kill 
experiments and 23 simultaneously solved differential equations. 
Table H.31: Full Model Initial Parameter Estimates for 24 Meropenem Monotherapy 
Parameter gS gR Nmax kS k'R 
Value 1.71 1.22 4.03E+10 3.69 0.010 
Lower 
Bound 1.4 0.63 1.58E+10 3.12 0.003 
Upper 
Bound 2.03 1.82 6.48E+10 4.26 0.017 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Growth 
control 
model fit 
Growth 
control 
model fit 
Growth 
control 
model fit 
Net effect 
model fit 
Average of 
pairwise kR 
data  
Source of 
bounds 
Univar. 
bounds 
Planar 
bounds 
Univar. 
bounds 
Planar 
bounds 
Lowest and 
Greatest kR / 
EC50R 
Units: g (h-1); Nmax (CFU/mL); k (h-1); k’ (L/mg*h-1) 
Table H.32: Full Model Final Parameter Estimates for 24 Meropenem Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 2.03 0.25 13 1.52 2.54 
gR 1.70 0.07 4 1.56 1.83 
Nmax 5.2E+10 2.06E+10 40 1.1E+10 9.3E+10 
kS 3.72 0.30 8 3.13 4.31 
k'R 0.013 0.000 5 0.012 0.014 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); k’ (L/mg*h-1) 
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Table H.33: Full Model Final Secondary Parameter Estimates for 24 Meropenem 
Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) - - - 
SCR (mg/L) 131 2.42 2 
dS (min) 20.5 2.57 13 
dR (min) 24.5 0.96 4 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
 
Figure H.9: Predicted and Observed Time-kill Data for Meropenem against Isolate 24. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a meropenem MIC > 64 mg/L. Other data indicate 
the total colony count with the given concentration of meropenem present in the time-kill 
flask. 
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Figure H.10: Observed vs. Predicted Data for Meropenem Monotherapy Model against 
Isolate 24. 
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Pharmacodynamic Model of Isolate 44 Meropenem Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (1) and equation (11) were utilized for a total of 5 parameters, 13 time-kill 
experiments and 24 simultaneously solved differential equations. 
Table H.34: Full Model Initial Parameter Estimates for 44 Meropenem Monotherapy 
Parameter gS gR Nmax kS EC50S 
Value 2.55 2.27 1.20E+11 4.1 38.340 
Lower 
Bound 1.97 1.28 1.29E+10 0.43 1.000 
Upper 
Bound 3.13 3.26 2.27E+11 7.77 205.010 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Growth 
control 
model fit 
Growth 
control 
model fit 
Growth 
control 
model fit 
Net effect 
model fit 
Net effect 
model fit 
Source of 
bounds 
Univar. 
bounds 
Planar 
bounds 
Univar. 
bounds 
Planar 
bounds 
Planar 
bounds 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
Table H.35: Full Model Final Parameter Estimates for 44 Meropenem Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 2.68 0.20 8 2.26 3.09 
gR 1.58 0.14 9 1.31 1.85 
Nmax 7.0E+10 1.52E+10 22 4.0E+10 1.0E+11 
kS 6.07 0.96 16 4.15 7.99 
EC50S 66.60 25.11 38 16.35 116.85 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L) 
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Table H.36: Full Model Final Secondary Parameter Estimates for 44 Meropenem 
Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) 52.5 3.42 7 
SCR (mg/L) - - - 
dS (min) 15.6 1.19 8 
dR (min) 26.3 2.26 9 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
 
Figure H.11: Predicted and Observed Time-kill Data for Meropenem against Isolate 44. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a meropenem MIC > 64 mg/L. Other data indicate 
the total colony count with the given concentration of meropenem present in the time-kill 
flask. 
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Figure H.12: Observed vs. Predicted Data for Meropenem Monotherapy Model against 
Isolate 44.
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Pharmacodynamic Mathematical Model of Polymyxin B Monotherapy 
Model input data for all mathematical models can be found in Appendix F. 
Phoenix® 8.1 Win Nonlin® code utilized for each model can be found in Appendix G. 
Determination of initial parameter estimates for the polymyxin B models are discussed in 
Full Model Initial Estimates of Parameters. The two population models (Equations 1 and 
2), initial parameter estimates, and final parameter estimates are presented here. 
Susceptible model equation (1) and resistant model equation (2) reproduced here for easier 
reader reference: 
𝒅𝒅𝒅𝒅
𝒅𝒅𝒅𝒅 = �𝒈𝒈𝒅𝒅 �𝟏𝟏 −
𝒅𝒅 + 𝑹𝑹
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂� − 𝒌𝒌𝒅𝒅
𝑪𝑪
𝑪𝑪 + 𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝒅𝒅
� 𝒅𝒅 
𝒅𝒅𝑹𝑹
𝒅𝒅𝒅𝒅 = �𝒈𝒈𝑹𝑹 �𝟏𝟏 −
𝒅𝒅 + 𝑹𝑹
𝑵𝑵𝒎𝒎𝒂𝒂𝒂𝒂� − 𝒌𝒌𝑹𝑹
𝑪𝑪
𝑪𝑪 + 𝑬𝑬𝑪𝑪𝟓𝟓𝟓𝟓𝑹𝑹
� 𝑹𝑹 
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Pharmacodynamic Model of Isolate 34 Polymyxin B Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (1) and equation (11) were utilized for a total of 6 parameters, 19 time-kill 
experiments and 36 simultaneously solved differential equations. 
Table H.37: Full Model Initial Parameter Estimates for 34 Polymyxin B Monotherapy 
Parameter gS gR Nmax kS EC50S k'R 
Value 3.43 1.37 2.34E+11 9.78 0.05 0.03 
Lower 
Bound 2.84 0.79 6.31E+10 8.06 0.02 0.01 
Upper 
Bound 4.01 1.94 4.04E+11 11.50 0.08 0.05 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Growth 
control 
model fit 
Growth 
control 
model fit 
Growth 
control 
model fit 
Net effect 
model fit 
Net effect 
model fit 
Average of 
pairwise kR 
data  
Source of 
bounds 
Univar. 
bounds 
Planar 
bounds 
Univar. 
bounds 
Planar 
bounds 
Planar 
bounds 
Lowest and 
Greatest kR 
/ EC50R 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1) 
Table H.38: Full Model Final Parameter Estimates for 34 Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 3.92 0.44 11 3.04 4.80 
gR 1.22 0.05 4 1.11 1.32 
Nmax 1.01E+11 2.19E+10 22 5.76E+10 1.44E+11 
kS 11.18 0.70 6 9.80 12.56 
EC50S 0.07 0.01 17 0.05 0.10 
k'R 0.08 0.02 22 0.05 0.12 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1) 
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Table H.39: Full Model Final Secondary Parameter Estimates for 34 Polymyxin B 
Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) 0.04 0.00 10 
SCR (mg/L) 14.8 2.80 19 
dS (min) 10.6 1.20 11 
dR (min) 34.2 1.45 4 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
 
Figure H.13: Predicted and Observed Time-kill Data for Polymyxin B against Isolate 34. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a polymyxin B MIC > 4 mg/L. Other data indicate 
the total colony count with the given concentration of polymyxin B present in the time-kill 
flask. 
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Figure H.14: Observed vs. Predicted Data for Polymyxin B Monotherapy Model against 
Isolate 34.  
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Pharmacodynamic Model of Isolate 22 Polymyxin B Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (10) and equation (11) were utilized for a total of 5 parameters, 16 time-kill 
experiments and 28 simultaneously solved differential equations. 
Table H.40: Full Model Initial Parameter Estimates for 22 Polymyxin B Monotherapy 
Parameter gS gR Nmax kS k'R 
Value 3.69 1.52 5.14E+10 14.31 0.03 
Lower 
Bound 3.05 0.31 1.78E+10 6.63 0.00 
Upper 
Bound 4.34 2.74 8.50E+10 21.99 0.05 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Growth 
control 
model fit 
Growth 
control 
model fit 
Growth 
control 
model fit 
Net effect 
model fit 
Average of 
pairwise kR 
data 
Source of 
bounds 
Univar. 
bounds 
Planar 
bounds 
Univar. 
bounds 
Planar 
bounds 
Lowest and 
Greatest kR / 
EC50R 
Units: g (h-1); Nmax (CFU/mL); k (h-1); k’ (L/mg*h-1) 
Table H.41: Full Model Final Parameter Estimates for 22 Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 3.67 0.42 11 2.84 4.50 
gR 1.19 0.06 5 1.07 1.32 
Nmax 8.5E+10 2.2E+10 26 4.1E+10 1.3E+11 
kS 8.83 0.62 7 7.58 10.07 
k'R 0.05 0.02 39 0.01 0.09 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); k’ (L/mg*h-1) 
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Table H.42: Full Model Final Secondary Parameter Estimates for 22 Polymyxin B 
Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) - - - 
SCR (mg/L) 23.7 8.21 35 
dS (min) 11.3 1.28 11 
dR (min) 34.8 1.82 5 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
 
Figure H.15: Predicted and Observed Time-kill Data for Polymyxin B against Isolate 22. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a polymyxin B MIC > 4 mg/L. Other data indicate 
the total colony count with the given concentration of polymyxin B present in the time-kill 
flask. 
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Figure H.16: Observed vs. Predicted Data for Polymyxin B Monotherapy Model against 
Isolate 22.  
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Pharmacodynamic Model of Isolate 24 Polymyxin B Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (1) and equation (11) were utilized for a total of 6 parameters, 18 time-kill 
experiments and 34 simultaneously solved differential equations. 
Table H.43: Full Model Initial Parameter Estimates for 24 Polymyxin B Monotherapy 
Parameter gS gR Nmax kS EC50S k'R 
Value 1.71 1.22 4.33E+10 7.83 0.06 0.10 
Lower 
Bound 1.40 0.86 1.94E+09 5.14 0.01 0.01 
Upper 
Bound 2.03 1.59 8.84E+10 10.53 0.11 0.25 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Growth 
control 
model fit 
Growth 
control 
model fit 
Growth 
control 
model fit 
Net effect 
model fit 
Net effect 
model fit 
Average of 
pairwise kR 
data  
Source of 
bounds 
Univar. 
bounds 
Planar 
bounds 
Univar. 
bounds 
Planar 
bounds 
Planar 
bounds 
Lowest and 
Greatest kR 
/ EC50R 
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1) 
Table H.44: Full Model Final Parameter Estimates for 24 Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 3.92 0.44 11 3.04 4.80 
gR 1.22 0.05 4 1.11 1.32 
Nmax 1.01E+11 2.19E+10 22 5.76E+10 1.44E+11 
kS 11.18 0.70 6 9.80 12.56 
EC50S 0.07 0.01 17 0.05 0.10 
k'R 0.08 0.02 22 0.05 0.12 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); EC50 (mg/L); k’ (L/mg*h-1) 
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Table H.45: Full Model Final Secondary Parameter Estimates for 24 Polymyxin B 
Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) 0.02 0.01 31 
SCR (mg/L) 9.32 0.80 9 
dS (min) 20.5 2.36 11 
dR (min) 40.1 1.20 3 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
 
Figure H.17: Predicted and Observed Time-kill Data for Polymyxin B against Isolate 24. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a polymyxin B MIC > 4 mg/L. Other data indicate 
the total colony count with the given concentration of polymyxin B present in the time-kill 
flask. 
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Figure H.18: Observed vs. Predicted Data for Polymyxin B Monotherapy Model against 
Isolate 24. 
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Pharmacodynamic Model of Isolate 44 Polymyxin B Monotherapy Experiments 
According to the protocol discussed in Pharmacodynamic Mathematical Modeling, 
equation (10) and equation (11) were utilized for a total of 5 parameters, 25 time-kill 
experiments and 43 simultaneously solved differential equations. 
Table H.46: Full Model Initial Parameter Estimates for 44 Polymyxin B Monotherapy 
Parameter gS gR Nmax kS k'R 
Value 2.63 1.26 1.15E+11 10.75 0.02 
Lower 
Bound 1.75 0.73 2.9E+10 8.46 0.00 
Upper 
Bound 3.50 1.80 2.02E+11 13.04 0.20 
Type User-defined 
User-
defined 
User-
defined 
User-
defined 
User-
defined 
Source of 
estimate 
Growth 
control 
model fit 
Growth 
control 
model fit 
Growth 
control 
model fit 
Net effect 
model fit 
Average of 
pairwise kR 
data 
Source of 
bounds 
Univar. 
bounds 
Planar 
bounds 
Univar. 
bounds 
Planar 
bounds 
Lowest and 
Greatest kR / 
EC50R 
Units: g (h-1); Nmax (CFU/mL); k (h-1); k’ (L/mg*h-1) 
Table H.47: Full Model Final Parameter Estimates for 44 Polymyxin B Monotherapy 
Parameter Estimate SE CV % 
Lower 
univariate 
CI 
Upper 
univariate 
CI 
gS 2.65 0.58 22 1.51 3.80 
gR 0.79 0.04 5 0.71 0.87 
Nmax 5.4E+10 2.6E+10 48 2.3E+09 1.1E+11 
kS 9.23 1.04 11 7.18 11.29 
k'R 0.04 0.01 39 0.01 0.07 
SE – Standard Error; CV – Coefficient of Variation; CI – 95% confidence interval;  
Units: g (h-1); Nmax (CFU/mL); k (h-1); k’ (L/mg*h-1) 
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Table H.48: Full Model Final Secondary Parameter Estimates for 44 Polymyxin B 
Monotherapy 
Parameter Estimate SE CV % 
SCS (mg/L) - - - 
SCR (mg/L) 19.7 6.71 34 
dS (min) 15.8 3.45 22 
dR (min) 52.7 2.67 5 
SE – Standard Error; CV – Coefficient of Variation; SC – Stationary Concentration;  
d – doubling time 
 
 
Figure H.19: Predicted and Observed Time-kill Data for Polymyxin B against Isolate 44. 
Observed data represent geometric means with standard deviations of at least 2 time-kill 
experiments except for green data which was only performed once. Note that some error 
bars are smaller than the symbol. Blue data represent the sum of both populations. Green 
data represent the subpopulation with a polymyxin B MIC > 4 mg/L. Other data indicate 
the total colony count with the given concentration of polymyxin B present in the time-kill 
flask. 
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Figure H.20: Observed vs. Predicted Data for Polymyxin B Monotherapy Model against 
Isolate 44. 
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